Transition Metal-Catalyzed Isocyanide Insertions::From Noble to Base Metal Catalysis by Collet, Jurriën Wilkin
VU Research Portal




Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Collet, J. W. (2021). Transition Metal-Catalyzed Isocyanide Insertions: From Noble to Base Metal Catalysis. s.n.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl




Transition Metal-Catalyzed Isocyanide Insertions: 



































This work represents research performed at the Vrije Universiteit Amsterdam and 
the Universiteit Antwerpen, which was financially supported by the Dutch Research 
Organization (NWO, TOP Grant to R.V.A. Orru, 2014), and Flanders Research 
Organisation (FWO, International Joint degree Grant to J.W. Collet, 2018). 
Printed by: ProefschriftMaken 
Cover Design: Mark Rong 
 





Transition Metal-Catalyzed Isocyanide Insertions: 
From Noble to Base Metal Catalysis 
 
ACADEMISCH PROEFSCHRIFT 
ter verkrijging van de graad Doctor  
aan de Vrije Universiteit Amsterdam 
en de Universiteit Antwerpen, 
op gezag van de rectores magnifici 
prof.dr. V. Subramaniam en prof.dr. H. van Goethem, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de Faculteit der Bètawetenschappen 
op maandag 13 september 2021 om 13.45 uur 
in de aula van de universiteit, 
De Boelelaan 1105 
 
door 
Jurriën Wilkin Collet 




promotoren: prof.dr.ir. R.V.A. Orru 
  prof.dr. B.U.W. Maes 








Van Edel- naar Onedelmetaalkatalyse 
Academisch proefschrift tot het behalen van de graad van Doctor in 
de Wetenschappen: Chemie 
aan de Universiteit Antwerpen 
en de Vrije Universiteit Amsterdam 
te verdedigen door: 
 
Jurriën W. Collet 
 
Promotoren: 
prof.dr.ir. Romano V.A. Orru 
prof.dr. Bert U.W. Maes 
Copromotor: 





















Voor Peter van der Linde, 








Table of Contents 
 
 List of Abbreviations 11 
 Preface 13 
Chapter 1 
 
Palladium-Catalyzed Isocyanide Insertions 15 
Chapter 2  
 
Base Metal-Catalyzed Isocyanide Insertions 81 
Chapter 3 
 
Synthesis of 4-Aminoquinolines via Imidoylative 
Sonogashira Cross-Coupling 
119 
Chapter 4  
 
Palladium-Catalyzed Imidoylative Cyanate Coupling / 





Synthesis of Polysubstituted Pyrimidouracils by Nickel-




Synthesis of Quinazolin-4-ones by a Copper-Catalyzed 
Amination / Cyclocondensation Cascade 
183 
Chapter 7 Outlook and Future Directions 203 
 Summary 225 
 Samenvatting 231 
 Acknowledgements 237 
 List of Publications 244 
   
   
   
   










List of Abbreviations 
3-CR 3 Component Reaction 
4-AQ 4-aminoquinoline 










bd (NMR) broad doublet 


































dd (NMR) doublet of doublets 









DME  1,2-dimethoxyetane 
DMF N,N-dimethylformamide 





















e.g. exempli gratia 
EDG electrondonating group 
ee enantiomeric excess 
EG ethylene glycol 
ESI electron spray ionization 
Et ethyl- 
et al. et alii (and others) 
EWG electronwithdrawing group 











m (NMR) multiplet 
M.P.  melting point 
MCHr epidermal growth factor receptor 
MCR multicomponent reaction 
Me methyl- 





n.r. no reaction 
NHC N-heterocyclic carbene 
NMP N-methyl pyrrolidone 







Ox. Add. oxidative addition 
PC propylene carbonate 
PG protecting group 
Q- 8-quinolinyl- 
q (NMR) quartet 
quant. quantitative 
Red. El. reductive elimination 
RNC general isocyanide 
rt room temperature 
s (NMR) singlet 
sat. saturated 









SNAr nucleophilic aromatic substitution 







TFA trifluoroacetic acid 
TFAA Trifluoroacetic anhydride 
THF tetrahydrofuran 
TLC thin layer chromatography 
TM transition metal 
TMEDA tetramethylethylenediamine 
TMS- trimethylsilyl- 
TosMIC toluenemethylsulfonyl isocyanide 
Ts tosyl, 4-methylbenzenesulfonyl- 















Isocyanides are versatile compounds, and are used as powerful reagents in a 
plethora of chemical conversions. Their conventional use in organic reactions such 
as the Nef reaction, as well as multicomponent reactions, like the Ugi- and Passerini 
reactions is well documented. More recently, the isoelectronic nature of 
isocyanides to CO has also allowed them to be inserted in metal-catalyzed cross-
coupling reactions, opening up broader synthetic avenues towards nitrogen-
containing products. 
Chapter 1 provides an updated summary of all currently known palladium-
catalyzed isocyanide insertion reactions. This chapter clearly illustrates the 
versatility of palladium in metal-catalyzed imidoylations. However, while palladium 
has shown itself to be a highly useful metal in these transformations, it is limited by 
its inherent tendency to only undergo two-electron processes. Additionally, the 
compatibility of palladium with primary, and functionalized isocyanides is typically 
low. Chapter 2 illustrates the next stage in metal-catalyzed isocyanide insertions. 
By replacing palladium with more abundant base metals, novel reactivities are 
unearthed. A complete overview of the catalytic activities of row IV metals is 
provided, and show the propensity of these metals to react with isocyanides in 
ways the noble metals are unable to (e.g. through one-electron processes).  
Chapter 3 and 4 illustrate our efforts to elaborate on palladium-catalyzed 
isocyanide insertion processes by providing an imidoylation product that is 
susceptible to cascade cyclizations. In chapter 3 we show novel reactivities of the 
known imidoylative Sonogashira reaction. We were able to greatly increase the 
isocyanide tolerance of this transformation, and provide a one-pot cascade reaction 
that generates 4-aminoquinolines. Although the 4-aminoquinolines are generally 
formed in good yields, when electron withdrawing substituents are present, yields 
are typically moderate. This reactivity was extended in chapter 4, where we 
developed a novel 3-component reaction between haloarenes, isocyanides and 
cyanates to form 4-aminobenzoxazin-2-ones and 4-aminoquinazolin-2-ones. These 
products are obtained in moderate yields, and more optimization is required to 




In chapter 5, we attempted to move from palladium towards nickel catalysis. This 
chapter shows the nickel(II)-catalyzed isocyanide insertion in amidinouracils. This 
oxidative imidoylation affords the corresponding, underinvestigated bicyclic 
pyrimidouracils in up to quantitative yields. Further work investigating base metal-
catalyzed isocyanide insertions is reported in chapter 6, where we use copper(II) 
salts as an Lewis acid. With this catalyst, we were able to subject o-
isocyanobenzoates to amination and subsequent lactamization to afford 
quinazoline-4-ones under mild conditions, and in high yields. Finally, chapter 7 
reflects on the possibilities of using the chemistry in this thesis to further expand 












Palladium-Catalyzed Isocyanide Insertions 
 
Abstract: Isocyanides have long been known as versatile chemical reagents in 
organic synthesis. Their ambivalent nature also allows them to function as a CO-
substitute in palladium-catalyzed cross-couplings. Over the past decades, 
isocyanides have emerged as practical and versatile C1 building blocks, whose 
inherent N-substitution allows for the rapid incorporation of nitrogeneous 
fragments in a wide variety of products. Recent developments in palladium-
catalyzed isocyanide insertion reactions have significantly expanded the scope and 
applicability of these imidoylative cross-couplings. This chapter highlights the 













1.1.1. Palladium catalysis 
Palladium-catalyzed cross-couplings were discovered close to 50 years ago. Since 
then, this class of transformations has evolved into one of the most widely applied 
reactions. Almost a quarter of all chemical reactions performed in medicinal 
chemistry are palladium-catalyzed cross-couplings.[1] The versatility of palladium-
catalyzed couplings originates from the predictable and promiscuous catalytic 
reactivity of palladium. This also makes these catalysts ideal for cascade-type 
chemistry, where the active catalyst plays multiple roles.[2] Further developments 
in palladium catalysis have led to an ever increasing scope of chemical 
methodologies, leading to milder conditions, lower catalyst loadings, and more 
robust and general cross-couplings. These aspects have made palladium-catalyzed 
cross-coupling reactions a critical staple in the development of chemical pathways 
to valuable fine chemicals. 
1.1.2. Isocyanides 
Next to the use of isocyanides in multicomponent chemistry (e.g. Passerini or Ugi-
type reactions),[3] many other synthetic applications of these versatile building 
blocks have been known for a long time.[4] A relatively recent use of isocyanide 
building blocks combines their ambiphilic nature with well-defined transition 
metal-catalyzed cross-couplings. In these transformations isocyanides are inserted 
into a metal-carbon or metal-heteroatom bond[5], similar to better-known 
carbonylative cross-couplings.[6] The ability to insert an isocyanide into two 
coupling partners also makes this type of reactions interesting for the development 
of new types of multicomponent reactions (MCRs). While various metals are known 
to facilitate these ‘imidoylative’ cross-couplings, palladium is by far the most widely 
used metal in these transformations. In addition, the entire field of palladium-
catalyzed isocyanide insertions has matured significantly over the past couple of 
years, with many new reactivities being reported (Figure 1). In this chapter we 
discuss all recent examples in which isocyanides are used as a reactant in palladium-
catalyzed cross-couplings. We focus on cascade transformations or processes that 
couple three or more reactants in a single reaction.  





Figure 1. Publications per year reporting on reactions involving isocyanide reactant using palladium 
catalysis. 
This chapter augments our earlier comprehensive overviews of both palladium-
catalyzed[5b] and base metal-catalyzed[5c] isocyanide insertions. As the synthetic 
applicability of these convergent synthetic strategies often hinges on the ability of 
the catalytic system to tolerate variations of the isocyanide substituent, we will 
especially discuss the isocyanide scope in each report. While tertiary isocyanides 
have traditionally been the main focus in most reports, this has changed more 
recently. Over the past decade more robust catalytic conversions have been 
reported, often being much more tolerant of isocyanide input. Additionally, using 
palladium catalysis to insert an isocyanide, followed by the hydrolysis of the newly 
formed imine has rendered isocyanide insertions an effective tool for ´CO-free 
carbonylation’, essentially utilizing the isocyanide as a carbonyl surrogate. Nickel-
catalyzed polymerization of isocyanides to helical polyimines is extensively 
reported in literature.[7] Recently, significant advances have been made in using 
palladium catalysis for similar transformations to polyimines.[8] Due to the nature 
of this transformation, affording polymeric structures rather than small molecules, 





















































































































































1.2. Pd0-Catalyzed Isocyanide Insertions. 
1.2.1. Imidoylation Initiated by Oxidative Addition of Carbohalides. 
Since the early discoveries in the 1970s, much of palladium catalysis still utilizes the 
propensity of aryl halides to undergo oxidative addition to an active Pd0 complex. 
This typically results in the formation of an aryl palladium complex I (Scheme 1). 
This complex can rapidly undergo 1,1-migratory insertion of isocyanides into the 
activated aryl palladium bond, furnishing imidoyl palladium complex II. Next, a 
ligand exchange can take place, either with ambient nucleophiles, or the complex 
II undergoes a transmetalation with metal-based coupling partners, resulting in the 
formation of complex III or IV. Subsequent reductive elimination then affords the 
imidoylative cross-coupling imine products, while regenerating the active Pd0 
catalyst, thus closing the catalytic cycle. In the following sections we discuss in more 
detail the catalytic processes, organized along the nature of the respective coupling 
partner. 
 
Scheme 1. Typical catalytic cycle for redox-neutral Pd-catalyzed isocyanide insertion reactions. 
1.2.1.1. Cross-Couplings with Organometallic Carbon Nucleophiles. 
The ‘classic’ palladium-catalyzed cross-couplings almost all follow the typical 
pattern of oxidative addition, transmetalation, and reductive elimination, thus 
employing an external R’-M species as the coupling partner. Transmetalation is 
commonly an integrated step in the catalytic cycle of these processes, except 
perhaps for the well-known Mizoroki-Heck reaction which is terminated by alkene 




insertion and β-hydride elimination. The first example of an imidoylation involving 
transmetalation by Mitiga et al. (imidoylative Stille coupling)[9] was followed by 
many studies that report major improvements in coupling partners, catalytic 
conditions, as well as tolerance for all coupling partners. Current methodologies 
have thus impressively matured over the past decade.  
 
Scheme 2. Biaryl ketone synthesis via imidoylative Suzuki-Miyaura reaction. 
Although the extension of the well-known Suzuki-Miyaura reaction using 
isocyanides as starting material was already known,[10] a new version of this cross-
coupling reaction was introduced in 2014, describing an imidoylative synthesis of 
biarylketones 4.[11] This redox-neutral cross-coupling of aryl iodides 1, aryl boronic 
acids 2 and t-BuNC (3) proceeds in good yields, although the use of sterically 
congested aryl iodides 1 leads to somewhat lower yields (Scheme 2). No attempts 
were made to investigate isocyanides other than t-butyl isocyanide 3, as post-
coupling acid hydrolysis cleaves of the isocyanide residue liberating the ketone 4. 
 
Scheme 3. One-pot double imidoylative Negishi reaction and biscondensation with o-





When the ‘classical’ palladium-catalyzed Negishi conditions are adapted by the 
addition of an isocyanide, a one-pot selective double isocyanide insertion was 
observed (Scheme 3).[12] The choice of ligand is instrumental in the double insertion, 
as ligands other than dppf give mixtures of mono- and diketone products 8. 
Although the catalytic system tolerates many different types of alkyl zinc reagents 
6, the use of isocyanides other than tert-butyl isocyanide resulted in poor to no 
conversion. This methodology was used to efficiently generate quinoxalines 7 via 
double condensation with o-phenylenediamine, in a three step sequence, without 
intermediate purification (Scheme 3).  
 
Scheme 4. (Double) isocyanide insertion using tetraaryl lead reactants. 
In an extension of this imidoylative cross-coupling using organozinc compounds (6) 
as coupling partners, the group of Ogawa reported a similar transformation with 
tetraaryl lead compounds 9 (Scheme 4).[13] Generally, this reaction appears to be 
more difficult to control, typically affording a mixture of mono- and diimidoylated 
cross-coupling products 11 and 21. However, this reaction proceeds without 
additives, and is compatible with aliphatic, benzylic, and aromatic isocyanides. 
Under the optimized reaction conditions, aliphatic isocyanides display a significant 
preference for coupling product diarylimines 11. When electron-rich aromatic 
isocyanides were employed, this product distribution switched to diimidoylated 
structures 12 as the main product. Reactions with electron-deficient aryl 
isocyanides did not afford any isolable products. 
1.2.1.2. Cross-Coupling with Other Carbon Nucleophiles. 
Similar to the imidoylative C-C bond formations via transmetalation with an 
organometallic reactant, the past decade has seen a significant surge in the use of 
other carbon nucleophiles as coupling partners, typically formed in situ via 
deprotonation with readily available bases. The drawback is that this is restricted 
to active methylenes, additionally, the carbon coupling partner formed should be 
nucleophilic enough to interact with electrophilic palladium complexes. However, 
many advancements have been made recently, greatly enhancing the scope of such 
imidoylative cross-couplings. There are also other ways to generate carbon 




nucleophiles, involving electrophilic substitutions, e.g. from electron-rich enamines 
or arenes, or via C-H activation. 
 
Scheme 5. Utilizing enolates of 3-(2-bromoaryl)propanediones as coupling partners in imidoylative 
cyclizations. 
In 2015, the group of Yang reported the Pd-catalyzed intramolecular C-C 
imidoylation with enolates of diones 14 to generate the 2-acyl-3-iminoindenes 
16.[14] This palladium-catalyzed isocyanide insertion is highly similar to those 
reported earlier by Ji et al., who reported an intramolecular isocyanide insertion 
and trapping of the imidoyl palladium intermediate with enols to afford the 
corresponding imidates.[15] Deprotonation by the stronger base tert-butoxide 
favors coupling with the enolate carbon over the enolate oxygen in moderate to 
good yields (Scheme 5). Similarly, omitting the distal ketone leads to a similar 
reactivity of o-bromoacetophenones 15, however, all inputs were hydrolyzed with 
aqueous hydrochloric acid, leading to 1,3-indanediones 17 in acceptable yields (61-
75%).  
This methodology was extended in the same year, introducing an additional 
methylene functionality to the substrate 19. In this case, medicinally relevant 
amino-hydroxynaphthyl ketones 21 were obtained in moderate to good yields.[16] 
The use of tertiary isocyanides typically affords the 4-tert-butylaminonaphth-2-ols 
in good yields under the optimized conditions (Scheme 6a). The authors did not 
fully investigate the scope regarding the isocyanide input, although a single 







Scheme 6. Utilizing enolates as coupling partners in imidoylative cyclizations. 
The tether to the internal enolate can also be shortened, and still afford analogous 
products. In this manner, acetophenones 25 can also be coupled with the formed 
imidoyl palladium intermediate, affording aminoindenones 26 (Scheme 6b). The 
scope of the reaction utilizing the corresponding enolate of acetophenones 25 is 
much less broad in terms of isocyanide substituents, as the yields of cyclic 
enaminones 26 drop significantly even when cyclohexyl isocyanide is used. 
 
Scheme 7. Using N-(2-iodoaryl)enaminones as coupling partners in imidoylative cyclizations. 
Another early example of imidoylation with a carbon coupling partner is shown in 
Scheme 7. The generated imidoyl palladium species is attacked by the electron-rich 




enamine carbon of enaminones 27, which affords the medicinally interesting 4-
aminoquinazoline derivatives 28 after reductive elimination.[17] The imidoylative 
cross-coupling proceeds with low catalyst loading, and generally affords annulated 
4-aminoquinoline products in yields of around 90%, though the cyclization 
efficiency is greatly diminished if acyclic enaminones are used. The use of secondary 
isocyanides also reduces the yields, and no isolable quantities are formed when 
aromatic or benzylic isocyanides are employed. 
 
Scheme 8. Utilizing an electron-rich arene of 2-(2-iodoarylamino)indoles in imidoylative 
cyclizations. 
Another example of the redox-neutral cross-coupling with carbon nucleophiles 
involves the synthesis of indoloquinolines 31 from 2-(2-iodoarylamino)indoles 29 
and isocyanides 30.[18] This reaction is postulated to proceed via isocyanide 
insertion into the generated aryl palladium bond, and subsequent electrophilic 
aromatic substitution at the highly electron-rich indole C3-position (Scheme 8). N-
substituted indoloquinolines 31 were isolated successfully from tertiary and 
secondary aliphatic isocyanides. A single example was reported starting from 4-
nitrophenyl isocyanide, although the corresponding indoloquinoline was formed in 
 
Scheme 9. Intramolecular imidoylation of aryl iodides with isocyanotryptophanes. 
much lower yield (26 %). The same group later facilitated the same reaction, with 





selective cytotoxicity for several cancer cell lines.[19]An imidoylative cross-couplings 
using an isocyanide with a tethered carbon nucleophile is highlighted in Scheme 9. 
Using the readily available tryptophan-derived isocyanides 32, a redox-neutral 
carboimidoylation was readily facilitated.[20] Regardless of the substituent pattern, 
all aryl iodides 33 afford β-carbolines 34 in good to excellent yields. The authors 
suspect that the initially formed dihydrocarbolines are oxidized under aerobic 
conditions during work-up to the medicinally valuable carbolines 34. 
 
Scheme 10. Substrate-dependent intramolecular carboimidoylation or aminoimidoylation. 
A final example of using indoles as cross-coupling partners is shown in Scheme 10, 
in which the divergent reactivity of 2-(2-bromoaryl)indoles 35 was highlighted.[21] 
In the case of N-unsubstituted indole, all employed conditions favor the Buchwald-
Hartwig-type amidination with the indole nitrogen, affording indoloindolones 36 by 
post-coupling hydrolysis of the amidine.  
 
Scheme 11. Utilizing an electron-rich arene of 2-(aryloxy, arylamino or arylphosphino)aryl 
isocyanides in imidoylative cyclizations. 
Implementation of a N-substituent favors formation of indoloindenones 37 via a 
carboimidoylation rather than an aminoimidolyation, in comparable yields. In all 
cases, only tert-butyl isocyanide was used, and the product ketimines were 




hydrolyzed by addition of aqueous HCl. Recently, the group of Zhu extended this 
reactivity, reporting a direct imidoylative annulation of substituted aromatic 
isocyanides 38 and aryl iodides 39, generating medicinally valuable dibenzazepines 
and dibenzoxazepines 40 (Scheme 11).[22] The cross-coupling of o-
isocyanodiphenylether affords significant amounts of double isocyanide insertion 
product. However, if 2,6-disubstituted phenyl isocyanides are used, formation of 
this side product is avoided, forming products 40 with surprising efficacy for a 
redox-neutral palladium-catalyzed aromatic isocyanide insertion. 
Dibenzodiazepines 40 (Y = NMe) were synthesized in similar yields via the same 
method.  
 
Scheme 12. Enantioselective desymmetrization of dibenzyl isocyanoacetates in a Pd-catalyzed 
imidoylative annulation. 
In 2017, the same group published an enantioselective desymmetrization of 
dibenzyl isocyanoacetates 41.[23] Isocyanide insertion into the formed arylpalladium 
affords the intermediate imidoyl palladium species 43, which undergoes an 
enantioselective carbocyclization to access the medicinally valuable 
dihydroisoquinolines 42 (Scheme 12). Utilization of the chiral spinol-derived ligand 





Additionally, a wide variety of aromatic substituents are tolerated on the dibenzyl 
isocyanoacetates 41.  
 
Scheme 13. Intramolecular imidoylation of aryl iodides with biaryl isocyanide and 
(benzylidene)isocyanoacetates s. 
The radical cyclization of o-isocyano biphenyls and related structures towards 
substituted phenanthridines was extensively reviewed by Studer in 2015.[24] 
However, several palladium-catalyzed ionic syntheses of phenanthridines were also 
reported recently. In most of these cases, the mechanistic implications of the 
cycloaromatization step are not fully elucidated. These formal C-H 
functionalizations can either rely on a classic two step SEAr, as several examples 
above, or have a more concerted character, bordering on electrocyclizations.  
The redox neutral imidoylation of aryl iodides 39 with biaryl isocyanides 44 was 
reported in 2015 as a direct method of generating phenanthridines 46 in good to 
near-quantitative yields (Scheme 13). The reaction proceeds via isocyanide 
insertion into the formed arylpalladium species. Then, C-H functionalization affords 
the re-aromatized phenanthridines 48.[25] Kinetic isotope effect experiments 
suggest that the annulation proceeds via C-H activation and reductive elimination, 
although an electrophilic aromatic substitution cannot be excluded. Changing the 
biaryl isocyanide to (benzylidene)isocyanoacetates 45 affords the corresponding 
isoquinolines 47 via a similar mechanism. Additionally, this method was also 
compatible with the alkylpalladate 51 generated by additional intramolecular 
proximal alkene insertion of methacrylamide 49, affording chemically complex 
structures 50 in a one-pot fashion (Scheme 14).  





Scheme 14. Intramolecular imidoylation of aryl iodides with biaryl isocyanide involving additional 
alkene insertion. 
 
Scheme 15. Asymmetric synthesis of pyrido fused ferrocenes. 
The same group later reported an asymmetric variation of this transformation 
(Scheme 15). By using (ferrocenyl)vinyl isocyanides 53 and aryl iodides 39 in 
combination with chiral ligand L2 pyrido-fused  ferrocenes 54 could be isolated in 
good to near-quantitative yields, with high ee[26] Similarly, with N-(2-iodophenyl)-
N-methylmethacrylamide 55 additional alkene insertion occurs prior to isocyanide 
insertion. This cascade affords the highly complex structures 56 with high e.e. 
However, the chiral induction of the indolinone is moderate, leading to a d.r. of only 






Scheme 16. Asymmetric synthesis of indolinone substituted pyrido fused ferrocenes. 
1.2.1.3. Cross-Couplings with Oxygen or Nitrogen Nucleophiles. 
In addition to transmetalation, the Buchwald-Hartwig reaction has received much 
attention by synthetic and medicinal chemists as this reaction proved instrumental 
in the synthesis of many novel pharmaceutical scaffolds and their decoration.[1] The 
imidoylative variant of the Buchwald-Hartwig reaction involves nucleophilic attack 
on the transient imidoyl palladium species allowing for the formation of substituted 
imidates and amidines, and imines, depending on the nucleophile used. These 
functionalities are quite useful and ubiquitous in nature and pharmaceutical 
intermediates. Recent studies in the field of isocyanide insertions are directed 
towards further development of these imidoylative Buchwald-Hartwig type cross-
couplings. To facilitate this, over the past couple of years there have been multiple 
 
Scheme 17. Cascade imidoylative Buchwald-Hartwig reaction  and cyclization via transimination. 




reports on the mechanistic aspects of these reactions, allowing chemists to easier 
predict catalytic behavior and develop more effective catalysts.[27] In 2014, 
Schipman et al. extended the imidoylative Buchwald-Hartwig type cross-coupling 
to include the use of diamines 57 as coupling partners.[28] This reaction is indicative 
for imidoylative Buchwald-Hartwig couplings, and proceeds via the oxidative 
addition of an aryl halide 5 to in situ generated Pd0, after which a well-documented 
1,1-migratory insertion of the isocyanide can take place.  
 
Scheme 18. One-step bisimidoylative synthesis of a chiral Pybim ligand. 
The transient imidoyl palladium intermediate 59 is readily attacked by ambient 
diamine 57, which affords the amidine 60 after reductive elimination. This amidine 
smoothly undergoes an intramolecular transimination to afford 2-arylated 
imidazolines 58 (Scheme 17), releasing t-butylamine. The products are typically 
formed in good yields, although somewhat lower yields are reported for sterically 
hindered aryl halides, or less nucleophilic variations of diamine 57, like o-
phenylenediamine. The authors also utilized this methodology to facilitate a direct 
synthesis of a complex chiral Pybim ligand 63 (Scheme 18). 
 
Scheme 19. Temperature-dependent hydroxyimidoylation and subsequent condensation cascade. 
A related method affords 2-substituted (3H)quinazolin-4-ones from N-acyl 2-
bromoanilines 64.[29] This method relies on the direct hydroxyimidoylation of the 





either tert-butyl isocyanide or cyclohexyl isocyanide (Scheme 19). If the 
temperature is raised to 160 °C, the generated bisamide undergoes a 
cyclocondensation to quinolinones 66, which is accompanied by spontaneous de-
tert-butylation. It should be noted that similar one-pot 
hydroxyimidoylation/cyclization cascades are also reported in the syntheses of 
indolin-1-ones[30] and fused dihydropyrrolimines.[31] 
 
Scheme 20. Intramolecular oxyimidoylation of (2-bromophenyl)ureas. 
In a related process, the cyclooxyimidoylation of (2-bromoaryl)ureas 67 proceeds 
with full selectivity to the urea oxygen, which results in iminobenzoxazinones 68 
(Scheme 20).[32] In contrast to the couplings above, this transformation is highly 
compatible with various isocyanides, as aliphatic, α-acidic, and aromatic 
isocyanides all afford the iminobenzoxazinones 68 in high yields, regardless of the 
isocyanide substituent. The iminobenzoxazinones 68 are readily converted to the 
medicinally useful corresponding 2-aminobenzoxazinones via hydrolysis with 
aqueous HCl, or can be converted to the corresponding 2-aminoquinazolin-3H-ones 
through a piperidine-mediated Mazurkiewicz-Ganesan rearrangement, similar to 
earlier reports.[33] The same authors reported a similar reactivity for (2-
bromophenyl)thioureas[34], and N-(2-bromoaryl)benzamides, yielding 2-
aminothiazin-4imines 2-arylbenzoxazin-4-imines, respectively.[35] 
 
Scheme 21. Fused quinazoline synthesis via intramolecular imidoylative Buchwald-Hartwig reaction 
of N-(pyridinyl)amidines . 




Early in the development of this research field our group also reported an 
intramolecular imidoylative Buchwald-Hartwig reaction towards highly electron-
deficient (aza)quinazoline 70 (Scheme 21).[36] The transformation is successful in 
combination with secondary isocyanides and tert-butyl isocyanide, although no 
other tertiary isocyanides were investigated. The more electron-deficient N-(2-
pyridyl)amidines 69 are more reactive towards imidoylative amidation than the 
regioisomeric N-(3-pyridyl)amidines, requiring lower temperatures, and affording 
the corresponding pyridopyrimidines 70 in higher yields.  
 
Scheme 22. Cascade imidoylative Buchwald-Hartwig coupling with (thio)hydrazides followed by 
condensation (X = O, S). 
The imidoylative Buchwald-Hartwig cross-coupling can also be employed in 
combination with (thio)hydrazides 71 in a redox-neutral synthesis of 1,3,4-
oxadiazoles and thiadiazoles 72.[37] As the isocyanide is only used as a C1 building 
block, the scope was left uninvestigated, and only t-BuNC was employed in this 
coupling (Scheme 22).  
 






The cross-coupling is also successful with aliphatic hydrazides, but results in a 
significantly reduced yield. The proposed intermediate  (thio)acylamidrazone 73 
undergoes a smooth cyclocondensation under the basic reaction conditions. 
Comparably, an initial Buchwald-Hartwig aminoimidoylation[38] can also be 
followed up by additional palladium-catalyzed cross-couplings in a one-pot 
fashion.[39] The multicomponent reaction (Scheme 23) generates 2-amino-3-
bromoquinolines via an imidoylative Buchwald-Hartwig coupling, after which a 
subsequent Suzuki coupling takes place, affording 2-amino-3-arylquinolines 75.  
 
Scheme 24. Imidoylative cross-coupling of 2-iodophenols and aziridines. 
Isocyanide insertion is fully selective; no indoles were formed through direct 
amination, and the follow-up Suzuki coupling proceeds completely without 
imidoylation. Although (tert-butylamino)quinolines 75 (R3 = tBu) are typically 
isolated in yields over 70 %, changing the isocyanide input significantly hampered 
the reaction. The use of cyclohexyl isocyanide led to isolation of the corresponding 
product in a disappointing 34 %, while 2,6-dimethylphenyl isocyanide gave only 
trace amounts of quinoline 75. Similarly, in the absence of an internal nucleophile 
hydroxyimidoylation of gem-dibromostyrenes to the corresponding alkynylamides 
is also possible.[40] 
An interesting multicomponent cascade reaction with N-tosylaziridines 76 and o-
iodophenols 77 affords access to benzoxazepines 78.[41] The cascade is initiated by 
the base-promoted ring-opening of the aziridine by iodophenol 77 (Scheme 24). A 
subsequent intramolecular aminoimidoylation directly affords the polysubstituted 




benzoxazepines 78 in good yields, and in full trans-selectivity. The regioselectivity 
is controlled by sterics, opening the aziridine on the least hindered carbon. Again, 
reactions with tertiary isocyanides afford the corresponding benzoxazepines in 
good yields. The only secondary isocyanide (cyclohexyl isocyanide) that was tested 
afforded the product in a moderate 42%. 
 
Scheme 25. Aminoimidoylation of 2-iodoanilines with double isocyanide insertion. 
An intramolecular Buchwald-Hartwig coupling with aryl iodides 80 bearing an 
internal nucleophile on the ortho position affords 2-amino-3-iminoindolenines 81 
via double isocyanide insertion (Scheme 25).[42] This reaction is fully compatible 
with tertiary, secondary, and aromatic isocyanides, but fails to afford any product 
81 when primary aliphatic or α-acidic isocyanides are employed.  
In an intermolecular variant of this double insertion, the group of Kègl investigated 
the substituent effects of aryl halides 83 on the imidoylative cross-coupling with 
tert-butyl isocyanide 3 and secondary amines 82.[43] Typically, this imidoylative 
Buchwald-Hartwig type multicomponent reaction affords the ketimine-amidine 85  
 
Scheme 26. Single or double isocyanide insertion in Buchwald-Hartwig reaction. 
in good yields, although in most cases a mixture of 85 and the amidine 84 is formed 
(Scheme 26).No linear Hammett correlation between the electron-donating or –
withdrawing substituents and the yield or selectivity of this transformation was 





analogues of 83 (X = Br) typically favor a single isocyanide insertion towards 
benzamidines 84, implying the halide plays a role in the mechanism. The broad 
substrate scope investigation was only performed with tert-butyl isocyanide and 
piperidine, other isocyanides showed no conversion under the reaction conditions.  
 
Scheme 27. Pd-catalyzed ketenimine formation with alpha bromoketones and isocyanides and 
interception with nitrogen nucleophiles. 
A Pd-catalyzed imidoylative MCR cascade to β-ketoamidines 90 or 5-
aminopyrazoles 91 was reported by the group of Zhu.[44] Oxidative addition of the 
alkyl halide 87, and subsequent isocyanide insertion is followed by β-hydride 
elimination of intermediate 92, affording the ketenimine 93 as a common 
intermediate (Scheme 27). Subsequent addition of either amines 88 or hydrazines 
89 as (bis)nucleophiles smoothly affords amidines 90 or 5-aminopyrazoles 91, 
respectively. A single pyrazole 91 was synthesized using cyclohexyl isocyanide, 
although further investigations of the isocyanide scope were not performed. 
Additionally, the ketenimine can also be trapped by hydrazoic acid, or Grignard 
reagents, highlighting the divergent nature of this transformation, and the 
versatility of intermediate ketenimine 93. The intramolecular imidoylative 
Buchwald-Hartwig reaction can also be performed under oxygen atmosphere 
yielding other products. Thus, imidoylation of the Ugi products 94 affords the 
isoindolimines 96, which oxidize spontaneously under O2 atmosphere, to form α-
hydroxy intermediate 97 (Scheme 28). Next, this intermediate isomerizes to form 
the thermodynamically more stable iminoisoindolinones derivatives 95.[45] 





Scheme 28. Imidoylative Buchwald-Hartwig reaction with Ugi products under O2 atmosphere. 
Curiously, the initial Buchwald-Hartwig imidoylation is successful under oxidative 
atmosphere, and does not require external stabilization by phosphine ligands. The 
transformation proceeds smoothly using aliphatic isocyanides, but is unsuccessful 
when aromatic isocyanides are employed, most likely due to their inherent 
instability. 
 





Carboxylic acids can also be used as nucleophiles, forming intermediate 101 
(Scheme 29).[46] Reductive elimination then affords the O-acylimidate 102 which 
undergoes a Mumm rearrangement, i.e. a spontaneous intramolecular acyl transfer 
into the N-arylimides 100. Several examples were performed with bifunctional o-
iodobenzoic acids, in which this imidoylative cross-coupling affords phthalimides in 
comparable yields to the untethered 3-CR variant. The reaction is highly compatible 
with aryl isocyanides, which is uncommon for redox-neutral palladium-catalyzed 
imidoylations. Additionally, through this method the authors facilitated late-stage 
diversification of well-known carboxylic acid pharmaceuticals (e.g. carboprofen, 
flurbiprofen).  
 
Scheme 30. Imidoylative Buchwald-Hartwig cross-coupling of dihydroquinazolinones. 
Further application of imidoylative Buchwald-Hartwig coupling includes the 
synthesis of fused tetracyclic scaffolds 104 (Scheme 30).[47] The substrate 
dihydroquinazolinone 103 is formed in a cascade manner from isatoic anhydrides, 
benzaldehydes and hydrazines. Fused hydrazide motifs have been reported for 
their analgesic and anti-inflammatory properties.[48] Although only tert-butyl 
isocyanide and cyclohexyl isocyanide were employed, both show similar reactivity 
in this redox-neutral imidoylation. Interestingly, when propargylated isatoic 
anhydrides are used to synthesize substrate 103 (R1 = CH2C≡CH), the product 104 
undergoes a base-promoted, palladium-catalyzed cascade depropargylation, 
resulting in the aromatized quinazolin-4-ones 105 in good yields.  
2-Alkynylated aromatic isocyanides 106 occasionally react in redox-neutral 
palladium-catalyzed isocyanide insertions (Scheme 31).[49] The only two variations 
of aryl isocyanide substitutions that were investigated indicate the reaction is less 
efficient when electron density is withdrawn from the isocyano moiety. The 
isocyanide insertion of isocyanophenylacetylene 106 is followed by a 6-exo-dig 
cyclopalladation of the generated intermediate 108. 





Scheme 31. Isocyanophenylacetylene cyclization into 3-acylindoles. R’ = -H, -CO2- 
The authors also showed the oxygen is most likely introduced either by residual 
water, or the carbonate base, which also liberates 3-acylindoles 107 upon 
hydrolysis. Intramolecular trapping of formed imidoyl palladium species by a 
nucleophile-bearing isocyanide 110 affords the polysubstituted oxazoles 111 
(Scheme 32).[50] While the reaction is compatible with multiple aryl halides 5, and 
typically affords the corresponding oxazoles in good yields, the isocyanoacetamide 
requires a tertiary amide. 
 
Scheme 32. Imidoylative Buchwald-Hartwig cross-coupling with isocyanoacetamides. 
Further α-substitutions of the isocyanoacetamide were not investigated. 
Additionally, replacing the aryl halide with vinyl triflates or alkenyl bromides also 
generate structural analogues of oxazoles 111 in good yields via the same 
mechanism. An oxidative homocoupling of isocyanides 110 to afford bisoxazoles 





1.2.2. Imidoylation Initiated by Oxidative Addition of Oximes 
Aside from the use of aryl halides as preoxidized substrates, recent reports have 
repeatedly included the propensity of oxidized amines and imines to undergo 
oxidative addition to a Pd0 catalyst. These acyloximes or acyloxyamines readily 
afford a N-Pd active site for isocyanide insertion, leading to more diverse, 
nitrogeneous cross-coupling products.  
 
Scheme 33. Intramolecular double imidoylation of O-acetyloximes. 
The combination of O-acetyloximes 113 with isocyanides was first reported by 
Wang et al. in 2017. Utilizing the inherent nucleophilicity of enamines, the 
intramolecular double imidoylation of 113 affords the 3-aminopyrrol-2-imines 114 
(Scheme 33).[52] The method is tolerant towards aliphatic and aromatic isocyanides, 
although utilization of aromatic isocyanides tends to afford the products 114 in 
moderately lower yields, and typically requires extended reaction times. 
 
Scheme 34. Imidoylation of O-acyloximes followed by dehydrogenative homocoupling. 




The same group later exploited this reliable reactivity of isocyanide insertion into 
O-acyloximes to facilitate the curious dehydrogenative insertion of benzyl 
isocyanide 116 into these oximes 115 (Scheme 34). This affords the pyrrolediimines 
118, which undergo in situ dehydrogenative homocoupling, leading to the 
diphenylated pyrroloquinoxalines 117 in surprisingly good yields (29-69%).[53] The 
benzylic isocyanide substituent is required, as the reaction fails with α-acidic 
isocyanides. The cross-dehydrogenative homocoupling of the benzylic substituents 
does not require an external oxidant. 
 
Scheme 35. Imidoylative coupling of tertiary isocyanoacetates and O-benzoylhydroxylamines. 
The methodology mentioned in Scheme 12 was later expanded by exploiting this 
oxidative addition of O-benzoyloxyamines 120 to the active Pd0 catalyst, and 
subsequent isocyanide insertion to generate the corresponding imidoyl palladium 
species (Scheme 35).[54] Pivalate-assisted C-H functionalization of the tethered 
arene and reductive elimination affords the 1-aminodihydroisoquinolines 121, 
typically in good yields. In this case no asymmetric variations were attempted. The 
efficacy of this transformation is not hampered by the introduction of electron-
withdrawing groups on the arene. No secondary isocyanoacetates (R1 = H) were 
reported. Additionally, benzoylhydroxylamines derived from primary amines were 
not tested under these conditions.  
Related to earlier mentioned phenanthridines synthesis (Scheme 14), but initiated 
by the oxidative addition of O-benzoyloxyamines 123 to Pd0, 6-
aminophenanthridines 124 or 1-aminoisoquinolines 125 are rapidly formed 
through a subsequent imidoylation and electrophilic aromatic substitution 
cascade.[55] Although the nature of the isocyanide substituents are of little 
consequence to the overall yield of these transformations, the reaction is only 
successful when N,N-disubstituted benzoyloxyamines are employed introducing 






Scheme 36. Intramolecular imidoylation of N,N-disubstituted O-benzoylhydroxylamines with biaryl 
isocyanide and (benzylidene)isocyanoacetates. 
1.2.3. Imidoylation Initiated by Oxidative Addition of Allyl(pseudo)halides. 
The first reported palladium-catalyzed imidoylation using allylic (pseudo)halides to 
initiate isocyanide insertion involves the synthesis of 3H-indolamines 128, bearing 
a quaternary carbon center at C3, utilizing complex bifunctional 2-(3-
acetyloxypropen-1-yl)aryl isocyanide 126 as coupling partner (Scheme 37).[56] The 
use of L-proline methyl ester as an amine component led to moderate 




Scheme 37. Intramolecular imidoylative Tsuji-Trost coupling with amines. 




The first intermolecular cross-coupling involving a π-allylpalladium complex and 
isocyanides was reported by Zhu et al. in 2016.[57] They used allylic carbonates 130 
to facilitate isocyanide insertion to give the corresponding vinylic ketenimines 133 
(Scheme 38), which were subjected to hydration or formal [3+2] cycloaddition with 
azides in a one pot fashion to afford β,γ-unsaturated amides 131 or tetrazoles 132, 
respectively. The reaction proceeds under remarkably mild conditions, and the 
products are typically isolated in good yields. As the product regiochemistry is 
under thermodynamic control, substitution at the R1 or R2 position can lead to 
formation of some regioisomers, or E/Z-diastereoisomers. While the authors report 
that the reaction is compatible with secondary and even aromatic isocyanides, 
these examples were not included in the initial publication. 
 
 
Scheme 38. Homologation of allyl carbonates to allylic amides and 1H-tetrazoles via ketenimine 
formation. 
An uncommon cyanation via isocyanide insertion into activated allylic 
(pseudo)halides can also proceed via a radical mechanism (Scheme 39). In a recent 
report by Zhu et al. the interesting conversion of allylic carbonates 134 and tertiary 
cyclic isocyanides 135, bearing an α-ester moiety was described.[58] The 
ketenimines 138 are formed, similar to Scheme 38, and are postulated to undergo 
homolysis to generate radical pair 140 and 141. The rapid isomerization is most 







Scheme 39. Tsuji-Trost imidoylation followed by radical rearrangement into cyanides. 
In 2017, Liang et al. reported a curious transformation, wherein readily available  
allyl benzoates 142 are readily converted to the corresponding N-benzoyl-N-
substituted crotonimides 143 (Scheme 40).[59] The reaction conditions are 
compatible with secondary and primary aliphatic isocyanides. Extensive 
mechanistic investigations were not performed, but the authors propose an 
isocyanide insertion into allylic Pd intermediate 144, followed by reductive 
elimination to afford imidate intermediate 145. 
 
Scheme 40. Imidoylative conversion of allyl benzoates into N-benzoyl-N-substituted crotonimides. 




This imidate undergoes an intramolecular acyl migration via Mumm rearrangement 
to afford the product imides 143. The reductive elimination, generating conjugated 
intermediates like 145 has not been reported anywhere else, although similar 
reactions have been published over the past couple of years.[56-58, 60] The authors 
make no mention of a possible hydride transfer. However, a post-coupling “chain-
running” allylic isomerization of vinylacetimide towards the more 
thermodynamically stable conjugated crotonimide seems likely. These 
isomerization processes can also be catalyzed by palladium.[61]  
Zhu and coworkers reported one of the first controlled palladium-catalyzed triple 
isocyanide insertion reactions, facilitating the synthesis of highly decorated 
aminopyrroles 148.[62] By extending the previously noted Tsuji-Trost activation of 
allylic acetates to propargylic carbonates 146, an allenylpalladium species is formed 
which can undergo isocyanide insertion, providing intermediate 149 (Scheme 41). 
Attack of a second isocyanide 20 forms an electron-deficient nitrilium species 150 
which is susceptible to external addition of yet another isocyanide, generating the 
postulated intermediate 151. Only now is the sequence terminated by the addition 
of  nucleophilic alcohol 147, which performs a conjugate addition to form the 
aminopyrroles 148. Only tertiary isocyanides were used in this triple insertion 
process. 
 





1.2.4. Imidoylation Initiated by Oxidative Addition of Activated Sulfur Compounds. 
Imidoylative variants of less common palladium-catalyzed cross-coupling reactions 
are also reported. In this respect, the Liebeskind-Srogl coupling, typically involving 
an activated thioether or thioester, is an interesting example.[63] Although early 
reports rely on both palladium and copper catalysis, new versions of this reaction  
 
Scheme 42. One-pot, two-stage imidoylative Liebeskind-Srogl coupling. 
typically only require either copper or palladium catalysts. The scope of this cross-
coupling has recently been extended to include isocyanides, although all 
imidoylative Liebeskind-Srogl-type reactions reported to date only insert an 
isocyanide into the activated substrate, retaining the leaving group, and therefore 
are formally not cross-coupling reactions. An early example (2017) of such an 
imidoylative Liebeskind-Srogl coupling was performed in a one-pot fashion as 
depicted in Scheme 42.[64] The thiophene 156 is formed via an S-
demethylation/Thorpe-Ziegler cyclization[65], and is directly subjected to the 
imidoylative reaction conditions. The reaction reliably affords the thioimidate 155 
in 62-74 % yield. Even when using cyclohexyl, or 2,6-dimethylphenyl isocyanide the 
yields were similar to the reactions performed with the benchmark tert-butyl 
isocyanide. As this transformation is not affected by the free amine on the 
intermediate thiophene 156, the product thioimidates could also be further 
derivatized by Cu/Pd-cocatalyzed amination of arylboronic acids, further increasing 
the chemical complexity in a one-pot, three-three stage reaction sequence. 





Scheme 43. Imidoylative Liebeskind-Srogl coupling of methyl heteroaryl thioethers followed by in-situ 
hydrolysis of the thioimidate yielding thioesters. 
Methyl heteroaryl thioethers 158 can be subjected to imidoylative conditions to 
selectively afford thioesters 159 (Scheme 43).[66] It should be noted that without 
the Zn(OAc)2 additive no scrambling of various mixed methyl- and ethyl thioethers 
occurred, which suggests that the Lewis acidic zinc ion activates the thioether 
towards oxidative addition to the palladium catalyst. As the thioimidate product is 
hydrolyzed, only tert-butyl isocyanide was used in the reported examples. 
Homologation of thiocarbamates 160 with isocyanides was also reported.[67] 
Treatment of thiocarbamates with a palladium catalyst and aromatic isocyanides 
results in the transient palladium complex 162 as an active intermediate. In silico 
experiments indicate the isocyanide insertion proceeds in the labile Pd-S bond. 
 
Scheme 44. Pd-catalyzed isocyanide insertion into thiocarbamates. 
Subsequent reductive elimination affords the thioimidates 161 (Scheme 44). The 
isocyanide scope was not studied in detail and only 2,6-disubstituted aromatic 
isocyanides 98 were reported. Although the reaction tolerates different 
substituents on the thiocarbamate nitrogen, only S-arylated thiocarbamates were 
employed. Additionally, selenocarbamate analogues of 160 displayed similar 






Scheme 45. β-thiolated acrylonitrile synthesis from disulfide, t-butyl isocyanide and internal alkynes. 
Another unconventional Liebeskind-Srogl-type activation proceeds via the 
oxidative addition of disulfide 164 to the active Pd0 catalyst, followed by 
thiopalladation of the internal alkyne 163 (Scheme 45).[68] The resulting 
vinylpalladium species 167 can undergo isocyanide insertion, after which δ-hydride 
elimination of the intermediate imidoyl palladium species 168 affords the β-
thiolated acrylonitrile 165, isobutene, and a thiol, while regenerating the Pd0 
catalyst. Interestingly, the thiol byproduct does not poison the catalyst towards 
further catalytic turnover. Unfortunately, the E/Z-stereoisomeric ratio appears to 
be under thermodynamic control, and affords configurational mixtures in all cases, 
typically slightly favoring E-configured acrylonitriles 165. Only a single asymmetric 
internal alkyne was probed, affording total regioselectivity, but still similar mixtures 
of E/Z-stereoisomers. 
1.2.5. Imidoylation of Palladium-Ligated Carbenes and Nitrenes. 
In 2020, the seminal work of Cai[69] and coworkers on carbene transfers to 
palladium isocyanide complexes was significantly extended to a cascade version. In 
this carbene transfer, which was reported by the group of Liu, the bifunctional 
nature of tryptamine-derived isocyanides 169 was utilized in an elegant fashion 
(Scheme 46).[70] The authors propose a palladium-catalyzed carbene transfer of 
diazoacetate 170 to the isocyanide, affording the corresponding ketenimine 175, 
which readily undergoes dearomatization-spirocyclization upon nucleophilic attack 





Scheme 46. Pd-catalyzed carbene transfer from diazo compounds to tryptamine-derived isocyanides. 
of the indole C3-position, affording indolenines 172. Further intramolecular 
annulation pathways are available if functionalized diazoacetates 171 are used, 
affording tetracyclic indolines 173 in moderate to excellent yields. It should be 
noted that the products 172 were readily derivatized in a enantioselective manner 
through asymmetric Mannich-type cyclization with chiral phosphoric acids. 
 





Further advancements include generating the intermediate palladium carbene 
complexes in other ways than via diazo compounds. The palladium carbene 
complex 179 was obtained via a 5-exo-dig cyclization of conjugated enynones 176, 
presumably via the zwitterionic intermediate 178 (Scheme 47).[71] The carbene 
transfer to the isocyanides 95 proceeds smoothly, affording the polyfunctionalized 
furans 177 in isolated yields of 41-72 %. In this case, only aromatic 2,6-disubstituted 
isocyanides were converted.  
Analogously, starting from organic azides, the palladium-catalyzed transfers of 
nitrenes to isocyanide functionalities can be achieved. In a recent example, Sawant 
et al. reported a ligand-free substrate-dependent synthesis of bicyclic systems from 
bifunctional arylazide substrates.[72] Molecular nitrogen is readily extruded from 
the azide substrates to generate a palladium-bound nitrene intermediate 184, 
which is subsequently transferred to the isocyanide to afford the short-lived 
carbodiimide 185, which readily undergoes intramolecular addition (Scheme 48). 
The substrate scope includes both 2-azidobenzoic acids and amides 180, which 
afford the corresponding benzoxazinones and quinazolinones 182 in good yields. 
 
Scheme 48. Pd-catalyzed nitrene transfer from bifunctional arylazides to isocyanides. 
Additionally, 2-azidoanilines and 2-azido(thio)phenols can also be converted to the 
corresponding 2-aminobenzimidazoles, -oxazoles, and -thiazoles 183 in good yields. 
These syntheses were only attempted with tert-butyl and cyclohexyl isocyanide. 
Extensive DFT calculations indicate the rate-determining step is the loss of nitrogen 




from the azide-palladium complex. The resulting nitrene is transferred to the 
isocyanide, and the resulting carbodiimide undergoes cyclization to afford the 
heterocycles 182 and 183. In the same year, Ding et al. reported multiple one-pot 
post-imidoylation cascade transformations based on similar starting materials.[73] 
 
Scheme 49. Pd-catalyzed nitrene transfer from azide to isocyanides and subsequent [3+2] 
cycloaddition. 
This group further expanded the follow-up chemistry in a one-pot process.[74] The 
initial nitrene transfer of azide precursors 186 to isocyanides 5 under Pd catalysis 
proceeds in yields up to 90 %. Post-coupling with trimethylsilyl azide in the presence 
of FeCl3 affords the medicinally valuable 5-amino-1H-tetrazoles 187 (Scheme 49). 
This transformation tolerates tertiary, secondary and aromatic isocyanides 
affording the corresponding aminotetrazole 187 with full regioselectivity in good to 
excellent yields. However, only starting materials are isolated if aliphatic azides are 
employed. 
 
Scheme 50. 4-Component reaction towards pyrazolo[1,5-c]quinazolines, initiated by nitrene transfer 





An interesting 4-CR, initiated by palladium-catalyzed nitrene transfer of 2-
azidobenzaldehydes 190 to isocyanides selectively affords carbodiimide 192 
(Scheme 50).[75]  The authors postulate biscondensation with N-tosylhydrazine 189 
forms the zwitterionic quinazolines 193. Subsequent cyclocondensation with 
primary nitriles 188 yields tricyclic pyrazolo[1,5-c]quinazolines 191 bearing a free 
amine moiety. These products  exhibit high EGFR inhibition, and are thus of interest 
as potential anti-cancer agents. 
 
Scheme 51. 4-Component reaction towards pyrazolo[1,5-c]quinazolines, initiated by nitrene transfer 
from 2- azidobenzaldehydes to isocyanides involving olefins. 
Additionally, the formed zwitterionic quinazolines 193 can undergo reaction with 
other partners than nitrile. A silver-catalyzed annulation with alkynes 194 cleanly 
affords the tricyclic pyrazoloquinazolines 196 under remarkably mild conditions 
(Scheme 51).[76] The expulsion of p-toluenesulfinic acid  occurs upon aromatizating 
formation of product 195. If alkenes 195 are used in this 4-CR, the coupling 
generates the corresponding fused N-tosyl-tetrahydro pyrazoloquinazolines 197. 
 
1.2.6. Miscellaneous Pd0-Catalyzed Isocyanide Insertions 
Our group developed a quite uncommon sequential insertion of isocyanides and 
carbon dioxide.[77] This reaction proceeds via the Pd0-catalyzed imidoylation of o-
bromoaniline 12 to form imidoyl palladium complex 199 (Scheme 52). A relatively 
high CO2 pressure is required to prevent this intermediate from undergoing a 
second isocyanide insertion (see 81, Scheme 25), and favoring carboxylation. 
Subsequent reductive elimination affords the benzoxazinones 200, which undergo 
a Mazurkiewicz-Ganesan-type rearrangement under the optimized reaction 
conditions, resulting in the thermodynamically more stable substituted 
quinazolinediones 198. This multicomponent cross-coupling tolerates tertiary, 
secondary, and primary, (including benzylic) isocyanides. The yield of the 
quinazolinediones 198 does not depend on the type of isocyanide employed, but 
appears to be correlated to the electron density of the used aniline 12.  





Scheme 52. Sequential insertion of isocyanides and carbon dioxide in 2-bromoanilines. 
A similar methodology was simultaneously reported by Ji et al.[78] Recently, 
palladium immobilized on an aminated graphene oxide layer was utilized as a 
heterogeneous catalyst in this imidoylative MCR. This catalyst requires 2-
iodoanilines but the reaction can be executed at only 1 bar of CO2.[79] 
 
Scheme 53. Synthesis of imidoylcyanides via reaction of aryl halides and tert-butyl isocyanide. 
Another uncommon, but highly interesting formal cyanoimidoylation of aryl halides 
affords α-iminonitriles 202 through sequential isocyanide insertion/de-tert-





reductive elimination, regenerating Pd0. The reaction conditions are remarkably 
tolerant of various substituents on the aryl halide 201, including nucleophiles and 
heterocycles. However, introduction of an o-substitution significantly diminishes 
the yield. Again, the tertiary isocyanide functionality is required, as the reaction 
fails with other isocyanide substituents.  
Over the past couple of years, alkene insertions involving isocyanide insertion have 
become an increasingly popular method to generate chemical complexity. 
Currently, the only report of a true imidoylative Heck-reaction is shown in Scheme 
54, effectively inserting the isocyanide between the aryl halide and the activated 
alkene, in a tunable synthesis of iminoaurones.[81] 
 
Scheme 54. Imidoylative Heck-cyclizations (X = I, Br). 
The iminoaurones 206 are generated in good to excellent yields. Satisfyingly, the 
catalytic system functions without any ligands, and tolerates various aromatic 
isocyanides, as even the unstable 2-naphtyl isocyanide afforded the corresponding 
iminoaurone in 54% yield. Post-coupling hydrolysis with aqueous HCl cleanly 
affords the corresponding aurones 207 with virtually no loss in yield. Curiously, 
when 2-bromophenoxyacrylates 205 were used, the main product was the 
dihydrobenzofuran 208. The authors showed that β-hydride elimination leads to 
the HPdBr, which does not undergo reductive elimination as readily as its iodide 
analogue, but rather transfers a hydride to the newly formed imine. 
Dihydrobenzofurans 208 were isolated in moderate yields, and only tertiary 
isocyanides were tolerated. 





Scheme 55. Imidoylative cross-couplings through alkene insertion/isocyanide insertion/reaction with 
nucleophiles. 
Intramolecular alkene insertion preceding imidoylation are more common. Bringing 
alkenes in close proximity to an in situ formed aryl palladium species typically leads 
to 5-exo-dig carbopalladation. In the absence of β-hydrogens, no β-hydride 
elimination (Heck reaction) can occur, and the formed alkylpalladium intermediate 
210 instead undergoes imidoylative cross-couplings. As two insertions selectively 
and sequentially occur we treat these examples in this miscellaneous section. The 
group of Zhu communicated several excellent examples of this reactivity, reporting 
a series of palladium-catalyzed reaction cascades. Intramolecular alkene insertion 
in N-(2-iodoaryl)acrylamides 209 delivers  common intermediates 210, which can 
undergo an isocyanide insertion (Scheme 55). Subsequent cross-coupling with 
oxadiazoles 211 involving C-H activation gave the ketones 213 after acid-mediated 
hydrolysis of the formed imine.[82] The authors further highlight the divergent 
nature of this cascade by changing the nucleophilic coupling partner. Utilization of 
KOH as a nucleophilic base affords the amides 214, whereas the use of alkoxides 
leads to formation of the corresponding esters 215. Additionally, substituting tert-
butyl isocyanide for aromatic 2-acetoxyphenyl isocyanide 212 in which the 
acetylated phenol itself acts as a coupling partner, affording benzoxazoles 216 in 
good yields. This specific transformation might also result from of the base-





isocyanide insertion occurs. Additionally, using the chiral DuanPhos ligand, the 
authors could also isolate analogs of amides 214 with up to 75% ee. 
 
Scheme 56. Imidoylative cross-couplings through alkene insertion/isocyanide insertion/reaction with 
nucleophiles. 
Allenes can also be employed in these type of cascade transformations. The 
intramolecular carbopalladation of the distal double bond in N-protected N-allenyl-
2-iodoanilines 217 proceeds selectively prior to isocyanide insertion.[83] The authors 
highlighted the divergent value of the synthetic method by trapping the 
intermediate ketenimine 220 with nucleophilic species such as water (Scheme 56). 
As a proof of concept, the intermediate 220 was also reacted by azides, alcohols 
and amines to afford tetrazoles, esters, and amidines, respectively. Unfortunately, 
this transformation is only successful with tertiary isocyanides.  
Very recently, Jiang et al. reported the first dearomative imidoylation of indoles[84] 
extending their earlier work with alkenyl isocyanides.[85] Combining readily 
available N-(2-bromobenzoyl)indoles 221, with these alkenyl isocyanides 222 gives 
a cascade reaction. The dearomative intramolecular carbopalladation outcompetes 
direct isocyanide insertion, forming the tetracyclic intermediate 224 (Scheme 57). 
Subsequent isocyanide insertion, and intramolecular Heck-type cyclization of the 
formed imidoyl-palladium species 225 afford s indolines 223. 





Scheme 57. Dearomative imidoylation of indoles. 
Unfortunately, the isocyanide requires slow addition over the course of the 
reaction, and the final Heck-cyclization is only successful if α-allyl isocyanoacetates 
are used. Longer or shorter tethers between the alkene and isocyanide moieties do 
not result in any product formation. 
 
Scheme 58. Reductive Pd-catalyzed isocyanide insertion using triethylsilane. 
In 2014, the first reductive synthesis of aldehydes through a hydroimidoylation of 
aryl halides 5 was reported.[86] Although the reductive isocyanide insertion was only 
performed using tert-butyl isocyanide, the aryl halide input was varied extensively, 
affording aldehydes 227 in good to excellent yields, regardless of the steric or 
electronic influence of the arene substituents (Scheme 58). Triethylsilane 226 gives 
the best results, although other silanes also afford the target benzaldehydes. The 





intermediate imidoylpalladium species, but does not undergo reductive side 
reactions with the product aldimines . These aldimines undergo spontaneous 
hydrolysis upon aqueous workup.  
 
Scheme 59. Reductive Pd-catalyzed isocyanide insertion using sodium formate. 
A similar reductive isocyanide insertion generates benzaldehydes 227 from aryl 
iodides 5 (Scheme 60).[87] In this case sodium formate was found to be an effective 
reducing agent in polar solvents, allowing for the isolation of the product  
 
Scheme 60. Imidoylative synthesis of 2-(benzofuran-3-yl)quinoxalines. 
benzaldehydes in good yields, regardless of the aryl substitution pattern. Post-
imidoylative hydrolysis of the aldimines occurred spontaneously upon extraction of 
the crude mixtures. The use of aryl bromides typically led to diminished yields, even 
under prolonged reaction times. A divergent palladium-catalyzed synthesis of 
substituted 2-(benzofuran-3-yl)quinoxalines 230 has been shown quite effective.[88] 
The redox-neutral cross-coupling is initiated by the oxidative insertion of Pd0 into 
the allyl phenyl ether, which initiates a 5-endo-dig cyclization, furnishing the 
corresponding benzofuran palladium species (Scheme 60). For reasons that remain 




uninvestigated, this specific imidoylation proceeds through a double isocyanide 
insertion. Curiously, the resulting diimine complex 231 undergoes 
protodemetalation rather than hydroxylation. The authors did not investigate 
whether this process releases allyl alcohol or N-tert-butyl but-3-enamide as a 
byproduct. The formed glyoxal diimines 232 are subjected to sequential hydrolysis 
with aqueous HCl and biscondensation with phenylenediamines in a three-stage 
reaction. Additionally, the authors showed the versatility of this imidoylative 
synthesis by replacing the diamine condensation several oxidative follow-up 
reactions.  
A novel imidoylative Liebeskind-Srogl-type reaction, with interesting mechanistic 
implications was reported recently.[89] Oxidative insertion of Pd0 into the thioether  
 
Scheme 61. Imidolyative synthesis of 5-hydroxylated γ-lactams. 
233, and subsequent isocyanide insertion affords intermediate 236, which is 
reduced by triphenylsilane, producing the enimine 237 (Scheme 61). The authors 
postulate that this enimine is the final product of the reaction, and only oxidizes to 
the oxaziridine upon aerobic workup, which rearranges to the lactams 235. The role 
of the water in this process is not fully understood. The resulting 5-hydroxy-γ-
lactams are isolated in good to excellent yields, although the use of 
isocyanoacetates 234 is critical in this transformation. The use of alkyl isocyanides 
led to uncyclized acrylamide analogs through a hydroxyimidoylation, whereas 





1.3. PdII-Catalyzed Isocyanide Insertions 
1.3.1. Introduction 
The use of PdII as an active catalyst in cross-couplings involving isocyanide insertions 
largely concerns oxidative imidoylations. This allows the use of non-preactivated 
substrates. An oxidant is required to close the catalytic cycle. Conceptually, these 
reactions can be considered much more environmentally friendly, although in 
reality this may depend on the reoxidizing agent used. In general, for scale-up 
purposes, oxidants which are cheap, low in mass, only produce benign by-products 
which can be safely disposed are preferred, such as O2, H2O2, NaOCl, AcOOH, and t-
BuOOH.[90] A generalized catalytic cycle is characterized by a nucleophilic  
 
Scheme 62. General catalytic cycle for cross-coupling via oxidative isocyanide insertions. 
displacement of an anionic ligand from the active PdII catalyst, generating complex 
I (Scheme 62). Subsequent 1,1-migratory insertion of the isocyanide affords the 
imidoyl palladium species II, which is similar to the mechanism described in Scheme 
1. Intermediate II can undergo a second nucleophilic displacement, upon which the 
intermediate III affords the reaction product upon reductive elimination. Finally, an 
oxidizing agent is needed to regenerate the active PdII catalyst. It should be noted 
that nucleophile has to be interpreted in the most general meaning, i.e.  C-H 
activation can also give access to a Pd-C covalent bond without altering the 
oxidation state, still allowing for the formation of intermediates I and III.  
 
1.3.2. PdII-Catalyzed Intermolecular Oxidative Isocyanide Insertions 
A direct synthesis of benzamides 240 from arenes 239, isocyanides 13 and water 
was recently reported by Akbari et al. (Scheme 63).[91] This C-H functionalization 




takes place on the most electron-rich position, implying an electrophilic aromatic 
substitution with the active palladium(II) species for C-H activation, i.e. through 
intermediate 242 rather than 241, although the mechanism has not been fully 
elucidated. The authors believe that imidoylation of the afforded aryl palladium 
intermediate generates 243 which yields benzamides 240 upon reaction with 
water. (NH4)2S2O8 was used as the terminal oxidant. Peroxydisulfates are cheap 
oxidants produced on large scale in in industry, mainly used to initiate 
polymerization and to etch metal.[92] This oxidative amidation exhibits a remarkable 
tolerance with regards to the isocyanide scope, as aliphatic, benzylic, aromatic, and 
α-acidic isocyanides all afford the benzamides 240 in good to excellent yields. 
 
 
Scheme 63. Oxidative C-H functionalization of arenes with isocyanides and water. (X = OAc) 
The group of Yu reported an efficient C(sp2)-H imidoylation using N-
methoxybenzamides 245 as a substrate and a directing group for the rate-
determining C-H activation.[93]  The active catalyst 247 is was later proposed[94] to 
deprotonate the hydroxybenzamide, forming palladium carboximidamide 
intermediate 248. The authors found the rearrangement is not a post-imidoylative 
Mazurkiewicz-type process but rather occurs via an acyl-migration in this 






Scheme 64. Oxidative C-H functionalization of N-methoxybenzamides with isocyanides providing 
iminophthalimides. 
undergoes C-H activation to 250 and reductive elimination. This reaction tolerates 
many different substitutions on the benzamide, and also affords the corresponding 
fused iminophthalimides 246 when heterocyclic N-methoxyamides are employed. 
However, only t-BuNC was used as an isocyanide input. The reaction still affords 
iminophthalimides 246 when the benzamide ring is substituted with other potential 
directing groups, known to facilitate C-H functionalization. The products 246 are 
susceptible to catalytic hydrogenation, affording isoindolin-1-ones, effectively 
using isocyanides as a formal CH2-donor. 
 
Scheme 65. Double isocyanide insertion using triaryl bismuth reactants.  
An example of a selective formal double isocyanide insertion is shown in Scheme 
65, using an unconventional triarylbismuth reactant 252 as a transmetallating 
agent. The authors propose that selective formation of the bisimine product 253 




proceeds via Pd species 254.[95] The reaction is significantly more effective under air 
atmosphere, implying reoxidation of Pd0 is more efficient with molecular oxygen 
than with Bi(OAc)3. Surprisingly, cross-coupling with arylbismuths 252 tolerates 
various isocyanides, inserting aliphatic, benzylic, and even aromatic isocyanides in 
an effective manner.  
The oxidative Pd-catalyzed synthesis of iminomaleimides 257 from alkynes, tert-
butyl isocyanide and one equivalent of water has been reported. Electronically and 
sterically diverse alkynes 256 are compatible with the devised methodology, 
although no internal alkynes were included.[96] The authors propose copper acetate  
 
Scheme 66. Iminomaleimides from two isocyanides, water and terminal alkynes (X = OAc, Cl). 
acts solely as an oxidant, although the possible catalytic activity towards the 
proposed intermediate 258 was not investigated in more detail. As copper is added 
in a catalytic amount air functions as the terminal oxidant. External attack of a 
second isocyanide is hypothesized to form the cationic intermediate 259. While this 
transformation was successful with tertiary isocyanides, all other isocyanides failed 
to give the corresponding N-substituted analogs of 257 (Scheme 66). 
The same year, it was reported that maleimides 260 can be synthesized via a similar 
oxidative double imidoylation of internal alkynes 163 affording the corresponding 
maleimides 260 in good yields (Scheme 67).[97] Air acts as terminal oxidant. In this 
particular reaction various substituents on the alkyne are well tolerated, as even 






Scheme 67. Maleimides from two isocyanides, water and alkynes. 
Due to the hydrolytic cleavage of the imine, forming the symmetrical maleimides 
260 are always obtained, no investigations were made into the regioselectivity of 
this coupling. Finally, the compatibility with tertiary, secondary, and primary 
isocyanides is high, but no further investigations into the isocyanide scope were 
performed. The same group later reported a similar transformation to phthalimides 
from o-bromobenzonitriles.[98] 
 
Scheme 68. Imide snthesis from alkynes, isocyanides and sodium carboxylates. 
Follow-up chemistry using this reaction involved the trapping of the transient 
yniminyl palladium species with carboxylates (Scheme 68).[99] Curiously, the 
utilization of carboxylates as coupling reactants rather than water does not lead to 
a nucleophilic attack of a second isocyanide, as observed above (Scheme 67). 
Instead, reductive elimination affords the O-acylimidate intermediate 265, which 
can undergo a Mumm-type intramolecular acyl transfer to generate the product 
imides 263. This transformation is highly compatible with primary and aromatic 
alkynes, as well as with benzylic and aromatic isocyanides. Although this method is 
highly compatible with benzylic or aromatic isocyanides, this specific 




transformation did not afford any product when tertiary or secondary aliphatic 
isocyanides were used. Also in this case air acts as the terminal oxidant reoxidizing 
Pd0. 
Another interesting Pd/Ag dual catalytic method was reported for the synthesis of 
enol esters 267.[100] The reaction is initiated by the insertion of the terminal alkyne 
256 into the silver carboxylate, generating intermediate 269 (Scheme 69). 
Transmetalation to PdII, and subsequent hydroxyimidoylation affords the product 
267 in moderate to good yields. 
 
Scheme 69. Oxidative Pd/Ag dual-catalyzed synthesis of α-acyloxyacrylamides. 
The formed Pd0 is readily reoxidized by the presence of stoichiometric Ag2O. Silver 
therefore plays a dual role here. This reaction is highly compatible with aliphatic 
and aromatic alkynes, however, when α-acidic isocyanoacetates are employed, no 
product is observed.  
In 2013, Zhu et al. communicated an indole-3-carboximidamides synthesis from N-
trifluoracetyl-2-alkynylanilines 271 via a 5-endo-dig cyclization, and subsequent 
aminoimidoylation.[101] O2 is used as terminal oxidant. This oxidative cyclization is 
compatible with various aromatic substituents, regardless of the electronic nature 
(Scheme 70). Both secondary and primary amines 272 (R5 = H) are also readily 
converted to the corresponding amidine, but the use of aromatic amines leads to 






Scheme 70. Oxidative Pd-catalyzed 5-endo-dig cyclization followed by aminoimidoylation. 
Although secondary and primary isocyanides are tolerated, the yields decrease 
dramatically when these non-tertiary isocyanides are used (39-45 %). It is likely that 
aqueous workup leads to rapid hydrolysis of the initial N-trifluoroacetylated indole 
product. 
 
Scheme 71. Oxidative Pd-catalyzed formation of N-acylguanidines using amides and isocyanides. 
Additionally, an oxidative aminoiminoylation of primary amides 274 affords the 
substituted N-acylguanidines 275 (Scheme 71).[102] This reaction was only tried with 
tert-butyl and cyclohexyl isocyanides, and proceeds rapidly, using air as the 
(re)oxidant. An equivalent of amine is formed by the known[103] oxidation of 
isocyanide to isocyanate, and its subsequent hydrolysis, effectively using the 
isocyanide as a dual reactant. 
A different approach to the utilization of isocyanide as dual reactant is shown in 
Scheme 72. The cationic intermediate 278 is generated via a 6-endo-dig cyclization 
of t-butyl(2-alkynyl)benzaldimines, facilitating the anti-iminopalladation. 
Subsequent isocyanide insertion provides an imidoylpalladium species 279 that 
dealkylates affording the 4-cyanoisoquinoline 277. Regeneration of the PdII catalyst 
occurs via oxidation with silver triflate.[104] Although cyanations with isocyanide as 
a CN-donor typically utilize tert-butyl isocyanide, due to its relatively facile 
dealkylation, this transformation also affords 277 if cyclohexyl isocyanide is  





Scheme 72. 3-Cyanoisoquinoline synthesis via a 6-endo-dig cyclization/isocyanide insertion/double 
dealkylation cascade. 
inserted, albeit in somewhat lower yields. Additionally, if the solvent contains 
trace amounts of water, hydroxyimidoylation is preferred over dealkylation, 
affording the corresponding isoquinoline-4-carboxamides. 
 
Scheme 73. 3-Cyano-N-methylindole synthesis through an anti-palladation/isocyanide 
insertion/dealkyation cascade. 
Similarly, the formation of 3-cyano-N-methylindoles 281 occurs through a one-pot 
5-endo-dig palladation/imidoylation/dealkylation/demethylation cascade from 2-
alkynyl-N,N-dimethylanilines 280 and isocyanides (Scheme 73).[105] A similar 
intermediate imidoyl palladium species as shown above (Scheme 72) is involved. 
Lack of a suitable coupling partner initiates R3 dealkylation. Here too, dealkylation 
occurs if tert-butyl- or cyclohexyl isocyanide is used. The authors do not comment 






Scheme 74. Pd/Cu co-catalyzed formation of benzamides or biaryl ketones. 
Finally, intermolecular oxidative imidoylative cross-couplings can also be initiated 
by the addition of a boronic acid to an active PdII catalytic center. This effectively 
generates an aryl palladium intermediate (similar to Scheme 1) that readily 
undergoes 1,1-migratory insertion of an isocyanide. Such an imidoylation can take 
place under Pd/Cu co-catalysis, as evidenced by the divergent synthesis of 
benzamides 283 or biaryl ketones 284 in Scheme 74.[106] Equimolar amounts of 
arylboronic acid 282 and isocyanides 13 afford the benzamides 283 where the 
intermediate imidoyl palladium species is quenched with ambient water. The 
authors propose that Cu(OH)2 serves to reoxidize the palladium catalyst, but no 
actual experimental study towards the role of copper in this mechanism was 
conducted. The isocyanide scope for this amidation is broad, tolerating aliphatic, as 
well as benzylic isocyanides. Aromatic isocyanides are also compatible with this 
amidation, even generating phenyl benzamide in 50 % isolated yield, starting from 
the notoriously hard to handle phenyl isocyanide. On the other hand, when this 
reaction is performed with 5 equivalents of boronic acid under mild acidic 
conditions, an imidoylative Suzuki-type homocoupling is observed, affording 
biarylketones 284 after in situ hydrolysis. Although the isocyanide is cleaved off, the 
authors showed that this homocoupling is compatible with several isocyanides, 
mirroring the efficiency shown for the synthesis of benzamides 283.  
Isocyanide insertion can be used in the acetoxyimidoylation of boronic acids 282, 
utilizing t-BuNC as a C1 donor and subsequent hydrolysis (Scheme 75).[107] The 
carboxylic acids 285 were formed in good yields, regardless of the electronic nature  





Scheme 75. Synthesis of benzoic acids from arylboronic acids using isocyanides as a C1 building block. 
of the boronic acid. The reaction is sensitive to water during the cross-coupling, but 
hydrolysis of the formed intermediate 286 occurs upon quenching. The Cu(OAc)2 
additive acts both as a stoichiometric oxidant to reform the active Pd(II) species, 
and as an acetate donor in the formation of 286. No isocyanide variations were 
studied besides tert-butyl isocyanide.  
 
Scheme 76. Pd-catalyzed Buchwald-Hartwig imidoylation followed by copper-mediated 5-endo-dig 
cyclization. 
Pd-catalyzed imidoylative Buchwald-Hartwig reaction can also be combined with a 
cascade transition metal-catalyzed cyclization.[108] Transmetalation with 





palladium species 290, which is subsequently trapped by the nucleophilic 2-
alkynylaniline 296 (Scheme 76). The formed intermediate amidine 291 undergoes 
a copper-mediated 5-endo-dig cyclization to afford the substituted N-
imidoylindoles 289 in varying yields. Copper also acts as a reoxidant for Pd0. The 
yields drop most noticeably when labile substituents are introduced on the boronic 
acid. The authors attempted a single deviation from tertiary isocyanides as a 
substrate, affording the corresponding product 289 in 53 % when cyclohexyl 
isocyanide is used. Aromatic isocyanides are incompatible with this methodology. 
1.3.3. PdII-Catalyzed Intramolecular Oxidative Isocyanide Insertions 
 
Scheme 77. Oxidative isocyanide insertion into anthranilic acids 
Our group reported one of the first aerobic Pd-catalyzed formation of 
benzoxazinones 293 through the direct coupling of anthranilic acids 292 with 
isocyanides (Scheme 77).[109] The reaction is compatible with several secondary and 
primary isocyanides, although utilization of non-tertiary isocyanides leads to a 
moderate yield of 293, even at higher catalyst loadings (10 mol%). 
 
Scheme 78. Oxidative isocyanide insertion into anthranilamides formed from isatoic anhydrides and 
amines. 




Such bisnucleophilic substrates can also be generated in situ (Scheme 78). The 
condensation of isatoic anhydrides 295 with various aliphatic or aromatic amines 
294 can be followed by addition of isocyanide and a palladium catalyst, without 
isolation of intermediate 297 or solvent switches, to afford 2-aminoquinazolinones 
296 in a one-pot process.[110] For this palladium-catalyzed imidoylation silver 
carbonate was found to be the optimal terminal oxidant. Unfortunately, while the 
reaction does appear to be fully compatible with tertiary and secondary 
isocyanides, the isocyanide scope was not extensively investigated. 
 
Scheme 79. Oxidative isocyanide insertion into (N-acetylated) benzhydrazides. 
An aerobic oxidative Pd-catalyzed imidoylative cross-coupling towards oxadiazoles 
300 was performed by Fang et al.[111] Interestingly, the reaction is much more 
effective when N-acetylated benzhydrazides 298 are used, compared to N-H free 
hydrazides (299, R2 = H), although no explanation is offered. The acetylated 
oxadiazoles hydrolyze towards oxadiazoles 300 upon aqueous workup. 
Additionally, the incorporation of a substituent to the terminal nitrogen of the 
hydrazide 299 does not hamper the formation of the corresponding oxadiazol-
2(3H)-imines 301 (Scheme 79), which have been reported as angiotensin II 
antagonists, and are typically difficult to prepare via other procedures.[112] Although 
the reaction is compatible with tertiary and secondary isocyanides, phenyl 






Scheme 80. Oxidative isocyanide insertion into 2-aminostyrenes. 
Similarly, electron-rich o-aminostyrenes 304 can also be subjected to oxidative 
isocyanide insertion, generating the 2-aminoquinoline scaffold (Scheme 80).[113] 
The reaction is initiated by coordination of the aniline to the active PdII complex. 
The aminoquinolines 305 are obtained in lower yields if electron-withdrawing 
aromatic substituents (R1) are present. Limited studies have been performed 
towards the tolerance for isocyanides. When primary or secondary aliphatic 
isocyanides are used the 2-aminoquinolines 305 are obtained in moderate yields 
(48-61 %). Again, the reaction conditions proved incompatible with any aromatic 
isocyanides. 
 
Scheme 81. Oxidative imidoylation of 2-indazolylphenol and -aniline. 
Treatment of electron-rich 2-indazol-2-yl phenols and –anilines were treated with 
isocyanides under aerobic oxidative conditions, in the presence of a palladium 
catalyst furnished the corresponding tetracyclic fused indazole scaffolds 307.[114] 
While the synthesis of indazolo[2,3-a]quinoxalines 307 is relatively harsh, the use 
of 2-indazolylphenol (306, Y = O) affords the corresponding cycloimidate product 
308 in up to 98% yield, and does not require the addition of either copper, or 
Cs2CO3. In all cases, only tert-butyl and cyclohexyl isocyanide were successfully 
converted to the tetracyclic scaffolds 307 and 308.  





Scheme 82. Oxidative isocyanide insertion in N,1-diarylethan-1-imines featuring double C-H 
functionalization. 
In 2013, our group reported the first palladium-catalyzed imidoylative double C-H 
functionalization of N,1-diarylethan-1-imines 309, affording the useful 4-
aminoquinoline scaffold.[115] Although the yields of 4-aminoquinolines 310 are low, 
we were able to specifically direct imidoylative cross-coupling to two carbon 
nucleophiles, using molecular oxygen as a sustainable stoichiometric sustainable 
oxidant (Scheme 82). The yield of aminoquinazolines 310 decreases to only 13 % if 
isopropyl isocyanide is employed (1 example). 
 
Scheme 83. Substrate-dependent oxidative isocyanide insertion into N-arylenaminones. 
Interestingly, a substrate-dependent chemoselective transformation with N-
arylenaminones 311 was communicated by Luo et al. (Scheme 83).[116]  Tertiary 
aliphatic isocyanides afford the carboxamides 313 via hydroxyimidoylation, which 
was later corroborated by Luo et al.[117] However, the use of aromatic isocyanides 





via the C-H functionalization of enaminone 311 and subsequent isocyanide 
insertion, affording the common intermediate imidoyl palladium species 314. Bulky 
aliphatic isocyanide substituents induce a rapid ligand exchange between chloride 
and water in intermediate 314, affording 316. The 1,3-palladium migration was only 
observed in palladacycles 314 generated with aromatic isocyanides. The palladium 
N to C migration forms intermediate 315, which affords tacrines 315 in up to 60 % 
yield (Scheme 83).  
1.3.4. Miscellaneous PdII-Catalyzed Isocyanide Insertions  
Imidoylations can also occur through metal-induced cyclization and exo-palladation 
of unsaturated substrates, generating a heteroaryl palladium intermediate. These 
intermediates can undergo various imidoylative cross-coupling, similar to examples 
mentioned above. These reactions are catalyzed by PdII, and proceed in a redox-
neutral manner, as such, these methods do not require an external oxidant to close 
the catalytic cycle.  
 
Scheme 84. Synthesis of cyanated aminopyrroles from substituted ynimines and isoycanides. (X = OAc) 
The synthesis of polysubstituted aminopyrroles proceeds via a palladium(II)-
catalyzed cycloimidoylation of ynimines 317 (Scheme 84).[118] The isocyanide has a 
dual purpose, acting as a C1 building block in the initial formal [4+1] cycloaddition 
to form intermediate 319, and as a cyanation source through de-tert-butylation of 
320, obtained via isocyanide insertion into the C-Pd bond of 319. The authors 
propose a mechanism in which the palladium hydride expelled in the de-tert-
butylation of 320 acts as a hydride donor (rather than undergoing reductive 




elimination), thus reducing the cationic intermediate 321, thereby affording 
aminopyrroles 318, and regenerating Pd(OAc)2. While tert-octyl isocyanide is 
equally well tolerated, the reaction is incompatible with the use of primary or 
secondary aliphatic isocyanides. Deuteration studies indicate the aminopyrrole NH 
proton originates from the tert-butyl fragment, explaining the reason behind this 
incompatibility.  
Another report communicated a similar synthesis of 2-aminoquinoline from N-
trifluoroacetylated ortho-alkynylanilines 322 and isocyanides.[119] In this study, the 
authors postulate that amination of the PdII catalyst is followed by isocyanide 
insertion, generating intermediate imidoyl palladium species 324, which is 2 
bonded with the alkyne (Scheme 85). 
 
Scheme 85. Synthesis of 2-aminoquinolines from orho-alkynylanilines and isocyanides. (X = OAc) 
This intermediate subsequently undergoes an anti-carbopalladation presumably 
involving a second Pd(II) complex. The formed bicyclic carbopalladate 325 affords 
the 2-aminoquinolines 323 upon  protodemetalation and intramolecular acyl 
migration (endo- to exocyclic nitrogen). This imidoylative annulation works well 
with tertiary isocyanides. A single secondary isocyanide was also attempted, 






Scheme 86. Synthesis of benzofurans via Pd-catalyzed 5-exo-dig cyclization and isocyanide insertion. 
The same group later used this methodology to access tricyclic systems through 
further functionalization of the intermediate 325.[120] 5-Exo-dig cyclization of 2-(1-
hydroxyprop-2-yn-1-yl)phenols 326 and subsequent imidoylation affording 
intermediate imidoyl palladium complex 328 is proposed to lead to benzoxazoles 
327 (Scheme 86). Transformation of 328 into 327 is proposed to occur via 
cycloalkoxylation in 328 and subsequent Pd-mediated reductive ring-opening. 
However, full elucidation of the reaction mechanism was not performed, and 
therefore alternate mechanisms cannot completely be excluded. This 
transformation is equally successful with tertiary and secondary isocyanides, 
although the scope was not further investigated. Similarly, trifluoroacetylated 
aniline analogs 329 react towards indoles 330 under nearly identical conditions 
(Scheme 87). In this case, the trifluoroacetamide undergoes post-hydrolysis by 
atmospheric moisture, releasing N-unsubstituted indole derivatives 330. This 
indole formation was only attempted with tertiary isocyanides.[121] 
 
Scheme 87. Synthesis of indoles via Pd-catalyzed 5-exo-dig cyclization and isocyanide insertion. 





Palladium-catalyzed cross-coupling reactions involving isocyanide insertions have 
matured significantly over the past decade.  With an increasing number of 
intermolecular examples, it is clear the scope of the coupling partners has also 
increased significantly, as new types of imidoylations catalyzed by palladium are 
still being reported. The main bottleneck in utilizing palladium for isocyanide 
insertions still appears to be the unpredictable compatibility of various 
functionalized isocyanide reactants. Although here too some impressive 
advancements have been made, extension from tertiary to other isocyanides is still 
challenging. Additionally, imidoylative cross-couplings are increasingly compatible 
with other occurring cascade processes, opening new avenues for the ever-
improving generation of molecular complexity in a single reaction vessel. With the 
progress in this field made, there have been more and more cases of imidoylative 
MCRs where the cross-coupling partners no longer need to be linked to achieve 
high selectivity and efficiency. Continued improvements on all these facets of 
palladium-catalyzed isocyanide insertions are necessary to increase the synthetic 
applications of these transformations, and to utilize imidoylative pathways in 
medicinally relevant synthetic procedures. It is our hope that the coming decade 
will see further improvements in the field of palladium-catalyzed imidoylations, 
leading to even more robust reactions, i.e. allowing milder reaction conditions and 
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Base Metal-Catalyzed Isocyanide Insertions 
 
Abstract: Isocyanides are diverse C1 building blocks given their potential to react 
with nucleophiles, electrophiles and radicals. Therefore, perhaps not surprisingly, 
isocyanides are highly valuable as inputs for multicomponent reactions (MCRs) and 
other one-pot cascade processes. In the field of organometallic chemistry, 
isocyanides typically serve as ligands for transition metals. The tuneable reactivity 
of the isocyanide functional group by transition metals has evolved into numerous 
useful applications. Especially palladium-catalyzed isocyanide insertion processes 
have emerged as powerful reactions in the past decade. However, hitherto, reports 
on the use of earth abundant and cheap base metals in these type of 
transformations are scattered and received far less attention. This chapter focuses 
on these emerging base metal-catalyzed reactions and highlights their potential in 
synthetic organic chemistry. Although mechanistic studies are still scarce, we 
discuss distinct proposed catalytic cycles and categorize the literature according to 
(i) the (hetero)atom bound to and (ii) the type of bonding with the transition metal 
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2.1.1  From Noble to Base Metals 
Transition metal catalysis is an established and highly efficient method for the 
formation of C-C bonds. Although palladium (Pd) is still the most widely employed 
transition metal (TM), row IV base metals are rapidly emerging as equally (or more) 
efficient alternatives.[1] Although catalyst loadings are often still high, the large 
earth-abundance and low cost of base metals compared to Pd make them highly 
attractive from an economic standpoint (Table 1) Ligand design will play a major 
role in further development of these catalysts.[2] Isocyanides (RNCs) are versatile 
building blocks for the synthesis of small molecules, and have found widespread 
use in medicinal[3] and combinatorial chemistry.[4] Most prominently, RNCs are 
highly valuable for multicomponent reactions (MCRs) and one-pot cascade 
processes in the context of diversity oriented synthesis.[5] More recently, RNCs have 
also been utilized in transition metal-catalyzed cross-couplings, exploiting their 
isoelectronic nature to carbon monoxide (Figure 1).[6]  
 
The interest in transition metal-catalyzed reactions involving isocyanides has 
increased significantly over the past decade (Figure 2).[9] Due to its predictable 
nature and well-defined catalytic reactivity, Pd in particular has been extensively 
investigated in these imidoylative couplings.[10] Despite the ubiquity of Pd in these 
imidoylative cross-couplings, recent studies increasingly employ base metal 
(complexes) as alternative catalysts. Apart from the economic benefits, base metals 
Table 1. Earth abundancy and bulk cost of row IV transition metals and Pd 
 
Group Metal Earth’s Crust Content (ppm)[7] Price (EUR/mol)[8] 
IV Ti 5600 0.21a 
V V 160 4.22a 
VI Cr 100 0.49a 
VII Mn 950 0.12 
VIII Fe 41000 0.004 
IX Co 10 3.17 
X Ni 70 0.62 
X Pd 0.01 4693.12 
XI Cu 100 0.35 
XII Zn 75 0.14 
a Mined and sold as the bulk ferrous metal 




are more likely to undergo single electron processes, whereas Pd participates in 
two-electron processes. 
 
Figure 1. Isoelectronic nature of RNCs and CO. 
This shift poses new challenges and introduces novel catalytic mechanisms of 
action that offer exciting opportunities for further reaction development.[11] In this 
chapter we would like to focus the attention of the synthetic organic chemist to 
promising base metal-catalyzed processes involving isocyanide insertion and 
highlight proposed mechanistic aspects of these interesting reactions. 
 
Figure 2. Number of publications reporting on isocyanide insertions since 1970. 
2.1.2.   Isocyanide Insertion pathways 
The term ‘isocyanide insertion’ is commonly used by organic chemists to describe 
TM-mediated or -catalyzed transformations, in which the isocyanide moiety is 




























































































































and does not suggest a mechanism. Upon studying the reported mechanistic 
proposals of the base metal-catalyzed imidoylation reactions, different insertion 
pathways affording the reactive imidoyl metal intermediate can be distinguished 
(Scheme 1). Firstly, 1,1-migratory insertion of the isocyanide into an in situ formed 
metal-carbon bond (1) furnishes the imidoyl metal species 2 (Type I, Scheme 1a, 
a1). Similarly, 1,1-migratory insertions of isocyanides into in situ formed metal-
hetero or carbon atom bonds, via transmetalation or coordination/deprotonation 
on TMn+2, have also been reported (Type I, Scheme 1a, a2, Y = C, N, O, S, etc.). 
 
Scheme 1. Isocyanide insertion pathways (Nu = nucleophile, El = electrophile). 
These insertion mechanisms have been studied extensively in imidoylative 
transformations[12], and are observed for most of the row IV base metals (Sc[13], 
Ti[14], V[15], Mn[16], Fe[17], Co[18], Ni[19] and Cu[20]). The isocyanide metal interaction is 
a coordinate covalent bond. The resulting imidoyl metal species 2 can react with a 




variety of coupling partners, including nucleophiles (oxidatively), electrophiles 
(redox-neutral), and radical acceptors in order to arrive at the overall insertion 
reaction product 3. In addition, the increased electrophilicity of coordinated 
isocyanides, especially when coordinated to higher-valent TMn centers (4), allows 
for direct attack of a nucleophile on the isocyanide carbon, resulting in imidoyl 
metal species 2 (Type II, Scheme 1b).[6a] This is similar to intermediate 2 in Type I 
insertion processes making Type I and II imidoylative pathways often 
indistinguishable. To date, theoretical and experimental investigations to clarify the 
exact mechanisms of imidoylative couplings are still limited.[21]  
Next to Type I and II pathways, various other base metal-catalyzed and mediated 
transformations involving carbene- or nitrene transfer have been referred to as 
isocyanide insertion reactions. From a mechanistic point of view, isocyanide 
migratory insertion occurs into the metal-carbon or metal-heteroatom -bond 
rather than the -bond, yielding metallacycle 6 and subsequently N-metalated 
ketenimine/carbodiimide 7. Upon reaction with a nucleophile product 3 is 
obtained. Therefore, these reactions can mechanistically be regarded as ‘formal 
insertions’ starting from the corresponding metal-nitrene or -carbene species 5 and 
they will be discussed in a different category (Type III, Scheme 1c). The use of 
isocyanides as radical acceptors in cyclization reactions will not be discussed in this 
chapter as these reactions were extensively reviewed by Studer in 2015.[22] These 
transformations are often not catalytic, applying the metal as a stoichiometric 
oxidant. Alternatively, a catalytic base metal can be used in combination with a 
stoichiometric organic oxidant. In both cases, there is mechanistically no insertion 
with a metal bound isocyanide involved, but again rather a formal insertion based 
on a radical relay cascade.  
This chapter aims to highlight the versatile insertion chemistry of isocyanides with 
first-row transition metals. To the best of our knowledge, all examples concerning 
isocyanide insertion known at the time of writing are included. The diverse 
examples of base metal-catalyzed imidoylations appearing in recent literature were 
categorized according to the TM species involved in the (formal) insertion 
proposals. The synthetic utility of these processes largely depends on the variety of 
isocyanides which can be used. Therefore, we point specific attention in the 
discussion to the scope regarding the isocyanides utilized, highlighting current 





are discussed, the different components have been color-coded so that the origin 
of the different atoms in the final products is easily recognized. 
2.2. Insertions of Isocyanides into Carbon-Metal Species  
2.2.1  Imidoylations initiated by oxidative addition of carbon halides 
One of the most facile and widespread ways of constructing C-TM bonds is the 
oxidative addition of aryl(pseudo)halides to low-valent transition metals. 
Subsequent imidoylation typically occurs via a 1,1-migratory insertion reaction of 
Type I into the preformed TM-C bond. An early example involving imidoylative 
cobalt catalysis was reported by Yamamoto et al. in 1991 (Scheme 2). Diiminofurans 
10 were obtained in moderate yields, although no optimization was reported. 
Mechanistic investigations imply that the active catalyst is a Co(I) species. Initial 
oxidative addition of α-bromoacetophenone (8) is followed by double isocyanide 
insertion. Then, intramolecular alkoxylation via the corresponding enolate and 
subsequent reductive elimination of intermediate 12 affords the diiminofurans 
10.[23] 
 
Scheme 2. Co(I)-catalyzed synthesis of diiminofurans 10. 
The group of Zhu reported a nickel-catalyzed synthesis of isocoumarins 15 and 3-
alkylidenephthalides 17 (Scheme 3). The reaction starts with oxidative insertion of 
Ni(0) into a C(sp2)-halide, followed by 1,1-migratory insertion of Type I. The 
resulting imidoyl nickel species undergoes intramolecular nucleophilic attack by an 
enolate similar to the reaction described in Scheme 2. Acidic hydrolysis of the 
iminolactone affords the products 15 or 17 in good to excellent yields.[24] The 




isocyanide was used as a CO surrogate and only tert-butyl isocyanide (14) was 
employed in these reactions. 
 
Scheme 3. Ni(0)-catalyzed alkoxyimidoylation. 
Wang et al. reported the synthesis of 2-substituted benzoxazoles (20) via a Ni-
catalyzed reaction (Scheme 4a).[25] The 3-CR proceeds via an imidoylative 
Buchwald-Hartwig-type reaction forming amidine 21, which subsequently 
undergoes intramolecular condensation.  
 
Scheme 4. Ni(0)-catalyzed aminoimidoylation/condensation cascade. 
Only t-BuNC (14) was used as a C1-donor. In addition, saturated 2-aminoalcohols 22 
afford the corresponding oxazolines (23) in good yields (Scheme 4b). The authors 
do not comment on the proposed formation of the active Ni(0) catalyst from NiCl2. 
The efficiency is competitive to the analogous Pd-catalyzed synthesis.[26] Recently, 





aminocarbonylation.[27] The mechanism presumably involves the oxidative addition 
of the aryl halide to the Cu(I) center. The use of aryl iodides or bromides (19a-b) 
affords benzamides 24 in excellent yields (Scheme 5). However, by employing aryl 
chlorides the yields were reduced significantly. Both secondary and tertiary 
aliphatic isocyanides were well tolerated in this reaction, but primary aliphatic 
isocyanides were not investigated. 
 
Scheme 5. Cu(I)-catalyzed hydroxyimidoylation of aryl halides. 
A similar transformation was accomplished by using aryldiazonium salts 25 (Scheme 
6). Again, secondary and tertiary aliphatic isocyanides were well tolerated.[28] The 
yields of the benzamides 26 were substantially lower than reported for the 
analogous process described in Scheme 5. However, the reaction does proceed at 
significantly lower temperatures, requiring a much lower catalyst loading. 
 
Scheme 6. Cu(I)-catalyzed hydroxyimidolyation of aryldiazonium salts. 
Another interesting Type I process furnishes 2-borylated indoles 29 from o-
isocyanostyrenes 28 under Cu(I) catalysis.[29] Utilizing boronic esters, rather than 
aryl halides, the in situ formed borylcopper species 30 undergoes 1,1-migratory 
insertion of isocyanide 28 to afford imidoyl copper species 31 (Scheme 7). 
Hereafter, alkene insertion and methanol-mediated protolysis afford the 2-
borylated indoles 29 in good yields. The copper-catalyzed reaction is compatible 
with diversely functionalized o-isocyanostyrenes 28, although electron-poor 
substrates give lower yields. The synthetic utility of product 29 was demonstrated 
by several post-cyclization modifications, including a highly efficient total synthesis 
of the kinase inhibitor paullone 33. 





Scheme 7. 2-Borylindole synthesis via Cu(I)-catalyzed coupling and application to the synthesis of 
Paullone (33) 
In a related process, the transmetalation of arylboronic acids 34 to Cu(II) salts 
furnishes aryl copper species 36. Subsequent 1,1-migratory insertion of isocyanide 
28 into the copper-carbon bond furnishes the imidoylcopper species 37 (Scheme 
8). This is followed by a cyclization and protodemetalation of intermediate 38 to 
afford the 2-arylated indoles 35.[30] The proton source is unclear here and the 
authors do not comment on it. The reaction tolerates electron-donating and 
electron-withdrawing substituents on both the boronic acid (34) and the isocyanide 
(28). However, 2-isocyanostyrenes without an electron-withdrawing group at the 






Scheme 8. Cu(II)-catalyzed borylation. 
2.2.2  Imidoylations initiated by C-H bond cleavage 
Direct C-H functionalization by transition metals is more attractive than using 
preactivated organo(pseudo)halides in cross-coupling chemistry and can be 
considered as a potentially more sustainable process.[31] Besides oxidative addition, 
other mechanisms for C-H bond cleavage forming a TM-C bond are possible (e.g. 
concerted metalation deprotonation (CMD), σ-bond metathesis). Subsequent 
isocyanide insertion into a TM-C bond then typically occurs via a Type I 1,1-
migratory insertion (Scheme 1). Although TM-catalyzed C-H bond functionalization 
combined with CO or isocyanide insertion is still dominated by Pd,[32] recently, 
significant advances have been made in analogous base metal-catalyzed processes. 
Already in 1987, Jones and coworkers reported the C(sp2)-H activation of benzene 
via oxidative addition using an electron-rich iron catalyst. Combination of the Fe(0) 
catalytic system shown in Scheme 9a with neopentyl isocyanide 39 and benzene 
affords the corresponding aldimine 40.[33] This reaction also proved successful using 
toluene or xylene instead of benzene. Curiously, this iron catalyst is inactivated if 
irradiation is halted. The authors propose a light-induced dissociation of isocyanide 
to the catalytically active Fe0(RNC)2(PMe3)2 complex 41 (Scheme 9b). Increasing the 
isocyanide concentration leads to formation of Fe(RNC)3(PMe3) via ligand 
exchange, inhibiting imidoylation. 





Scheme 9. Aldimine synthesis by Fe(0)-catalyzed imidoylation of arenes. 
The first cobalt-catalyzed imidoylative process involving C-H activation was 
reported in 2017. In this process, iminoindolinones 46 were obtained from 
benzamides 45 employing Ag2CO3 as the optimal stoichiometric oxidant (Scheme 
10a).[34] The oxidant brings the cobalt salt to the required oxidation state. The 
bidentate 8-aminoquinoline functionality is essential and serves as a directing 
group presumably initiating the formation of cobaltacycle 47. Though not 
mentioned, C-H cleavage presumably occurs via a CMD mechanism. Only t-BuNC 
and 2,6-xylyl isocyanide were used successfully in this transformation. 
The use of weakly acidic trifluoroethanol (TFE) as a solvent yields other products 
from benzamides 45 (Scheme 10b).[35] Interestingly, under these conditions 
another iminoindolinone isomer 49 was predominantly obtained. The key step in 
this reaction is most likely the oxidative alkoxyimidoylation of 45 to eventually form 
imidate 50. This involves an initial directing group assisted C-H activation via CMD 
and a 1,1-migratory insertion of the precoordinated isocyanide to afford 
intermediate 48. From this intermediate the authors propose that a reductive 
addition of TFE to the imidoyl-Co(III) moiety followed by protodemetallation, 





subsequently oxidized by Ag(I) to the active Co(III) species. Subsequent 
intramolecular transamidation of intermediate 50 furnishes product 49. 
 
 
Scheme 10. Co(III)-catalyzed amidoimidoylation of benzamides. (Q = 8-quinolinyl). 
Mechanistic studies measuring a kinetic isotope effect, adding a radical scavenger 
and experiments with isolated Co complexes support the catalytic cycle put 
forward. Interestingly, the C-H activation step was not found to be rate limiting. Gu 
and coworkers reported a similar transformation, employing t-BuOOH as an 
alternative oxidant (Scheme 11a).[36] Their conditions tolerate functionalized 
acrylamides 51 next to benzamides (45), although also only in combination with 
tertiary aliphatic and xylyl isocyanides. The chemoselectivity is sufficiently high to 
simultaneously tolerate the presence of other directing groups on substrate 51 (e.g. 
(di)azine, pyrazole), selectively affording quite a range of functionalized 




iminophthalimides 52 in moderate to excellent yields. The authors propose similar 
intermediates for this reaction towards 52 as were postulated for the imidoylative 
C-H functionalization reaction of benzamides 45 described above in Scheme 10. 
 
Scheme 11. Row IV-TM-catalyzed amidoimidoylation of benzamides and acrylamides (Q = 8-
quinolinyl). 
Starting from similar N-quinolinylbenzamides 45, a nickel-catalyzed C-H 
functionalization is also possible employing tert-butylperoxide as oxidant and 
provides the corresponding iminoisoindolinone 46 in reasonable yields (Scheme 
11b).[37] An intramolecular kinetic isotope effect of this Ni(II)-catalyzed reaction 
indicates that C-H cleavage is a kinetically relevant process (not necessarily the rate 
limiting step of the cycle). Though not mentioned it presumably occurs via a CMD 
mechanism. No radical mechanism seems to be involved based on studies using 
TEMPO addition. The reaction is, however, also quite limited in isocyanide scope 
(R2 = xylyl- or t-Bu). The first copper-catalyzed imidoylative C-H functionalization 
was reported by Miura et al. (Scheme 11c). Compared to the above Co- or Ni-
catalyzed processes this Type I imidoylative reaction requires harsher conditions 
and higher catalyst loadings.[38] The type and stoichiometry of the additives was 
optimized experimentally, although their exact role is unclear. The regioselectivity 
of this Cu(I)-catalyzed imidoylative C-H functionalization using 3-substituted 
benzamides 45 towards the corresponding iminoisoindolinones 46 is moderate to 
good (1.5:1 – 7.2:1). However, only xylyl and tertiary aliphatic isocyanides proved 
successful.  
Finally, a Type I 1,1-migratory insertion process was used to prepare 1,2,3-triazolo-





(Scheme 12).[39] The cycloaddition reaction of azide 54 and an in situ formed copper-
alkynyl species followed by intramolecular isocyanide insertion facilitates 
formation of the organocopper intermediate 57. The triazoloquinoxalines 55 are 
generated by subsequent protodemetalation with terminal alkynes concomitantly 
forming back the copper alkynyl species. Although the authors did not comment on 
the actual oxidation state of the active organocopper species in this reaction, Cu(I)-
catalysis seems likely. Both aromatic and aliphatic terminal alkynes are tolerated. 
The authors also report extensive Rh-catalyzed follow-up chemistry with the 
reaction products. 
 
Scheme 12. Triazoloquinoxaline (55) synthesis most likely catalyzed by Cu(I).  (AAC = azide-alkyne 
[3+2] cycloaddition) 
2.2.3  Imidoylations initiated by cyclometalation 
Cycloadditions are widely appreciated as effective C-C bond forming reactions.[40] 
In particular, the Pauson-Khand reaction is a well-known cycloaddition involving CO 
as a C1-reactant.[41] In relation to this, we discuss in the section below recent 
advances in combining in situ formed cyclometalates with isocyanides. These 
Pauson-Khand type processes are very interesting considering the involvement of 
multiple bond forming transformations generating relatively high levels of 
complexity in a single step. The insertion step proceeds via a Type I 1,1-migratory 
insertion into a TM-C bond. An early example of a Nickel-mediated Pauson-Khand 
type reaction involving an isocyanide in combination with tethered enynes was 
reported by Tamao and coworkers (Scheme 13).[42] The reaction presumably 
proceeds via coordination of the enyne (58) to the Ni(0)-center followed by 




oxidative cyclometalation to furnish nickelacycle intermediate 61. Subsequent Type 
I 1,1-migratory insertion of xylyl isocyanide (9) affords imidoyl nickel intermediate 
62, which can undergo reductive elimination to afford product 59. 
 
 
Scheme 13. Ni(0)-mediated imidoylative Pauson-Khand type reaction to enimines 59. 
Excess isocyanide poisons the Ni(0) catalyst, requiring stoichiometric Ni(cod)2 to 
bring the reaction to completion. A variant of the same reaction was reported by 
Zhang et al. (Scheme 14).[43] They used silyl cyanide 63, which is in equilibrium with 
its silyl isocyanide isomer (see Scheme 15), to keep the effective isocyanide 
concentration as low as possible, preventing poisoning of the Ni(0) catalyst. 
 
Scheme 14. Ni(0)-catalyzed imidoylative Pauson-Khand type reaction with silyl cyanides. 
Imidoylative Pauson-Khand type reactions have also been reported with other 
metals as exemplified by a titanocene(II) catalyst (Scheme 15).[44] Again, to prevent 
inhibition, the isocyanide concentration was kept low by employing silyl cyanide 63. 
Post-cyclization hydrolysis gave the corresponding bicyclic enones 64 in good 
yields. A hetero [2+2+1] Pauson-Khand type cycloaddition of 2-alkynylaryl 
isothiocyanates 68 and isocyanides yields thieno[2,3‐b]indoles 69 (Scheme 16). The 
cyclonickelate intermediate 70 is formed via oxidative cycloaddition.[45] Control 






Scheme 15. Ti(II)-catalyzed Pauson-Khand type reaction with silyl cyanides. 
generated in situ from the Ni(II) precursor without addition of an external reducing 
agent. Notably, the catalyst loading is low, and the reaction tolerates a broad range 
of aliphatic, aromatic and α-acidic isocyanides. The yield is somewhat lower for the 
notoriously unstable naphthyl isocyanide (60%), but in general this transformation 
proceeds with high efficiency. 
 
Scheme 16. Ni(0)-catalyzed imidoylative hetero Pauson-Khand-type reaction. 
Odom and coworkers communicated a three-component reaction of amines, 
internal alkynes and isocyanides to give enaminoimines 74, catalyzed by titanium 
catalyst 73 (Scheme 17).[46] With unsymmetrical alkynes, the regioisomers of 74 
depicted in Scheme 17 were formed in moderate to good (1.2:1 – 6:1) selectivity. 
The mechanism proceeds via a metathesis-like reaction of an alkyne (72) with the 
in situ formed titanium nitrene 75, forming azatitanacyclobutene 76.[47] Subsequent 
isocyanide insertion affords imidoyl intermediate 77. This intermediate can 
undergo double protodemetalation by another amine (71) to ultimately (via 78 and 
79) furnish 1-azadienes 74, regenerating the titanium nitrene 75. These 
enaminoimines 74 are precursors to various chemically and medicinally relevant 
heterocycles.[48] 





Scheme 17. Ti(IV)-catalyzed three-component reaction of amines, alkynes and isocyanides. 
Interestingly, when another titanium(IV) catalyst is used, a double isocyanide 
insertion occurs, affording densely functionalized diaminopyrroles 80 (Scheme 
18).[49] This pseudo-four-component reaction proceeds efficiently with both 
terminal and unsymmetrical internal alkynes. After initial formation of 
azatitanacyclobutene 81, the increased electron density around the metal 
suppresses the protodemetalation step after the first insertion, favoring a second 
insertion to furnish intermediate 82. Odom et al. argue that protodemetalation 
with this ligand system is slower due to the decreased acidity of the coordinated 
amine prior to protodemetalation after the first insertion (78; Scheme 17). In this 
transformation only the sterically encumbered t-BuNC proved successful. Sterically 
less demanding isocyanides tend to react in a three-component reaction 






Scheme 18. Ti(IV)-catalyzed pseudo-four-component reaction to diaminopyrroles. 
2.2.4  Imidoylations initiated by other processes 
In an intriguing report, Hojoh and coworkers disclosed the only known example of 
a base metal-catalyzed isocyanide insertion reaction affording enantioenriched 
products (Scheme 19a), by employing Cu(I) complexed to a chiral NHC-ligand L4.[50] 
Although the mechanism has not been fully investigated, the authors propose a 
Type II process involving a silicate intermediate (Scheme 19). However, as the 
insertion of isocyanides in Cu-H bonds is known[51], the possibility of a 1,1,-
migratory insertion following a Type I process into copper hydride species 88 
cannot be excluded without further studies. Formal enantioselective SN2’ attack of 
the organocopper species 87 on the allylic phosphate 83 affords aldimines 84 in 
excellent yields with moderate to excellent ee. Both primary and secondary 
aliphatic isocyanides as well as p-methoxyphenyl isocyanide afford the 
corresponding aldimines 84 efficiently. As aldimines derived from non-aromatic 
isocyanides tend to partially hydrolyze to the corresponding aldehyde during work 
up, these aliphatic products required full hydrolysis to prevent formation of 
complex product mixtures. As such, the reported yields correspond to the final 
aldehyde product obtained after hydrolysis. 





Scheme 19. Asymmetric Cu(I)-catalyzed synthesis of α-quaternary aldimines employing chiral N-
heterocyclic carbenes. 
2.1 Insertions of Isocyanides into Heteroatom-Metal Species 
The number of examples in literature of base metal-catalyzed isocyanide insertions 
involving a TM-Z species where Z is heteroatom -rather than carbon based- has 
increased substantially since 2014. Type I a2 and Type II imidoylations are typically 
involved in these reactions (Scheme 1).  
 





Application to the synthesis of several interesting molecular scaffolds has been 
reported and will be discussed in this section. An interesting example is the 
synthesis of unsymmetrically substituted arylguanidines 90 using a cobalt catalyst 
under ultrasound heating (Scheme 20).[52] The process involves the imidoylative 
coupling of an aliphatic and aromatic amine using tert-butyl peroxide as oxidant. 
The initially formed aromatic C-amidinoylcobalt intermediate 92 can be formed by 
either a Type I or a Type II pathway (Scheme 21). After imidoylation, the authors 
suggest that one-electron oxidation to intermediate 94 followed by homolysis of 
the C—Co bond and further oxidation of amidinoyl radical 95, affords 
alkylcyanamidium ion 96, which is trapped by the aliphatic amine. The reaction 
tolerates both primary, secondary and tertiary isocyanides, but most examples 
utilize t-BuNC (14). A similar Co(II)-catalyzed transformation using water or 
elemental sulfur to quench the intermediate alkylcyanamidium 96 leads to 
unsymmetrical (thio)ureas, again starting from anilines 89.[53] 
 
Scheme 21. Proposed catalytic cycle of the Co(II)-catalyzed unsymmetrical arylguanidine synthesis. 
In 2014, Zhu et al. devised a novel approach to the construction of benzo-fused 2-
aminoquinolines 98.[54] Under similar catalytic conditions as described in Scheme 
20, a complex of o-aminobiphenyls 97 and CoIIX2 undergoes deprotonation, 
isocyanide insertion and one-electron oxidation to afford amidinoyl Co(III) species  






Scheme 22. 6-Aminophenantridine synthesis using a Co(II)-catalyzed aminoimidoylation/homolytic 
aromatic substitution (HAS) cascade process. 
99 (Scheme 22). The authors propose that subsequent homolysis of the cobalt-
carbon in Co(III) species 99, furnishes amidinoyl radical 100, which undergoes an 
intramolecular homolytic aromatic substitution (HAS), affording the biologically 
valuable 6-aminophenantridines 98 in low to moderate yields. Molecular oxygen 
was used as the optimal oxidant.  
 
 





Although tertiary and secondary aliphatic isocyanides react well, reactions of 
aromatic and primary aliphatic isocyanides did not afford any of the desired 
products. A similar radical relay process was used to access 2-aminoquinolines 103 
by using the vinyl of o-aminostyrenes 102 as radical acceptors (Scheme 23).[55] 
Although this reaction proceeds via a similar mechanism as described in Scheme 
22, in this case only tertiary isocyanides led to efficient formation of 2-
aminoquinolines 103. The authors performed radical trapping experiments with 
TEMPO and indeed detected the TEMPO-105 adduct by LC-MS analysis together 
with a trace amount of product 103. The authors claim that this suggests the 
involvement of a radical process. However, in the reactions discussed in Scheme 20 
and Scheme 22, no further detailed mechanistic investigations were reported. 
 
Scheme 24. Co(II)/Ag(I) tandem catalysis to iminopyrroloindoles. 
An interesting cobalt-catalyzed double insertion/silver-catalyzed [3+2] 
cycloaddition cascade approach to iminopyrroloindoles 108 was reported by Gao 
and coworkers.[56] Formamidine 109 is formed via isocyanide insertion in an 
anilinocobalt species, formed from 2-alkynylaniline 107 and Co(acac)2. 
Subsequently, the authors propose an unconventional second insertion, affording 
the 1,3-dipole intermediate 110, which undergoes a silver-catalyzed [3+2] 
cycloaddition. The authors did not provide detailed mechanistic work to support 
the formation of 1,3-dipole intermediate 110 from formamidine 109. However, 
when subjecting the uncoordinated formamidine in intermediate 109 to the 




standard reaction conditions with 1.1 equivalent of isocyanide, product 108 did 
form in excellent yield, which makes the involvement of intermediate 109 plausible 
(Scheme 24). Initially, the corresponding pyrroloindoles are formed, but these 
oxidize rapidly under air to the observed fused iminopyrroloindole 108. The 
reaction tolerates both aromatic and aliphatic isocyanides. However, an aromatic 
substituent on the alkyne is required. More recently, the same group extended this 
protocol to a three-component reaction. By adding an additional aniline (89), 
product 111 was obtained via a thermodynamically and kinetically favored 
transimination (Scheme 25).[57] 
 
Scheme 25. Co(II)/Ag(I) tandem catalysis/transimination cascade to 111. 
In relation to this, it is perhaps surprising that as early as 1974, Knol and coworkers 
showed that formimidates 113 can be formed by insertion of aryl isocyanides into 
the OH bond of ethanol (Scheme 26).[58] The mechanism has remained largely 
uninvestigated, but the authors propose a nucleophilic attack of ethoxide onto the 
copper coordinated isocyanide (complex 112) (Type II, Scheme 1b). Several kinetic 
experiments indeed support this hypothesis.  
 
Scheme 26. Early copper-mediated N-aryl imidate synthesis. 
Similar in situ formed imidates can be used in a one-pot Van Leusen-type formal 
[3+2] cycloaddition with α-acidic benzyl isocyanides.[21a] Here, N,3-diarylimidazoles 
116 are formed in high yields and with high chemoselectivity under Cu(I)-catalysis 






Scheme 27. N,3-diarylimidazole synthesis by Cu(I)-catalyzed alkoxyimidoylation/[3+2] cycloaddition 
cascade. 
electron-deficient to be efficiently transformed to the intermediate imidates 119, 
which undergo the subsequent cycloaddition with α-acidic benzyl isocyanide 114. 
Both experimental results and in silico investigations suggest that the K+ counterion 
is essential to obtain high yields of 116. Various substituted benzylic and aryl 
isocyanides afford imidazoles 116 in moderate to excellent yield. Additional DFT 
calculations indicate that the energetic difference between possible Type I 2a and 
Type II insertion (see Scheme 1a-b) in this reaction is less than 1 kcal/mol, meaning 
both can occur. 
 
Scheme 28. Cu(I)-catalyzed alkoxyimidoylation/condensation cascade. 
Another Cu(I)-catalyzed alkoxyimidoylation/condensation cascade reaction was 
reported by Kim et al. (Scheme 28).[59] The in situ formed formimidate intermediate 




123 condenses with the α-acidic arylacetonitrile (120), affording 3-amino-2-
arylacrylonitriles (121) in moderate to excellent yields.  
 
Scheme 29. Fused heterocycles via Co(II)-catalyzed imidolyation of diamine bisnucleophiles. 
Apart from the above discussed substrates, the use of bisnucleophiles has been 
ubiquitous in imidoylative transformations as they are valuable precursors to a 
broad range of heterocycles. This is especially highlighted by the numerous 





catalyzed oxidative imidoylation of bisnucleophiles was first reported by our group 
in 2012.[60] Since then, various base metal-catalyzed variants have been published. 
The cobalt-catalyzed insertion of isocyanides into 2-(2-aminoaryl)benzimidazoles 
124 (Scheme 29a) affords benzimidazole fused 2-aminoquinazolines 125.[61] A 
plausible mechanism proceeds via the intermediate amidinoyl cobalt(II) species 
126, which undergoes a single electron oxidation initiating the reductive 
elimination. Further one-electron oxidation of the liberated Co(I) species 
regenerates the active catalyst. Other nitrogen nucleophiles, such as the 
anthranilamide 128 can also be involved. In a similar process 2-(2-
aminophenyl)tetrazoles 129 and N-(benzimidazol-2-yl)guanidine 132[62] proved to 
be suitable substrates (Scheme 29b-c). Compared to the Pd-catalyzed process[63], 
this cobalt catalysis has a higher tolerance for aliphatic and aromatic isocyanides. 
Cheap K2S2O8 is the preferred oxidant in these reactions, unfortunately, O2 does not 
appear to be a suitable oxidant. A nickel-catalyzed version with similar substrates 
124 was reported to afford aminobenzimidazoquinazolines 125 (Scheme 30).[64] 
Interestingly, the scope of isocyanides tolerated by this reaction is broader than 
under the comparable cobalt-catalyzed processes discussed in Scheme 29, even 
tolerating benzylic and α-acidic isocyanides. Moreover, oxygen, the most abundant 
and sustainable oxidant, can be used in this reaction. Also, this Ni(II)-catalyzed 
process could be extended to a one-pot reaction starting from isatoic anhydrides 
134, affording the fused tetracycles 125 in reasonable 30-76% yields. In 2013, Ji et 
al. reported the synthesis of 2-aminobenzimidazoles, -benzoxazoles, and -
benzothiazoles (137) via a Co(II)-catalyzed reaction of isocyanide with 2-
aminoanilines, 2-aminophenols and 2-aminothiophenols (136), respectively 
(Scheme 31).[65]  
 
Scheme 30. Ni(II)-catalyzed imidoylation towards aminobenzimidazoquinazolines (125). 





Scheme 31. Co(II)-catalyzed imidoylation of 2-aminoaniline or 2-amino(thio)phenols. 
This exemplifies that bisnucleophiles do not need to be diamines. While the 
reported yields are lower than for the analogous Pd-catalyzed reactions,[60] this 
transformation is significantly more compatible with aliphatic, aromatic, and α-
acidic isocyanides. Again, K2S2O8 is applied as oxidant. These privileged scaffolds 
(137) are also accessible via oxidative nickel catalysis[66] and both primary, 
secondary, tertiary aliphatic, as well as aromatic isocyanides afforded the products 
137 in moderate to excellent yields (Scheme 32). 
 
Scheme 32. Ni(II)-catalyzed imidoylation of 2-aminoaniline or 2-amino(thio)phenols. 
 
Scheme 33. Ni(II)-catalyzed double isocyanide insertion to 2,4,5-triiminothiazole (139). 
Recently, the group of Li reported the first base metal-catalyzed aerobic double 
isocyanide insertion (Scheme 33) to access triiminothiazoles 139.[67] The authors 
propose that molecular oxygen from air facilitates the oxidation of Ni(0) to Ni(II), 
thus closing the catalytic cycle. The Ni(II)-catalyzed reaction tolerates electronically 





substituted thioureas (138), mixtures of regioisomeric iminothiazoles (139a:139b, 
1:1 to 9:1) were obtained in reasonable to good yields. 
 
Scheme 34. Auto-tandem Cu(I)-catalyzed reaction to benzothiazolethiones. 
The last bisnucleophile-based insertion reaction discussed here is the Cu(I)-
catalyzed access to benzothiazolethiones (143) reported by Liang and coworkers. 
In their reaction the N,S-bisnucleophile 144 was generated in situ by a non-
imidoylative Cu(I)-catalyzed Ullmann coupling between the iodoaniline 140 and K2S 
(Scheme 34).[68] This is followed by an interesting Cu-catalyzed reaction with 
isocyanide 141 and K2S. The nature of the oxidation state of copper in the 
intermediates is unclear. Although the isocyanide in this reaction serves merely as 
a C1 donor, the use of toluenesulfonylmethyl isocyanide (141) is essential. 
Employing t-BuNC leads to significant formation of 2-aminobenzothioazoles (137; 
Scheme 32, R2 = t-Bu,Y = S). 
2.2 Insertion of isocyanides in TM=C and TM=N Bonds 
2.4.1 Insertion of Isocyanides in Metal Carbene complexes 
Metallocarbenes derived from base metals have been used as substrates in 
reactions with isocyanides. The reaction of an isocyanide with a TM=C -bond can 
be categorized as a Type III insertion (Scheme 1c). The general mechanism of 
insertion of isocyanides via carbene transfer in the TM=C bond of Fischer carbenes 
147 was extensively investigated in silico by Fernández et al.[69] They showed that a 




metalacyclopropanimine intermediate 150 is more likely than the previously 
considered metallate 149 (Scheme 35). 1,2-Metallotropic rearrangement of 150 
then affords N-metalated ketenimine 148.[6a, 70] 
 
Scheme 35. General mechanism for carbene transfer to isocyanides. 
Although the reported examples make use of stoichiometric metallocarbenes, 
there is potential for being adapted to catalytic variants, e.g. from diazo 
compounds, in which the in situ generated ketenimines are immediately used in  
 
Scheme 36. Three-component reaction with Fischer carbene 151. 
follow-up reactions. A recent example uses Fischer carbene 151 that gives 
intermediate species 154 after [3+2] cycloaddition with 152 (Scheme 36). 
Subsequent isocyanide insertion furnishes the electron-rich ketenimine 155, which 
then undergoes a 6π-electrocyclization to give bis-annulated anisole derivatives 






2.4.2  Insertion of Isocyanides in Metal Nitrene Complexes 
Closely related to the carbene transfer to isocyanides is the insertion of isocyanides 
into metal nitrene complexes, typically leading to carbodiimides. As metal nitrene 
complexes are mostly generated in situ from azides, catalytic metal complexes can 
be used. Although some interesting examples have been reported, development of 
these base metal-catalyzed reactions is still in its infancy. 
 
Scheme 37. Cr(II)-catalyzed carbodiimide formation from aryl azides and isocyanides. 
A reaction based on this principle is shown in Scheme 37. The carbodiimides (157) 
can be prepared by a Cr-catalyzed nitrene transfer to isocyanides.[72] The bulkiness 
of both the azide and the isocyanide input proved highly important. The use of 
sterically less demanding azides results in the formation of an unreactive, saturated 
Cr(VI) complex. Holland and coworkers reported a similar reaction that presumably 
proceeds via an Fe(I)-complex of aryl azides 156 and isocyanides (Scheme 38). 
Mechanistic studies reveal that transition state 160 is involved and that most likely 
imido attack occurs to the metal-bound isocyanide (Type III insertion, Scheme 1c). 
The scope with regard to both the isocyanide and azide is rather limited.[73] Only t-
BuNC and 2,6-xylyl isocyanide gave successful reactions affording the 
corresponding carbodiimides in good to excellent yields. It should be noted that 
Wiese and coworkers reported a Ni(I)-catalyzed process utilizing similar diamino-
ligands.[74] Although the carbodiimines 157 are formed in less reproducible yield 
compared to the Fe-catalyzed pathway, the reaction with Ni tolerates electronically 




more diverse azides, like sulfonyl azides and acylazides. Again, only tert-butyl and 
xylyl isocyanide were employed in this Ni(I)-catalyzed process. 
 
Scheme 38. Fe(I)-catalyzed carbodiimide synthesis from aryl azides and isocyanides. 
 
Scheme 39. Three-component synthesis of unsymmetrical N-sulfonylated guanidines via Co(II)-
catalysis. 
With an additional nucleophile present these carbodiimides can be in situ 
transformed. The catalyst can then additionally act as a Lewis acid, facilitating 
addition. Recently, Ji reported a 3-CR affording highly substituted guanidines 163 
(Scheme 39a).[21b] This cobalt-catalyzed process does not require special ligands or 
glovebox conditions. Extensive EPR analysis and theoretical calculations suggest a 
catalytic mechanism involving a nitrene radical (165; Scheme 40). This pathway 
allows formation of carbodiimide 167, via a CoII/CoIII-catalyzed process, which then 





tolerates a wide variety of aliphatic, aromatic and α-acidic isocyanides. A similar 
transformation using alcohols instead of amines was developed to furnish the 
corresponding N-sulfonyl isoureas 170 (Scheme 39b) in comparable yields to the 
guanidine synthesis.[75]  
 
Scheme 40. Proposed mechanism for the Co(II)-catalyzed formation of guanidines via intermediate 
carbodiimide species. 
Furthermore, a pseudo four-component reaction involving two isocyanides, 
sulfonyl azide and water affording α-amidoamidines under cobalt catalysis was 
recently described.[76] Interestingly, in this reaction the in situ formed electron 
deficient carbodiimide 172 undergoes selective nucleophilic attack by a second 
isocyanide 105 before addition of less nucleophilic water to nitrillium ion 173 
occurs, to give N-sulfonyl α-amidoamidines 171 (Scheme 41a). On the other hand, 
utilizing aromatic isocyanides in the absence of water (Scheme 41b) facilitates an 
intramolecular electrophilic aromatic substitution of nitrillium ion intermediate 
176, affording stable aminoiminoindoles 174 in moderate to high yields. 





Scheme 41. Multicomponent synthesis of α-amidoamidines via Co(II) catalysis. 
2.3 Summary and Outlook 
Base metal-catalyzed isocyanide insertion processes, although still in its infancy, 
hold great potential for application in organic and heterocyclic synthesis. The 
(formal) migratory insertion of isocyanides into in situ formed TM-C, TM-X, TM=C 
and TM=N bonds provides promising pathways to utilize isocyanides as valuable C1 
building blocks in organic synthesis. However, many reports only show application 
of rather simple and hindered isocyanides. In particular, cobalt- and nickel-based 
reactions discussed here often show a remarkable tolerance for more advanced 
functionalized isocyanides. When other base metals are used the more challenging 
unhindered and/or aromatic isocyanides typically still limit the overall scope. This 
is mainly due to the occurrence of multiple insertions resulting in competing 
polymerization. In oxidative processes the combination with cheap oxidants 
(peroxides, peroxydisulphate, oxygen) proves quite productive. However, the 
loading of the base metal catalysts applied is often still relatively high. On the other 
hand, toxicity issues related to some specific base metal salts (like e.g. some Co-
salts) require careful analysis of the alternatives for the traditional noble TM-based 
catalytic systems.[77] To advance this chemistry towards predictable 
transformations for synthetic organic chemists detailed mechanistic studies are of 





do not focus on a clear understanding of what is actually going on in the underlying 
catalytic process. This, to our opinion, is the major unsolved issue in this field. 
Mechanistic insight in combination with rational ligand design should, however, 
bring this methodology to the next level, similar to what has happened in the 
development of reactions involving Pd-catalyzed isocyanide insertions.[78] At 
present the catalytic cycles are still largely speculative, which is not uncommon for 
an emerging field. The carbene and nitrene transfer processes in particular hold 
much synthetic promise, but have only scarcely been investigated so far. We 
believe that the future of this type of chemistry aligns with the general strive 
towards the development of more sustainable methodologies, in which the use of 
catalysts based on more abundant, cheaper and less toxic base metals instead of 
noble metals takes a pivotal role.  
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Abstract: We developed a two-stage synthetic route to substituted 4-
aminoquinolines involving an imidoylative Sonogashira coupling followed by acid-
mediated cyclization. This three-component reaction affords pharmaceutically 
valuable 4-aminoquinolines in a one-pot procedure from readily available starting 
materials. The reaction tolerates various substituents on the arene as well as the 
use of secondary and even primary isocyanides. Additionally, the wide tolerance for 
functionalized isocyanides allows for the one-pot synthesis of various substituted 












4-Aminoquinolines (4-AQs) have been widely investigated for their pharmaceutical 
potential, in particular their antimalarial properties.[1] Recently, B ring substituted 
(in particular 7-halogenated) 4-AQs were shown to display enhanced activities 
against highly resistant strains of P. falciparum.[2] Consequently, this scaffold is still 
of high interest for the development of novel antimalarials.[3] Additionally, 
chloroquine and amodiaquine (Figure 1) have recently been flagged as leads against 
Ebola and Marburg viruses.[4] These known antimalarials also inhibit endosomal 
Toll-like receptors.[5] Recently, other applications of 4-AQs have also been reported, 
as diversely substituted 4-AQs have been identified as promising antifilarials,[6] 
translocator protein biomarker ligands,[7] tuberculosis ATP synthase inhibitors,[8] 
and as nociceptin receptor antagonists (Figure 1).[9] Additionally, 4-AQs bearing 2-
(hetero)aryl functionalities also show promise as non-nucleoside HIV-1 
inhibitors.[10] Not surprisingly, there is great interest to efficiently access the 4-AQ 
core and over the past decades, several cascade reactions towards these 
medicinally valuable scaffolds have been developed (Scheme 1).[11]   
 
Figure 1. Examples of medicinally relevant 4-aminoquinolines. 
For example, 4-AQs can be obtained from the reaction of ynamides and nitrilium 
species, resulting from either arylation of nitriles[11a] or dehydration of anilides.[11b] 
The Cu(I)-catalyzed cyclization of imidoylacetylenes and sulfonyl azides affords 4-
AQs as well.[12] A carbonylative Sonogashira reaction of 2-ethynylanilines with in 
situ amination at C4 also provides access to 4-AQs.[11e] 





Scheme 1. Previous  routes to 4-aminoquinolines. 
Finally, our group recently showed that palladium-catalyzed oxidative isocyanide 
insertion of N-aryl imines by double C-H functionalization also affords 4-AQs.[11f] 
However, these methods rely on rather specialized starting materials[11a-d] and/or 
afford the desired 4-AQs in disappointing yields.[11b, 11f] Most diversity-oriented 
routes toward 4-AQs rely on the amination of 4-haloquinolines, in turn derived 
from the corresponding 4-quinolones.[13] Such multisubstituted quinolones (2) are 
generally difficult to synthesize by traditional condensation methods.[14] However, 
quinolones 2 are accessible via a carbonylative Sonogashira coupling (Scheme 2), 
using organic base to mediate the post-coupling cyclization.[15] To the best of our 
knowledge, only one example of isocyanide insertion in a Sonogashira coupling has 
been reported, where the product ynimines are hydrolyzed in situ to the 
corresponding ynones.[16] Based on this, we envisioned  a direct, one-pot synthesis 
of 4-AQs 4 via an imidoylative Sonogashira coupling and subsequent 
cycloaromatization (Scheme 2). Such an approach avoids the use of toxic CO gas, 






Scheme 2. Carbonylative and imidoylative Sonogashira coupling to 4-aminoquinolines. 
3.2. Results and discussion 
Our initial studies showed that such an imidoylative Sonogashira approach using 5, 
6a, and 7a  afforded a range of products as a difficult to analyze mixture under 
typical conditions (Scheme 3). Most notably, with temperatures under 50°C or CuBr 
loadings approaching stoichiometric amounts, only the alkyne homocoupling 
product 10 was isolated. Additionally, SFC-MS analysis indicated that the use of o-
iodoaniline promotes intramolecular Buchwald-Hartwig-type reactivity with double 
isocyanide insertion, resulting in the formation of isatin diimine 11. If o-
bromoaniline is employed, formation of 11 is suppressed to trace amounts, which 
is known for the synthesis of these isatinimines.[17] Surprisingly, these initial 
experiments revealed that the main product in all cases is the intermediate 
 
Scheme 3. Initial imidoylative Sonogashira studies towards 4-AQs and side products. 
imidoylative Sonogashira product 8, with only trace amounts of the desired 
cyclization product 9. Direct formation of 4-AQs 9 from these previously 
underexplored ynimines 8 appears to be rather difficult. Consequently, we focused 
our attention on the optimization of the final cycloaromatization step. Multiple 




cyclization conditions were investigated for the formation of aminoquinoline 9 
from the proposed intermediate ynimine 8. Neither strong nor weak bases proved 
effective in facilitating this cyclization (Table 1, entries 1-2). Weak acids (SiO2, AcOH) 
were applied to activate the imine towards cyclization, but only afforded cyclization 
product 9a in trace quantities (entries 3, 4). However, stronger acids like TFA, 
phenylphosphinic acid and methylsulphonic acid rapidly afforded 4-aminoquinoline 
9a, even after short reaction times at ambient temperature (entries 8-10).  
Interestingly, HCl also facilitated the cycloaromatization, even when employed as 
an aqueous solution. Curiously, acids with non-nucleophilic conjugate bases also 
afford aminoquinoline 9a in high to quantitative yield (Table 1, entries 8, 10). This 
implies either an intermolecular Michael/Michael/retro-Michael mechanism,[15] or 
a direct intramolecular Michael reaction. Regardless, post-coupling addition of 
aqueous hydrochloric acid was selected as the optimal cyclization condition. While 
the addition of 1 M aqueous HCl readily facilitated cycloaromatization of 8 to 9a, 
we opted for slightly harsher conditions (2 M aq. HCl (4 mL), 15 min., rt) for the in 
situ cyclization following the imidoylative Sonogashira reaction to account for 
Table 1. Ynimine cyclization optimization. 
 
entrya Additive (equiv.) yield 9 (%)b 
1 NaOEt (2.0) n.r. 
2 HNEt3 (2.0) n.r. 
3c SiO2 trace 
4 AcOH (4.0) trace 
5 2 M HCl in H2O (4.0) 100 
6 2 MHCl in MeOH (4.0) 96 
7 4 M HCl in dioxane (4.0) 99 
8 TFA (4.0) 80 
9 PhP(OH)2 (4.0) 85 
10 MeSO3H (4.0) 100 
a Conditions: ynimine 8 (0.55 mmol) in DMF (1 mL), additive, rt, 1 h. b Yield determined by NMR 
using  an internal standard (1,3,5-trimethoxybenzene). c 0.150 g of SiO2 was used. n.r. = no 





excess Cs2CO3 as well as any residual starting materials. With the optimized 
cyclization protocol in hand, we turned our attention to the optimization of the 
imidoylative Sonogashira coupling. Using standard conditions (5 mol % Pd(PPh3)4, 
15 mol % CuBr, 2.0 equiv. Cs2CO3, DMSO, 90 °C, 16 h) we obtained the desired 4-
AQ 9a in 61% yield (Table 2, entry 2).  When the Cu(I)Br co-catalyst was omitted,  
only isatin diimine 11 was obtained (entry 1). Subsequent solvent screening 
indicated that the transformation proceeds most efficiently in polar aprotic 
solvents, with DMF giving superior results (entries 2-5). As expected, a 
heterogeneous palladium catalyst (Pd/C) did not catalyze the reaction (entry 6). 
Table 2. Optimization of the imidoylative Sonogashira/cyclization conditions.a 
 
entry Pd source ligand base solvent 9a (%)b 
1c Pd(PPh3)4 -- Cs2CO3 DMSO -- 
2 Pd(PPh3)4 -- Cs2CO3 DMSO 61 
3 Pd(PPh3)4 -- Cs2CO3 toluene 27 
4 Pd(PPh3)4 -- Cs2CO3 dioxane 13 
5 Pd(PPh3)4 -- Cs2CO3 DMF 70 
6 Pd/C -- Cs2CO3 DMF -- 
7 Pd(OAc)2 PPh3 Cs2CO3 DMF 82 
8 Pd(OAc)2 Bu3P Cs2CO3 DMF -- 
9 Pd(OAc)2 DPEPhos Cs2CO3 DMF 82 
10 Pd(OAc)2 XantPhos Cs2CO3 DMF 91 
11 Pd(OAc)2 XantPhos KOtBu DMF -- 
12 Pd(OAc)2 XantPhos K2CO3 DMF 56 
13 Pd(OAc)2 XantPhos NEt3 DMF -- 
14 Pd(OAc)2 XantPhos DBU DMF 31 
15 Pd(OAc)2 - Cs2CO3 DMF -- 
16 - XantPhos Cs2CO3 DMF -- 
a Reaction conditions: 2-bromoaniline (12a, 0.5 mmol, 1 eq), phenylacetylene (6a, 1 mmol, 2 eq), 
tert-butyl isocyanide (7a, 0.625 mmol, 1.25 eq), catalyst (5 mol %), ligand (monodentate: 15 mol 
%, bidentate: 10 mol %), CuBr (15 mol %), Cs2CO3 (1 mmol, 2 eq) in solvent (3.0 mL) were stirred at 
100° C for 16-20 h under N2 atmosphere. b Yields determined by 1H NMR analysis using 2,5-
dimethylfuran as internal standard. c Reaction performed in the absence of CuBr. 
 




Switching from Pd(PPh3)4 to an in situ formed Pd0 complex allowed for a ligand 
screening (entries 7-10). Interestingly, in addition to the highest 4-AQ yield, the use 
of Xantphos as a ligand completely inhibited the formation of isatin diimine 11 
(Table 1, entry 10). Changing the base from Cs2CO3 to other inorganic or organic 
bases (KOtBu, K2CO3, Et3N, DBU) did not lead to an increase in yield (entries 11-14). 
Finally, as anticipated, 9a  was not formed when either the palladium source or the 
ligand was omitted (entries 15, 16).  
With the complete set of optimized reaction conditions in hand, we set out to 
explore the compatibility of diversely substituted o-bromoanilines and terminal 
alkynes with our three-component reaction (Scheme 4). The reaction proved 
 
Scheme 4. Alkyne and o-bromoaniline variation. a Reaction performed on a 10.0 mmol scale. b Closed 





compatible with neutral and moderately electron-donating substituents (9a,b). The 
use of halo-substituted o-bromoanilines did not lead to lower yields (9c-g). 
Decoration of the o-bromoaniline or the arylalkyne with electron-donating 
functionalities afforded the substituted 4-AQs in high yields (9h-k). However, o-
bromoanilines bearing electron-withdrawing substituents displayed lower 
compatibility with the three-component cascade protocol. When 3-bromo-4-
aminobenzoate was used, the corresponding aminoquinoline 9l was isolated in 
lower yield. Similar results were observed for 9m, where the introduction of an 
additional distal electron acceptor on the opposite side of the ynimine renders the 
alkyne susceptible to 5-exo-dig cyclization. This cyclization to an aza-aurone side 
product most likely accounts for the diminished yields, as it does not require 
external acid activation and can therefore take place during the reaction. 
Additionally, it is possible that withdrawing electron density through substituent 
effects renders ynimines 8 more susceptible to hydrolysis during the cyclization 
stage. Gratifyingly, the developed conditions proved to tolerate aliphatic alkynes as 
well, which was demonstrated by the isolation of 9n and 9o in reasonable to good 
yields.  
Interestingly, this palladium-catalyzed imidoylative Sonogashira coupling displayed 
high tolerance with regard to the isocyanide input (Scheme 5). Secondary 
isocyanides, which are known to undergo double insertion more readily under 
palladium catalysis,[18] proved fully compatible with this protocol (9p-r). 
Satisfyingly, even primary isocyanide insertion afforded aminoquinoline 9s in 
acceptable yield. The use of bromoanilines and arylalkynes bearing electron-
withdrawing substituents afforded the corresponding products in lower yields, in 
accordance with earlier results (9t-u). 
Unfortunately, the use of 4-methoxyphenyl isocyanide did not afford isolable 
quantities of the corresponding 4-arylaminoquinoline 9v. We then investigated the 
utility of our method in the synthesis of pharmaceutically relevant 4-AQs. The use 
of readily accessible N,N-diethyl-4-isocyanopentan-1-amine provided access to a 
variety of chloroquine analogues (9w-9y) in high yields. Similarly, the use of the 
isocyanide derived from the known vasoconstrictor octodrine[19] afforded 9aa in 
good yield. Analogues of this highly fluorescent 2-naphtyl-4-AQ have been 
identified as potent immunostumulatory CpG-oligonucleotide antagonists.[20] 
Furthermore, the use of 2-bromo-5-fluoroaniline, combined with N,N-diethyl-4-




isocyano-pentan-1-amine and cyclohexylacetylene furnishes 4-amino-2-cyclohexyl-
7-fluoroquinoline (9z). Structures of this type have been described as promising 
antileishmanial compounds.[21]  
 
Scheme 5. Isocyanide variation. 
Finally, ethyl 4-isocyanopiperidine-1- carboxylate can be used to construct 9ab in 
68% yield, providing a handle for further functionalization of these medicinally 
valuable scaffolds. The reaction is proposed to proceed identical to the earlier 
postulated mechanism[16a], in which the Pd(II) precatalysts is reduced in situ. 





of the isocyanide to afford imidoyl palladium species II. As noted earlier, by using 
Xantphos as a ligand, transmetallation of copper acetylide III outcompetes a 
secondary isocyanide insertion, hereby bypassing the formation of byproduct 11 
(Scheme 3). 
 
Scheme 6. Proposed mechanism of the imidoylative Sonogashira coupling. 
3.3. Conclusion 
In conclusion, we have developed a novel one- pot imidoylative Sonogashira cross-
coupling/acid-mediated cyclization toward 4-aminoquinolines. The methodology is 
highly compatible with electronically diverse o-bromoanilines, arylalkynes and 
aliphatic alkynes, although electron-withdrawing substituents on either arene lead 
to lower yields. The transformation is compatible with tertiary, secondary, and even 
primary aliphatic isocyanides. Additionally, using functionalized alkyl isocyanides, 
this method can be used to directly synthesize 2-substituted 4-aminoquinolines of 
high medicinal relevance.  
  




3.4. Experimental section 
General remarks 
Chemicals were purchased from Sigma Aldrich or Fluorochem and were used without purification. 
Solvents were purchased from VWR Chemicals (CH2Cl2), or Sigma Aldrich (toluene, dioxane, DMSO) 
and used without purification, unless stated otherwise. Dry solvents were dried over an Inert PS-MD-
5 Solvent Purification System, equipped with an activated alumina/copper wire column. 1H NMR 
measurements were acquired on a Bruker Avance 300 (300.13 MHz) or Bruker Avance 500 (500.23 
MHz) spectrometer. 13C NMR measurements were acquired on a Bruker Avance 500 (125.78 MHz) 
spectrometer. Chemical shifts are reported in ppm downfield of tetramethylsilane, and are corrected 
according to solvent. Mass analysis was performed using a Bruker MicrOTOF-Q instrument on a 
positive ion polarity mode for ESI (Electrospray Ionization). Capillary charge: 4000V. Melting points 
were measured using a Büchi M-565 melting point apparatus. SiO2 column chromatography was 
performed using Merck Silica Gel C60 (particle size 40-60 μm). TLC chromatography was performed 
on Merck Silica Gel C60 F254 plates (silica coat on aluminum support). All isolated yields are corrected 
for present impurities (if present) 
General procedure A for the synthesis of 4-tert-butylaminoquinolines from o-bromoanilines, 
alkynes and tert-butylisocyanide: 
A solution of Pd(OAc)2 (0.011 g, 0.05 mmol) and Xantphos (0.058 g, 0.10 mmol) in dry DMF (8 mL) was 
stirred for 20 min at RT under N2 atmosphere, forming a yellow suspension. To this mixture were 
added consecutively Cs2CO3 (0.651 g, 2.0 mmol), o-bromoaniline (1.0 mmol), tert-butyl isocyanide 
(0.141 mL, 1.25 mmol), CuBr (0.021 g, 0.15 mmol) and alkyne (2.0 mmol). The resulting mixture was 
stirred 90°C for 16 h. Hereafter, the reaction was allowed to cool to RT, after which 4 mL 2 M HCl was 
added and stirred for 15 min. The mixture was diluted with DCM, filtered over a pad of diatomaceous 
earth, and washed with 1 M HCl and sat. NaHCO3, before being dried over anhydrous Na2SO4, filtered, 
and concentrated in vacuo. Purification was performed by column chromatography (gradient, 
cHex:EtOAc:Et3N 19:1:0.01 – 1:1:0.01, unless stated otherwise) to afford the pure 4-aminoquinoline 
derivative.  
General procedure B for the synthesis of 4-aminoquinazolines from o-bromoanilines, alkynes, and 
isocyanides: 
A solution of Pd(OAc)2 (0.011 g, 0.05 mmol) and Xantphos (0.058 g, 0.10 mmol) in dry DMF (8 mL) was 
stirred for 20 min at RT under N2 atmosphere, forming a yellow suspension. To this mixture were 
added consecutively Cs2CO3 (0.651 g, 2.0 mmol), o-bromoaniline (1.0 mmol), isocyanide (1.75 mmol), 
CuBr (0.021 g, 0.15 mmol) and alkyne (2.0 mmol). The resulting mixture was stirred 90°C for 16 h. 
Hereafter, the reaction was allowed to cool to RT, after which 2-4 mL 2 M HCl was added and stirred 
for 15 min. The mixture was diluted with DCM, filtered over a pad of diatomaceous earth, and washed 
with 1 M HCl and sat. NaHCO3, before being dried over anhydrous Na2SO4, filtered, and concentrated 
in vacuo. Purification was performed by column chromatography (gradient, cHex:EtOAc:Et3N 












Synthesized in accordance with general procedure A. Isolated as a yellow solid 
(0.234 g, 79%). RF = 0.19 (cHex:EtOAc:NEt3 ; 4:1:0.05). 1H NMR (500.23  MHz, 
CDCl3): δ 8.10-8.03 (m, 3H), 7.68 (dd, J = 1.5, 8.5 Hz, 1H), 7.63 (ddd, J = 1.5, 7.0, 
8.5, 1H), 7.51 (t, J = 7.5 Hz, 2H), 7.47-7.38 (m, 2H), 7.12 (s, 1H), 5.03 (bs, 1H), 1.60 
(s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 157.9, 148.8, 148.3, 141.2, 130.5, 129.0, 
128.8, 128.6, 127.5, 124.3, 118.9, 118.5, 99.1, 51.5, 29.4. HRMS (ESI): m/z 
calculated for C19H21N2+ [M+H]+ 277.1695, found: 277.1707. M.p.: 139 °C. 
 
N-(tert-butyl)-7-methyl-2-phenylquinolin-4-amine (9b) 
Synthesized in accordance with general procedure A. Isolated as a yellow solid 
(0.237 g, 78%). RF = 0.33 (cHex_EtOAc:NEt3 ; 4:1:0.05). 1H NMR (500.23  MHz, 
CDCl3): δ 8.05 (dd, J = 1.5, 7.5 Hz, 2H), 7.85 (s, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.50 
(t, J = 7.5 Hz, 2H), 7.47-7.40 (m, 1H), 7.23 (dd, J = 7.5, 8.5 Hz, 1H), 7.07 (d, J = 
1.5 Hz, 1H), 4.99 (bs, 1H), 2.52 (s, 3H), 1.59 (s, 9H). 13C NMR (125.97 MHz, 
CDCl3): δ 157.9, 149.0, 148.3, 141.3, 139.0, 129.7, 128.7, 128.6, 127.5, 126.4, 
118.6, 116.4, 98.7, 51.4, 29.4, 21.5. HRMS (ESI): m/z calculated for C20H23N2+ [M+H]+291.1851, found: 
291.1854. M.p.: 134 °C. 
 
N-(tert-butyl)-6-fluoro-2-phenylquinolin-4-amine (9c) 
Synthesized in accordance with general procedure A. Isolated as a light brown 
solid (0.232 g, 79%). RF = 0.44 (cHex:EtOAc:NEt3 ; 4:1:0.05). 1H NMR (500.23  
MHz, CDCl3): δ 8.14-8.06 (m, 3H), 7.54 (t, J = 7.5 Hz, 2H), 7.50-7.44 (m, 1H), 
7.48-7.37 (m, 1H), 7.36 (dd, J = 2.5, 10.0 Hz, 1H), 7.17 (s, 1H), 4.79 (bs, 1H), 1.57 
(s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 159.5 (d, J = 245.0 Hz), 157.3 (d, J = 2.5 
Hz), 147.9 (d, J = 4.5 Hz), 145.8, 140.9, 132.8 (d, J = 8.5 Hz), 128.8, 128.6, 127.4, 
118.9 (d, J = 8.0 Hz), 118.6 (d, J = 24.5 Hz), 103.3 (d, J = 23.0 Hz), 99.4, 51.6, 29.3.  HRMS 
(ESI): m/z calculated for C19H20N2F+ [M+H]+ 295.1601, found: 295.1604. M.p.: 163 °C. 
 
N-(tert-butyl)-6-fluoro-2-(p-tolyl)quinolin-4-amine (9d) 
Synthesized in accordance with general procedure A. Isolated as a light 
brown solid (0.241 g, 78%). RF = 0.43 (cHex:EtOAc:NEt3 ; 4:1:0.05). 1H NMR 
(500.23  MHz, CDCl3): δ 8.04 (dd, J = 5.5, 9.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 2H), 
7.42-7.36 (m, 1H), 7.34-7.27 (m, 3H), 7.12 (s, 1H), 4.74 (bs, 1H), 2.43 (s, 3H), 
1.59 (s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 159.5 (d, J = 245.0 Hz), 157.3 
(d, J = 2.5 Hz), 147.8 (d, J = 5.0 Hz), 145.8, 138.8, 138.0, 132.7 (d, J = 8.5 Hz), 
129.4, 127.3, 118.9 (d, J = 8.0 Hz), 118.5 (d, J = 25.0 Hz), 103.3 (d, J = 23.0 
Hz), 99.3, 51.5, 29.3, 21.3. HRMS (ESI): m/z calculated for C20H22N2F+ [M+H]+ 309.1757, found: 
309.1769. M.p.: 155 °C. 
 
N-(tert-butyl)-6-chloro-8-fluoro-2-(p-tolyl)quinolin-4-amine (9e) 
Synthesized in accordance with general procedure A. Isolated as a yellow 
solid (0.253 g, 78%). RF = 0.69 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR (500.23  
MHz, CDCl3): δ 7.98 (dd, J = 8.0, 2.0 Hz, 1H), 7.42 (s, 1H), 7.34-7.28 (m, 3H), 
7.17 (s, 1H), 4.86 (s, 0H), 2.42 (s, 3H), 1.59 (s, 9H). 13C NMR (125.97 MHz, 
CDCl3): δ 159.8, 157.8 (d, J = 18.5 Hz), 147.3 (d, J = 3.5 Hz), 138.4 (d, J = 
235.5 Hz), 138.2 (d, J = 11.0 Hz), 129.4, 128.5 (d, J = 11.0 Hz), 127.37, 120.6 
(d, J = 3.5 Hz), 114.7 (d, J = 23.0 Hz), 114.4 (d, J = 4.5 Hz), 100.1, 51.8, 29.3, 21.4. HRMS 
(ESI): m/z calculated for C20H21N2ClF+ [M+H]+ 343.1368, found: 343.1376. M.p.: 166-167 °C.  
 





Synthesized in accordance with general procedure A. Isolated as a yellow 
solid (0.231 g, 67%). RF = 0.58 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR 
(500.23  MHz, CDCl3): δ 8.08-7.98 (m, 2H), 7.89 (d, J = 6.5 Hz, 1H), 7.59 (d, 
J = 9.0 Hz, 1H), 7.47-7.39 (m, 2H), 7.34 (d, J = 9.0 Hz, 1H), 7.04 (s, 1H), 5.03 
(bs, 1H), 1.59 (s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 157.3, 149.5, 148.6, 
142.5, 135.0, 134.7, 129.9, 129.3, 129.0, 127.6, 125.5, 125.2, 120.5, 117.0, 




Synthesized in accordance with general procedure A. Isolated as a yellow solid 
(0.252 g, 77%). RF = 0.33 (cHex:EtOAc:NEt3 ; 4:1:0.05). 1H NMR (500.23  MHz, 
CDCl3): δ 8.09-8.01 (m, 3H), 7.68 (d, J = 8.5 Hz, 1H), 7.67-7.60 (m, 1H), 7.44-
7.37 (m, 1H), 7.19 (t, J = 8.5 Hz, 2H), 7.06 (s, 1H), 5.05 (bs, 1H), 1.60 (s, 9H). 
13C NMR (125.97 MHz, CDCl3): δ 163.4 (d, J = 248.0 Hz), 156.8, 148.8, 148.4, 
137.3 (d, J = 3.0 Hz), 130.4, 129.2 (d, J = 8.5 Hz), 129.1, 124.4, 118.9, 118.4, 
115.5 (d, J = 21.5 Hz), 98.7. HRMS (ESI): m/z calculated for C19H20N2F+ [M+H]+ 
295.1601, found: 295.1601. M.p.: 138 °C.  
 
N-(tert-butyl)-7-fluoro-2-(4-methoxyphenyl)quinolin-4-amine (9h) 
Synthesized in accordance with general procedure A. Isolated as a 
yellow solid (0.257 g, 79%). RF = 0.38 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H 
NMR (500.23  MHz, CDCl3): δ 8.11-7.99 (m, 2H), 7.78-7.57 (m, 2H), 7.13 
(t, J = 8.5 Hz, 1H), 7.08-6.93 (m, 3H), 4.97 (bs, 1H), 3.88 (s, 3H), 1.59 (s, 
9H). 13C NMR (125.97 MHz, CDCl3): δ 163.0 (d, J = 248.0), 160.5, 158.5, 
150.3 (d, J = 12 Hz), 148.4, 133.3, 128.8, 121.1 (d, J = 10.0 Hz), 114.0, 
113.7 (d, J = 19.5), 113.6 (d, J = 25.0 Hz), 98.3, 55.4, 51.6, 29.4). HRMS 
(ESI): m/z calculated +for C20H22N2FO+ [M+H]+ 325.1706, found: 326.1723. M.p.: 47-49 °C.  
 
N-(tert-butyl)-7-methoxy-2-phenylquinolin-4-amine (9i) 
Synthesized in accordance with general procedure A. Isolated as a bright 
yellow solid (0.236 g, 77%). RF = 0.29 (cHex:EtOAc:NEt3 ; 4:1:0.01). 1H 
NMR (500.23  MHz, CDCl3): δ 8.06 (m, 2H), 7.57 (d, J = 9.0, 1H), 7.54-7.47 
(m, 2H), 7.46-7.41 (m, 2H), 7.04 (dd, J = 2.5, 9.0 Hz, 1H), 7.02 s, 1H), 4.96 
(bs, 1H), 3.94 (s, 3H), 1.58 (s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 160.2, 
158.4, 150.7, 148.5, 141.3, 128.7, 128.6, 127.4, 120.2, 116.7, 112.9, 108.6, 
98.2, 55.4, 51.5, 29.4. HRMS (ESI): m/z calculated for C20H23N2O+ [M+H]+ 
307.1800, found: 307.1788. M.p.: 56-61 °C. 
 
N-(tert-butyl)-2-(3,4,5-trimethoxyphenyl)quinolin-4-amine (9j) 
Synthesized in accordance with general procedure A. Isolated as a yellow 
solid (0.319 g, 87%). RF = 0.10 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR 
(500.23  MHz, CDCl3): δ 8.06 (d, J = 8.5 Hz, 1H), 7.68 (d, J = 8.5 Hz, 1H), 7.63 
(t, J = 7.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.26 (s, 2H), 7.03 (s, 1H), 5.06 (bs, 
1H), 3.99 (s, 6H), 3.90 (s, 3H), 1.59 (s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 
157.8, 153.3, 184.6, 148.6, 148.4, 138.9, 130.3, 129.1, 124.4, 118.9, 118.4, 
104.9, 99.1, 60.3, 56.2, 51.5, 29.4. HRMS (ESI): m/z calculated for 






Synthesized in accordance with general procedure A. Isolated as a 
yellow solid (0.328 g, 82%). RF = 0.28 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H 
NMR (500.23  MHz, CDCl3): δ 8.03 (s, 1H), 7.60 (dd, J = 2.0, 9.0 Hz, 1H), 
7.33 (dt, J = 2.0, 9.0 Hz, 1H), 7.25 (d, J = 1.5 Hz, 2H), 7.02 (d, J = 1.5 Hz, 
1H), 5.00 (bs, 1H), 3.98 (s, 6H), 3.91 (s, 3H), 1.59 (s, 9H). 13C NMR (125.97 
MHz, CDCl3): δ 158.7, 153.3, 149.5, 148.4, 139.1, 136.6, 134.9, 129.2, 
124.9, 120.5, 116.9, 104.8, 99.2, 60.9, 56.3, 51.7, 29.3. HRMS 
(ESI): m/z calculated for C22H26N2O3Cl+ [M+H]+ 401.1621, found: 
401.1634. M.p.: 68-70 °C. 
 
Methyl 4-(tert-butylamino)-2-phenylquinoline-6-carboxylate (9l) 
Synthesized in accordance with general procedure A. Isolated as a yellow 
solid (0.147 g, 44%). RF = 0.38 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR 
(500.23  MHz, CDCl3): δ 8.49 (s, 1H), 8.19 (dd, J = 2.0, 8.5 Hz, 1H), 8.11-
8.02 (m, 3H), 7.56-7.49 (m, 2H), 7.49-7.45 (m, 1H), 7.15 (s, 1H), 5.27 (bs, 
1H), 3.99 (s, 3H), 1.62 (s, 9H). 13C NMR (125.97 MHz, CDCl3): δ 167.0, 
159.8, 151.3, 149.4, 140.7, 130.5, 129.3, 128.7, 128.6, 127.6, 125.2, 122.5, 
117.7, 99.5, 52.3, 51.9, 29.3. HRMS (ESI): m/z calculated for C21H23N2O2+ 
[M+H]+ 335.1749, found: 335.1759. M.p.: 131-134 °C.  
 
4-(4-(tert-butylamino)quinolin-2-yl)benzonitrile (9m) 
Synthesized in accordance with general procedure A. Isolated as a yellow 
solid (0.090 g, 31%). RF = 0.33 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR (500.23 
MHz, CDCl3): δ 8.18 (d, J = 8.5 Hz, 2H), 8.04 (dd, J = 1.5, 8.5 Hz, 1H), 7.79 (d, J 
= 8.5 Hz, 2H), 7.70 (dd, J = 1.5, 8.5 Hz, 1H), 7.66 (ddd, J = 1.5, 7.0, 8.5 Hz, 1H), 
7.45 (ddd, J = 1.5, 7.0, 8.5 Hz), 7.09 (s, 1H), 5.13 (bs, 1H), 1.61 (s, 9H). 13C NMR 
(125.97 MHz, CDCl3): δ 155.6, 148.7, 145.4, 132.5, 130.6, 129.4, 128.1, 125.1, 
119.0, 118.9, 118.6, 112.2, 98.7, 51.7, 29.3. HRMS (ESI): m/z calculated for 
C20H20N3+ [M+H]+ 302.1648, found: 302.1656. M.p.: 79-81 °C.  
 
N-(tert-butyl)-2-butylquinolin-4-amine (9n) 
Synthesized in accordance with general procedure A. Isolated as a brown solid 
(0.129 g, 50%). RF = 0.53 (EtOAc: Et3N ; 100:1). 1H NMR (500.23 MHz, CDCl3): δ 
7.91 (d, J = 8.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.59-7.53 (m, 1H), 7.35 (ddd, J = 
1.0, 7.0, 8.5 Hz, 1H), 6.57 (s, 1H), 4.91 (bs, 1H), 2.87-2.79 (m, 2H), 1.81-1.72 (m, 
2H), 1.54 (s, 9H), 1.51-1.40 (m, 2H), 0.96 (t, J = 7.5 Hz, 3H). 13C NMR (125.97 
MHz, CDCl3): δ 163.0, 148.4, 147.8, 129.5, 128.7, 123.7, 118.8, 118.1, 100.8, 
51.4, 39.6, 32.4, 29.3, 22.7, 14.1. HRMS (ESI): m/z calculated for C17H25N2+ [M+H]+ 257.2007, found: 
257.2023. M.p.: 68-70 °C. 
 
N-(tert-butyl)-2-decylquinolin-4-amine (9o) 
Synthesized in accordance with general procedure A. Isolated as 
a red-brown wax (0.255 g, 75%). RF = 0.62 (EtOAc:Et3N ; 
100:1). 1H NMR (500.23  MHz, CDCl3): δ 7.92 (d, J = 8.5 Hz, 1H), 
7.62 (d, J = 8.5 Hz, 1H), 7.56 (ddd, J = 1.5, 7.0, 8.5 Hz, 1H), 7.34 (t, 
J = 1.5, 7.5, 7.0 Hz, 1H), 6.57 (s, 1H), 4.91 (bs, 1H), 2.82 (t, J = 8.0 
Hz, 2H), 1.78 (p, J = 8.0 Hz, 2H), 1.53 (s, 9H), 1.46-1.38 (m, 2H), 1.38-1.32 (m, 2H), 1.31-1.21 (m, 10H), 
0.87 (t, J = 7.0 Hz, 3H). 13C NMR (125.97 MHz, CDCl3): δ 163.0, 148.4, 147.8, 129.5, 128.6, 123.7, 118.8, 




118.1, 100.8, 51.3, 39.9, 31.9, 30.2, 29.62, 29.58, 29.56, 29.3, 29.2, 22.6, 14.1. HRMS (ESI): m/z 
calculated for C23H37N2+[M+H]+ 341.2943, found: 341.2965. 
 
N-isopropyl-2-phenylquinolin-4-amine (9p) 
Synthesized in accordance with general procedure B. Isolated as a red-brown solid 
(0.216 g, 81%). RF = 0.16 (cHex:EtOAc:NEt3 ; 4:1:0.05). 1H NMR (500.23  MHz, 
CDCl3): δ 8.12 (m, 3H), 7.72 (d, J = 8.5 Hz, 1H), 7.68-7.61 (m, 1H), 7.51 (t, J = 7.5 
Hz, 2H), 7.48-7.38 (m, 2H), 6.89 (s, 1H), 4.87 (bd, J = 7.0 Hz, 1H), 4.04-3.92 (m, 1H), 
1.40 (dd, J = 1.5, 6.5 Hz, 6H). 13C NMR (125.97 MHz, CDCl3): δ 158.4, 149.0, 148.7, 
141.1, 130.3, 129.1, 128.7, 128.5, 127.5, 124.2, 119.0, 117.8, 97.0, 43.9, 22.5. 
HRMS (ESI): m/z calculated for C18H19N2+ [M+H]+ 263.1539, found: 163.1556. M.p.: 176 °C.  
 
N-cyclohexyl-6-fluoro-2-phenylquinolin-4-amine (9q) 
Synthesized in accordance with general procedure B. Isolated as a yellow solid 
(0.229 g, 80%). RF = 0.50 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR (500.23  MHz, 
CDCl3): δ 8.09-8.06 (m, 1H), 8.04 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 7.0, 2H), 7.47-
7.37 (m, 2H), 7.34 (dd, J = 2.0, 10.0, 1H), 6.86 (s, 1H), 4.71 (bd, J = 7.5 Hz, 1H), 
3.66-3.56 (m, 1H), 2.20 (dd, J = 4.0, 13.0, 2H), 1.89-1.81 (m, 2H), 1.76-1.70 (m, 
1H), 1.53-1.44 (m, 2H), 1.42-1.30 (m, 3H). 13C NMR (125.97 MHz, CDCl3): δ 
159.5 (d, J = 245.0), 157.9 (d, J = 2.5 Hz), 148.6 (d, J = 5.0 Hz), 145.7, 140.8, 
132.5 (d, J = 8.5 Hz), 128.9, 128.6, 127.5, 118.8 (d, J = 25.0 Hz), 118.2 (d, J = 8.0 Hz), 103.4 (d, J = 23.0 
Hz), 97.3, 51.3, 32.8, 25.7, 24.8. HRMS (ESI): m/z calculated for C21H22N2F+ [M+H]+ 321.1757, found: 
321.1776. M.p.: 146-149 °C.  
 
7-chloro-N-isopropyl-2-phenylquinolin-4-amine (9r) 
Synthesized in accordance with general procedure B. Isolated as a yellow solid 
(0.175, 60%). RF = 0.47 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR (500.23  MHz, 
CDCl3): δ 8.11-8.00 (m, 3H), 7.65 (d, J = 9.0 Hz, 1H), 7.53-7.48 (m, 2H), 7.47-
7.43 (m, 1H), 7.34(dd, J = 2.0, 9.0 Hz, 1H), 6.85 (s, 1H), 4.88 (bs, 1H), 4.04-3.91 
(m, 1H), 1.40 (d, J = 6.5 Hz, 6H). 13C NMR (125.97 MHz, CDCl3): δ 159.3, 149.4, 
149.2, 140.5, 135.0, 129.1, 129.0, 128.6, 127.5, 124.9, 120.6, 116.2, 97.2, 
44.1, 22.5. HRMS (ESI): m/z calculated for C18H18N2Cl+ [M+H]+ 297.1150, found: 297.1163. M.p.: 147-
148 °C.  
 
N-pentyl-2-phenylquinolin-4-amine (9s) 
Synthesized in accordance with general procedure B. Isolated as a red-brown 
wax (0.131 g, 48 %). RF = 0.35 (cHex:EtOAC:NEt3 ; 4:1:0.01). 1H NMR (500.23  
MHz, CDCl3): δ 8.14-8.06 (m, 3H), 7.72 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 7.5 Hz, 
1H)m 7.51 (t, J = 7.5 Hz, 2H), 7.47-7.38 (m, 2H), 6.86 (s, 1H), 5.00 (bt, J = 5.0 Hz, 
1H), 3.36 (q, J = 6.5 Hz, 2H), 1.79 (p, J = 7.5 Hz, 2H), 1.53-1.37 (m, 4H), 0.96 (t, J 
= 7.0 Hz, 3H). 13C NMR (125.97 MHz, CDCl3): δ 158.4, 150.1, 148.6, 141.0, 130.2, 
129.1, 128.8, 128.5, 127.5, 124.3, 119.0, 117.8, 96.6, 43.2, 29.3 28.6, 22.4, 14.0. HRMS 








Synthesized in accordance with general procedure B. Isolated as a yellow 
solid (0.074 g, 24%). RF = 0.39 (cHex:EtOAc:Et3N ; 4:1:0.01). 1H NMR (500.23  
MHz, CDCl3): δ 8.18 (d, J = 8.0 Hz, 2H), 8.07 (d, J = 8.5 Hz, 1H), 7.79-7.70 (m, 
3H), 7.67 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.5 Hz, 1H), 6.86 (s, 1H), 4.93 (bd, J = 
7.0 Hz, 1H), 4.05-3.96 (m, 1H), 1.41 (d, J = 6.5 Hz, 6H). 13C NMR (125.97 MHz, 
CDCl3): δ 156.8, 149.3, 148.7, 144.4, 130.6 (q, J = 32.5 Hz), 130.4, 129.4, 
127.8, 125.5 (q, J = 4.0 Hz), 124.8, 124.3 (q, J = 271.5 Hz), 119.0, 117.9, 96.8, 
40.0, 22.5. HRMS (ESI): m/z calculated for C19H18N2F3+ [M+H]+ 331.1413, found: 331.1429. M.p.: 60-
63 °C. 
 
Methyl 4-(cyclohexylamino)-2-(3,4,5-trimethoxyphenyl)quinoline-6-carboxylate (9u) 
Synthesized in accordance with general procedure B. Isolated as a 
dark yellow solid (0.167 g, 39%). RF = 0.13 (cHex:EtOAc:Et3N ; 
4:1:0.01). 1H NMR (500.23  MHz, CDCl3): δ 8.52 (d, J = 2.0 Hz, 1H), 
8.20 (dd, J = 2.0, 9.0 Hz, 1H), 8.03 (d, J = 9.0 Hz, 1H), 7.27 (s, 2H), 
6.80 (s, 1H), 5.19 (bd, J = 7.0 Hz, 4.11-3.95 (m, 9H), 3.91 (s, 3H), 3.63 
(dtt, J = 3.5, 7.0, 10.0 Hz, 1H), 2.24-2.17 (m, 2H), 1.97-1.82 (m, 2H), 
1.81-1.68 (m, 2H), 1.52-1.37 (m, 4H). 13C NMR (125.97 MHz, CDCl3): 
δ 167.0, 160.3, 153.3, 151.1, 149.9, 139.3, 136.5, 130.2, 128.8, 
125.1, 122.7, 117.0, 105.1, 97.1, 60.9, 56.3, 52.3, 51.5, 32.7, 25.6, 24.9. HRMS (ESI): m/z calculated for 
C26H31N2O5+ [M+H]+ 451.2220, found: 451.2236. M.p.: 141-143 °C.  
 
N1,N1-diethyl-N4-(2-phenylquinolin-4-yl)pentane-1,4-diamine (9w) 
Synthesized in accordance with general procedure B. Isolated as a red-
brown wax (0.287 g, 79%). RF = 0.09 (EtOAc:Et3N ; 100:1). 1H NMR (500.23  
MHz, CDCl3): δ 8.09-8.02 (m, 3H), 7.76 (d, J = 8.0 Hz, 1H), 7.67-7.60 (m, 1H), 
7.50 (t, J = 7.5 Hz, 2H), 7.47-7.37 (m, 2H), 6.86 (s, 1H), 5.18 (bd, J = 7.5 Hz, 
1H), 3.90-3.80 (m, 1H), 2.57 (q, J = 7.0 Hz, 4H), 2.50 (t, J = 7.0 Hz, 2H), 1.85-
1.75 (m, 1H), 1.73-1.63 (m, 2H), 1.37 (d, J = 6.5 H, 3H), 1.03 (t, J = 7.0 Hz, 
6H). 13C NMR (125.97 MHz, CDCl3): δ 158.5, 149.3, 148.8, 141.2, 130.3, 
129.1, 128.7, 128.6, 127.5, 124.2, 119.2, 117.9, 96.9, 52.6, 48.2, 46.8, 34.7, 23.8, 20.4, 11.4. HRMS 
(ESI): m/z calculated for C24H32N3+[M+H]+ 362.2584, found: 362.2595. 
 
N4-(3-(benzo[d][1,3]dioxol-5-yl)-6-chloronaphthalen-1-yl)-N1,N1-diethylpentane-1,4-diamine (9x) 
Synthesized in accordance with general procedure B. Isolated as a 
yellow-brown solid (0.327 g, 78 %). RF = 0.15 (EtOAc:NEt3 ; 99:1). 1H 
NMR (500.23  MHz, CDCl3): δ 7.98 (d, J = 2.0 Hz, 1H), 7.63 (d, J = 9.0 Hz, 
1H), 7.60 (d, J = 2.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.29 (d, J = 9.0 Hz, 
1H), 6.91 (d, J = 8.0 Hz, 1H), 6.76 (s, 1H), 6.01 (s, 2H), 5.25 (bd, J = 7.0 
Hz, 1H), 3.79 (hept, J = 6.5 Hz, 1H), 2.53 (q, J = 7.0 Hz, 4H), 2.46 (t, J = 
7.0 Hz, 2H), 1.81-1.65 (m, 2H), 1.65-1.59 (m, 2H), 1.34 (d, J = 6.5 Hz, 
3H), 1.00 (t, J = 7.0 Hz, 6H). 13C NMR (125.97 MHz, CDCl3): δ 158.6, 149.5, 149.3, 148.5, 148.0, 135.1, 
134.8, 128.9, 124.4, 121.5, 120.9, 116.3, 108.2, 107.9, 101.2, 96.5, 52.4, 48.2, 46.7, 34.5, 23.8, 20.2, 











Synthesized in accordance with general procedure B. Isolated as a red-
brown wax (0.326 g, 82%). RF = 0.14 (EtOAc:NEt3 ; 99:1). 1H NMR 
(500.23  MHz, CDCl3): δ 8.08-8.02 (m, 3H), 7.67 (d, J = 9.0 Hz, 1H), 7.50 
(t, J = 7.0 Hz, 2H), 7.48-7.40 (m, 1H), 7.33 (dd, J = 2.0, 9.0 Hz, 1H), 6.85 
(s, 1H), 5.29 (bd, J = 7.0 Hz, 1H), 3.82 (hept, J = 6.5, 1H), 2.54 (q, J = 7.0 
Hz, 4H), 2.47 (t, J = 7.0 Hz, 2H), 1.83-1.74 (m, 1H), 1.74-1.60 (m, 3H), 
1.36 (d, J = 6.5 Hz, 3H), 1.01 (t, J = 7.0 Hz, 6H). 13C NMR (125.97 MHz, 
CDCl3): δ 159.4, 149.6, 149.5, 140.7, 134.9, 129.1, 129.0, 128.6, 127.5, 124.7, 120.9, 116.4, 97.1, 52.5, 




Synthesized in accordance with general procedure B. Isolated as a red-
brown wax (0.268 g, 70 %). RF = 0.14 (EtOAc:NEt3 ; 99:1). 1H NMR 
(500.23  MHz, CDCl3): δ 7.71-7.64 (m, 1H), 7.53 (dt, J = 2.0, 10.5 Hz, 1H), 
7.06 (t, J = 8.5 Hz, 1H), 6.28 (d, J = 2.0 Hz, 1H), 5.16 (bd, J = 7.0 Hz, 1H), 
3.72 (p, J = 6.5 Hz, 1H), 2.72 (td, J = 3.0, 12.0 Hz, 1H), 2.52 (q, J = 7.0 Hz, 
4H), 2.45 (t, J = 7.0 Hz, 2H), 2.01-1.94 (m, 2H), 1.87-1.81 (m, 2H), 1.77-
1.69 (m, 2H), 1.65-1.50 (m, 5H), 1.42 (q, J = 11.5 Hz, 2H), 1.34-1.24 (m, 
1H), 1.30 (d, J = 6.5 Hz, 3H), 1.00 (td, J = 2.0, 7.0, 6H). 13C NMR (125.97 MHz, CDCl3): δ 168.7, 162.9 (d, 
J = 247.5 Hz), 149.6 (d, J = 12.5 Hz), 149.3, 121.5 (d, J = 10.5 Hz), 114.8, 113.1 (d, J = 25.0 Hz), 112.8 (d, 
J = 20.0 Hz), 96.3, 52.5, 48.0, 47.9, 46.7, 34.5, 32.89, 32.86, 26.5, 26.0, 23.7, 20.2, 11.2. HRMS 
(ESI): m/z calculated for C24H37N3F+[M+H]+ 386.2958, found: 386.2970. 
 
N-(6-methylheptan-2-yl)-2-(naphthalen-2-yl)quinolin-4-amine (9aa) 
Synthesized in accordance with general procedure B. Isolated as a red-brown 
solid (0.294 g, 77 %). RF = 0.26 (cHex:EtOAc:NEt3 ; 4:1:0.01). 1H NMR (500.23  
MHz, CDCl3): δ 8.57-8.53 (m, 1H), 8.26 (dd, J = 2.8, 8.5 Hz, 1H), 8.13 (d, J = 8.5 
Hz, 1H), 8.01-7.98 m, 1H), 7.98 (d, J = 9.0 Hz, 1H), 7.92-7.87 (m, 1H), 7.76-
7.72 (m, 1H), 7.67 (ddd, J = 1.5, 7.0, 8.5 Hz, 1H), 7.54-7.49 (m, 2H), 7.44 (ddd, 
J = 1.5, 7.0, 8.5 Hz, 1M), 7.01 (s, 1H), 4.90 (bd, J = 7.5 Hz, 1H), 3.89 (hept, J = 
6.5 Hz, 1H), 1.81-1.73 (m, 1H), 1.70-1.53 (m, 3H), 1.53-1.44 (m, 2H), 1.39 (d, J = 6.5 Hz, 3H), 1.30-1.24 
(m, 2H), 0.90 (d, J = 1.5 Hz, 3H), 0.89 (d, J = 1.5 Hz, 3H). 13C NMR (125.97 MHz, CDCl3): δ 158.2, 149.4, 
148.8, 138.3, 133.7, 133.4, 130.3, 129.3, 128.7, 128.2, 127.7, 126.9, 126.4, 126.1, 125.4, 124.4, 119.0, 
117.9, 97.0, 48.3, 38.9, 37.1, 27.9, 24.0, 22.60, 22.58, 20.4. HRMS (ESI): m/z calculated for 
C27H31N2+ [M+H]+ 383.2475, found: 383.2490. M.p.: 128-129 °C. 
 
ethyl 4-((7-chloro-2-phenylquinolin-4-yl)amino)piperidine-1-carboxylate (9ab) 
Synthesized in accordance with general procedure B. Isolated as a 
yellow-orange solid (0.277 g, 68%). RF = 0.11 (cHex:EtOAc:NEt3 ; 
4:1:0.01). 1H NMR (500.23  MHz, CDCl3): δ 8.07 (d, J = 2.0 Hz, 1H), 8.05-
8.03 (m, 1H), 8.03-8.01 (m, 1H), 7.65 d, J = 9.0 Hz, 1H), 7.68-7.62 (m, 
2H), 7.50-7.42 (m, 1H), 7.35 (dd, J = 2.0, 9.0 Hz, 1H), 6.85 (s, 1H), 4.95 
(bs, 1H), 4.32-4.25 m, 2H), 4.17 (q, J = 7.0 Hz, 2H), 3.80 (tdt, J = 4.0, 7.5, 
10.5 Hz, 1H), 3.08 (t, J = 12.5 Hz, 2H), 2.28-2.14 (m, 2H), 1.64-1.48 (m, 
2H), 1.29 (t, J = 7.0 Hz, 3H). 13C NMR (125.97 MHz, CDCl3): 159.3, 155.4, 
148.7, 140.3, 135.3, 129.3, 129.1,128.7, 127.6, 125.2, 120.6, 116.2, 97.2, 61.6, 49.7, 42.6, 31.7, 14.7. 







N1,N1-diethylpentane-1,4-diamine (3.87 mL, 20 mmol) was refluxed in ethyl 
formate (4.82 mL, 60 mmol) for 16 h., after which the solvent was removed in 
vacuo. A solution of the crude product (3.00 g, 16.1 mmol) in dry DCM (80 mL) 
was added DIPEA (7.01 mL, 40.25 mmol) and cooled to -40°C. Triphosgene (1.67 g, 5.64 mmol) was 
added portionwise, after which the mixture was allowed to warm to 0°C, and stirred for 2h. The crude 
product was poured in water (80 mL), and the organic layer was dried over Na2SO4 and concentrated 
in vacuo to afford the title compound as a pale yellow liquid (2.370 g, 88%). RF = 0.11 
(EtOAc:MeOH:Et3N ; 9:1:0.09). 1H NMR (500.23  MHz, CDCl3): δ 3.71-3.59 (m, 1H), 2.52 (q, J = 7.0 Hz, 
4H), 2.44 (t, J = 7.0 Hz, 2H), 1.70-1.52 (m, 4H), 1.37 (dt, JHN = 2.0 Hz, JHH = 7.0 Hz, 3H), 1.02 (t, J = 7.0 
Hz, 3H). 13C NMR (125.97 MHz, CDCl3): δ 154.2 (t, JC(sp)N = 5.0 Hz), 52.0, 50.3 (t, JC(sp3)N = 5.5 Hz), 46.8, 
34.8, 23.3, 21.8, 11.6. HRMS (ESI): m/z calculated for C10H21N2+ [M+H]+ 169.1695, found: 169.1705. 
 
ethyl 4-isocyanopiperidine-1-carboxylate (7ab) 
 Ethyl 4-aminopiperidine-1-carboxylate (4.03 mL, 29.0 mmol)  was refluxed in 
ethyl formate (7.01 mL, 87.1 mmol) for 16 h., after which the solvent was 
removed in vacuo. To a solution of the crude formamide (3.10 g, 15.5 mmol) in 
dry DCM (45 mL) was added Et3N (4.32 mL, 31 mmol). The solution was cooled 
to -40 °C, after which triphosgene (1.61 g, 5.52 mmol) was added portionwise. The resulting mixture 
was slowly warmed to room temperature, and stirred for 3 h. Hereafter, the reaction was quenched 
with ice-water (50 mL), and the resulting biphasic system was separated. The organic layer was 
washed with 1 M HCl, saturated NaHCO3, and water, dried over Na2SO4, filtered, and concentrated in 
vacuo, affording the target isocyanide as a pale yellow oil. (2.471 g, 88 %). RF = 0.16 (cHex:EtOAc:NEt3 
; 4:1:0.01). 1H NMR (500.23  MHz, CDCl3): δ 4.12 (q, J = 7.0 Hz, 2H), 3.89-3.81 (m, 1H), 3.60 (ddd, J = 
3.5, 8.0, 14.0 Hz, 2H), 3.54-3.44 (m, 1H), 1.93-1.83 M, 2H), 1.83-1.75 (m, 2H), 1.25 (t, J = 7.0 Hz, 3H). 
13C NMR (125.97 MHz, CDCl3): 156.2 (t, J = 5.0 Hz), 155.2, 61.6, 49.3 (t, J = 6.0 Hz), 40.0, 31.2, 14.6. 
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Abstract: Herein we report a novel 3-component reaction affording 4-
aminobenzoxazin-2-ones and 4-aminoquinazolin-2-ones, using sodium cyanate as a 
coupling partner in the imidoylative cross-coupling. The yields of both the 
benzoxazin-2-ones and the quinazolin-2-ones are moderate, and dependent on the 
substituent pattern of the corresponding aryl halide input. However, this synthetic 
strategy allows us to generate two rather underexplored bicyclic aromatic 
heterocyclic cores in a one-pot reaction. As such, this method can serve as a stepping 
stone to further develop multicomponent and cascade reactions initiated by metal-








After the excellent results on the palladium-catalyzed 3-CR imidoylations for the 
synthesis of nitrogen heterocycles (Chapter 3), we wanted to further explore this 
chemistry. As such, we were most curious about utilizing a similar method, based 
on aryl halides decorated with an pendant nucleophile. We envisioned a similar 
post-imidoylative cyclization cascade, which would generate intermediates similar 
to the electrophilic ynimine 3 (Scheme 1), which are prone to undergo 
cycloaromatization. To develop this chemistry towards a 3-CR, we were interested 
in incorporating a carbamoyl group as an internal electrophile.  
We realized that a carbamoyl functionality could be readily installed by using 
primary carbamates in combination with aryl halides 1 and isocyanides 2. This 
would replace the Sonogashira reactivity with a Buchwald-Hartwig-type 
imidoylamidation, generating imidoyl carbamates 5, which in turn would form the 
unusual benzoxazin-2-ones or quinazolin-2-ones 6 upon cycloaromatization. 
 
Scheme 1. Imidoylative cross-couplings with aryl halides bearing an internal nucleophile. 
The benzoxazin-2-one heterocyclic core is a useful scaffold and has been reported 
as a substructure in DNA topoisomerase IV inhibitors[1], cathepsin S inhibitors[2] or 
DNA gyrase inhibitors[1], as well as EGFR tyrosine kinase inhibitors (Figure 1).[3] 
Additionally, using o-bromoanilines as starting materials would afford quinazolin-
2-ones via a similar mechanism. Quinazolin-2-ones are reported i.a. as NSAIDs 
(proquazone).[4] Furthermore, aza-analogous 4-aminoquinazolin-2-ones show 
medicinal promise as MCHr1 antagonists[5] (Figure 1). 




Figure 1. Medicinal compounds with a benzoxazin-2-one or quinazolin-2-one core. 
Traditional methods to construct substituted 4-aminobenzoxazin-2-ones 9 start 
from cyanophenols 7 and isocyanates 8 and involve a two-stage condensation.[6] 
However, only aromatic isocyanates have been reported as successful inputs for 
this procedure. Alternatively, 2-hydroxybenzamidines can be treated with 
triphosgene (11) to afford similar benzoxazin-2-ones 12.[7] This methodology 
affords 4-aminobenzoxazin-2-ones in high yields, but requires the use of complex 
starting materials 10 (Scheme 2), which are not readily available. 
 







Compared to the benzoxazin-2-one scaffold, 1-substituted 4-aminoquinazolin-2-
ones 14 are much more common in synthetic chemistry. However, most complex 
substituted motifs are derived from readily deprotected 3-substituted 
quinazolinediones 13. These quinazolinediones can be reliably converted to 4-
aminoquinazolin-2-ones 14 through POX3-mediated dehydration and subsequent 
SNAr, although this typically requires at least four reactions, depending on the 
amine substituent.[5]  
In short, a modular Buchwald-Hartwig-type imidoylamidation/cycloaromatization 
cascade would significantly improve existing synthetic methodologies to access 
these relatively underexplored but interesting heterocyclic scaffolds. Here we 
report our initial results towards such a one-pot three-component protocol. 
4.2. Results and Discussion 
Initial attempts for the one-pot 3-CR of o-bromophenol (15a), tert-butyl isocyanide 
(16a) and methyl carbamate (17) gave disappointing isolated yields of the desired 
benzoxazin-2-one 12a. However, in apolar solvents under strong basic conditions, 
conversions were in typically rather promising (Table 1, Entry 1-6, selected results). 
This motivated us to do an extensive optimization study varying the solvent, ligand, 
and base. We were pleased to find that performing the reaction in DMF, using K3PO4 
as the base afforded the product 12a in higher, albeit still moderate yields (entries 
9 and 10). The use of other bases in DMF with either lower or higher pKa values 
gave unsatisfactory yields of 12a (entries 7 and 8, selected results). Switching to 
DMSO and further ligand screening indicated dppf to be the most effective ligand, 
giving superior results when used in combination with K3PO4 (entry 11-15). 
However, when we substituted methyl carbamate with sodium cyanate, 
benzoxazin-2-one 12a was formed in considerably higher yields. (entry 16-18). 
Notably, tetramethylguanidine (TMG) affords the product 12a in comparable yields 
to K3PO4 (entry 17). The addition of molecular sieves to the reaction mixture further 
increased the yield of benzoxazin-2-one 12a to 72 % (entry 21). Although 
microwave heating generated the same product in only 20 minutes, this led to a 
somewhat lower yield (67 %, entry 22). 
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Table 1. Optimization of 3-component synthesis of benzoxazin-2-one 12a. 
 
Entry Solvent Ligand Base Conversion (%) Yield 12a (%) 
1 MePh PPh3 KOtBu >99 3 
2 MePh XantPhos TMEDA 23 - 
3 MePh dppe K3PO4 >99 - 
4 Dioxane Bu3P KOtBu 90 - 
5 Dioxane XantPhos TMEDA 22 - 
6 Dioxane dppe K3PO4 89 3 
7 DMF PPh3 TMEDA 0 - 
8 DMF dppe KOtBu 35 - 
9 DMF Bu3P K3PO4 55 23 
10 DMF Xantphos K3PO4 70 34 
11 DMSO DPEPhos K3PO4 74 15 
12 DMSO Xantphos K3PO4 15 8 
13 DMSO dppe K3PO4 82 23 
14 DMSO CyJohnPhos K3PO4 71 30 
15 DMSO dppf K3PO4 89 52 
16b DMSO dppf Cs2CO3 100 55 
17b DMSO dppf TMG 78 58 
18b DMSO dppf K3PO4 95 61 
19b,c DMSO dppf TMEDA 98 42 
20b,c DMSO dppf TMG 97 70 
21b,c DMSO dppf K3PO4 100 72 
22b,c,d DMSO dppf K3PO4 97 67 
a Reaction conditions: 15a (0.5 mmol), 16a (1.5 mmol, 3.0 eq.), 17, (1.5 mmol, 3.0 eq.), Pd(OAc)2 (5 
mol%) and ligand (20 mol% for monodendates and 10 mol% for bidentates) and base (1.5 mmol, 
3.0 eq.), stirred under N2 atmosphere for 16 h. at 100 °C. b 4 Å molecular sieves added (1.0 g/mmol). 
c NaNCO (1.5 mmol, 3.0 eq) was used instead of 17. d Heated to 140 °C by microwave irradiation, 
closed vial. 
 
A notable side product that we observed is salicylamide 18. We believe that  
competing hydroxyimidoylation may occur due to the relatively low nucleophilicity 
of the carbamate coupling partner. Performing the reaction under dry conditions, 
in the presence of molecular sieves mostly prevents this side reaction. With these 
conditions in hand, we set out to investigate the scope of this cross-coupling 
cascade. Although GC optimization studies showed that benzoxazinone 12a was 







Scheme 3. Scope of ICCC cascade. 
Decoration of the o-bromophenol 15 with a chloride substituent leads to a 
significant drop in the isolated yield of the corresponding product 12b, most likely 
due to the lower electron density of the phenolate. In this case, significantly more 
of the side product (5-chloro)salicylamide was formed, even under dry conditions. 
Alternatively, using the more electron-rich 5-bromosesamol led to a slightly higher 
isolated yield of the corresponding benzoxazinone 12c (52 %). Efforts to insert 
different isocyanide inputs did not afford isolable quantities of the cyclohexyl 
analog 12d. Ineffective palladium-catalyzed imidoylations with non-tertiary 
isocyanides has been reported multiple times before.[8]   
As an extension of this methodology, we also envisioned the aza-analogous cross-
coupling of o-bromoanilines with cyanate and isocyanides. To this end, we 
performed a minor optimization study, probing for more effective catalytic 
conditions. Initially, DMF appeared to give superior results, compared to the 
benzoxazin-2-one formation (Table 1 vs. Table 2). This 3-CR coupling towards 
quinazolin-2-ones 21a product formation is observed using various types of ligands 
(Table 2, entry 1-6). Further optimization of the employed base indicated K3PO4 is 
preferred in this transformation (entry 5). Interestingly, this transformation is 
successful even with more nucleophilic bases like NaOH and NaNH2, albeit only with 
moderate yields of 21a (entry 7-8). Switching the solvent to DMSO led to a 
moderate increase in the yield of 21a, and an additional optimization indicated 
DPEPhos to be the optimal ligand, in combination with K3PO4 as a base.  
Palladium-Catalyzed Imidoylative Cyanate Coupling/Cyclization Cascade of Aryl Halides, Isocyanides and Cyanates. 
 
145 
Again, the addition of molecular sieves increased the yield of 21a, although the 
effect was less pronounced than in the synthesis of these benzoxazin-2-ones 12. In 
all tested cases, using microwave irradiation afforded the quinazolin-2-one 21a in 
higher yield than the use of conventional heating, contrary to the synthesis of 
benzoxazin-2-ones 12.  
With these conditions in hand, we set out to investigate the scope of this 
transformation with various o-bromoanilines. Using microwave irradiation, 21a was 
isolated in a reasonable 72 % yield, compared to 47 % for the oxo-analogous 
benzoxazin-2one 12a. With this 3-CR methodology the methyl analog 21b could be 
isolated in 48 %. This is likely because of the decreased steric hindrance around the 
intermediate palladium complexes in combination with the fact that this 
methylated analog was less readily purified by column chromatography, due to 
increased tailing. 
Table 2. Optimization of 3-component synthesis of quinazolin-2-one 21a. 
 
Entry Solvent Ligand Base Yield 21a 
1 DMF PPh3 K3PO4 8 
2 DMF XantPhos K3PO4 13 
3 DMF (±)-BINAP K3PO4 22 
4 DMF dppb K3PO4 61 
5c DMF dppf K3PO4 65 
6b DMF dppf K3PO4 36 
7 DMF dppf NaOH 26 
8 DMF dppf NaNH2 35 
9 DMF dppf KOtBu - 
10 DMF dppf Cs2CO3 36 
11 DMSO dppf K3PO4 61 
12 DMSO DPEPhos K3PO4 67 
13 DMSO DPEPhos K2CO3 59 
14 DMSO dppb K3PO4 29 
15c DMSO DPEPhos K3PO4 73 
a Reaction conditions: 20a (0.5 mmol), 16a (1.5 mmol, 3.0 eq.), 19, (1.5 mmol, 3.0 eq.), Pd(OAc)2 
(5 mol%) and ligand (20 mol% for monodendate and 10 mol% for bidentate) and base (1.5 
mmol, 3.0 eq.), stirred under N2 atmosphere for 16 h. at 100 °C. b Reaction was performed in 







Scheme 4. Scope of ICCC cascade synthesis of 4-aminoquinazolin-2-ones 
Unfortunately, the reaction of unsubstituted bromoaniline 20 (R = H) did not afford 
quinazolin-2-one 21c. Rather, the strong intramolecular coordination of the 
unhindered amine to the aryl palladium intermediate facilitates a double 
imidoylative Buchwald-Hartwig coupling, generating isatin diimine 22 as the main 
product (65 % yield). This reactivity was described by Jiang et al. in 2015.[9] We 
expect the additional steric hindrance of a substituent on the aniline nitrogen to be 
a prerequisite for the cyanate transmetalation to outcompete double isocyanide 
insertion. In order to liberate the more chemically diverse N-unsubstituted 4-
aminoquinazolin-2-one 23, the purified insertion product 21a was subjected to 5 
equivalents of triflic acid in CH2Cl2. This method allowed for the direct isolation of 
the de-tert-butylated product 23 in near-quantitative yields.  
 
Scheme 5. Synthesis of free aminoquinazolin-2-one through acid-mediated de-tert-butylation. 
Mechanistically, the imidoylative cross-coupling likely follows the traditional 
reaction pathway.[10] Here, oxidative addition of the aryl halide to the in situ 
generated Pd0 complex affords the intermediate arylpalladium species I, which can 
undergo a 1,1-migratory insertion of ligated isocyanide (Scheme 6). The resulting 
imidoyl palladium species II subsequently undergoes transmetalation with sodium 
cyanate. Direct, non-imidoylative cross-coupling of aryl halides and cyanates 
indicates an O-selective reductive elimination of IIIb to the corresponding cyanate 
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ester is unlikely.[11] Additionally, no O-coupling intermediates[12] were observed. As 
such, intermediate III is expected to afford the imidoyl isocyanate 24 upon 
reductive elimination, which generates the bicycles 6 via cycloaromatization. 
Alternatively, earlier reports on the carbonylative synthesis of similar structures 
imply the transmetalation step is only successful if the coordinated cyanate is 
substituted with any ambient nucleophile.[13]  In our imidoylative case, the exact 
mechanistic pathway is currently not fully known. 
 
Scheme 6. Tentative generalized mechanism. 
4.3. Conclusion 
By combining 2-brominated anilines or –phenols, isocyanides and cyanates with a 
palladium catalyst, we were able to synthesize several substituted 4-
aminobenzoxazin-2-ones and 4-aminoquinazolin-2-ones. We believe the rapid 
development of MCRs combined with palladium-catalyzed isocyanide insertions 
has a high potential for the efficient generation of molecular complexity in a single 
reaction vessel. This project utilized the inherent cascade nature of isocyanide 
insertions with the use of cyanate as a nucleophile in a novel palladium-catalyzed 
3-CR towards synthetically and medicinally valuable bicyclic systems. 
Unfortunately, the yields are still moderate, and the method needs further 





4.4. Experimental Section 
General remarks 
Chemicals were purchased from Sigma Aldrich or Fluorochem and were used without purification. 
Solvents were purchased from VWR Chemicals (CH2Cl2), or Sigma Aldrich (toluene, dioxane, DMSO) 
and used without purification, unless stated otherwise. Dry solvents were dried over an Inert PS-MD-
5 Solvent Purification System, equipped with an activated alumina/copper wire column. 1H NMR 
measurements were acquired on a Bruker Avance 300 (300.13 MHz) or Bruker Avance 500 (500.23 
MHz) spectrometer. 13C NMR measurements were acquired on a Bruker Avance 500 (125.78 MHz) 
spectrometer. Chemical shifts are reported in ppm downfield of tetramethylsilane, and are corrected 
according to solvent. Mass analysis was performed using a Bruker MicrOTOF-Q instrument on a 
positive ion polarity mode for ESI (Electrospray Ionization). Capillary charge: 4000V. Melting points 
were measured using a Büchi M-565 melting point apparatus. SiO2 column chromatography was 
performed using Merck Silica Gel C60 (particle size 40-60 μm). TLC chromatography was performed 
on Merck Silica Gel C60 F254 plates (silica coat on aluminum support). All isolated yields are corrected 
for impurities (if present). 
 
General procedure A for the synthesis of 4-tert-butylbenzoxazin-2-ones 12 from o-bromophenols, 
sodium cyanate and tert-butyl isocyanide: 
A solution of Pd(OAc)2 (0.006 g, 0.025 mmol) and dppf (0.028 g, 0.05 mmol) in dry DMSO (2 mL) was 
stirred for 20 min at RT under N2 atmosphere. To this mixture were sequentially added 4 Å molecular 
sieves (0.5 g), K3PO3 (0.319 g, 1.5 mmol), NaNCO (0.098 g, 1.5 mmol), o-bromophenol (0.5 mmol), and 
tert-butyl isocyanide (0.141 mL, 1.25 mmol). The resulting mixture was stirred under nitrogen 
atmosphere, at 100 °C for 16 h. Hereafter, the heating mantle was removed, and the suspension was 
allowed to cool to rt. The crude mixture was diluted with CH2Cl2 (~20 mL), and sat. aqueous NaHCO3 
(~20 mL) and transferred to a separatory funnel. The layers were separated, and the organic layer was 
extracted 5 times with 20 mL sat NaHCO3 to ensure complete removal of DMSO. The organic layers 
were combined, dried over Na2SO4, and loaded onto silica. Purification took place through column 
chromatography (gradient; cHex:EtOAc:NEt3 = 9:1:0.01 – 1:1:0.01) 
 
General procedure B for the synthesis of 4-tert-butylquinazolin-2-ones 21 from N-substituted o-
bromoanilines, sodium cyanate and tert-butyl isocyanide: 
A solution of Pd(OAc)2 (0.006 g, 0.025 mmol) and DPEPhos (0.028 g, 0.05 mmol) in dry DMSO (2 mL) 
was stirred for 20 min at RT under N2 atmosphere. To this mixture were sequentially added 4 Å 
molecular sieves (0.5 g), K3PO3 (0.319 g, 1.5 mmol), NaNCO (0.098 g, 1.5 mmol), o-bromoanilines (0.5 
mmol), and tert-butyl isocyanide (0.141 mL, 1.25 mmol). The vial was capped, and the mixture was 
heated by microwave irradiation to 120 °C for 30 minutes. Hereafter, the formed suspension was 
allowed to cool to rt. The crude mixture was diluted with CH2Cl2 (~20 mL), and sat. aqueous NaHCO3 
(~20 mL) and transferred to a separatory funnel. The layers were separated, and the organic layer was 
extracted 5 times with 20 mL sat NaHCO3 to ensure complete removal of DMSO. The organic layers 
were combined, dried over Na2SO4, and loaded onto silica. Purification took place through column 
chromatography (gradient; cHex:EtOAc:NEt3 = 9:1:0.01 – 1:1:0.01) 
 
N-methyl-2-bromoaniline  
Synthesized in accordance with literature.[14] To a solution at -78°C of 2-bromoaniline 
(100 mmol, 17.2 g) in THF (200 mL),  BuLi (2.5 M in Hexane, 20.0 mL, 50 mmol) was 
added dropwise, after which the reaction was stirred at the same temperature for 15 
min. Then iodomethane (6.85 mL, 110 mmol) was added dropwise. The reaction was 
stirred at room temperature for 14 hours. The mixture was quenched with H2O (200 mL) and extracted 
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with EtOAc (3 x 10 mL). The combined organic extracts were washed with brine, dried over Na2SO4 
and concentrated to afford a colorless oil, which was purified by chromatography on silica gel eluting 
with cHex : EtOAc (20:1-10:1) to afford the title compound as a light yellow oil (5.902 g, 64 %). The 
spectral data corresponded to the literature.[15] RF = 0.80 (cHex : EtOAc = 4:1). 1H NMR (500 MHz, 
CDCl3) δ 7.42 (dd, J = 7.9, 1.5 Hz, 1H), 7.22 (ddd, J = 8.1, 7.3, 1.5 Hz, 1H), 6.66 (d, J = 8.1 Hz, 1H), 6.59 
(td, J = 7.5, 1.5 Hz, 1H), 4.66 (bs, 1H), 2.90 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 145.6, 132.3, 128.5, 
117.9, 111.0, 109.7, 30.7. 
 
N-benzyl-2-bromoaniline 
Synthesized in accordance with the literature.[16] To a solution of 2-bromoaniline 
(8.6 g, 50 mmol) and benzaldehyde (7.96 g, 75 mmol) in methanol (200 mL) was 
added acetic acid (4.5 g, 75.0 mmol), and the reaction was stirred at room 
temperature for 30 min. Then, the reaction was cooled down to 0 °C, and sodium 
cyanoborohydride (4.7 g, 75 mmol) was added in two portions over 30 min. The 
reaction was allowed to stir from 0 °C to room temperature until complete by TLC. 
The reaction was quenched with a saturated aq solution of Na2CO3 (90 mL) and 
then extracted with ether (3 × 30 mL). The combined organic layers were dried with anhydrous Na2SO4 
filtered, and the solvent was removed under reduced pressure. The crude was purified by column 
chromatography on silica gel in cHex: CH2Cl2 (3:1) ether to afford the title compound as a white solid 
(8.4 g, 64 %). The spectral data corresponded to the literature.[16]  RF = 0.72 (cHex: CH2Cl2= 3:2). 1H 
NMR (500 MHz, CDCl3) δ 7.45 (dd, J = 7.9, 1.5 Hz, 1H), 7.41 – 7.32 (m, 4H), 7.34 – 7.26 (m, 1H), 7.13 
(ddd, J = 8.5, 7.3, 1.5 Hz, 1H), 6.64 (dd, J = 8.1, 1.5 Hz, 1H), 6.60 (td, J = 7.6, 1.5 Hz, 1H), 5.13 (bs, 1H), 




Synthesized according to general procedure A, isolated as a colorless solid (0.051 g, 
47 %) RF = 0.13 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 7.61 – 7.56 (m, 2H), 
7.25 – 7.21 (m, 2H), 6.21 (s, 1H), 1.58 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 161.1, 
155.7, 152.3, 134.4, 123.4, 121.5, 117.4, 109.9, 54.0, 28.4. HRMS (ESI): m/z 
calculated for C12H15N2O2 [M+H]+ = 219.1128, found = 219.1126.  
 
 
4-(tert-butylamino)- -chloro-2H-benzo[e][1,3]oxazin-2-one (12b) 
Synthesized according to general procedure A, isolated as an off-white solid (0.028 g, 22 %).  1H 
NMR (500 MHz, CDCl3) δ. 7.66 (d, J = 2.3 Hz, 1H), 7.53, dd, J = 8.8,  2.3 Hz, 1H), 
7.19 (d, J = 8.8 Hz, 1H), 6.37 (bs, 1H), 1.57 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 
160.4, 154.5, 152.3, 134.8, 129.1, 122.1, 119.2, 111.4, 54.8, 28.7. HRMS (ESI): 
m/z calculated for C12H14ClN2O2 [M+H]+ = 253.0738, found = 253.0749.  
 
 
8-(tert-butylamino)-6H-[1,3]dioxolo[4',5':4,5]benzo[1,2-e][1,3]oxazin-6-one  (12d) 
Synthesized according to general procedure A, isolated as an off-white solid 
(0.068 g, 52 %). 1H NMR (500 MHz, CDCl3) δ 6.89 (s, 1H), 6.69 (s, 1H), 6.06 (s, 
2H), 5.82 (bs, 1H), 1.56 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 161.4, 153.6, 153.3, 
153.2, 144.8, 103.2, 102.7, 99.5, 98.5, 54.3, 28.9. HRMS (ESI): m/z calculated 







Synthesized according to the general procedure B, isolated as a colorless solid 
(0.111 g, 72 %). RF = 0.12 (cHex:EtOac = 2:1). 1H NMR (500 MHz, CDCl3) δ 7.53 
(d, J = 7.9 Hz, 1H), 7.44 (dd, J = 8.6, 7.0 Hz, 1H), 7.28 (m, 4H), 7.22 (td, J = 6.0, 2.6 
Hz, 1H), 7.09 (dd, J = 8.1, 5.6 Hz, 2H), 5.81 (bs, 1H), 5.42 (s, 2H), 1.62 (s, 9H).  13C 
NMR (126 MHz, CDCl3) δ 159.5, 156, 142.6, 137.0, 133.8, 128.9, 127.3, 126.9, 
122.7, 121.6, 115.5, 111.0, 53.6, 47.2, 29.1. HRMS (ESI): m/z calculated for 




Synthesized according to the general procedure B, isolated as a colorless solid 
(0.056 g, 48 %). RF = 0.08 (cHex:EtOac = 2:1). 1H NMR (500 MHz, CDCl3) δ 7.60 (t, J = 
7.7 Hz, 1H), 7.54 (d, J = 7.7 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 7.14 (t, J = 7.3 Hz, 1H), 
5.72 (bs, 1H), 3.59 (s, 3H), 1.58 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 159.2, 156.0, 
143.1, 133.5, 122.2, 121.1, 114.3, 110.6, 53.0, 30.5, 28.8. HRMS (ESI): m/z 
calculated for C13H17N3O = 232.1445, found = 232.1444. M.p.: 214-215 °C. 
 
4-amino-1-benzyl-quinazolin-2-(1H)-one (23) 
To a solution of N-benzyl-4(tert-butylamino)quinazolin-2(1H)-one 21b (0.5 mmol, 
154 mg) in CH2Cl2 (5 mL)  was added triflic acid (2.5 mmol, 375 mg). The mixture 
was stirred for 16 hours at room temperature. Hereafter, water (2 mL) and 
saturated Na2CO3 (3 mL) were added and stirred until gas formation ceased. Then 
the mixture was extracted using (3 x 10 ml) CH2Cl2, dried over Na2SO4. The solvent 
was removed in vacuo, to afford the pure title compound as a colorless solid 
(0.124 g, 99 %). 
 RF = 0.06 (CH2Cl2:MeOH = 98:2). 1H NMR (500 MHz, DMSO-d6) δ 8.07 (dd, J = 8.0, 
1.5 Hz, 1H), 8.00 (bs, 1H), 7.86 (bs, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.33-7.23 (m, 2H), 7.24-7.12 (m, 5H), 
5.32 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.0, 155.7, 142.4, 137.5, 134.0, 128.5, 126.9, 126.5, 
125.0, 121.0, 114.7, 109.7, 45.4. HRMS (ESI): m/z calculated for C15H14N3O [M+H]+ = 252.1131, found 
= 252.1109. M.p.: 201-202 °C 
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Synthesis of Polysubstituted Pyrimidouracils by Nickel-Catalyzed 





Abstract: In this chapter, we report a robust nickel-catalyzed oxidative isocyanide 
insertion/C-H amination by reaction of N-uracil-amidines with isocyanides to afford 
polysubstituted pyrimidouracils. The reaction  proceeds in moderate to quantitative 
yield, under mild conditions (i.e. green solvent, air atmosphere, moderate 
temperature). The broad range of structurally diverse isocyanides and N-uracil-
amidines that are tolerated make this method an interesting alternative to the 













The field of transition metal-catalyzed isocyanide insertions has traditionally been 
dominated by palladium catalysis[1], but the last couple of years have seen a surge 
in row IV base metal catalysis.[2] Next to their higher natural abundancy and lower 
cost, which render these base metals more interesting from an economic and 
sustainability standpoint, row IV metals can also participate in one-electron 
transfer processes.[3] This reactivity is not observed in palladium catalysis, and 
opens up new, mechanistically distinct reaction pathways for the synthesis of 
heterocyclic  
 
Figure 1. Selected pyrimidouracils and related heterocycles 
scaffolds. For example, fused pyrimidine scaffolds commonly occur in nature, and 
related heterocycles have been reported to demonstrate a variety of biological 
activities, like adenosine potentiating (coronary dilatators),[4] antioxidant,[5] 
antifungal,[6] antiviral,[7] and antibacterial[8] activities. Additionally, similar 
structures have been reported as phosphoribosyl-1-pyrophosphate synthetase 
inhibitors[9] and dihydrofolate reductase inhibitors[10] (Figure 1).  
  
Scheme 1. Direct oxidative and oxidative imidoylative amination of N-uracil-amidines 
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Although these pyrimidouracils show promise as biologically active scaffolds, the 
current syntheses have a very narrow scope, utilize highly specific reactants, or 
require harsh conditions. Recently, we reported the Cu(I)-catalyzed oxidative 
amination of N-uracil-amidines 1 to afford substituted xanthines (Scheme 1).[11] We 
envisioned that combining this reactivity with isocyanide insertion could provide 
efficient access to pyrimido[4,5-d]pyrimidine-2,4-diones (pyrimidouracils) (Scheme 
1). The starting material N-uracil-amidines (1) are readily available from 6-
chlorouracils.[11]  
5.2. Results and discussion 
We started our studies to develop an intramolecular imidoylative amination 
towards functionalized pyrimidouracils with the model reaction of N-(1,3-
dibenzyluracil)benzamidine 1a and t-BuNC (2a). When applying the reaction 
conditions developed to obtain 1,3-dibenzyl-8-phenylxanthine (Scheme 1) in 
combination with 2a, no formation of the desired compound 3a was observed, 
irrespective of the oxidant.[11] Extensive optimization of the transition metal led to 
Ni(OAc)2.4H2O as the most effective catalyst.[12] Nickel catalysis has been 
extensively investigated in polymerization of isocyanides.[13] Although imidoylative 
nickel catalysis in small molecule synthesis was first reported in 1993,[14] it has 
remained underinvestigated, and only a handful of redox-neutral,[15] and 
oxidative[16] examples have been reported since. Satisfyingly, 15 mol% 
Ni(OAc)2.4H2O in DMSO at 120°C under an oxygen atmosphere afforded 93% 
pyrimidouracil 3a after 5 hours (Table 1, entry 1). Subsequently, the influence of 
the temperature, reaction time, and solvent was studied. The temperature could 
be lowered to 50 °C without a significant drop in yield of 3a (entries 1-6). At this 
temperature, the reaction is effective in both polar and apolar aprotic solvents. The 
efficacy of recommended solvents with respect to green chemistry[17] was 
investigated, most of which afforded 3a in good yield (entries 9-13), although protic 
ethylene glycol did not lead to product formation (entry 8). Anisole proved to be 
the optimal solvent in terms of both efficiency and green credentials, affording 3a 
in 99% yield after 16 h at 50 °C (entry 11). When we performed the reaction under 
air rather than under an atmosphere of molecular oxygen no discernable decrease 
in yield of 3a (entries 11 and 14) was observed. In the model reaction, combining 





this low loading was later found to give diminished yields when isocyanides other 
than t-BuNC (2a) were employed. Thus, we selected 5 mol% catalyst as the optimal 
conditions for this imidoylative amination (entry 14). Curiously, when the  reaction 
was performed under argon atmosphere under otherwise identical conditions, the 
corresponding pyrimidouracil 3a was still formed in high yield (entry 16).[18]  
With these conditions in hand, we set out to investigate the scope of this 
transformation. First we investigated the reaction of different isocyanides 2 with 
benzimidamide 1a, affording pyrimidouracils 3 (Scheme 2). Tertiary aliphatic 
isocyanides smoothly couple with 1a to afford the corresponding pyrimidouracils 






T (°C) t (h) conversion (%) yield (%)c 
1 DMSO 15 O2 120 5 100 93 
2 DMSO 15 O2 60 5 100 94 
3 DMSO 15 O2 40 18 100 90 
4 DMSO 15 O2 25 18 80 68 
5 DMSO 5 O2 40 18 95 91 
6 DMSO 5 O2 50 18 100 97 
7 CHCl3 5 O2 50 16 67 66 
8 EG 5 O2 50 48 24 - 
9 MIBK 5 O2 50 48 98 95 
10 BuOAc 5 O2 50 48 95 93 
11 Anisole 5 O2 50 16 100 99 
12 DMC 5 O2 50 48 100 94 
13 PC 5 O2 50 48 100 95 
14 Anisole 5 Air 50 16 100 99 
15 Anisole 1 Air 50 16 100 99 
16 Anisole 5 Ar 50 16 90 90 
a Selected examples. Reaction conditions: N-(1,3-dibenzyluracil)benzimidamide (1a, 0.5 mmol, 1 
equiv), tert-butyl isocyanide (2a, 1.5 mmol, 3.0 equiv), and Ni(OAc)2•4H2O, (0.025 mmol, 5 mol%) 
were stirred at indicated temperature for indicated time. b Colored according to Chem21 solvent 
guide[17] (red = hazardous, yellow = problematic, green = recommended) c Yield determined by 1H 
NMR analysis using 1,3,5-trimethoxybenzene as internal standard. DMSO = dimethyl sulfoxide EG 
= ethylene glycol, MIBK = methyl isobutyl ketone, DMC = dimethyl carbonate, PC = propylene 
carbonate. 
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3a and 3f under the optimized conditions. Utilization of aliphatic secondary 
isocyanides afforded pyrimidouracils 3b and 3c, in good yields, and even the use of 
functionalized N,N-diethyl-4-isocyanopentan-1-amine furnished the product 3g in 
acceptable yield. Both cyclic (3c) and acyclic (3b, 3g) secondary isocyanides are 
tolerated. Primary and benzylic isocyanides were also readily inserted, leading to 
the corresponding pyrimidouracils 3d, 3e, 3h and 3i in high yield. Even aromatic 
isocyanides appear compatible with the optimized conditions. For example 
pyrimidouracil 3j was formed in good yield using our methodology. The electron-
deficient methyl 2-isocyanobenzoate could also be converted into pyrimidouracil 
3m, although in diminished yield. Employing the notoriously unstable 2-naphtyl 
isocyanide, did not furnish pyrimidouracil 3k, but led to immediate and full 
decomposition. 
 







Scheme 3. Isocyanide scope in combination with substituted N-(1,3-dibenzyluracil)benzimidamides   
1b-d. 
Next we turned our attention to chart the scope of the N-(1,3-
dibenzyluracil)amidines 1 in this nickel-catalyzed cross-dehydrogenative 
imidoylative amination process. First we studied substitutions on the N-(1,3-
dibenzyluracil)benzimidamides (1b-d) as input for our reaction (Scheme 3). The use 
of N-(1,3-dibenzyluracil)-4-chlorobenzimidamide 1b with differently substituted 
isocyanides 2 led to the isolation of the corresponding functionalized 
pyrimidouracils 4a-c in excellent yields. With a stronger electron-withdrawing 
trifluoromethyl group on the benzimidamide moiety (1c) our protocol generally 
afforded pyrimidouracils 4d-f in slightly lower yields. Similar observations were 
observed with the more electron-rich N-(1,3-dibenzyluracil)-4-methoxybenzimid-
amide 1d affording pyrimidouracils 4g-i (Scheme 3). These results confirm the 
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above described finding that our reaction is not only compatible with tertiary but 
also tolerating primary, secondary aliphatic and aromatic isocyanides.  
 
Scheme 4. Isocyanide scope in combination with N-(1,3-dibenzyluracil)alkanimidamides 1e-g. 
Hereafter, N-(1,3-dibenzyluracil)alkimidamides  1e-g featuring an aliphatic rather 
than an aromatic R2-functionality were also investigated (Scheme 4). Gratifyingly, 





corresponding pyrimidouracils 5a-h under the previously optimized conditions 
using a range of diversely functionalized isocyanides 2. Pyrimidouracil 5b was 
isolated in moderate yield (30%), presumably due to the volatility of isopropyl 
isocyanide. Compared to the 2-arylated pyrimidouracils 4, the 2-
methylpyrimidouracils 5 are generally produced in somewhat lower yields.  
 
Scheme 5. Isocyanide scope in combination with N-(1,3-dimethyluracil)benzimidamide 1h. 
The relatively low yield of 5g can be explained by the promiscuous reactivity of N-
(2-isocyanoethyl)morpholine. These β-amino isocyanides are known to 
intramolecularly form internal imidoyl species as a side reaction.[19] Aromatic 
isocyanides such as 2,6-dimethylphenyl isocyanide are compatible with the 
developed conditions (5h), although naphthyl isocyanide again did not furnish 
isolable quantities of 5i. Increasing the size of the amidine substituent (R2) leads to 
a significant and consistent increase in the yield of pyrimidouracils 5. Thus, when 
isopropyl-substituted amidine 1f was reacted with tert-butyl-, cyclohexyl-, and 2,6-
dimethylphenyl isocyanide, the corresponding pyrimidouracils 5j-m could be 
isolated in good to near-quantitative yield. Unfortunately, immediate 
polymerization was observed in the synthesis of 5n, as the reaction mixture turned 
black and turbid upon adding 2-bromo-4-fluorophenyl isocyanide. Pyrimidouracil 
5n was not observed. Satisfyingly, our catalytic system has a high tolerance for the 
amidine substrate, as illustrated by the use of N-(1,3-dibenzyluracil)pivalimidamide 
1g (Scheme 4). The corresponding 7-tert-butyl pyrimidouracils 5o-s could be 
obtained in good to excellent yields under the optimized conditions. The substrate 
1g showed excellent compatibility with secondary and tertiary aliphatic isocyanides 
to afford 5o and 5p, but also with benzyl isocyanide, allowing for the formation of 
5q. Our system proves compatible with commercially available aromatic 
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isocyanides as well, as evidenced by the isolation of 5r and 5s in good yields. Even 
the use of the α-acidic methyl isocyanoacetate led to the formation of 5t, albeit in 
low yield (14%).  
To directly access pyrimidouracils of type 6, featuring N-methylsubstituents, we 
also performed several reactions with N-(1,3-dimethyluracil)benzimidamide 1h 
(Scheme 5). The combination of 1h with primary, secondary and tertiary aliphatic 
isocyanides gave the corresponding dimethylated pyrimidouracils 6a-c in good to 
excellent yields. Pyrimidouracils 6 are more prone to tailing, rendering column 
chromatography more cumbersome. Still, functionalized isocyanides perform 
rather well in combination with 1h. For example, the N5-functionalized 
pyrimidouracil 6d was isolated in a respectable 51 % while 49% of the substrate 1h 
could be recovered. Apparently this reaction proceeds less readily, similar to the 
formation of 5g (Scheme 4). Satisfyingly, the reaction with aromatic 4-
methoxyphenyl isocyanide afforded the corresponding 1,3-dimethylated-5-(4-
methoxy-phenyl)-pyrimidouracil 6e, albeit in only 21% yield. It is noteworthy that 
our methodology can be used in combination with a deprotection step to liberate 
1,3-unsubstituted pyrimidouracils 7 or 5-aminopyrimidouracils 8 allowing post-
functionalization  (Scheme 6a). 
 
Scheme 6. Post-functionalization of pyrimidouracils. 
Palladium-catalyzed hydrogenolysis afforded the 1,3-debenzylated pyrimidouracil 
7 with excellent conversion. However, purification proved challenging, providing 
the target compound 7 in only 50% isolated yield. Similarly, when pyrimidouracil 1a 
was treated with triflic acid the amine 8 was obtained quantitatively without 







Scheme 7. Control experiments 
In order to elucidate the mechanism, several control experiments were performed 
(Scheme 7). A radical mechanism[20] involving homolytic aromatic substitution is not 
deemed likely, as addition of TEMPO (2.0 equiv) does not hamper the formation of 
pyrimidouracil 3a under standard reaction conditions, and no TEMPO adducts were 
observed (Scheme 7a).[20a, 21] Such a mechanism would imply a heterolytic aromatic 
substitution,[20a, 21] which is unlikely due to the fact this reactivity is not observed in 
the less electron-rich benzamidine analogue 9, even under elevated temperatures. 
Additionally, we investigated the possibility of β-hydride elimination of proposed 
intermediate II (Scheme 8). Replacing the amidine proton with a benzyl 
functionality (11) completely inhibits the conversion to 5-(tert-butylimino)-5,6-
dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione 12.  
While this lends some credibility to a mechanism including a β-hydride elimination 
mediated formation of the corresponding carbodiimide V, it does not fully exclude 
the Ni(II)/Ni(III)-catalyzed mechanism (Scheme 8).[16a, 16b, 22] The reaction is initiated 
by the formationof N-amidinonickel intermediate I. Subsequent insertion of the 
isocyanide affords C-amidinonickel intermediate II. This intermediate undergoes C-
H functionalization to give nickelacycle intermediate III. After one-electron 
oxidation to cyclic Ni(III) intermediate IV, reductive elimination furnishes the 
observed pyrimidouracils and a Ni(I) species, which undergoes a second one-
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electron oxidation to regenerate the Ni(II) catalyst. Alternatively, β-hydride 
elimination from the likely intermediate II affords the carbodiimide V, which may 
cyclize to the product 3. 
 
Scheme 8. Proposed mechanism. 
5.3. Conclusio 
In conclusion, we have developed a highly effective and robust nickel-catalyzed 
cross-dehydrogenative imidoylative amination of N-uracil-amidines (1) with 
isocyanides affording underexplored fused pyrimidouracils. The transformation 
proceeds with high efficiency, regardless of the steric and electronic nature of the 
N-uracil-amidine substrate. Additionally, this imidoylative C-H functionalization is 
compatible with a broad range of isocyanides, including primary, secondary and 
tertiary aliphatic as well as benzylic, and aromatic isocyanides. Finally, we were able 
to liberate the corresponding deprotected products 7 and 8 using standard 
procedures. Current efforts in our labs are directed towards a better understanding 
of the mechanism of this type of transformation as well as further scaffold 






5.4. Experimental section 
General remarks 
Chemicals were purchased from Fischer Chemicals, TCI Chemicals or Sigma Aldrich and used without 
purification. Solvents were purchased from Fischer Chemicals (toluene, DCM, hexanes, EtOAc), or 
Acros Organics (DMSO, anisole) and used without purification, unless stated otherwise. NMR 
measurements were acquired either on a Bruker Avance 400 (1H NMR: 400.13 MHz, 13C NMR: 100.61 
MHz, performed in CDCl3 (deuteration grade >99.8%, containing 0.03 (v/v)% SiMe4)) or a Bruker 
Avance 500.23 (1H NMR: 500.23 MHz, 13C NMR: 125.78 MHz (in APT mode)), performed in CDCl3 
(deuteration grade >99.8%) All shifts are reported in ppm downfield of tetramethylsilane, and are 
corrected according to solvent. SiO2 column chromatography was performed using Silicycle Siliaflash 
P60 Gel C60 (particle size 40-63 μm) on a Teledyne CombiFlash Rf automated chromatography system, 
or by hand on Merck Silica Gel C60 (particle size: 40-60 μm). TLC chromatography was performed on 
Merck Silica Gel C60 F254 plates (silica coat on aluminum support). HRMS was performed on an Ion 
Cyclotron Resonance (ICR) spectrometer with a positive ion polarity mode. All measured compounds 
displayed <5.0 ppm deviated from calculated values. All isolated yields are corrected for trace 
impurities, if present.  
General procedure A: 
The N-uracil-amidines 1 have been synthesized according to our previously reported procedure.[11] An 
oven-dried 10 mL pressure vial was loaded with N,N’-dibenzyl-6-chlorouracil (1.0 equiv), the amidine 
(2.3 equiv) and anhydrous 3-ethyl-3-pentanol (0.5 mL), and closed with a septum. The resulting 
mixture was stirred at 100 °C under N2 atmosphere for 24 h. The mixture was extracted with ethyl 
acetate (60 mL), and washed with water (20 mL). The organic layer was dried over MgSO4, filtered, 
concentrated under reduced pressure. The resulting residue was either purified by chromatography 
using the eluent indicated below.  
General procedure B: 
A 10 mL pressure vial, equipped with a stir bar, was charged with N-(1,3-dibenzyluracil)benzimidamide 
1 (0.5 mmol, 1.0 equiv), Ni(OAc)2.4H2O (6 mg, 0.025 mmol, 5 mol %) and anisole (2.0 mL). Hereafter, 
the isocyanide (1.0 mmol, 2.0 equiv or 1.5 mmol, 3.0 eq.) was added dropwise with a syringe (if liquid) 
or with a funnel (if solid). Subsequently, the reaction mixture was again heated to 50°C in an oil bath 
for 18 hours. The reaction mixture was kept under air atmosphere with a balloon (connection with a 
needle through the septum), although no significantly different results were obtained if the vessel 
was left open to air. When the reaction mixture was cooled down it was diluted with ethyl acetate (60 
mL), and washed with NH4OH (aq.): brine (3:2, 20 mL). The organic fraction was dried over anhydrous 
Na2SO4, filtered, concentrated in vacuo, and loaded onto silica. The products were purified by flash 
column chromatography on SiO2, using the eluent indicated below. 
N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)benzimidamide (1a) 
Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione (6.54 g, 20.0 mmol, 1.0 equiv) benzamidine 
(5.53, 46 mmol, 2.3 equiv) and DBU (5.97 mL, 40 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using 
cHex:EtOAc:NEt3 (gradient = 10:1:0.01-0:1:0.01). The title compound was 
isolated as a yellow solid (5.12 g, 62%). Spectroscopic data are in accordance with the literature.[11] 
RF = 0.14 (cHex:EtOAc:NEt3 ; 1:1:0.01). 1H NMR (300 MHz, CDCl3): δ 7.76 (d, J = 7.1 Hz, 2H), 7.59 - 7.51 
(m, 1H), 7.51 - 7.41 (m, 4H), 7.35 - 7.19 (m, 8H), 5.95 (bs, 2H), 5.28 (s, 1H), 5.20 (s, 2H), 5.12 (s, 2H) 
ppm. 13C NMR (150.90 MHz, CDCl3): δ 163.5 (C), 157.8 (C), 157.2 (C), 152.5 (C), 137.3 (C), 133.3 (C), 
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131.8 (CH), 128.6 (CH), 128.4 (CH), 128.4 (CH), 128.2 (CH), 127.6 (CH), 127.3 (CH), 127.3 (CH), 127.0 
(CH), 87.5 (CH), 46.6 (CH2), 44.2 (CH2) ppm (1 CHAr missing due to overlapping signal). HRMS (ESI): m/z 
calculated for C25H23N4O2 [M+H]+ = 411.1816, found = 411.1828. M.p.: 168-170 °C (lit. 169 °C).[11] 
 
 N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-chlorobenzimidamide (1b)  
Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione ( 1.82 g, 5.6 mmol, 1.0 equiv), 4-
chlorobenzamidine hydrochloride (1.60 g, 8.4 mmol, 1.5 equiv) and DBU 
(1.8 mL, 12.3 mmol, 2.2 equiv). The compound was purified by manual flash 
chromatography using cHex:EtOAc:NEt3 (gradient = 10:1:0.01-0:1:0.01).  
The title compound was isolated as a yellow solid (0.925 g, 37%). RF = 0.13 (EtOAc:cHex:NEt3 = 
1:1:0.01). 1H NMR (300 MHz, CDCl3): δ 7.67 (d, J = 9.0 Hz, 2H), 7.44 (d, J = 9.0 Hz, 2H), 7.39 (d, J = 9.0 
Hz, 2H), 7.33 - 7.26 (m, 2H), 7.25-  7.12 (m, 6H), 5.93 (s, 2H), 5.23 (s, 1H), 5.15 (s, 2H), 5.10 (s, 2H) 
ppm. 13C NMR (125 MHz, CDCl3): δ 163.4 (C), 156.8 (C), 152.5 (C), 138.3 (C), 137.24 (C), 137.22 (C), 
131.6 (C), 129.0 (CH), 128.6 (CH), 128.5 (CH), 128.3 (CH), 127.6 (CH), 127.5 (CH), 127.4 (CH), 87.8 (C), 
46.7 (CH2), 44.4 (CH2) ppm. HRMS (ESI): m/z calculated for C25H22N4O2Cl [M+H]+ = 445.1431, found = 
445.1426. M.p.: 115 ° C. 
 
N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-(trifluoromethyl)benzimidamide (1c) 
Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione (3.3 g, 10 mmol, 1.0 equiv), 4-
trifluoromethylbenzamidine hydrochloride dihydrate (3.9 g, 15 mmol, 1.5 
equiv) and DBU (1.05 mL, 9 mmol). The compound was purified by manual 
flash chromatography using cHex:EtOAc:NEt3 (gradient = 10:1:0.01-
0:1:0.01). The title compound was isolated as a light green solid (1.186 g, 
25%). RF = 0.33 (cHex:EtOAc:NEt3 = 1:1:0.01). 1H NMR (300 MHz, CDCl3): δ 7.81 (d, J = 6.0 Hz, 2H), 7.70 
(d, J = 6.0 Hz, 2H), 7.49 (d, J = 6.0 Hz, 2H), 7.35-7.27 (m, 2H), 7.25-7.16 (m, 6H), 5.71 (s, 2H), 5.27 (s, 
1H), 5.17 (s, 2H), 5.15 (s, 2H). 13C NMR (150.90 MHz, CDCl3): δ 163.4 (C), 156.6 (C), 156.3 (C), 152.5 
(C), 137.21 (C), 137.18 (C), 136.6 (C), 133.6 (q, 2J = 33 Hz, C), 128.7 (CH), 128.5 (CH), 128.4 (CH), 127.8 
(CH), 127.53 (CH), 127.50 (CH), 127.47 (CH), 125.8 (q, 3J = 5 Hz), 125.7 (q, 3J = 5 Hz, CH), 123.5 (q, 1J 
= 270 Hz, CH), 87.9 (CH), 46.8 (CH2), 44.4 (CH2). HRMS (ESI): m/z calculated for C26H22N4O2F3 [M+H]+ = 
479.1666, found = 479.1689. M.p.: 95 °C. 
 
N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-4-methoxybenzimidamide (1d)  
Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione (1.961 g, 6 mmol, 1.0 equiv), 4-
methoxybenzamidine hydrochloride (1.68 g, 9 mmol, 1.5 equiv) and DBU 
(2.0 mL, 13.2 mmol). The compound was purified by manual flash 
chromatography using cHex:EtOAc:NEt3 (gradient = 10:1:0.01-0:1:0.01).  
The title compound was isolated as a white solid (1.13 g, 43%). RF = 0.17 (cHex:EtOAc:NEt3 = 
1:1:0.01). 1H NMR (300 MHz, CDCl3): δ 7.68 (d, J = 8.3 Hz, 2H), 7.49 (d, J = 6.4 Hz, 2H), 7.38 - 7.13 (m, 
8H), 6.93 (d, J = 8.4 Hz, 2H), 5.54 (bs, 2H), 5.26 (s, 1H), 5.19 (s, 2H), 5.16 (s, 2H), 3.86 (s, 3H) ppm. 13C 
NMR (151 MHz, CDCl3): δ 163.3 (C), 162.7 (C), 157.0 (C), 156.9 (C), 152.6 (C), 137.5 (C), 137.4 (C), 
128.85 (CH), 128.83 (CH), 128.4 (CH), 128.3 (CH), 127.8 (CH), 127.4 (CH), 127.3 (CH), 125.3 (C), 114.0 
(CH), 87.7 (CH), 55.5 (CH3), 46.6 (CH2), 43.3 (CH2) ppm. HRMS (ESI): m/z calculated for 






N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)acetimidamide (1e)  
Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione (3.27 g, 10 mmol, 1.0 equiv), ethanimidamide 
hydrochloride (1.48 g, 15 mmol, 1.5 equiv) and DBU (3.3 mL, 22 mmol, 2.2 equiv). 
The compound was purified by manual flash chromatography using 
cHex:EtOAc:NEt3 (gradient = 10:1:0.01-1:1:0.01). The title compound was isolated 
as a white solid (2.50 g, 73%). RF = 0.28 (cHex:EtOAc:NEt3 = 1:1:0.1). 1H NMR (600 MHz, CDCl3): δ 7.49 
(d, J = 6.0 Hz, 2H), 7.35 - 7.26 (m, 4H), 7.25-7.19 (m, 4H), 5.29 (bs, 1H), 5.15 (s, 2H), 5.08 (s, 3H), 4.96 
(bs, 1H), 1.78 (s, 3H). 13C NMR (125 MHz, CDCl3): δ 13C NMR (151 MHz, DMSO-d6) δ 162.0 (C), 161.5 
(C), 157.6, (C) 152.1 (C), 137.9 (C), 137.9 (C), 128.3 (CH), 128.2 (CH), 127.4 (CH), 126.94 (CH), 126.92 
(CH), 126.89 (CH), 86.7 (CH), 45.5 (C), 43.3 (C), 18.9 (CH3), HRMS (ESI): m/z calculated for 
C20H21N4O2 [M+H]+ = 349.1657, found = 349.1659. M.p.: 163 ° C. 
 
N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)isobutyrimidamide (1f) 
 Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione (3.45 g, 10.6 mmol, 1.0 equiv) 2-
methylpropanimidamide hydrochloride (1.94 g, 15.8 mmol, 1.5 equiv) and DBU 
(3.5 mL, 23.2 mmol, 2.2 equiv). The compound was purified by manual flash 
chromatography using cHex:EtOAc:NEt3 (gradient = 10:1:0.01-0:1:0.01).  The title 
compound was isolated as an off-white solid (2.17 g, 55%). RF = 0.17 (cHex:EtOAc:NEt3 = 1:1:0.01). 1H 
NMR (300 MHz, CDCl3): δ 7.44 (dd, J = 6.0, 9.0 Hz, 2H), 7.35 - 7.26 (m, 2H), 7.25 - 7.15 (m, 6H), 5.35 
(bs, 2H), 5.16 (s, 1H), 5.11 (s, 2H), 5.10 (s, 2H), 2.42 (sep, J = 6.0 Hz, 1H), 1.09 (d, J = 6.0 Hz, 6H) ppm. 13C 
NMR (125 MHz, CDCl3): δ 167.0 (C), 163.4 (C), 157.2 (C), 152.5 (C), 137.3 (C), 137.3 (C), 128.4 (CH), 
128.4 (CH), 128.2 (CH), 127.2 (CH), 127.2 (CH), 127.1 (CH), 87.3 (CH), 46.3 (CH2), 44.2 (CH2), 34.7 (CH), 
20.1 (CH3). HRMS (ESI): m/z calculated for C22H25N4O2 [M+H]+ = 377.1972, found = 377.1972. M.p.: 
152 ° C. 
 
N'-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)pivalimidamide (1g) 
Synthesized according to general procedure A, using 1,3-dibenzyl-6-
chloropyridinine-2,4(1H,3H)-dione (1.14 g, 3.5 mmol, 1.0 equiv) 2,2-
dimethylpropanimidamide hydrochloride (710 mg, 5.2 mmol, 1.5 equiv) and DBU 
(1.1 mL, 9.6 mmol, 2.2 equiv). The compound was purified by manual flash 
chromatography using cHex:EtOAc:NEt3 (gradient = 10:1:0.01-0:1:0.01). The title 
compound was isolated as a white solid (0.855 g, 62%). RF = 0.40 (cHex:EtOAc:NEt3 = 1:1:0.01). 1H 
NMR (300 MHz, CDCl3): δ 7.45 (d, J = 10.0 Hz, 2H), 7.32 - 7.26 (m, 3H), 7.25 - 7.17 (m, 5H), 5.34 (bs, 
2H), 5.17 (s, 1H), 5.12 (s, 2H), 5.11 (s, 2H), 1.16 (s, 9H) ppm. 13C NMR (125 MHz, CDCl3): δ 168.5 (C), 
163.4 (C), 157.2 (C), 152.6 (C), 137.4 (C), 137.3 (C), 128.7 (CH), 128.4 (CH), 128.3 (CH), 127.3 (CH), 
127.2 (CH), 127.0 (CH), 87.1 (CH), 46.3 (CH2), 44.2 (CH2), 37.7 (C), 28.0 (CH3) ppm. HRMS 
(ESI): m/z calculated for C23H27N4O2 [M+H]+ = 391.2132, found = 391.2129. M.p.: 159 ° C. 
 
1,3-dibenzyl-5-(tert-butylamino)-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (3a) 
To a solution of N-(1,3-dibenzyluracil)benzimidamide (1a, 410 mg, 1.0 mmol, 
1.0 equiv) and Ni(OAc)2.4H2O (0.011 g, 0.05 mmol, 0.05 equiv) in anisole (4.0 
mL) was added tert-butyl isocyanide (2a, 226 µL, 2.0 mmol, 2.0 equiv). The 
mixture was stirred open to air for 16 hours, after which the reaction was 
cooled, and the mixture was diluted with 50 mL EtOAc. The crude product was 
washed subsequently with NH4OH(aq.), sat. NaHCO3, and brine. The organic 
fraction was dried over anhydrous NaSO4, concentrated in vacuo, and the crude product was loaded 
onto SiO2 with DCM. The compound was purified by an automated flash chromatography system using 
cHex:EtOAc (gradient = 1:0-3:1). The title compound was isolated as a white solid (476 mg, 97%).  RF = 
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0.16 (cHex:EtOAc:NEt3 ; 9:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.22 (bs, 1H), 8.47 (d, J = 8.0 Hz, 1H), 
7.61 - 7.42 (m, 7H), 7.39 - 7.20 (m, 7H), 5.59 (s, 2H), 5.21 (s, 2H), 1.62 (s, 9H) ppm. 13C NMR (100 MHz, 
CDCl3)  165.6 (C), 162.9 (C), 161.5 (C), 157.5 (C), 151.4 (C), 137.7 (C), 137.4 (C), 136.9 (C), 131.7 (CH), 
129.1 (CH), 128.76 (CH), 128.75 (CH), 128.62 (CH), 128.61 (CH), 128.55, 127.76 (CH), 127.74 (CH), 89.0 
(C), 52.8 (C), 45.6 (CH2), 44.6 (CH2), 29.3 (CH3) ppm. HRMS (ESI): m/z calculated for C30H30N5O2 [M+H]+ 
= 492.2394, found = 492.2390. M.p.: 189 °C. 
 
1,3-dibenzyl-5-(isopropylamino)-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (3b) 
The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and isopropyl 
isocyanide (140 µL, 1.5 mmol, 3.0 equiv). The compound was purified by an 
automated flash chromatography system using a heptane/EtOAc gradient 
(from 100% heptane to 35% ethyl acetate over 20 min, 35 mL/min). The title 
compound was isolated as a white solid (141 mg, 59%).  RF = 0.12 
(cHex:EtOAc:NEt3 ; 9:1:0.01). 1H NMR (400 MHz, CDCl3)  9.04 (bd, J = 7.1 Hz, 
1H), 8.47 (d, J = 6.8 Hz, 2H), 7.55 - 7.46 (m, 7H), 7.32 - 7.24 (m, 6H), 5.59 (s, 2H), 5.21 (s, 2H), 4.62 
(oct, J = 6.6 Hz, 1H), 1.35 (d, J = 6.6 Hz, 6H) ppm. 13C NMR (100 MHz, CDCl3)  166.0 (C), 162.8 (C), 
161.1 (C), 157.5 (C), 151.5 (C), 137.5 (C), 136.9 (C), 131.7 (C), 129.1 (CH), 128.8 (CH), 128.7 (CH), 128.6 
(CH), 128.6 (CH), 128.5 (CH), 127.8 (CH), 127.8 (CH), 88.6 (C), 45.7 (CH2), 44.6 (CH2), 43.0 (CH), 22.8 
(CH3) ppm (1 CHAr missing due to overlapping signals). HRMS (ESI): m/z calculated for 
C29H28N5O2 [M+H]+ = 478.2243, found = 478.2258. M.p.: 183 °C. 
 
1,3-dibenzyl-5-(cyclohexylamino)-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (3c) 
The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and 
cyclohexyl isocyanide (194 µL, 1.5 mmol, 3.0 equiv). The compound was 
purified by an automated flash chromatography system using a 
heptane/EtOAc gradient (from 100% heptane to 20% ethyl acetate over 20 
min, 35 mL/min). The title compound was isolated as a white solid (206 mg, 
80%).  RF = 0.12 (cHex:EtOAc:NEt3 ; 9:1:0.01). 1H NMR (400 MHz, CDCl3)  8.99 
(bd, J = 7.5 Hz, 1H), 8.47 - 8.43 (m, 2H), 7.52 (d, J = 7.0 Hz, 2H), 7.51 - 7.45 (m, 5H), 7.32 - 7.20 (m, 6H), 
5.55 (s, 2H), 5.19 (s, 2H), 4.36 - 4.27 (m, 1H), 2.11 - 2.04 (m, 2H), 1.86 - 1.77 (m, 2H), 1.71 - 1.63 (m, 
1H), 1.53 - 1.25 (m, 5H). 13C NMR (100 MHz, CDCl3)  165.9 (C), 162.7 (C), 161.0 (C), 157.5 (C), 151.4 
(C), 137.5 (C), 137.3 (C), 136.9 (C), 131.6 (CH), 129.0 (CH), 128.8 (CH), 128.6 (CH), 128.6 (CH), 128.4 
(CH), 127.7 (CH), 127.7 (CH), 88.5 (C), 49.8 (CH), 45.6 (CH2), 44.5 (CH2), 32.8 (CH2), 25.8 (CH2), 24.9 
(CH2) ppm, (1 CHAr missing due to overlapping signals). HRMS (ESI): m/z calculated for 
C32H32N5O2 [M+H]+ = 519.2556, found = 519.2570. M.p.: 205 °C. 
 
1,3-dibenzyl-5-(pentylamino)-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (3d) 
The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and n-
pentyl isocyanide (130 µL, 1.5 mmol, 3.0 equiv). The compound was purified 
by an automated flash chromatography system using a heptane/EtOAc 
gradient (from 100% heptane to 10% ethyl acetate over 30 min, 35 mL/min). 
The title compound was isolated as a white solid (205 mg, 82%).  RF = 0.12 (cHex:EtOAc:NEt3 ; 
9:1:0.01). 1H NMR (400 MHz, CDCl3)  9.04 (bt, J = 5.1 Hz, 1H), 8.48 (d, J = 6.8 Hz, 2H), 7.56 - 7.46 (m, 
7H), 7.34 - 7.23 (m, 6H), 5.59 (s, 2H), 5.21 (s, 2H), 3.70 (q, J = 6.8 Hz, 2H), 1.71 (quint, J = 7.1 Hz, 2H), 
1.45 - 1.37 (m, 4H), 0.93 (t, J = 6.9 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3)  166.1 (C), 162.8 (C), 
161.9 (C), 157.5 (C), 151.5 (C), 137.5 (C), 137.3 (C), 136.9 (C), 131.7 (CH), 129.1 (CH), 128.8 (CH), 128.8 





(CH2), 29.4 (CH2), 29.3 (CH2), 22.6 (CH2), 14.1 (CH3) ppm. HRMS (ESI): m/z calculated for 
C31H32N5O2 [M+H]+ = 506.2556, found = 506.2559. M.p.: 144 °C. 
 
1,3-dibenzyl-5-(benzylamino)-7-phenylpyrimido[4,5-d]pyrimidine-2,4-(1H,3H)-dione (3e) 
The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and benzyl 
isocyanide (122 µL, 1.5 mmol, 3.0 equiv). The compound was purified by an 
automated flash chromatography system using a heptane/EtOAc gradient 
(from 100% heptane to 16% ethyl acetate over 20 min, 35 mL/min). The title 
compound was isolated as yellowish solid (204 mg, 78%).  RF = 0.07 (cHex:EtOAc:NEt3 ; 9:1:0.01). 1H 
NMR (400 MHz, CDCl3)  9.38 (bt, J = 5.4 Hz, 1H), 8.46 (d, J = 7.0 Hz, 2H), 7.55 - 7.24 (m, 18H), 5.58 (s, 
2H), 5.19 (s, 2H), 4.92 (d, J = 5.9 Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3)  166.2 (C), 162.8 (C), 161.9 
(C), 157.6 (C), 151.4 (C), 138.5 (C), 137.3 (C), 137.3 (C), 136.8 (C), 131.9 (CH), 129.2 (CH), 128.9 (CH), 
128.9 (CH), 128.8 (CH), 128.6 (CH), 128.5 (CH), 127.9 (CH), 127.8 (CH), 127.8 (CH), 127.6 (CH), 88.9 (C), 
45.7 (CH2), 44.9 (CH2), 44.7 (CH2) ppm (1 CHAr missing due to overlapping signals). HRMS 




The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and 1,1,3,3-
tetramethylbutyl isocyanide (175 µL, 1.5 mmol, 3.0 equiv). The compound was 
purified by an automated flash chromatography system using a 
heptane/EtOAc gradient (from 100% heptane to 16% ethyl acetate over 20 
min, 10 mL/min). The title compound was isolated as yellowish solid (235 mg, 86%).  RF = 0.16 
(cHex:EtOAc:NEt3 ; 9:1:0.01). 1H NMR (400 MHz, CDCl3)  9.28 (bs, 1H), 8.22 (d, J = 6.3 Hz, 2H), 7.54 
(d, J = 7.0 Hz, 2H), 7.52 - 7.45 (m, 5H), 7.33 - 7.22 (m, 6H), 5.57 (s, 2H), 5.20 (s, 2H), 2.09 (s, 2H), 1.65 
(s, 6H), 1.0 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3)  165.2 (C), 162.9 (C), 161.4 (C), 157.5 (C), 151.3 
(C), 137.7 (C), 137.4 (C), 136.9 (C), 131.6 (CH), 129.1 (CH), 128.9 (CH), 128.9 (CH), 128.6 (CH), 128.6 
(CH), 128.6 (CH), 127.8 (CH), 88.9 (C), 56.6 (C), 51.6 (CH2), 45.6 (CH2), 44.5 (CH2), 31.9 (C), 31.7 (CH3), 
29.9 (CH3) ppm (1 CHAr missing due to overlapping signals). HRMS (ESI): m/z calculated for 




The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and 
1,1,3,3-tetramethylbutyl isocyanide (168 mg, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using a 
cHex:EtOAc:NEt3 gradient (10:1:0.01-1:1:0.01) . The title compound was 
isolated as an off-white solid (145 mg, 51%).  1H NMR (300 MHz, CDCl3) δ 8.92 (d, J = 8.1 Hz, 1H), 8.52 
- 8.42 (m, 2H), 7.58 - 7.42 (m, 7H), 7.36 - 7.22 (m, 6H), 5.58 (s, 2H), 5.20 (s, 2H), 4.66 - 4.51 (m, 1H), 
2.50 (q, J = 7.0 Hz, 4H), 2.45 (t, J = 6.5 Hz, 2H), 1.76 - 1.50 (m, 4H), 1.33 (d, J = 6.5 Hz, 3H), 0.99 (t, J = 
7.1 Hz, 6H) ppm. 13C NMR (101 MHz, CDCl3) δ 165.8 (C), 162.6 (C), 161.2 (C), 157.4 (C), 151.3 (C), 137.3 
(C), 137.2 (C), 136.7 (C), 131.5 (CH), 128.9 (CH), 128.6 (CH), 128.5, 128.4 (CH), 128.3 (CH), 127.6 (CH), 
127.6 (CH), 88.4 (C), 52.8 (CH2), 46.8 (CH2), 46.7 (CH), 45.5 (CH2), 44.4 (CH2), 34.9 (CH2), 23.9 (CH2), 
20.9 (CH3), 11.6 (CH3) ppm. HRMS (ESI): m/z calculated for C35H41N6O2 [M+H]+ = 577.3286, found = 
577.3299. M.p.: 76 °C. 
 





The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and 2-
morpholinoethyl isocyanide (140 µL, 1.0 mmol, 2.0 equiv). The compound 
was purified by an automated flash chromatography system using a 
heptane/EtOAc gradient (from 100% heptane to 50% ethyl acetate over 70 
min, 35 mL/min). The title compound was isolated as a white solid (271 mg, 
79%).  RF = 0.28 (cHex:EtOAc:NEt3 ; 9:1:0.01). 1H NMR (400 MHz, CDCl3)  9.25 (bt, J = 5.0 Hz, 1H), 
8.46 (d, J = 6.9 Hz, 2H), 7.54 - 7.45 (m, 7H), 7.33 - 7.22 (m, 6H), 5.58 (s, 2H), 5.21 (s, 2H), 3.83 (q, J = 
6.3 Hz, 2H), 3.75 (t, J = 4.6 Hz, 4H), 2.68 (t, J = 6.5 Hz, 2H), 2.55 (t, J = 4.4 Hz, 4H) ppm. 13C NMR (100 
MHz, CDCl3)  165.9 (C), 162.5 (C), 161.7 (C), 157.3 (C), 151.3 (C), 137.3 (C), 137.2 (C), 136.9 (C), 131.7 
(CH), 129.0 (CH), 128.9 (CH), 128.7 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 127.8 (CH), 127.7 (CH), 
88.9 (C), 67.1 (CH2), 57.2 (CH2), 53.7 (CH2), 45.6 (CH2), 44.5 (CH2), 37.9 (CH2) ppm. HRMS 




The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and 4-
(2-isocyanoethyl)-1,2-dimethoxybenzene (191 mg, 1.0 mmol, 2.0 
equiv). The compound was purified by manual flash chromatography 
system using a cHex:EtOAc:NEt3 (10:1:0.01) as eluent. The title 
compound was isolated as a white solid (256 mg, 85%).  RF = 0.37 
(cHex:EtOAc:NEt3 = 5:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.15 (bt, J = 6.5 Hz, 1H), 8.53 (d, J = 6.6 Hz, 
2H), 7.62 - 7.44 (m, 7H), 7.39 - 7.26 (m, 6H), 6.85 (m, 3H), 5.61 (s, 2H), 5.22 (s, 2H), 3.96 (q, J = 6.9 Hz, 
2H), 3.89 (s, 6H), 2.99 (t, J = 7.3 Hz, 2H) ppm. 13C NMR (101 MHz, CDCl3) δ 165.9 (C), 162.5 (C), 161.7 
(C), 157.3 (C), 151.2 (C), 149.0 (C), 147.8 (C), 137.2 (C), 137.1 (C), 136.7 (C), 131.6 (CH), 131.6 (C), 129.0 
(CH), 128.7 (CH), 128.6 (CH), 128.5 (2CH), 128.4 (CH), 127.7 (CH), 127.6 (CH), 120.7 (CH), 112.2 (CH), 
111.5 (CH), 88.7 (C), 56.0 (CH3), 55.8 (CH3), 45.6 (CH2), 44.5 (CH2), 42.8 (CH2), 35.4 (CH2) ppm. HRMS 




The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and 2,6-
dimethylphenyl isocyanide (131 mg, 1.0 mmol, 2.0 equiv). The compound was 
purified by an automated flash chromatography system using a heptane/EtOAc 
gradient (from 100% heptane to 10% EtOAc over 20 min, 35 mL/min). The title 
compound was isolated as a white solid (214 mg, 79%). RF = 0.12 
(cHex:EtOAc:NEt3 ; 9:1:0.01). 1H NMR (400 MHz, CDCl3)  10.35 (bs, 1H), 8.22 (d, J = 7.2 Hz, 2H), 7.59 
(d, J = 7.0 Hz, 2H), 7.53 (d, J = 7.0 Hz, 2H), 7.46 - 7.42 (m, 1H), 7.38 - 7.26 (m, 8H), 7.20 - 7.14 (m, 3H), 
5.60 (s, 2H), 5.26 (s, 2H), 2.24 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3)  166.2 (C), 163.1 (C), 161.1 (C), 
157.7 (C), 151.4 (C), 137.2 (C), 137.1 (C), 136.8 (C), 135.6 (C), 135.1(C), 131.8 (CH), 129.2 (CH), 129.1 
(CH), 129.0 (CH), 128.7 (CH), 128.7 (CH), 128.5 (CH), 128.2 (CH), 127.9 (CH), 127.9 (CH), 127.2 (CH), 
89.0 (C), 45.8 (CH2), 44.8 (CH2), 18.9 (CH3) ppm. HRMS (ESI): m/z calculated for C34H30N5O2 [M+H]+ = 










The general procedure B was applied using N-(1,3-
dibenzyluracil)benzimidamide (1a, 205 mg, 0.5 mmol, 1.0 equiv) and methyl 
2-isocyanobenzoate (161 mg, 1.0 mmol, 2.0 equiv). The compound was 
purified by manual flash chromatography using cHex:EtOAc:NEt3 (10:1:0.01) 
as eluent. The title compound was isolated as a white solid (56 mg, 21%).  RF = 
0.62 (cHex:EtOAc = 4:1). 1H NMR (300 MHz, CDCl3) δ 12.44 (s, 1H), 8.47 (d, J = 
8.3 Hz, 1H), 8.41 (d, J = 7.2 Hz, 2H), 8.07 (dd, J = 7.9, 1.7 Hz, 1H), 7.63 (t, J = 7.4 
Hz, 1H), 7.56 - 7.45 (m, J = 9.2 Hz, 5H), 7.47 (t, J = 7.4 Hz, 2H), 7.35 - 7.21 (m, 7H), 5.62 (s, 2H), 5.32 (s, 
2H), 3.96 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) δ 167.1 (C), 165.7 (C), 161.9 (C), 159.7 (C), 157.7 (C), 
151.1 (C), 139.0 (C), 136.9 (C), 136.8 (C), 136.6 (C), 132.6 (CH), 131.9 (CH), 131.1 (CH), 129.1 (CH), 
128.9 (CH), 128.5 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 127.7 (CH), 127.7 (CH), 124.9 (CH), 123.8 
(CH), 120.7 (C), 90.3 (C), 52.5 (CH3), 45.7 (CH2), 44.5 (CH2) ppm. HRMS (ESI): m/z calculated for 




The general procedure B was applied using 4-chloro-N-(1,3-dibenzyl-2,6-
dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)benzimidamide (1b, 223 mg, 0.5 
mmol, 1.0 equiv) and tert-butyl isocyanide (2a, 119 µL, 1.0 mmol, 2.0 
equiv). The compound was purified by manual flash chromatography using 
cHex:EtOAc:NEt3 (25:1:0.01) as eluent. The title compound was isolated as 
a white solid (234 mg, 89%).  RF = 0.45 (cHex:EtOAc:NEt3 ; 15:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.24 
(bs, 1H), 8.38 (d, J = 8.5 Hz, 2H), 7.58 - 7.39 (m, 6H), 7.38 - 7.17 (m, 6H), 5.56 (s, 2H), 5.20 (s, 2H), 1.60 
(s, 9H) ppm.13C NMR (126 MHz, CDCl3): δ 164.1 (C), 162.7 (C), 161.2 (C), 157.3 (C), 151.1 (C), 137.8 (C), 
137.1 (C), 136.6 (C), 136.0 (C), 130.2 (CH), 128.6 (CH), 128.6 (CH), 128.5 (CH), 128.5 (CH), 127.6 (CH), 
88.8 (C), 52.6 (C), 45.5 (CH2), 44.4 (CH2), 29.0 (CH3) ppm. HRMS (ESI): m/z calculated for 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-chloro-benzimidamide (1b, 223 mg, 0.5 
mmol, 1.0 equiv) and 2,6-dimethylphenyl isocyanide (131 mg, 1.0 mmol, 
2.0 equiv). The compound was purified by manual flash chromatography 
using cHex:EtOAc:NEt3 (10:1:0.01) as eluent. The title compound was 
isolated as a white solid (290 mg, 99%).  RF = 0.22 (cHex:EtOAc:NEt3 ; 
9:1:0.01). 1H NMR (300 MHz, CDCl3): δ 10.39(bs, 1H), 8.15 (d, J = 8.6 Hz, 2H), 7.61 - 7.51 (m, 4H), 7.40 
- 7.25 (m, 8H), 7.24 - 7.12 (m, 3H), 5.59 (s, 2H), 5.27 (s, 2H), 2.24 (s, 6H) ppm.  13C NMR (101 MHz, 
CDCl3) δ 165.1 (C), 162.8 (C), 160.9 (C), 157.5 (C), 151.2 (C), 138.0 (C), 136.9 (C), 136.6 (C), 135.42 (C) 
135.41 (C), 134.8 (C), 130.3 (CH), 129.0 (CH), 128.7 (CH), 128.6 (CH), 128.55 (CH), 128.54 (CH), 128.0 
(CH), 127.79 (CH), 127.78 (CH), 127.3 (CH), 88.9 (C), 45.7 (CH2), 44.7 (CH2), 18.8 (CH3) ppm. HRMS 
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1,3-dibenzyl-5-(butylamino)-7-(4-chlorophenyl)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (4c)  
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-chlorobenzimidamide (1b, 223 mg, 0.5 
mmol, 1.0 equiv) and n-butyl isocyanide (105 µL, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using 
cHex:EtOAc:NEt3 (10:1:0.01) as eluent. The title compound was isolated as 
a white solid (260 mg, 99%).  RF = 0.21 (cHex:EtOAc:NEt3 ; 9:1:0.01). 1H 
NMR (300 MHz, CDCl3): δ 9.09 (bt, J = 5.7 Hz, 1H), 8.43 (d, J = 8.7 Hz, 2H), 7.65 - 7.40 (m, 6H), 7.40 - 
7.22 (m, 6H), 5.58 (s, 2H), 5.23 (s, 2H), 3.72 (q, J = 6.7 Hz, 2H), 1.72 (p, J = 7.2 Hz, 2H), 1.59-1.40 (m, 
2H), 1.02 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 164.9 (C), 162.6 (C), 161.7 (C), 157.3 (C), 
151.2 (C), 137.9 (C), 137.1 (C), 136.7 (C), 135.8 (C), 130.3 (CH), 128.7 (CH), 128.6 (CH), 128.51 (CH), 
128.49 (CH), 127.7 (CH), 127.7 (CH), 88.6 (C), 45.6 (CH2), 44.5 (CH2), 40.7 (CH2), 31.5 (CH2), 20.2 (CH2), 
13.8 (CH3) ppm. HRMS (ESI): m/z calculated for C30H28N5O2ClNa [M+Na]+ = 548.1824, found = 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-(trifluoromethyl) benzimidamide (1c, 
239 mg, 0.5 mmol, 1.0 equiv) and tert-butyl isocyanide (119 µL, 1.0 mmol, 
2.0 equiv). The compound was purified by manual flash chromatography 
using cHex:EtOAc:NEt3 (25:1:0.01) as eluent. The title compound was 
isolated as a white solid (174 mg, 62%).  RF = 0.44 (cHex:EtOAc:NEt3 = 10:1:0.01). 1H NMR (300 MHz, 
CDCl3): δ 9.29 (br s, 1H), 8.54 (d, J = 9.0 Hz, 2H), 7.75 (d, J = 9.0 Hz, 2H), 7.52 (dd, J = 3.0, 9.0 Hz, 2H), 
7.48 (dd, J = 3.0, 9.0 Hz, 2H), 7.35-7.25 (m, 6H), 5.57 (s, 2H), 5.21 (s, 2H), 1.61 (s, 9H). 13C NMR (126 
MHz, CDCl3): δ 163.8 (C), 162.7 (C), 161.3 (C), 157.3 (C), 151.1 (C), 140.8 (C), 137.0 (C), 136.5 (C), 132.9 
(q, 2J = 33 Hz, C), 129.1 (CH), 128.6 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 127.7 (CH), 127.7 (CH), 
125.3 (q, 3J = 5 Hz, CH), 124.0 (q, 1J = 270 Hz, C), 89.1 (C), 52.8 (C), 45.6 (CH2), 44.5 (CH2), 29.0 (CH3) 





The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-(trifluoromethyl) benzimidamide (1c, 
239 mg, 0.5 mmol, 1.0 equiv) and cyclohexyl isocyanide (124 µL, 1.0 mmol, 
2.0 equiv). The compound was purified by manual flash chromatography 
using cHex:EtOAc:NEt3 (50:1:0.01) as eluent. The title compound was 
isolated as a white solid (152 mg, 52%). RF = 0.48 (cHex :EtOAc:NEt3 = 
10:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.07 (d, J = 9.0 Hz, 1H), 8.54 (d, J = 9.0 Hz, 2H), 7.74 (d, J = 9.0 
Hz, 2H), 7.52 (d, J = 9.0 Hz, 2H), 7.49 (d, J = 9.0 Hz, 2H), 7.37 - 7.27 (m, 6H), 5.58 (s, 2H), 5.22 (s, 2H), 
4.38 - 4.27 (m, 1H), 2.14 - 2.03 (m, 2H), 1.89 - 1.78 (m, 2H), 1.74 - 1.65 (m, 1H), 1.60 – 1.50 (m, 1H), 
1.48 – 1.24 (m, 4H) -. 13C NMR (126 MHz, CDCl3): δ 164.5 (C), 162.5 (C), 160.8 (C), 157.4 (C), 151.2 (C), 
140.6 (C), 137.0 (C), 136.5 (C), 132.9 (q, 2J = 33 Hz, C), 129.1 (CH), 128.6 (CH), 128.5(CH), 128.5 (CH), 
128.4 (CH), 127.7 (CH), 127.7 (CH), 125.3 (q, 3J = 5 Hz, CH), 124.0 (q, 1J = 270 Hz, C), 88.7 (C), 49.8 (CH), 
45.6 (CH2), 44.5 (CH2), 32.6 (CH2), 25.6 (CH2), 24.7 (CH2) ppm. HRMS (ESI): m/z calculated for 








The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-(trifluoromethyl) benzimidamide (1c, 
239 mg, 0.5 mmol, 1.0 equiv) and benzyl isocyanide (122 µL, 1.0 mmol, 
2.0 equiv). The compound was purified by manual flash chromatography 
using cHex:EtOAc:NEt3 (25:1:0.01) as eluent. The title compound was 
isolated as a white solid (172 mg, 58%).   RF = 0.37 (cHex:EtOAc:NEt3 = 10:1:0.01). 1H NMR (300 MHz, 
CDCl3): δ 9.49 - 9.43 (m, 1H), 8.54 (d, J = 6.0 Hz, 2H), 7.72 (d, J = 6.0 Hz, 2H), 7.52 (dd, J = 3.0, 9.0 Hz, 
2H), 7.47 (dd, J = 3.0, 9.0 Hz, 2H), 7.43-7.27 (m, 11H), 5.58 (s, 2H), 5.21 (s, 2H), 4.92 (d, J = 6.0 Hz, 2H) 
ppm. 13C NMR (126 MHz, CDCl3): δ 164.7 (C), 162.5 (C), 161.7 (C), 157.4 (C), 151.1 (C), 140.4 (C), 138.1 
(C), 136.8 (C), 136.5 (C), 133.0 (q, 2J = 33 Hz, C), 129.2 (CH), 128.8 (CH), 128.7 (CH), 128.5 (CH), 128.5 
(CH), 128.5 (CH), 127.7 (CH), 127.7 (CH), 127.6 (CH), 125.3 (q, 3J = 5 Hz, CH), 124.0 (q, 1J = 270 Hz, C), 
89.1 (C), 45.7 (CH2), 44.9 (CH2), 44.6 (CH2) ppm. HRMS (ESI): m/z calculated for C34H27N5O2F3 [M+H]+ = 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-methoxybenzimidamide (1d, 220 
mg, 0.5 mmol, 1.0 equiv) and tert-butyl isocyanide (2a, 220 µL, 1.5 mmol, 
3.0 equiv). The compound was purified by manual flash chromatography 
using cHex:EtOAc:NEt3 (gradient = 40:1:0.01 – 10:1:0.01) as eluent. The 
title compound was isolated as a white solid (178 mg, 68%).  RF = 0.25 (cHex:EtOAc:NEt3 = 
15:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.17 (s, 1H), 8.43 (d, J = 9.0 Hz, 2H), 7.54 (d, J = 6.0 Hz, 2H), 
7.46 (d, J = 6.0 Hz, 2H), 7.37-7.21 (m, 6H), 7.00 (d, J = 6.0 Hz, 2H), 5.57 (s, 2H), 5.19 (s, 2H), 3.89 (s, 3H), 
1.61 (s, 9H) ppm. 13C NMR (150.90 MHz, CDCl3): δ 164.8 (C), 162.7 (C), 162.6 (C), 161.2 (C), 157.2 (C), 
151.3 (C), 137.3 (C), 136.7 (C), 130.8 (CH), 130.1 (C), 128.6 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 
127.6 (CH), 127.6 (CH), 113.7 (CH), 88.4 (C), 55.4 (CH3), 52.5 (C), 45.3 (CH2), 44.3 (CH2), 29.1 (CH3) 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-methoxybenzimidamide (1d, 220 
mg, 0.5 mmol, 1.0 equiv) and 2,6-dimethylphenyl isocyanide (131 mg, 
1.0 mmol, 2.0 equiv). The compound was purified by manual flash 
chromatography using cHex:EtOAc:NEt3 (15:1:0.01) as eluent. The title 
compound was isolated as an off-white solid (224 mg, 79%).  RF = 0.39 
(cHex:EtOAc:NEt3 = 7:1:0.01). 1H NMR (300 MHz, CDCl3): δ 10.33 (s, 1H), 8.19 (d, J = 6.0 Hz, 2H), 7.60 
(d, J = 6.0 Hz, 2H), 7.54 (d, J = 6.0 Hz, 2H), 7.40 - 7.27 (m, 6H), 7.21-7.12 (m, 3H), 6.88 (d, J = 6.0 Hz, 
2H), 5.60 (s, 2H), 5.26 (s, 2H), 3.83 (s, 3H), 2.24 (s, 6H) ppm. 13C NMR (126 MHz, CDCl3): δ 165.7 (C), 
162.9 (C), 162.7 (C), 160.8 (C), 157.4 (C), 151.3 (C), 137.1 (C), 136.7 (C), 135.4 (C), 135.0 (C), 130.9 (CH), 
129.5 (C), 128.9 (CH), 128.8 (CH), 128.50 (CH), 128.49 (CH), 127.9 (CH), 127.7 (CH), 127.7 (CH), 126.9 
(CH), 113.7 (CH), 88.4 (C), 55.4 (CH3), 45.5 (CH2), 44.6 (CH2), 18.8 (CH3) ppm. HRMS 
(ESI): m/z calculated for C35H32N5O3 [M+H]+ = 570.2500, found = 570.2500. M.p.: 237 °C. 
 





The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)-4-methoxybenzimidamide (1d, 220 
mg, 0.5 mmol, 1.0 equiv) and cyclohexyl isocyanide (124 μL, 1.0 mmol, 
2.0 equiv). The compound was purified by manual flash chromatography 
using cHex:EtOAc:NEt3 (gradient = 20:1:0.01-10:1:0.01) as eluent. The 
title compound was isolated as an off-white solid (211 mg, 77%). RF = 0.41 
(cHex:EtOAc:NEt3 = 7:1:0.01). 1H NMR (300 MHz, CDCl3): δ 8.96 (d, J = 9.0, 1H), 8.42 (d, J = 9.0, 2H), 
7.53 (d, J = 9.0 Hz, 2H), 7.46 (d, J = 9.0 Hz, 2H), 7.37 - 7.20 (m, 6H), 6.98 (d, J = 9.0 Hz, 2H), 5.56 (s, 2H), 
5.19 (s, 2H), 4.39 - 4.22 (m, 1H), 3.89 (s, 3H), 2.15 - 1.99 (m, 2H), 1.89 - 1.75 (m, 2H), 1.73 - 1.62 (m, 
1H), 1.55 - 1.22 (m, 5H). 13C NMR (126 MHz, CDCl3): δ 165.5 (C), 162.6 (C), 162.6 (C), 160.7 (C), 157.3 
(C), 151.3 (C), 137.2 (C), 136.8 (C), 130.8 (CH), 130.0 (C), 128.6 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 
127.6 (CH), 127.5 (CH), 113.7 (CH), 88.0 (C), 55.4 (CH3), 49.6 (CH), 45.4 (CH2), 44.3 (CH2), 32.7 (CH2), 
25.7 (CH2), 24.8 (CH2) ppm. HRMS (ESI): m/z calculated for C33H34N5O3 [M+H]+ = 548.2656, found 
=  548.2632. M.p.: 205 °C. 
 
1,3-dibenzyl-5-(tert-butylamino)-7-methylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5a)  
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 equiv) and 
tert-butyl isocyanide (113 mg, 1.0 mmol, 2.0 equiv). The compound was purified by 
manual flash chromatography using cHex:EtOAc:NEt3 (45:1:0.01) as eluent. The 
title compound was isolated as a white solid (181 mg, 85%).  RF = 0.20 (cHex:EtOAc 
:NEt3 = 20:1:1). 1H NMR (300 MHz, CDCl3): δ 9.10 (s, 1H), 7.53 (d, J = 6.0 Hz, 2H), 
7.47 (d, J = 6.0 Hz, 2H), 7.37 - 7.23 (m, 6H), 5.46 (s, 2H), 5.20 (s, 2H), 2.51 (s, 3H), 1.54 (s, 9H) ppm. 13C 
NMR (150.90 MHz, CDCl3): δ 170.4 (C), 162.8 (C), 161.1 (C), 156.9 (C), 151.1 (C), 137.1 (C), 136.7 (C), 
128.9 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 127.5 (CH), 127.5 (CH), 88.1 (C), 52.5 (C), 45.0 (CH2), 
44.3 (CH2), 28.9 (CH3), 27.0 (CH3) ppm. HRMS (ESI): m/z calculated for C25H28N5O2 [M+H]+ = 430.2238, 
found = 430.2238. M.p.: 100 °C. 
 
1,3-dibenzyl-5-(isopropylamino)-7-methylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5b)  
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 equiv) and 
isopropyl isocyanide (94 µL, 1.0 mmol, 2.0 equiv). The compound was purified by 
manual flash chromatography using cHex:EtOAc (30:1) as eluent. The title 
compound was isolated as a white solid (56 mg, 30%). RF = 0.31 (cHex:EtOAc:NEt3 = 
10:1:1). 1H NMR (300 MHz, CDCl3): δ 8.88 - 8.76 (m, 1H), 7.50 (d, J = 6.0 Hz, 2H), 
7.44 (d, J = 6.0 Hz, 2H), 7.36 - 7.21 (m, 6H), 5.44 (s, 2H), 5.17 (s, 2H), 4.47 (sep, J = 6.0 Hz, 1H), 2.49 (s, 
3H), 1.27 (d, J = 6.0 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3): δ 171.4 (C), 162.6 (C), 160.6 (C), 156.9 
(C), 151.2 (C), 137.1 (C), 136.7 (C), 128.9 (CH), 128.5 (CH), 128.5 (CH), 128.3 (CH), 127.6 (CH), 127.5 
(CH), 87.7 (C), 45.2 (CH2), 44.3 (CH2), 42.5 (CH), 26.9 (CH3), 22.7 (CH3) ppm. HRMS (ESI): m/z calculated 
for C24H26N5O2 [M+H]+ = 416.2081, found = 416.2077. M.p.: 121 °C. 
 
1,3-dibenzyl-5-(cyclohexylamino)-7-methylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5c)  
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 equiv) and 
cyclohexyl isocyanide (124 μL, 1.0 mmol, 2.0 equiv). The compound was purified 
by manual flash chromatography using cHex:EtOAc (30:1) as eluent. The title 
compound was isolated as a white solid (153 mg, 67%). RF = 0.25 





7.53 (d, J = 6.0 Hz, 2H), 7.48 (d, J = 6.0 Hz, 2H), 7.38 - 7.24 (m, 6H), 5.47 (s, 2H), 5.20 (s, 2H), 4.28 - 4.14 
(m, 1H), 2.52 (s, 3H), 2.07 - 1.96 (m, 2H), 1.85 - 1.75 (m, 2H), 1.72 - 1.61 (m, 1H), 1.55 - 1.21 (m, 5H) 
ppm. 13C NMR (126 MHz, CDCl3): δ 171.4 (C), 162.6 (C), 160.5 (C), 156.9 (C), 151.2 (C), 137.1 (C), 136.7 
(C), 128.9 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 127.6 (CH), 127.5 (CH), 87.7 (C), 49.1 (CH), 45.1 
(CH2), 44.3 (CH2), 32.8 (CH2), 26.9 (CH3), 25.6 (CH2), 24.6 (CH2) ppm. HRMS (ESI): m/z calculated for 
C27H30N5O2 [M+H]+ = 456.2394, found = 456.2394. M.p.: 127 °C. 
 
1,3-dibenzyl-7-methyl-5-(pentylamino)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5d) 
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 
equiv) and n-pentyl isocyanide (126 µL, 1.0 mmol, 2.0 equiv). The compound 
was purified by manual flash chromatography using cHex:EtOAc (10:1) as 
eluent. The title compound was isolated as a yellow oil (126 mg, 57%). RF = 
0.21 (cHex:EtOAc:NEt3 = 10:1:1). 1H NMR (300 MHz, CDCl3): δ 9.05 - 8.85 (m, 1H), 7.50 (d, J = 6.0 Hz, 
2H), 7.44 (d, J = 6.0 Hz, 2H), 7.36 - 7.20 (m, 6H), 5.44 (s, 2H), 5.17 (s, 2H), 3.55 (q, J = 6.0 Hz, 2H), 2.49 
(s, 3H), 1.73 - 1.50 (m, 2H), 1.45-1.30 (m, 4H), 1.00 - 0.80 (m, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 
171.4 (C), 162.7 (C), 161.4 (C), 156.9 (C), 151.2 (C), 137.0 (C), 136.7 (C), 128.9 (CH), 128.6 (CH), 128.5 
(CH), 128.3 (CH), 127.6 (CH), 127.6 (CH), 87.9 (C), 45.2 (CH), 44.4 (CH2), 40.8 (CH2), 29.7 (CH2), 29.1 
(CH2), 26.9 (CH3), 22.3 (CH2), 14.0 (CH3) ppm. HRMS (ESI): m/z calculated for C26H30N5O2 [M+H]+ = 
444.2394, found = 444.2394. 
 
1,3-dibenzyl-5-(benzylamino)-7-methylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5e) 
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 equiv) and 
benzyl isocyanide (122 µL, 1.0 mmol, 2.0 equiv). The compound was purified 
by manual flash chromatography using cHex:EtOAc (10:1) as eluent. The title 
compound was isolated as a green oil (40 mg, 17%). RF = 0.18 (cHex:EtOAc:NEt3 
= 10:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.27 (s, 1H), 7.50 (d, J = 6.0 Hz, 2H), 
7.43 (d, J = 6.0 Hz, 2H), 7.38 - 7.31 (m, 5H), 7.30 - 7.20 (m, 6H), 5.45 (s, 2H), 5.16 (s, 2H), 4.86-4.74 (m, 
2H), 2.52 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 171.5 (C), 162.6 (C), 161.4 (C), 156.9 (C), 151.1 (C), 
138.1 (C), 136.9 (C), 136.6 (C), 128.9 (CH), 128.6 (CH), 128.6 (CH), 128.5 (CH), 128.3 (CH), 127.8 (CH), 
127.6 (CH), 127.6 (CH), 127.4 (CH), 88.1 (C), 45.3 (CH2), 44.6 (CH2), 44.4 (CH2), 26.9 (CH3) ppm. HRMS 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 equiv) and 
2-isocyano-2,4,4-trimethylpentane (175 µL, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using cHex:EtOAc 
(30:1) as eluent. The title compound was isolated as a green oil (188 mg, 77%).  
RF = 0.53 (cHex:EtOAc:NEt3 = 10:1:1). 1H NMR (300 MHz, CDCl3): δ 9.15 (s, 1H), 7.53 (d, J = 6.0 Hz, 2H), 
7.46 (d, J = 6.0 Hz, 2H), 7.37 - 7.23 (m, 6H), 5.44 (s, 2H), 5.19 (s, 2H), 2.50 (s, 3H), 1.99 (s, 2H), 1.58 (s, 
6H), 1.00 (s, 9H) ppm. 13C NMR (150.90 MHz, CDCl3): δ 170.2 (C), 162.8 (C), 161.0 (C), 156.9 (C), 151.1 
(C), 137.1 (C), 136.7 (C), 129.0 (CH), 128.6 (CH), 128.4 (CH), 128.3 (CH), 127.5 (CH), 127.5 (CH), 88.0 
(C), 56.4 (C), 51.2 (CH2), 45.0 (CH2), 44.2 (CH2), 31.7 (C), 31.5 (CH3), 29.5 (CH3), 27.0 (CH3) ppm. HRMS 
(ESI): m/z calculated for C29H36N5O2 [M+H]+ = 486.2839, found = 486.2864. 
 





The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 
equiv) and 2-morpholinoethyl isocyanide (140 µL, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using cHex:EtOAc 
(gradient = 6:1-3:1) as eluent. The title compound was isolated as a green oil 
(60 mg, 25%). RF = 0.32 (EtOAc:DCM = 2:3). 1H NMR (300 MHz, CDCl3): δ 9.25 - 9.10 (m, 1H), 7.54 - 
7.42 (m, 4H), 7.35 - 7.21 (m, 6H), 5.43 (s, 2H), 5.18 (s, 2H), 3.80-3.73 (m, 4H), 3.72-3.64 (m, 2H), 2.68-
2.58 (m, 2H), 2.57-2.50 (m, 4H), 2.48 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3): δ 171.5 (C), 162.5 (C), 
161.5 (C), 157.0 (C), 151.3 (C), 137.1 (C), 136.8 (C), 129.0 (CH), 128.8 (CH), 128.5 (CH), 128.4 (CH), 
127.7 (CH), 127.7 (CH), 88.3 (C), 67.0 (CH2), 57.1 (CH2), 53.5 (CH2), 45.3 (CH2), 44.4 (CH2), 37.5 (CH2), 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)acetimidamide (1e, 174 mg, 0.5 mmol, 1.0 equiv) and 
2,6-dimethylphenyl isocyanide (131 mg, 1.0 mmol, 2.0 equiv). The compound 
was purified by manual flash chromatography using cHex:EtOAc (20:1) as eluent. 
The title compound was isolated as an off-white solid (184 mg, 77%). RF = 0.13 
(cHex:EtOAc:NEt3 = 20:1:0.01). 1H NMR (300 MHz, CDCl3): δ 10.30 (bs, 1H), 7.55 
(d, J = 9.0 Hz, 2H), 7.51 (d, J = 9.0 Hz, 2H), 7.38 - 7.23 (m, 6H), 7.20 - 2.05 (m, 3H), 5.46 (s, 2H), 5.23 (s, 
2H), 2.40 (s, 3H), 2.20 (s, 6H) ppm. 13C NMR (126 MHz, CDCl3): δ 171.9 (C), 163.0 (C), 160.7 (C), 157.0 
(C), 151.2 (C), 136.9 (C), 136.6 (C), 135.5 (C), 134.7 (C), 129.1 (CH), 128.9 (CH), 128.5 (CH), 128.4 (CH), 
128.0 (CH), 127.7 (CH), 127.7 (CH), 127.1 (CH), 88.2 (C), 45.3 (CH2), 44.6 (CH2), 27.0 (CH3), 18.8 (CH3) 
ppm. HRMS (ESI): m/z calculated for C29H28N5O2 [M+H]+ = 478.2230, found = 478.2238. M.p.: 179 °C. 
 
1,3-dibenzyl-5-(tert-butylamino)-7-isopropylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5j)  
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)isobutyrimidamide (1f, 188 mg, 0.5 mmol, 1.0 equiv) 
and tert-butyl isocyanide (2a, 131 mg, 1.0 mmol, 2.0 equiv). The compound was 
purified by manual flash chromatography using heptane/EtOAc (9:1) as eluent. 
The title compound was isolated as a yellow oil (225 mg, 98%). RF = 0.40 
(EtOAc:cHex:NEt3 = 1:15:0.01). 1H NMR (300 MHz, CDCl3): δ 9.03 (s, 1H), 7.52 
(dd, J = 3.0, 9.0 Hz, 2H), 7.43 (dd, J = 3.0, 9.0 Hz, 2H), 7.35 - 7.20 (m, 6H), 5.45 (s, 2H), 5.17 (s, 2H), 2.96 
(hep, J = 6.0 Hz, 1H), 1.52 (s, 9H), 1.29 (d, 9.0 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3): δ 177.5 (C), 
162.8 (C), 161.3 (C), 156.9 (C), 151.3 (C), 137.2 (C), 136.7 (C), 129.0 (CH), 128.4 (CH), 128.4 (CH), 128.3 
(CH), 127.5 (CH), 127.5 (CH), 88.3 (C), 52.5 (C), 45.2 (CH2), 44.3 (CH2), 38.1 (CH), 29.0 (CH3), 21.2 (CH3) 
ppm. HRMS (ESI): m/z calculated for C27H32N5O2 [M+H]+ = 458.2551, found = 458.2551. 
 
1,3-dibenzyl-5-(cyclohexylamino)-7-isopropylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5k)  
The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)isobutyrimidamide (1f, 188 mg, 0.5 mmol, 1.0 equiv) 
and cyclohexyl isocyanide (124 μL, 1.0 mmol, 2.0 equiv). The compound was 
purified by manual flash chromatography using heptane/EtOAc (9:1) as eluent. 
The title compound was isolated as a white solid (200 mg, 83%).  RF = 0.19 
(cHex:EtOAc:NEt3 ; 9:1:0.01).  1H NMR (300 MHz, CDCl3): δ 8.88 (d, J = 7.8 Hz, 1H), 
7.59 - 7.52 (m, 2H), 7.49 - 7.44 (m, 2H), 7.37 - 7.24 (m, 6H), 5.48 (s, 2H), 5.21 (s, 





(m, 5H), 1.31 (d, J = 6.8 Hz, 6H) ppm. 13C NMR (126 MHz, CDCl3): δ 178.4 (C), 162.7 (C), 160.8 (C), 157.1 
(C), 151.4 (C), 137.3 (C), 136.8 (C), 129.0 (CH), 128.5 (CH), 128.4 (CH), 128.2 (CH), 127.5 (CH), 127.5 
(CH), 88.0 (C), 49.3 (CH), 45.2 (CH2), 44.3 (CH2), 38.1 (CH), 32.6 (CH2), 25.7 (CH2), 24.7 (CH2), 21.2 (CH3) 




The general procedure B was applied using N-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)isobutyrimidamide (1f, 188 mg, 0.5 mmol, 1.0 equiv) 
and 2,6-dimethylphenyl isocyanide (131 mg, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using cHex:EtOAc:NEt3 
(10:1:0.01) as eluent. The title compound was isolated as a white solid (252 mg, 
99%).  RF = 0.25 (cHex:EtOAc:NEt3 ; 9:1:0.01).  1H NMR (300 MHz, CDCl3): δ 10.26 
(bs, 1H), 7.61 (d, J = 6.6 Hz, 2H), 7.53 (d, J = 7.0 Hz, 2H), 7.40 - 7.25 (m, 6H), 7.19-7.02 (m, 3H), 5.50 (s, 
2H), 5.26 (s, 2H), 2.86 (hept, J = 6.9 Hz, 1H), 2.22 (s, 6H), 1.18 (d, J = 6.8 Hz, 6H) ppm. 13C NMR (125 
MHz, CDCl3) δ 178.9 (C), 163.0 (C), 160.9 (C), 157.2 (C), 151.3 (C), 137.1 (C), 136.7 (C), 135.5 (C), 134.9 
(C), 129.3 (CH), 128.8 (CH), 128.5 (CH), 128.3 (CH), 127.9 (CH), 127.8 (CH), 127.7 (CH), 126.9 (CH), 88.5 
(C), 45.4 (CH2), 44.6 (CH2), 37.9 (CH), 21.0 (CH3), 18.7 (CH3) ppm. HRMS (ESI): m/z calculated for 
C31H32N5O2 [M+H]+ = 506.2551, found = 506.2537. M.p.: 83-84 ° C. 
 
1,3-dibenzyl-7-(tert-butyl)-5-(tert-butylamino)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5o)  
The general procedure B was applied using N'-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)pivalimidamide (1g, 195 mg, 0.5 mmol, 1.0 equiv) and 
tert-butyl isocyanide (2a, 119 μL, 1.0 mmol, 2.0 equiv). The compound was 
purified by manual flash chromatography using cHex:EtOAc (15:1) as eluent. The 
title compound was isolated as a colorless oil (224 mg, 95%). RF = 0.33 
(cHex:EtOAc:NEt3 = 20:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.20 - 9.12 (m, 1H), 
7.67 - 7.59 (m, 2H), 7.57 - 7.50 (m, 2H), 7.42 - 7.34 (m, 4H), 7.33 - 7.28 (m, 2H), 5.54 (s, 2H), 5.27 (s, 
2H), 1.70 - 1.55 (m, 9H), 1.50 - 1.40 (m, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 179.3 (C), 162.7 (C), 
161.0 (C), 156.8 (C), 151.2 (C), 137.2 (C), 136.7 (C), 128.8 (CH), 128.4 (CH), 128.4 (CH), 128.3 (CH), 
128.2 (CH), 127.4 (CH), 88.0 (C), 52.2 (C), 45.2 (CH2), 44.2 (CH2), 40.1 (C), 29.1 (CH3), 28.9 (CH3) 
ppm. HRMS (ESI): m/z calculated for C28H34N5O2 [M+H]+ = 472.2704, found = 472.2707. 
 
1,3-dibenzyl-7-(tert-butyl)-5-(cyclohexylamino)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5p)  
The general procedure B was applied using N'-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)pivalimidamide (1g, 195 mg, 0.5 mmol, 1.0 equiv) and 
cyclohexyl isocyanide (124 μL, 1.0 mmol, 2.0 equiv). The compound was purified 
by manual flash chromatography using cHex:EtOAc:NEt3 (20:1:0.01) as eluent. 
The title compound was isolated as a white solid (194 mg, 81%). RF = 0.20 
(EtOAc:cHex:NEt3 = 1:20:0.01). 1H NMR (500 MHz, CDCl3): δ 8.84 (d, J = 3.0 Hz, 
1H), 7.55 (d, J = 10.0 Hz, 2H), 7.47 (d, J = 10.0 Hz, 2H), 7.36 - 7.25 (m, 6H), 5.49 (s, 
2H), 5.22 (s, 2H), 4.20 - 4.12 (m, 1H), 2.09 - 2.02 (m, 2H), 1.84 - 1.76 (m, 2H), 1.70 - 1.63 (m, 1H), 1.50 
- 1.38 (m, 4H), 1.37 (s, 9H), 1.36 - 1.23 (m, 1H) ppm. 13C NMR (126 MHz, CDCl3): δ 180.1 (C), 162.6 (C), 
160.5 (C), 156.9 (C), 151.4 (C), 137.2 (C), 136.7 (C), 128.8 (CH), 128.4 (CH), 128.4 (CH), 128.2 (CH), 
127.5 (CH), 127.4 (CH), 87.7 (C), 49.5 (CH), 45.3 (CH2), 44.2 (CH2), 40.0 (C), 32.5 (CH2), 29.1 (CH3), 25.7 
(CH2), 24.7 (CH2) ppm. HRMS (ESI): m/z calculated for C30H36N5O2 [M+H]+ = 498.2853, found = 








1,3-dibenzyl-5-(benzylamino)-7-(tert-butyl)pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (5q)  
The general procedure B was applied using N'-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)pivalimidamide (1g, 195 mg, 0.5 mmol, 1.0 equiv) 
and benzyl isocyanide (120 µL, 1.0 mmol, 2.0 equiv). The compound was 
purified by manual flash chromatography using cHex:EtOAc (40 ; 1) as eluent. 
The title compound was isolated as a white solid (202 mg, 80%). RF = 0.26 
(cHex:EtOAc:NEt3 = 20:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.30 - 9.22(m, 1H), 7.54 (dd, J = 3.0, 9.0 
Hz, 2H), 7.45 (dd, J = 3.0, 9.0 Hz, 2H), 7.41 - 7.22 (m, 11H), 5.49 (s, 2H), 5.20 (s, 2H), 4.81 (d, J = 6 Hz, 
2H), 1.36 (s, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 180.5 (C), 162.6 (C), 161.4 (C), 156.9 (C), 151.4 (C), 
138.6 (C), 137.1 (C), 136.7 (C), 128.8 (CH), 128.5 (CH), 128.5 (CH), 128.4 (CH), 128.3 (CH), 127.8 (CH), 
127.6 (CH), 127.5 (CH), 127.3 (CH), 88.1 (C), 45.4 (CH2), 44.5 (CH2), 44.4 (CH2), 40.2 (C), 29.1 (CH3) 
ppm. HRMS (ESI): m/z calculated for C31H32N5O2 [M+H]+ = 506.2525, found = 506.2551. M.p.: 133 °C. 
 
1,3-dibenzyl-7-(tert-butyl)-5-[(2,6-dimethylphenyl)amino]pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-
dione (5r)  
The general procedure B was applied using N'-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)pivalimidamide (1g, 195 mg, 0.5 mmol, 1.0 equiv) and 
2,6-dimethylphenyl isocyanide (131 mg, 1.0 mmol, 2.0 equiv). The compound 
was purified by manual flash chromatography using cHex:EtOAc:NEt3 (20:1:0.01) 
as eluent. The title compound was isolated as a white solid (242 mg, 93%). RF = 
0.43 (cHex:EtOAc:NEt3 = 20:1:0.01). 1H NMR (500 MHz, CDCl3): δ 10.22 (brs, 1H), 7.64 (d, J = 10 Hz, 
2H), 7.56 (d, J = 10 Hz, 2H), 7.40 - 7.34 (m, 4H), 7.33 - 7.29 (m, 2H), 7.19 - 7.12 (m, 3H), 5.54 (s, 2H), 
5.29 (s, 2H), 2.24 (s, 6H), 1.23 (s, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 180.6 (C), 162.9 (C), 160.7 (C), 
157.0 (C), 151.4 (C), 137.1 (C), 136.6 (C), 135.4 (C), 134.9 (C), 129.1 (CH), 128.8 (CH), 128.5 (CH), 128.3 
(CH), 127.7 (CH), 127.6 (CH), 127.6 (CH), 126.8 (CH), 88.1 (C), 45.4 (CH2), 44.5 (CH2), 40.0 (C), 28.9 
(CH3), 18.7 (CH3) ppm. HRMS (ESI): m/z calculated for C32H34N5O2 [M+H]+ = 520.2691, found = 




The general procedure B was applied using N'-(1,3-dibenzyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)pivalimidamide (1g, 205 mg, 0.5 mmol, 1.0 
equiv) and 4-methoxyphenyl isocyanide (133 μg, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using cHex:EtOAc 
(30:1) as eluent. The title compound was isolated as an off-white solid (170 
mg, 65%). RF = 0.19 (cHex:EtOAc:NEt3 = 20:1:0.01). 1H NMR (300 MHz, 
CDCl3): δ 10.95 (brs, 1H), 7.69 (d, J = 9.0 Hz, 2H), 7.52 (dd, J = 3.0, 9.0 Hz, 2H), 7.47 (dd, J = 3.0, 9.0 Hz, 
2H), 7.36 - 7.22 (m, 6H), 6.90 (d, J = 9.0 Hz, 2H), 5.49 (s, 2H), 5.23 (s, 2H), 3.82 (s, 3H), 1.36 (s, 9H) 
ppm. 13C NMR (126 MHz, CDCl3): δ 180.8 (C), 162.7 (C), 159.3 (C), 157.0 (C), 156.2 (C), 151.2 (C), 137.0 
(C), 136.5 (C), 131.4 (C), 128.8 (CH), 128.6 (CH), 128.5 (CH), 128.3 (CH), 127.7 (CH), 127.6 (CH), 123.0 
(CH), 113.9 (CH), 88.3 (C), 55.5 (CH3), 45.5 (CH2), 44.5 (CH2), 40.4 (C), 29.2 (CH3) ppm. HRMS 




The general procedure B was applied using N'-(1,3-dibenzyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)pivalimidamide (1g, 195 mg, 0.5 mmol, 1.0 equiv) and 
methyl 2-isocyanoacetate (93 µL, 1.0 mmol, 2.0 equiv). The compound was 





title compound was isolated as a clear oil (34 mg, 14%).  RF = 0.39 (EtOAc:c-Hex:NEt3 = 1:4:0.01). 1H 
NMR (300 MHz, CDCl3): δ 9.13 (t, J = 5.6, 1H), 7.53 - 7.41 (m, 4H), 7.34 - 7.20 (m, 6H), 5.45 (s, 2H), 5.19 
(s, 2H), 4.28 (d, J = 5.6 Hz, 2H), 3.75 (s, 3H), 1.30 (s, 9H) ppm. 13C NMR (126 MHz, CDCl3): δ 180.4 (C), 
170.1 (C), 162.4 (C), 161.3 (C), 156.8 (C), 151.3 (C), 137.0 (C), 136.6 (C), 128.8 (CH), 128.7 (CH), 128.4 
(CH), 128.3 (CH), 127.6 (CH), 127.6 (CH), 88.6 (C), 52.2 (CH3), 45.5 (CH2), 44.4 (CH2), 42.7 (CH2), 40.1 
(C), 29.0 (CH3) ppm. HRMS (ESI): m/z calculated for C27H30N5O4 [M+H]+ = 488.2260, found = 488.2292. 
 
5-(tert-butylamino)-1,3-dimethyl-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (6a)  
The general procedure B was applied using N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)benzimidamide (1h, 129 mg, 0.5 mmol, 1.0 equiv) and 
tert-butyl isocyanide (2a, 119 μL, 1.0 mmol, 2.0 equiv). The compound was purified 
by manual flash chromatography using cHex:EtOAc (10:1) as eluent. The title 
compound was isolated as a white solid (150 mg, 89%).  RF = 0.64 (cHex:EtOAc:NEt3 
; 5:1:0.01). 1H NMR (300 MHz, CDCl3): δ 9.21 (bs, 1H), 8.48 (d, J = 6.8 Hz, 2H), 7.58 
- 7.42 (m, 3H), 3.73 (s, 3H), 3.43 (s, 3H), 1.62 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3): δ 165.1 (C), 163.1 
(C), 161.2 (C), 157.4 (C), 151.4 (C), 137.5 (C), 131.5 (CH), 128.9 (CH), 128.3 (CH), 88.7 (C), 52.5 (C), 29.4 
(CH3), 29.1 (CH3), 27.8 (CH3) ppm. HRMS (ESI): m/z calculated for C18H21N5O2Na [M+Na]+ = 362.1587, 
found = 362.1568. M.p.: 242 °C. 
 
5-(Cyclohexylamino)-1,3-dimethyl-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (6b)  
The general procedure B was applied using N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)benzimidamide (1h, 129 mg, 0.5 mmol, 1.0 equiv) and 
cyclohexyl isocyanide (124 μL, 1.0 mmol, 2.0 equiv). The compound was purified 
by manual flash chromatography using heptane:EtOAc (10:1) as eluent. The title 
compound was isolated as a white solid (182 mg, 98%). RF = 0.58 
(cHex:EtOAc:NEt3 ; 5:1:0.01). 1H NMR (400 MHz, CDCl3) δ 9.02 (bd, J = 7.8 Hz, 1H), 
8.47 (dd, J = 1.7, 8.1 Hz, 2H), 7.62 - 7.36 (m, 3H), 4.34 (dtd, J = 3.7, 8.1, 12.9 Hz, 1H), 3.73 (s, 3H), 3.43 
(s, 3H), 2.15 - 2.02 (m, 2H), 1.86-1.76 (m, 2H), 1.69 - 1.65 (m, 1H), 1.57- 1.29 (m, 5H) ppm. 13C 
NMR (101 MHz, CDCl3) δ 165.9 (C), 163.0 (C), 160.8 (C), 157.6 (C), 151.5 (C), 137.4 (C), 131.5 (CH), 
128.9 (CH), 128.3 (CH), 88.3 (C), 49.5 (CH), 32.7 (CH2), 29.4 (CH2), 27.8 (CH2), 25.7 (CH2), 24.6  (CH2) 
ppm. HRMS (ESI): m/z calculated for C20H24N5O2 [M+H]+ = 366.1925, found = 366.1909. M.p.: 199 °C. 
 
5-(Butylamino)-1,3-dimethyl-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (6c)  
The general procedure B was applied using N-(1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl)benzimidamide (1h, 129 mg, 0.5 mmol, 1.0 equiv) and 
n-butyl isocyanide (105 µL, 1.0 mmol, 2.0 equiv). The compound was purified 
by manual flash chromatography using cHex:EtOAc (10:1) as eluent. The title 
compound was isolated as a white solid (125 mg, 74%). RF = 0.53 
(cHex:EtOAc:NEt3 ; 5:1:0.01). 1H NMR (400 MHz, CDCl3) δ 8.99 (bt, J = 5.7, 1H), 8.46 (dd, J = 1.5, 8.1 
Hz, 2H), 7.55 - 7.41 (m, 3H), 3.71 (q, J = 6.6 Hz, 2H), 3.70 (s, 3H), 3.40 (s, 3H), 1.70 (tt, J = 6.3, 7.3 Hz, 
2H), 1.49 (dt, 7.3, 14.9 Hz, 2H), 0.99 (t, J = 7.3 Hz, 3H) ppm. 13C NMR (101 MHz, CDCl3) δ 165.8 (C), 
162.9 (C), 161.6 (C), 157.4 (C), 151.4 (C), 137.2 (C), 131.5 (CH), 128.8 (CH), 128.2 (CH), 88.4 (C), 40.6 
(CH2), 31.5 (CH2), 29.4 (CH), 27.8 (CH), 20.2 (CH2), 13.8 (CH3) ppm. HRMS (ESI): m/z calculated for 
C18H21N5O2Na [M+Na]+ = 362.1587, found = 362.1570. M.p.: 160 °C. 
 





The general procedure B was applied using N-(1,3-dimethyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)benzimidamide (1h, 129 mg, 0.5 mmol, 1.0 
equiv) and 2-morpholinoethyl isocyanide (140 mg, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using 
cHex:EtOAc:NEt3 (gradient = 20:1:0.01-4:1:0.01) as eluent. The title 
compound 6d was isolated as a white solid (101 mg, 51%). The starting material was recovered via 
this isolation (63 mg, 49%). RF = 0.09 (cHex:EtOAc:NEt3 ;15:1:0.01). 1H NMR (300 MHz, CDCl3) δ 9.23 
(bt, J = 5.5 Hz, 1H), 8.47 (d, J = 6.2 Hz, 2H), 7.59 - 7.37 (m, 3H), 3.85 (q, J = 6.0 Hz, 2H), 3.76 (t, J = 4.6 
Hz, 4H), 3.73 (s, 3H), 3.44 (s, 3H), 2.69 (t, 6.3 Hz, 2H), 2.56 (t, J = 4.6 Hz, 4H) ppm. 13C NMR (101 MHz, 
CDCl3) δ 165.8 (C), 162.7 (C), 161.5 (C), 157.4 (C), 151.5 (C), 137.2 (C), 131.6 (CH), 128.8 (CH), 128.3 
(CH), 88.6 (C), 67.0 (CH2), 57.2 (CH2), 53.6 (CH2), 37.7 (CH2), 29.4 (CH3), 27.8 (CH3) ppm. HRMS 




The general procedure B was applied using N-(1,3-dimethyl-2,6-dioxo-
1,2,3,6-tetrahydropyrimidin-4-yl)benzimidamide (1h, 129 mg, 0.5 mmol, 1.0 
equiv) and 4-methoxyphenyl isocyanide (133 mg, 1.0 mmol, 2.0 equiv). The 
compound was purified by manual flash chromatography using 
cHex:EtOAc:NEt3 (4:1:0.01) as eluent. The title compound was isolated as a 
yellow solid (40 mg, 21%). RF = 0.27 (cHex:EtOAc = 4:1). 1H NMR (500 MHz, 
CDCl3) δ 11.01 (br s, 1H), 8.46 – 8.39 (m, 2H), 7.73 – 7.66 (m, 2H), 7.56 – 7.49 (m, 1H), 7.48 (dd, J = 8.2, 
6.5 Hz, 2H), 7.00 – 6.94 (m, 2H), 3.86 (s, 3H), 3.75 (s, 3H), 3.46 (s, 3H) ppm. 13C NMR (126 MHz, CDCl3) 
δ 166.0 (C), 162.9 (C), 159.4 (C), 157.4 (C), 156.5 (C), 151.2 (C), 136.9 (C), 131.8 (CH), 131.1 (C), 129.0 
(CH), 128.4 (CH), 123.4 (CH), 114.0 (CH), 88.6 (C), 55.5 (CH3), 29.5 (CH3), 28.0 (CH3) ppm. HRMS 
(ESI): m/z calculated for C21H20N5O3 [M+H]+ = 390.1561, found = 390.1570. M.p.: 209-213 °C. 
 
5-amino-1,3-dibenzyl-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (7) 
To a solution of 1,3-dibenzyl-5-(tert-butylamino)-7-methylpyrimido[4,5-
d]pyrimidine-2,4(1H,3H)-dione (5a, 0.246 g, 0.5 mmol, 1.0 equiv) in dry 
methanol (15 mL) was added ammonium formate (0.630 g, 10 mmol, 20 equiv) 
and Pd/C (10%, 0.08 g, 7.5 mol%) under argon. The resulting mixture was 
refluxed for 48 h. After TLC indicated full conversion, the mixture was filtered 
over a pad of diatomaceous earth. The solid residue was washed 4 times with 
MeOH (4x50 mL) The filtrate was diluted with DCM (80 mL), washed with sat. NaHCO3 (100 mL), dried 
over Na2SO4, and concentrated in vacuo. The title compound was isolated without further purification 
as a white solid (0.154 g, 50 %). RF = 0.29 (cHex:EtOAc:NEt3) = 1:1:0.01. 1H NMR (500 MHz, DMSO-d6) 
δ 11.69 (brs, 1H), 11.48 (brs, 1H), 8.98 (s, 1H), 8.36 (dd, J = 7.8, 1.9 Hz, 2H), 7.64 – 7.51 (m, 3H), 1.57 
(s, 9H) ppm. 13C NMR (125 MHz, DMSO-d6) δ 164.7 (C), 164.6 (C), 160.5 (C), 159.1 (C), 150.1 (C), 137.0 
(C), 131.6 (CH), 128.6 (CH), 128.2 (CH), 87.9 (C), 51.9 (C), 28.7 (CH3) ppm. HRMS (ESI): m/z calculated 
for C16H18N5O2 [M+H]+ = 312.1455, found = 312.1471. M.p.: 257-259 °C. 
 
5-amino-1,3-dibenzyl-7-phenylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione (8)  
To a solution of 1,3-dibenzyl-5-(tert-butylamino)-7-methylpyrimido[4,5-
d]pyrimidine-2,4(1H,3H)-dione (3a, 0.246 g, 0.5 mmol, 1.0 equiv) in DCM (5 
mL) was added triflic acid (0.139 g, 2.5 mmol, 5.0 equiv), after which the 
mixture was stirred at room temperature for 2 h. The resulting mixture was 





The solution was dried over Na2SO4, and concentrated in vacuo. The resulting solid was dried 
overnight on a lyophilizer to afford a fluffy white solid (0.218 g, 100%). 1H NMR (300 MHz, DMSO-d6): 
δ 8.42 (bd, J = 3.6 Hz, 1H), 8.37 - 8.30 (m, 3H), 8.32 (bd, J = 1.8 Hz, 1H), 7.59 - 7.45 (m, 3H), 7.40 (d, J = 
6.9 Hz, 2H), 7.36 - 7.20 (m, 7H), 5.48 (s, 2H), 5.11 (s, 2H) ppm. 13C NMR (101 MHz, DMSO-d6) δ 165.1 
(C), 163.1 (C), 161.9 (C), 157.4 (C), 150.9 (C), 137.4 (C), 137.0 (C), 136.6 (C), 131.9 (CH), 128.6 (CH), 
128.5 (CH), 127.5 (CH), 127.4 (CH), 127.3 (CH), 127.3 (CH), 88.2 (C), 45.3 (CH2), 44.1 (CH2) ppm (2 CHAr 
missing due to overlapping signal). HRMS (ESI): m/z calculated for C26H22N5O2 [M+H]+ = 436.1768, 
found = 436.1768. M.p.: 231 °C. 
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Abstract: We have developed a copper-catalyzed imidoylative cross-
coupling/cyclocondensation between 2-isocyanobenzoates and amines. The 
coupling utilizes a benign catalyst, mild base, and recommended solvent. 
Additionally, the reaction does not require dry conditions or inert atmospheres. The 
reaction tolerates various o-isocyanobenzoates, and is highly compatible with 




















There are significant economic and sustainability incentives to replace the current 
transition metal catalysts in isocyanide insertion processes with cheaper and more 
abundant base metals (e.g. iron, nickel, copper).[1] Although the reactivity of 
isocyanides in copper catalysis has long been known[2], isocyanide insertions using 
base metals are still underrepresented in literature.[1] 
 
Figure 1. Copper-catalyzed reactions with isocyanides towards N-heterocycles. 
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The copper‐catalyzed reactions involving isocyanides reported to date all proceed 
under strong alkaline conditions,[3] or involve otherwise rather harsh conditions and 
require an inert atmosphere (Figure 1a).[3b, 4] Thus, there is a clear need for efficient 
synthetic methodology that involves such copper‐catalyzed isocyanide insertion 
processes to produce high value products in a sustainable fashion.  
Quinazolin‐4‐ones 3 can be considered a privileged structure, prevalent in natural 
compounds.[5] The quinazolin‐4‐one core can also be found in pharmaceuticals 
demonstrating hypnotic,[6] antifungal,[7] anticonvulsant,[8] kinase inhibitory,[9] or 
antimalarial[10] activity (Figure 2). Synthetic approaches, including methodology 
involving Pd‐catalyzed isocyanide insertion, to access these high‐valued 
heterocycles receive quite some attention.11 We envisioned a robust transformation 
that takes advantage of economically more viable copper(II)‐based catalytic systems 
combining isocyanobenzoates 1 and amines to access 3‐substituted quinazolin‐4‐
ones 3 (Figure 1b). 
 
Figure 2. Selected natural products and pharmaceuticals bearing a quinazolin-4-one core.  
 
Herein, we report a robust copper-catalyzed transformation of isocyanobenzoates 
to 3-substituted quinazolin-4-ones. These quinazolin-4-ones 3 can be considered a 
privileged structure, prevalent in natural compounds.[5] The quinazolin-4-one core 
can also be found in pharmaceuticals demonstrating hypnotic,[6] antimicrobial,[11] 








6.2. Results and Discussion 
We started our studies by employing the conditions developed by Hong et al.,[3b, 3c] 
who utilized CuI under strongly basic conditions in a related reaction of aryl 
isocyanides to prepare the corresponding formimidates. However, under these 
conditions the benchmark reaction of isocyanobenzoate 1a and aniline 2a gave only 
moderate formation of product 3a in various solvents(Table 1, entries 1‐3). We 
quickly found that this transformation is more successful using Cu(II) acetate as the 
catalyst and the milder Et3N as a base (entry 4‐5). Other bases did not lead to a 
higher yield of the target quinazolinone 3a, regardless of their pKa (entry 6‐14). 
When we switched to the use of the recommended solvent anisole, as an 
alternative to DMF, the isolated yield of 3a improved a bit further (entry 17). 
Satisfyingly, use of Cu(II) acetate hydrate as a catalyst under air atmosphere only 
leads to trace amounts of N‐formyl antranilate and ethyl anthranilate at elevated 
Table 1. Optimization of the reaction between ethyl 2-isocyaniobenzoate and aniline.a 
 
Entry Solvent T (°C) Base (eq.) 3a (%)b 
1c THF 100 KOtBu (1.0) 14 
2c DMC 100 KOtBu (1.0) 15 
3c DMF 100 KOtBu (1.0) 47 
4 Dioxane 100 NEt3 (10) 76 
5 DMF 150 NEt3 (10) 85 
6 DMF 150 DMAP (10) 39 
7 DMF 150 DBU (10) 29 
8 DMF 150 DIPEA (10) 67 
9 DMF 150 Pyridine (10) 59 
10 DMF 150 K3PO4 (10) 35 
11 DMF 150 K2CO3 (10) 16 
12 DMF 150 Cs2CO3 (10) Trace 
13 DMF 150 NaOH (10) Traced 
14 DMF 150 NEt3 (2) 76 
15 Dioxane 150 NEt3 (2) 68 
16 DCE 150 NEt3 (2) 0 
17 Anisole 150 NEt3 (2) 79 
18 DMSO 150 NEt3 (2) 46 
a Reaction conditions: 1a (0.5 mmol, 1 eq.), aniline 2a (1.0 mmol, 2 equiv), Cu(OAc)2·H2O (0.05 
mmol), NEt3 (x eq.) in solvent (2mL). b Yield were determined by 1H-NMR analysis by using 1,3,5-
trimethoxybenzene as internal standard. c CuI (0.05 mmol) was used as the catalyst. d Formyl 
anthranilate and ethyl anthranilate observed as main products. Solvent color according to CHEM21 
solvent selection guide[12]; red = (highly) hazardous, yellow = problematic, green = recommended. 
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temperatures. In short, the reaction was optimized to afford the quinazolin‐4‐one 
3a using a benign catalyst, short reaction times, under air atmosphere in a green, 
recommended solvent.12  
 
Scheme 1. Reaction scope with regards to aromatic amines. Yields refer so isolated yields. Conditions: 
isocyanobenzoate 1a (0.088 g, 0.5 mmol), Cu(OAc)2.H2O (0.010 g, 0.05 mmol), amine (1.0 mmol) and   
NEt3 (0.140 mL, 1.0 mmol) in anisole (2.0 mL, 0.25 M)  
 
Next, we set out to investigate the scope of this reaction towards 3‐arylated 4‐
quinazolinones 3 (Scheme 1). The efficacy of utilizing anilines as coupling partners 
in this transformation correlates directly with their respective electron density. 
While the use of aniline and toluidines as well as of 4‐halogenated anilines led to 
formation of quinazolines 3a-d,g in moderate to good yields, the application of m‐ 
or p‐halogenated anilines afforded quinazolinones 3e and 3h in significantly lower 
yields. 2,6‐Dichloroaniline did not afford any of the corresponding quinazolinone 3f. 
The isolation of 3i from anthranilic isocyanide and mesityl amine in moderate yield 





employed. Curiously, use of the more electron‐deficient 2‐aminopyridine increased 
the yield to 71% (3j). Most likely, the additional coordination site provided by the 
pyridine functionality is responsible for the observed higher reactivity. This is 
supported by the formation of quinazolinone 3k in 90% yield when using 2‐
aminopyrazine. The use of 4‐aminopyridine as a nucleophile did not furnish the 
corresponding quinazolinone 3m, further corroborating this hypothesis. Finally, we 
were pleased to discover that our methodology is also compatible with the use of 
arylhydrazines as nucleophiles, affording the corresponding 3‐
(arylamino)quinazolinones 3n, p in moderate but still reasonable yields.  
 
Formation of 3-alkyl-4-quinazolinones by using the more nucleophilic aliphatic 
amines as coupling partners appeared to follow the same trends as observed in 
Table 1. Again, the utilization of KOtBu as a base did not lead to clean conversion 
or  to the quinazolinone 4a, unless thoroughly dried conditions were employed 
(Table 2, entry 1-2). Changing the base to trimethylamine led to a notable increase 
in yield of quinazolinone 4a. The reaction was more successful using either 
triethylamine (entry 6) or anisole (entry 7) as a solvent. Satisfyingly, ambient 
temperatures were sufficient to afford the quinazolinone 4a in near-quantitative 
yield, in short reaction times, under benign conditions in a recommended solvent 
(entry 8).  
Table 2. Optimization of the reaction between ethyl 2-isocyaniobenzoate and n-
pentylamine.a 
 
Entry Solvent T (°C) Base (eq.) 4a (%)b 
1c dioxane 100 KOtBu (1.0) 12 
2 dioxane 100 KOtBu (1.0) 40 
3 dioxane 100 NEt3 (2.0) 61 
4c dioxane 100 NEt3 (10) 67 
5 dioxane 100 NEt3 (10) 76 
6 NEt3 100 - 98 
7 Anisole 100 NEt3 (2.0) 84 
8 Anisole rt NEt3 (2.0) 98 
a Reaction conditions: 1a (0.5 mmol, 1 eq.), 1-pentylamine (1.0 mmol, 2 equiv), 
Cu(OAc)2·H2O (0.05 mmol), base (x eq.) in solvent (2mL). b Yield were determined by 1H-
NMR analysis by using 1,3,5-trimethoxybenzene as internal standard. c 0.5 mmol (1.0 
equiv) of 1-pentylamine used. 
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The optimized reaction conditions proved very tolerant of the use of primary 
amines, affording 4a-c in good yields and clean conversion. Benzylic amines also 
proved highly compatible with the devised methodology, as evidenced from the 
formation of 4d-h. As expected, the electronic nature of the benzylic moiety did not 
influence the yield of the corresponding quinazolinone. More sterically 
cumbersome secondary amines were also smoothly coupled with ethyl 2-
isocyanobenzoate 1a, affording quinazolinones 4i-k. Unfortunately, the utilization 
of the sterically demanding tert-butylamine did not lead to isolable quantities of 
quinazolinone 4l. 
 
Scheme 2. Reaction scope with regards to aliphatic amines. Yields refer to isolated yields. Conditions: 
isocyanobenzoate 1a (0.088 g, 0.5 mmol), Cu(OAc)2.H2O (0.010 g, 0.05 mmol), amine (1.0 mmol) and 
NEt3 (0.140 mL, 1.0 mmol) in anisole (2.0 mL, 0.25 M). a Performed on a 5.0 mmol scale. b Performed 
on a 1.2 mmol scale. 
 
Minor diversification of the anthranilic isocyanide afforded products 5a-e. The 
coupling of methyl 2-isocyano-3-methylbenzoate 1b afforded the 8-methylated 
quinazolinone 5a in good yield, regardless of the temperature at which the reaction 
was performed (Scheme 3). However, when the electron-rich methyl 2-isocyano-
4,5-dimethoxybenzoate 1c was employed, a significant drop in yield of 5b:A was 
observed. The lower yield is most likely due to the elevated electron density around 
the isocyano moiety, leading to diminished electrophilicity. Similarly, the increased 





cyclolactamization. However, elevating the reaction temperature to 150 °C by 
microwave irradiation (condition B) afforded the 6,7-dimethoxyquinazolinone 5b in 
good yield.  
 
Scheme 3. Isocyanide variation. Yields refer to isolated yields. Conditions: isocyanobenzoate 1 (0.05 
mmol), Cu(OAc)2.H2O (0.010 g, 0.005 mmol), amine (1.0 mmol) and NEt3 (0.140 mL, 1.0 mmol) in 
anisole (2.0 mL, 0.25 M) 
 
Similarly, the implementation of a weakly electron-withdrawing group on the o-
isocyanobenzoate appears to activate the substrate for 1c for amination of the 
isocyanide. While the reaction of with aliphatic amines affords quinazolin-4-ones 
5c-d in yields comparable to unsubstituted isocyanobenzoates 1a (Scheme 2), we 
were happily surprised to find the 3-arylated product 5e is isolated in good yields 
from both the reactions performed at 150 °C and at ambient temperature. A 
plausible mechanism is shown in Scheme 4. We postulate that the electron-
deficient isocyanoarene coordinates to the Cu(II) center, forming intermediate II. 
This complex might either directly be attacked by an ambient nucleophile to afford 
the carbamimidoyl copper intermediate IV.[13] Alternatively, complex II might 
undergo further base-mediated complexation with the amine to furnish copper 
complex III. This complex can also afford the same intermediate IV through 1,1-
migratory insertion.[4b, 14] The difference between Lewis acid catalysis (Scheme 4, 
route A) and a 1,1-migratory insertion pathway (Scheme 4, route B) is hard to 
distinguish. However, the noticeably increased difficulty in the synthesis of 5b 
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(Scheme 3), and the relatively facile synthesis of 5e imply the reactivity is inversely 
correlated to the electron density around the isocyanide carbon. Therefore, it is 
likely the copper catalyst acts more as a Lewis acid (route B), akin to recent results 




Scheme 4. Plausible mechanistic pathways. 
 
The synthetic utility of this methodology is underlined by the syntheses of several 
natural products in a single, post-insertion/condensation reaction. Firstly, we 
utilized the devised methodology to couple isocyanobenzoate 1a with 
ethanolamine 6 to afford the alkaloid echinozolinone[17] 7 in 90% yield (scheme 5a). 
Secondly, the tryptamine-derived quinazolinone 4c was converted to the alkaloid 
rutaecarpine 8 in a one-pot, two step oxidative annulation.[15] This methodology 
affords rutaecarpine in 56 % over two steps. Additionally, palladium-catalyzed 
Heck-type cyclization[18] of quinazolinone 4h afforded the pentacycle Luotonin A 9 






Scheme 5. Natural compound synthesis via Cu-cat. isocyanide insertion. 
 
6.3. Conclusion 
We have developed a one-pot cascade reaction to substituted (3H)quinazolin-4-
ones via a copper-catalyzed isocyanide insertion and subsequent 
cyclocondensation. The coupling is performed in the recommended solvent anisole, 
under air atmosphere and ambient temperature. Coupling anthranilic isocyanides 
with anilines requires microwave irradiation, which negates the necessity for longer 
reaction times. Generally, quinazolin-4-ones are isolated in good yields, although 
the yield is diminished when electron-deficient anilines are employed. Curiously, 
we observed a significant increase in the yields of quinazolinones whenever 2-
aminopyridines or 2-aminopyrazines, presumably through additional coordinating 
effects. The synthetic utility of this catalytic transformation was highlighted by the 
total synthesis of several natural products, by a single post-coupling reaction.  
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6.4. Experimental section 
General remarks 
 
Chemicals were purchased from SigmaAldrich or Fluorochem and were used without purification. 
Solvents were purchased from VWR Chemicals (CH2Cl2) or Sigma-Aldrich (toluene, dioxane, DMSO) 
and used without purification, unless stated otherwise. Dry solvents were dried over an inert PS-MD-
5 solvent purification system, equipped with an activated alumina/copper wire column. Microwave 
reactions were performed in a closed vessel in a Biotage Initiator, measuring temperature by IR. 1H 
NMR measurements were acquired on a Bruker Avance 300 (300.13 MHz) or Bruker Avance 500 
(500.23 MHz) spectrometer. 13C NMR measurements were acquired on a Bruker Avance 500 (125.78 
MHz) spectrometer. Chemical shifts are reported in parts per million downfield of tetramethylsilane 
and are corrected according to solvent. Mass analysis was performed using a Bruker MicrOTOF-Q 
instrument on a positive ion polarity mode for ESI (electrospray ionization). Capillary charge: 4000 V. 
Melting points were measured using a Büchi M-565 melting point apparatus. SiO2 column 
chromatography was performed using Merck silica gel C60 (particle size 40−60 μm). TLC 
chromatography was performed on Merck silica gel C60 F254 plates (silica coat on aluminum support). 
All isolated yields are corrected for impurities (if present).  
 
General Procedure 1 for the Synthesis of alkyl 2-isocyanobenzoates.  
A solution of acetic anhydride (47 mL, 500 mmol) and formic acid (57 mL, 1500 mmol) was stirred for 
90 min at rt. Hereafter, the mixture was cooled to 0 °C, and alkyl anthranilate (50 mmol) was added 
to the solution and stirred for another 2 hours. DCM (100 mL) was added to this mixture, separated, 
and the organic layer was washed with 2 M NaOH (100 mL) before being dried over Na2SO4, after 
which the solvent was removed in vacuo. The crude formyl anthranilate was dissolved in dry DCM 
(200 mL), NEt3 (84 mL, 0.6 mol) was added, and cooled to 0 °C. Hereafter, POCl3 (9.35 mL, 100 mmol) 
was added slowly, and the resulting mixture was allowed to warm to room temperature and stirred 
for 2 h. The reaction was quenched with 100 mL 2 M NaOH, and washed twice with water. The organic 
fraction was dried over Na2SO4, concentrated in vacuo and purified by column chromatography 
(cHex:EtOAc = 9:1-4:1)  to afford the pure 2-isocyanobenzoates 1.  
 
General Procedure 2 for the Synthesis of 3-alkylated quinazolinones 4.  
To a solution of ethyl 2-isocyaniobenzoate (0.088 g, 0.5 mmol) in anisole (2.0 mL) was added NEt3 
(0.140 mL, 1.0 mmol) and Cu(OAc)2.H2O (0.010 g, 0.05 mmol) was added aliphatic amine (1.0 mmol). 
The resulting mixture was stirred at rt for 20 minutes, after which DCM and NaHCO3 (sat.) were added. 
The aqueous layer was washed twice with DCM and the combined organic fractions were dried over 
Na2SO4, concentrated in vacuo and purified by column chromatography to afford 3-alkyl quinazolin-
4(3H)-ones.  
 
General Procedure 3 for the Synthesis of 3-arylated quinazolinones 3.  
To a solution of ethyl 2-isocyaniobenzoate (0.088 g, 0.5 mmol) in anisole (2.0 mL) was added NEt3 
(0.140 mL, 1.0 mmol) and Cu(OAc)2.H2O (0.010 g, 0.05 mmol) was added the aromatic amine (1.0 
mmol). The resulting mixture was stirred at under microwave irradiation for 20 minutes at 150 °C, 
after which DCM and NaHCO3 (sat.) were added. The aqueous layer was washed twice with DCM and 
the combined organic fractions were dried over Na2SO4, concentrated in vacuo and purified by column 






Ethyl 2-isocyanobenzoate (1a) 
Synthesized according to general procedure 1. Isolated as a pale yellow solid that 
rapidly reddens (7.07 g, 81 %); Rf = 0.66 (cHex:EtOAc = 2:1); 1H NMR (500 MHz, CDCl3) 
δ 7.93 (dd, J = 7.8, 2.1 Hz, 1H), 7.51 (tt, J = 7.6, 1.5 Hz, 1H), 7.42 (ddt, J = 8.0, 6.8, 1.7 
Hz, 2H), 4.37 (qt, J = 7.2, 1.8 Hz, 2H), 1.37 (tt, J = 7.2, 1.8 Hz, 3H); 13C NMR (126 MHz, 
CDCl3) δ 169.4, 163.9, 132.9, 131.2, 129.1, 128.7, 127.1 (t, J = 1.4 Hz), 125.3, 61.8, 14.0. HRMS 
(ESI): m/z calculated for C10H9O2NNa [M+Na]+ = 198.0525, found = 198.0518. M.p.: 31-34 °C. 
 
Methyl 2-isocyano-3-methylbenzoate (1b) 
Synthesized on a 1.9 mmol scale, according to general procedure 1. Isolated as a white 
solid (0.242 g, 73 %). RF = 0.71 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 7.81 
(dd, J = 7.8, 1.5 Hz, 1H), 7.49 – 7.46 (m, 1H), 7.36 (t, J = 7.7 Hz, 1H), 3.97 (s, 3H), 2.49 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 171.5, 165.1, 137.1, 134.3, 128.8, 128.7, 127.5, 52.8, 
19.5,. HRMS (ESI): m/z calculated for C10H10O2N [M+H]+ = 176.0706, found = 
176.0715. M.p.: 39-40 °C. 
 
Methyl 2-isocyano-4,5-dimethoxybenzoate (1c) 
Synthesized on a 2.0 mmol scale, according to general procedure 1. Isolated as a 
white solid (0.212 g, 49%). RF = 0.39 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, 
CDCl3) δ 7.43 (s, 1H), 6.89 (s, 1H), 3.94 (s, 3H), 3.92 (s, 6H). 13C NMR (126 MHz, 
CDCl3) δ 168.1, 164.4, 152.3, 149.1, 119.6, 119.4, 112.6, 111.3, 56.6, 56.4, 
52.6,. HRMS (ESI): m/z calculated for C11H12O4N [M+H]+ = 222.0761, found = 22.0768. M.p.: 161-162 
°C. 
 
Ethyl 5-bromo-2-isocyanobenzoate (1d) 
Synthesized on a 20 mmol scale according to general procedure 1. Isolated as a 
dark green solid (3.80 g, 75%). RF = 0.55 (cHex:EtOAc = 4:1). 1H NMR (500.23 
MHz, CDCl3) δ 8.13 (d, J = 2.3 Hz, 1H), 7.68 (dd, J = 2.3, 8.5 Hz, 1H), 7.35 (d, J = 
8.5 Hz, 1H), 4.44 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 171.1, 162.7, 135.9, 134.3, 130.1, 128.7, 124.3, 123.1, 62.4, 14.0. HRMS 
(ESI): m/z calculated for C10H9NO2Br [M+H]+ = 253.9811, found = 253.9800. M.p.: 89 °C. 
 
3-phenylquinazolin-4(3H)-one (3a) 
Synthesized according to general procedure 2. Isolated as an off-white solid 
(0.087 g, 77%). RF = 0.38 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.38 
(dt, J = 7.9, 1.0 Hz, 1H), 8.14 (s, 1H), 7.82 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.78 (dd, J = 
8.2, 1.7 Hz, 1H), 7.56 (td, J = 7.1, 1.1 Hz, 3H), 7.53 – 7.48 (m, 1H), 7.47 – 7.40 (m, 
2H). 13C NMR (126 MHz, CDCl3) δ 160.9, 148.0, 146.2, 137.6, 134.8, 129.8, 129.3, 127.8, 127.8, 127.4, 




Synthesized according to general procedure 3. Isolated as a grey solid (0.083 g, 
70%). RF = 0.42 (cHex:EtOAc =2:1). 1H NMR (500 MHz, CDCl3) δ 8.37 (dd, J = 8.0, 
1.5 Hz, 1H), 8.12 (s, 1H), 7.80 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.76 (dd, J = 8.3, 1.4 
Hz, 1H), 7.55 (ddd, J = 8.1, 6.9, 1.4 Hz, 1H), 7.37 – 7.33 (m, 2H), 7.32 – 7.28 (m, 
2H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 161.1, 148.0, 146.5, 139.4, 135.0, 
134.7, 130.4, 127.7, 127.7, 127.3, 126.9, 122.5, 21.4. HRMS (ESI): m/z calculated for C15H13N2O 
[M+H]+ = 237.1022, found = 237.1032. M.p.: 143 °C. 
 
Synthesis of Quinazolin-4-ones by a Copper-Catalyzed Amination/Cyclization Cascade 
 
195 
3-(o-tolyl)quinazolin-4(3H)-one (3c)  
Synthesized according to general procedure 3. Isolated as a brown solid (0.078 g, 
63%). RF = 0.44 (cHex:EtOAc =2:1). 1H NMR (500 MHz, CDCl3) δ 8.41 – 8.35 (m, 
1H), 8.00 (s, 1H), 7.87 – 7.74 (m, 2H), 7.56 (ddd, J = 8.2, 6.8, 1.5 Hz, 1H), 7.46 – 
7.32 (m, 3H), 7.27 – 7.24 (m, 1H), 2.21 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 160.6, 
148.2, 146.5, 136.8, 136.0, 134.7, 131.5, 129.9, 128.0, 127.8, 127.5, 127.3, 122.6, 17.9, HRMS 
(ESI): m/z calculated for C15H13N2O [M+H]+ = 237.1022, found = 237.1028. M.p.: 97 °C. 
 
3-(4-chlorophenyl)quinazolin-4(3H)-one (3d)  
Synthesized according to general procedure 3. Isolated as a light brown solid 
(0.079 g, 61%). RF = 0.46 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.35 
(dd, J = 8.1, 1.5 Hz, 1H), 8.08 (s, 1H), 7.81 (ddd, J = 8.4, 7.0, 1.6 Hz, 1H), 7.76 
(dd, J = 8.3, 1.3 Hz, 1H), 7.60 – 7.46 (m, 3H), 7.42 – 7.35 (m, 2H). 13C NMR (126 
MHz, CDCl3) δ 160.7, 147.9, 145.7, 136.0, 135.3, 134.9, 130.0, 128.5, 128.0, 
127.8, 127.3, 122.3,. HRMS (ESI): m/z calculated for C14H10N2OCl [M+H]+ = 257.0467, found = 
257.0468. M.p.: 180 °C. 
 
3-(3-chlorophenyl)quinazolin-4(3H)-one (3e)  
Synthesized according to general procedure 3. Isolated as a light brown solid 
(0.070 g, 53%). RF = 0.42 (cHex:EtOAc =2:1). 1H NMR (500 MHz, CDCl3) δ 8.36 
(dd, J = 7.9, 1.5 Hz, 1H), 8.09 (s, 1H), 7.82 (td, J = 7.6, 7.0, 1.5 Hz, 1H), 7.77 
(dd, J = 8.2, 1.3 Hz, 1H), 7.61 – 7.54 (m, 1H), 7.52 – 7.41 (m, 3H), 7.37 – 7.30 
(m, 1H). 13C NMR (126 MHz, CDCl3) δ 160.7, 147.9, 145.6, 138.5, 135.4, 135.0, 
130.8, 129.6, 128.0, 127.8, 127.6, 127.3, 125.4, 122.3,. HRMS (ESI): m/z calculated for C14H10N2OCl 
[M+H]+ = 257.0476, found = 257.0467. M.p.: 166 °C. 
 
3-(4-bromophenyl)quinazolin-4(3H)-one  (3g) 
Synthesized according to general procedure 3.  Isolated as a light grey solid 
(0.097 g, 63%). RF = 0.38 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.34 
(dd, J = 7.9, 1.5 Hz, 1H), 8.08 (s, 1H), 7.80 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.75 
(dd, J = 8.2, 1.3 Hz, 1H), 7.70 – 7.61 (m, 2H), 7.55 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 
7.36 – 7.24 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 160.6, 147.8, 145.6, 136.5, 
134.9, 133.0, 128.7, 128.0, 127.8, 127.3, 123.3, 122.3. HRMS (ESI): m/z calculated for C14H10N2OBr 
[M+H]+ = 300.9971, found = 300.9955. M.p.: 187-189 °C. 
 
3-(2-bromophenyl)quinazolin-4(3H)-one (3h) 
Synthesized according to general procedure 3. Isolated as an off-white solid 
(0.029 g, 17%). RF = 0.43 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.38 
(dd, J = 7.8, 1.5 Hz, 1H), 7.95 (s, 1H), 7.83 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.80 (dd, J = 
8.0, 1.4 Hz, 2H), 7.57 (ddd, J = 8.2, 6.8, 1.5 Hz, 1H), 7.52 (td, J = 7.6, 1.4 Hz, 1H), 
7.47 – 7.38 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 160.4, 148.1, 146.0, 136.8, 134.9, 
134.1, 131.4, 130.1, 129.0, 127.9, 127.9, 127.4, 122.6, 122.6,. HRMS (ESI): m/z calculated for 
C14H10N2OBr [M+H]+ = 300.9971, found = 300.9956. M.p.: 182 °C. 
 
3-mesitylquinazolin-4(3H)-one  (3i)  
Synthesized according to general procedure 3. Isolated as a light brown solid 
(0.066 g, 50%). RF = 0.60 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.41 – 
8.38 (m, 1H), 7.89 (s, 1H), 7.85 – 7.74 (m, 2H), 7.63 – 7.50 (m, 1H), 7.05 (s, 2H), 





139.6, 135.4, 134.7, 133.3, 129.7, 127.7, 127.6, 127.4, 122.7, 21.2, 18.0. HRMS (ESI): m/z calculated 
for C17H17N2O [M+H]+ = 265.1335, found = 265.1344. M.p.: 150 °C. 
 
3-(pyridin-2-yl)quinazolin-4(3H)-one (3j) 
Synthesized according to general procedure 3. Isolated as an off-white solid 
(0.085 g, 71%). RF = 0.25 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.63 
(d, J = 4.0 Hz, 2H), 8.39 (dd, J = 8.0, 1.4 Hz, 1H), 7.95 – 7.88 (m, 2H), 7.80 (ddd, J = 
12.9, 8.4, 6.9 Hz, 2H), 7.59 – 7.51 (m, 1H), 7.42 – 7.32 (m, 1H). 13C NMR (126 MHz, 
CDCl3) δ 160.6, 149.8, 149.4, 147.8, 145.0, 138.2, 135.0, 127.8, 127.8, 127.4, 
123.7, 122.3, 121.7,. HRMS (ESI): m/z calculated for C13H10N3O [M+H]+ = 257.0476, found = 
257.0470. M.p.: 131-132 °C. 
 
3-(pyrazin-2-yl)quinazolin-4(3H)-one (3k) 
Synthesized according to general procedure 3.  Isolated as an off-white solid 
(0.103 g, 90%). RF = 0.10 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 9.32 
(d, J = 1.5 Hz, 1H), 8.67 (d, J = 2.5 Hz, 1H), 8.65 – 8.59 (m, 2H), 8.40 (dd, J = 8.0, 1.5 
Hz, 1H), 7.84 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.79 (dd, J = 8.1, 1.3 Hz, 1H), 7.58 
(ddd, J = 8.2, 7.0, 1.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 160.3, 147.6, 146.50, 
143.9, 143.9, 143.3, 143.3, 135.4, 128.2, 128.0, 127.5, 121.9,. HRMS (ESI): m/z calculated for 
C12H9N4O [M+H]+ = 225.0771, found = 225.0782. M.p.: 158 °C. 
 
4-((4-oxoquinazolin-3(4H)-yl)amino)benzonitrile (3n) 
Synthesized according to general procedure 3. Isolated as an orange solid 
(0.041 g, 30%). RF = 0.14 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 
8.29 (ddd, J = 8.1, 1.5, 0.6 Hz, 1H), 8.24 (s, 1H), 7.91 – 7.79 (m, 2H), 7.65 – 
7.48 (m, 3H), 7.32 (s, 1H), 6.84 – 6.79 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 
160.3, 150.2, 147.8, 147.6, 135.4, 134.1, 128.3, 128.1, 127.2, 122.4, 118.9, 114.3, 106.1,. HRMS 
(ESI): m/z calculated for C15H11N4O [M+H]+ = 263.0927, found = 263.0918. M.p.: 190-193 °C. 
 
3-(p-tolylamino)quinazolin-4(3H)-one  (3p) 
Synthesized according to general procedure 3.  Isolated as a light yellow solid 
(0.062 g, 48%). RF = 0.38 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.31 
(s, 1H), 8.30 – 8.26 (m, 1H), 7.85 – 7.75 (m, 2H), 7.53 (ddd, J = 8.2, 5.8, 2.5 Hz, 
1H), 7.20 (s, 1H), 7.09 – 7.02 (m, 2H), 6.73 (d, J = 8.5 Hz, 2H), 2.26 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 160.7, 148.3, 148.0, 144.1, 134.8, 132.9, 130.1, 128.0, 127.6, 127.0, 122.6, 




Synthesized according to general procedure 2. Isolated as a light yellow solid 
(0.107 g, 99%). RF = 0.39 (cHex:EtOAc =2:1). 1H NMR (500 MHz, CDCl3) δ 8.32 
(dd, J = 7.9, 1.5 Hz, 1H), 8.03 (s, 1H), 7.76 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.71 
(dd, J = 8.1, 1.2 Hz, 1H), 7.51 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 4.02 – 3.97 (m, 
2H), 1.84 – 1.75 (m, 2H), 1.37 (tt, J = 7.2, 2.9 Hz, 4H), 0.99 – 0.82 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 
161.2, 148.3, 146.8, 134.3, 127.6, 127.4, 126.8, 122.3, 47.2, 29.2, 28.9, 22.4, 14.1. HRMS 









Synthesized according to general procedure 2. Isolated as an off-white solid 
(0.099 g, 78%). RF = 0.24 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CD3OD) δ 
8.28 (dd, J = 8.0, 1.4 Hz, 1H), 7.90 (s, 1H), 7.83 (ddd, J = 8.6, 7.1, 1.5 Hz, 1H), 
7.64 (dd, J = 8.2, 1.1 Hz, 1H), 7.58 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.29 – 7.24 
(m, 2H), 7.23 – 7.20 (m, 1H), 7.20 – 7.16 (m, 2H), 4.29 (t, J = 7.0 Hz, 2H), 3.10 (t, J = 7.0 Hz, 2H). 13C 
NMR (126 MHz, CD3OD) δ 162.6, 149.1, 149.0, 139.0, 135.8, 130.1, 129.8, 128.6, 127.9, 127.8, 127.4, 
122.9, 49.8, 35.6. HRMS (ESI): m/z calculated for C16H15N2O [M+H]+ = 251.1179, found = 
251.1174. M.p.: 100 °C. 
 
3-(2-(1H-indol-3-yl)ethyl)quinazolin-4(3H)-one (4c) 
Synthesized according to general procedure 2 on a 5 mmol scale. To a 
solution of isocyanobenzoate 1a (0.876 g, 5.0 mmol), Et3N (1.14 mL, 10 
mmol) and tryptamine (1.60 g, 10 mmol) in a 50 mL roundbottom flask 
was added Cu(OAc)2.H2O (0.100 g, 0.5 mmol). The resulting solution was 
stirred for 25 minutes at rt, under air atmosphere. After TLC indicated full 
conversion, the resulting mixture was diluted with CH2Cl2, and washed twice with saturated aqueous 
NaHCO3. The organic layer was dried over Na2SO4 and concentrated in vacuo, and loaded onto SiO2. 
Column chromatography took place on a SiO2 column, with a cHex:EtOAc:Et3N eluens (gradient: 
4:1:0.01-2:1:0.01).  Isolated as an off-white solid (1.121 g, 77%). RF = 0.16 (cHex:EtOAc =2:1). 1H 
NMR (500 MHz, CDCl3) δ 8.37 (dd, J = 8.0, 1.6 Hz, 1H), 8.08 (s, 1H), 7.74 (ddd, J = 8.4, 7.1, 1.6 Hz, 1H), 
7.65 (dd, J = 13.1, 8.1, 1.1 Hz, 2H), 7.54 – 7.48 (m, 2H), 7.37 (d, J = 8.2 Hz, 1H), 7.22 (ddd, J = 8.1, 6.9, 
1.2 Hz, 1H), 7.14 (td, J = 7.5, 7.0, 1.1 Hz, 1H), 6.88 (d, J = 2.4 Hz, 1H), 4.30 (t, J = 6.8 Hz, 2H), 3.27 (t, J = 
6.8 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 161.3, 148.3, 146.9, 136.6, 134.3, 127.5, 127.3, 126.9, 126.8, 
122.9, 122.6, 122.3, 119.9, 118.5, 111.6, 111.5, 47.7, 25.1. HRMS (ESI): m/z calculated for 
C18H16N3O [M+H]+ = 290.1288, found = 290.1274. M.p.: 164 °C. 
 
3-(4-methoxybenzyl)quinazolin-4(3H)-one (4d) 
Synthesized according to general procedure 2. Isolated as a light yellow 
solid (0.068 g, 75%). RF = 0.15 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, 
CDCl3) δ 8.33 (dd, J = 7.9, 1.5 Hz, 1H), 8.11 (s, 1H), 7.75 (ddd, J = 8.5, 7.0, 
1.5 Hz, 1H), 7.70 (dd, J = 8.2, 1.3 Hz, 1H), 7.51 (ddd, J = 8.1, 7.0, 1.3 Hz, 
1H), 7.32 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.14 (s, 2H), 3.79 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 161.2, 159.7, 148.2, 146.4, 134.4, 129.8, 127.9, 127.6, 127.5, 127.0, 122.4, 114.5, 55.5, 49.4. HRMS 
(ESI): m/z calculated for C16H15N2O2 [M+H]+ = 267.1128, found = 267.1117. M.p.: 134 °C. 
 
3-(4-nitrobenzyl)quinazolin-4(3H)-one (4e) 
Synthesized according to general procedure 2. Isolated as a light yellow 
solid (0.125 g, 82%). RF = 0.10 (cHex:EtOAc = 2:1). 1H NMR (300 MHz, 
CDCl3) δ 8.32 (d, J = 8.0 Hz, 1H), 8.23 (s, 1H), 8.20 (d, J = 4.8 Hz, 2H), 7.86 
– 7.72 (m, 2H), 7.59 – 7.49 (m, 3H), 5.29 (s, 2H). 13C NMR (126 MHz, CDCl3) 
δ 161.1, 148.0, 146.3, 142.8, 134.9, 128.81, 128.0, 127.8, 127.1, 124.4, 122.1, 62.3, 49.5,. HRMS (ESI): 
m/z calculated for C15H12N3O3 [M+H]+ = 282.0873, found = 282.0860. M.p.: 159 °C. 
 
3-(thiophen-2-ylmethyl)quinazolin-4(3H)-one (4f) 
Synthesized according to general procedure 2. Isolated as a light yellow solid 
(0.085 g, 70%). RF = 0.36 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.37 
(dd, J = 7.9, 1.5 Hz, 1H), 8.18 (s, 1H), 7.79 (ddd, J = 8.5, 7.0, 1.6 Hz, 1H), 7.73 
(dd, J = 8.2, 1.2 Hz, 1H), 7.57 – 7.53 (t, 1H), 7.31 (dd, J = 5.1, 1.2 Hz, 1H), 7.19 





145.9, 137.6, 134.5, 128.0, 127.7, 127.6, 127.3, 127.0, 126.8, 122.2, 44.4,. HRMS (ESI): m/z calculated 
for C13H11N2OS [M+H]+ = 243.0587, found = 243.0578. M.p.: 119 °C. 
 
3-(pyridin-2-ylmethyl)quinazolin-4(3H)-one (4g) 
Synthesized according to general procedure 2. Isolated as a light yellow solid 
(0.087 g, 72%). RF = 0.05 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.55 
(d, J = 4.6 Hz, 1H), 8.33 (s, 1H), 8.30 (dd, J = 8.0, 1.5 Hz, 1H), 7.76 (ddd, J = 8.2, 
6.7, 1.5 Hz, 1H), 7.73 (dd, J = 8.2, 1.6 Hz, 1H), 7.68 (td, J = 7.7, 1.8 Hz, 1H), 7.50 
(ddd, J = 8.2, 6.8, 1.6 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.22 (ddd, J = 7.6, 4.9, 1.1 Hz, 1H), 5.28 (s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 161.2, 155.0, 149.9, 148.40, 147.2, 137.2, 134.5, 129.9, 127.7, 127.4, 123.3, 
123.1, 122.3, 51.3,. HRMS (ESI): m/z calculated for C14H12N3O [M+H]+ = 238.0975, found = 
238.0986. M.p.: 113 °C.  
 
3-((2-chloroquinolin-3-yl)methyl)quinazolin-4(3H)-one (4h) 
Synthesized according to a modified general procedure 2, using ethyl 2-
isocyanobenzoate 1b (0.210 g, 1.2 mmol) and (2-chloroquinolin-3-
yl)methanamine (0.347 g, 1.8 mmol). Isolated as a white solid (0.220 g, 57 
%). RF = 0.59 (cHex:EtOAc = 1:1). 1H NMR (500 MHz, CDCl3) δ 8.34 (s, 1H), 
8.31 (dd, J = 8.0, 1.5 Hz, 1H), 8.21 (s, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.84-7.77 (m, 2H), 7.79-7.70 (m, 2H), 
7.59-7.51 (m, 2H), 5.42 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 161.4, 149.4, 148.2, 147.4, 146.6, 139.5, 
134.8, 131.2, 128.4, 127.92, 127.86, 127.8, 127.7, 127.1, 126.93, 126.91, 122.2, 48.1. HRMS 
(ESI): m/z calculated for C18H13N3OCl [M+H]+ = 322.0742, found = 322.0726. M.p.: 208-210 °C. 
 
3-isopropylquinazolin-4(3H)-one (4i)  
Synthesized according to general procedure 2. Isolated as a  light yellow solid (0.052 
g, 55%). RF = 0.33 (cHex:EtOAc =2:1). 1H NMR (500 MHz, CDCl3) δ 8.30 (dd, J = 8.0, 
1.5 Hz, 1H), 8.11 (s, 1H), 7.73 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.68 (dd, J = 8.2, 1.3 Hz, 
1H), 7.48 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 5.19 (hept, J = 6.9 Hz, 1H), 1.48 (d, J = 6.9 Hz, 
6H). 13C NMR (126 MHz, CDCl3) δ 160.8, 147.7, 143.7, 134.3, 127.4, 127.3, 127.0, 122.1, 46.1, 
22.1,. HRMS (ESI): m/z calculated for C11H13N2O [M+H]+ = 189.1022, found = 189.1018. M.p.: 89 °C. 
 
3-cyclohexylquinazolin-4(3H)-one (4j) 
Synthesized according to general procedure 2. Isolated as a light yellow solid 
(0.078 g, 64%). RF = 0.54 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.30 
(d, J = 8.0 Hz, 1H), 8.11 (s, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.48 
(t, J = 7.5 Hz, 1H), 4.81 (tt, J = 12.4, 3.7 Hz, 1H), 2.05 – 1.97 (m, 2H), 1.93 (d, J = 
13.1 Hz, 2H), 1.78 (d, J = 13.0 Hz, 1H), 1.63 (qd, J = 12.3, 3.3 Hz, 2H), 1.57 – 1.42 
(m, 2H), 1.25 (qt, J = 13.1, 3.8 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 160.8, 147.6, 144.0, 134.2, 127.4, 
127.2, 127.1, 122.0, 53.4, 32.7, 26.0, 25.4,. HRMS (ESI): m/z calculated for C14H17N2O [M+H]+ = 
229.1335, found = 229.1325. M.p.: 114 °C. 
 
3-(5-(diethylamino)pentan-2-yl)quinazolin-4(3H)-one (4k) 
Synthesized according to general procedure 2. Isolated as a brown 
orange oil (0.099 g, 69%). RF = 0.47 (EtOAc: NEt3 1: 0.05). 1H NMR (500 
MHz, CDCl3) δ 8.30 (dd, J = 8.0, 1.4 Hz, 1H), 8.06 (s, 1H), 7.75 (ddd, J = 
8.4, 7.0, 1.5 Hz, 1H), 7.70 (dd, J = 8.2, 1.3 Hz, 1H), 7.50 (ddd, J = 8.1, 7.0, 
1.3 Hz, 1H), 5.06 (h, J = 7.1 Hz, 1H), 2.57 – 2.43 (m, 6H), 1.84 (q, J = 7.7 
Hz, 2H), 1.59 – 1.39 (m, 5H), 1.02 (t, J = 7.2 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 161.1, 147.6, 143.9, 
134.4, 127.5, 127.4, 127.1, 122.0, 52.2, 46.8, 34.1, 31.1, 23.7, 20.8, 11.3. HRMS (ESI): m/z calculated 
for C17H26N3O [M+H]+ = 288.2070, found = 288.2084. 
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8-methyl-3-pentylquinazolin-4(3H)-one (5a)  
Synthesized according to general procedure 2.  Isolated as a light red solid 
(0.094 g, 81%). RF = 0.58 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, CDCl3) δ 8.16 
(d, J = 8.1 Hz, 1H), 8.04 (d, J = 1.8 Hz, 1H), 7.59 (dt, J = 7.3, 1.3 Hz, 1H), 7.38 
(td, J = 7.7, 2.6 Hz, 1H), 4.02 – 3.95 (m, 2H), 2.61 (s, 3H), 1.90 – 1.68 (m, 2H), 
1.36 (qp, J = 5.9, 3.1 Hz, 4H), 1.03 – 0.74 (m, 3H). 13C NMR (126 MHz, CDCl3) 
δ 161.5, 146.9, 145.6, 135.8, 134.9, 126.9, 124.5, 122.3, 47.1, 29.1, 28.9, 22.4, 17.6, 14.1. M.p.: 67 °C. 
 
6,7-dimethoxy-3-pentylquinazolin-4(3H)-one (5b)  
Synthesized according to general procedure 3.  Isolated as an off-white 
solid (0.109 g, 79%). RF = 0.10 (cHex:EtOAc = 2:1). 1H NMR (500 MHz, 
CDCl3) δ 7.95 (s, 1H), 7.63 (s, 1H), 7.09 (s, 1H), 4.00 (s, 8H), 1.79 (p, J = 
7.4 Hz, 2H), 1.39 – 1.30 (m, 4H), 0.97 – 0.85 (m, 3H). 13C NMR (126 MHz, 
CDCl3) δ 160.6, 154.8, 149.4, 145.5, 144.5, 115.7, 107.9, 105.6, 56.5, 56.4, 47.2, 29.3, 28.9, 22.4, 
14.1. M.p.: 109-110 °C. 
 
6-bromo-3-(4-methoxybenzyl)quinazolin-4(3H)-one (5c) 
Synthesized according to general procedure 2.  Isolated as an off-
white solid (0.142 g, 82%). RF = 0.67 (cHex:EtOAc = 1:1). 1H NMR 
(500.23 MHz, CDCl3) δ 8.45 (d, J = 2.4 Hz, 1H), 8.10 (s, 1H), 7.81 (dd, J = 
8.7, 2.4 Hz, 1H), 7.56 (d, J = 8.7 Hz, 1H), 7.30 (d, J = 8.7 Hz, 2H), 6.88 
(d, J = 8.7 Hz, 2H), 5.12 (s, 2H), 3.78 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.9, 159.6, 146.8, 146.5, 
137.4, 129.6, 129.4, 129.3, 127.4, 123.5, 120.9, 114.4, 55.3, 49.4. HRMS (ESI): m/z calculated for 
C16H14BrO2N2 [M+H]+ = 345.0233, found = 345.0217. M.p.: 136 °C. 
 
3-(2-(1H-indol-3-yl)ethyl)-6-bromoquinazolin-4(3H)-one (5d) 
Synthesized according to general procedure 2.  Isolated as an off-
white solid (0.113 g, 61%). RF = 0.48 (cHex:EtOAc = 1:1). 1H NMR 
(500.23 MHz, CDCl3) δ 8.49 (d, J = 2.4 Hz, 1H), 8.07 (s, 1H), 7.81 (dd, J = 
8.7, 2.4 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.47 
(s, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.13 (t, J = 7.5 
Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 4.29 (t, J = 6.7 Hz, 2H), 3.26 (t, J = 6.7 Hz, 2H). 13C NMR (126 MHz, 
CDCl3) δ 1560.0, 147.03, 147.02, 137.4, 136.4, 129.3, 126.8, 123.5, 122.8, 122.5, 120.7, 119.9, 118.3, 
111.6, 111.2, 47.7, 24.9. HRMS (ESI): m/z calculated for  C18H15N3OBr [M+H]+ = 368.0393, found = 
368.0376. M.p.: 212 °C. 
 
6-bromo-3-(p-tolyl)quinazolin-4(3H)-one (5e)  
Synthesized according to modified general procedure 2, stirred at rt for 1 
h.  Isolated as a tan solid (0.120 g, 76%). RF = 0.19 (cHex:EtOAc = 4:1). 1H 
NMR (500 MHz, CDCl3) δ 8.49 (d, J = 2.3 Hz, 1H), 8.11 (s, 1H), 7.87 (dd, J = 
8.7, 2.3 Hz, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.35 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 
8.2 Hz, 2H), 2.44 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.8, 146.8, 146.6, 
139.5, 137.7, 134.6, 130.4, 129.7, 129.4, 126.7, 123.8, 121.3, 21.2. HRMS (ESI): m/z calculated for 
C15H12N2OBr [M+H]+ = 315.0128, found = 315.0106. M.p.: 190-191 °C. 
 
Echinozolinone (7)  
Synthesized according to modified general procedure 2, stirred for 1 h. Isolated 
as an off-white solid (0.086 g, 90%). RF = 0.15 (EtOAc:NEt3 = 1:0.01). 1H 
NMR (500 MHz, CDCl3) δ 8.15 (d, J = 8.0 Hz, 1H), 8.09 (s, 1H), 7.72 (t, J = 7.6 Hz, 





4.7 Hz, 2H), 3.51 (bs, 1H). 13C NMR (126 MHz, CDCl3) δ 161.4, 147.6, 147.4, 134.3, 127.3, 127.0, 126.5, 
121.6, 60.5, 49.7. HRMS (ESI): m/z calculated for C10H11N2O2 [M+H]+ = 191.0815, found = 
191.0805. M.p.: 156 °C. 
 
Rutaecarpine (8) 
A solution of 4c (0.147 g, 0.5 mmol) in dry acetonitrile (5 mL) was cooled to 0 
°C, after which trifluoroacetic anhydride (0.347 mL, 2.5 mmol) was added 
dropwise. The ice-bath was removed, and the solution was stirred at rt for 30 
minutes, until TLC indicated complete consumption of 4c. The resulting solid 
was filtered off, and resolvated in H2O:EtOH (2:1, 7.5 mL). To this mixture was 
added KOH (0.056 g, 1.0 mmol), and H2O2 (30%, 1.13 mL, 3.0 mmol), and was 
heated to 60 °C for 4 hrs. The crude product was diluted with DCM, and quenched with NaHCO3 (sat. 
aq.), the organic layer was dried over Na2SO4, concentrated in vacuo and loaded onto silica. 
Purification by column chromatography (gradient EtOAc in cHex, 0-50%). Isolated as a white solid 
(0.104 g, 72%). RF = 0.57 (cHex:EtOAc = 2:1). 1H NMR (500.23 MHz, DMSO-d6) δ 11.89 (bs, 1H), 8.17 
(dd, J = 1.6, 7.9 Hz, 1H), 7.82, (ddd, J = 1.6, 7.0, 8.3 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 8.0 Hz, 
1H), 7.51-7.44 (m, 2H), 7.27 (ddd, J = 1.1, 6.9, 8.3 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 4.45 (t, J = 6.9 Hz, 
2H), 3.18 (t, J = 6.9 Hz, 2H). 13C NMR (126 MHz, DMSO-d6) δ 160.6, 147.4, 145.3, 138.7, 134.5, 127.1, 
126.6, 126.5, 126.0, 124.9, 124.8, 120.7, 120.0, 119.8, 117.9, 112.6, 40.9, 19.0. HRMS (ESI): m/z 
calculated for C18H14N3O [M+H]+ = 288.1131, found = 288.1120. M.p.: 261 °C. 
 
Luotonin A (9) 
To a solution of 4h (3-((2-chloroquinolin-3-yl)methyl)quinazolin-4(3H)-one) 
(0.101 g, 0.3 mmol), K3PO4 (0.063 g, 0.3 mmol) and KOAc (0.060 g, 0.6 mmol) 
in dry DMF (3.0 mL) was added Pd(OAc)2 (0.007 g, 0.03 mmol) and dppe 
(0.024 g, 0.06 mmol) in an oven-dried microwave vial. The vial was capped 
under N2, and heated by microwave irradiation to 200 °C for 30 minutes. The 
crude product was diluted with DCM, and washed with saturated aqueous 
NaHCO3. The organic layer was dried over Na2SO4, concentrated in vacuo, and loaded onto SiO2. The 
product was purified by column chromatography (gradient, 0-50 % EtOAc in cHex). The title compound 
Luotonin A was isolated as a white solid exhibiting blue fluorescence (0.075 g, 88 %). The spectral data 
was in accordance with the reported literature.[19] 1H NMR (500 MHz, DMSO-d6) δ 8.74 (s, 1H), 8.31-
8.22 (m, 2H), 8.15 (d, J = 8.2 Hz, 1H), 7.96-7.86 (m, 3H), 7.75 (t, J = 7.5 Hz, 1H), 7.67-7.57 (m, 1H), 5.29 
(s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 159.7, 153.1, 151.5, 149.0, 148.4, 134.5, 131.8, 131.0, 130.5, 
129.7, 128.48, 128.46, 128.3, 128.1, 127.2, 125.9, 121.1, 47.6. 
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The field of metal-catalyzed isocyanide insertions has grown significantly over the 
past decade. As stated in Chapter 1 and Chapter 2, the number of reports 
expanding on methodologies and applicability of isocyanides in small molecule 
syntheses is growing faster than ever before. Noble metals, like ruthenium, 
rhodium and palladium are making way for cheaper, more readily available catalytic 
systems based on nickel, cobalt, copper and iron. This shift towards base metal 
catalysis opens up new synthetic pathways through one-electron processes. There 
has been an increase in reports utilizing these radical processes to synthesize small 
nitrogen-containing molecules, as well as fine-tuning these processes to tolerate a 
broader range of isocyanide inputs. Although there is no reliable way to predict the 
isocyanide scope beforehand, this chapter will illustrate some future possibilities 
for small-molecule synthesis through isocyanide insertion. 
7.2. Future Directions in Palladium-Catalyzed Imidoylations 
Initially, we were most interested in incorporating the isocyanide functional group 
into existing metal-catalyzed cross-coupling processes. Numerous examples have 
been published over the past decades of novel imidoylative variants of known 
(often carbonylative) cross-couplings (e.g. Stille, Suzuki, Heck, Sonogashira).[1]  
 
Scheme 1. ITT/cyclization cascade to 1-naphtylamines.  
In this respect we envisioned an imidoylative Tsuji-Trost-type (ITT) coupling, 
effectively incorporating an isocyanide derived C1 synthon into an activated allyl 
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species. As we were most interested in the rapid generation of molecular 
complexity, our initial efforts focused on an ITT/cyclization cascade, wherein the 
intermediate allylic ketenimine 2 derived from electron-rich arene 1 or 1’ would 
undergo a 6π-electrocycization (Scheme 1a). The styrene E/Z isomerization should 
be facilitated by employing either electron-donating or -withdrawing substituents 
on the arene, in combination with elevated temperatures. However, when we 
employed such conditions (Scheme 1b) we found that the main product was the 
hydrolyzed form of the naphthylamine 5, naphtol 6. We suspect this unexpected 
reactivity is due to the high electron density of 1-naphthylamine 5, and easy 
protonation on the 2-position, allowing for facile hydrolysis.  
On the other hand, the use of tryptamine-derived allylic acetate 7 as an electron-
rich arene led to the formation of 1-aminocarbazole 8 via a similar mechanism. Such 
structures can be used as bidentate ligands, or pharmaceuticals.[2] The use of DBU 
as the base afforded the deacetylated carbazole 8a, whereas Cs2CO3 furnished 
mostly the acetylcarbazole 8b, both in 17 %. In both cases, significant amounts of 
rearrangement product 9 and hydrolyzed side product 10 were observed. The low 
yields and incomplete conversion led us to put this project temporarily on hold. The 
next year, in 2017, Zhu et al. reported an ITT reaction towards ketenimines 2, and 
subsequent non-annulating functionalization with several nucleophiles.[3]  
 
Scheme 2. ITT towards 2-aminocarbazoles. 
7.2.1. Further Studies toward Pd-Catalyzed Isocyanide Insertions 
While most classic palladium-catalyzed cross-coupling reactions have seen multiple 
imidoylative variants, the Mizuroki-Heck coupling between aryl halides and 
activated alkenes has not been investigated in detail. While several sequential 
alkene insertion/imidoylation cascades have been reported, these reactions are 





intermediate of N-(2-haloaryl)acrylamides (Chapter 1), followed by subsequent 
isocyanide insertion. True imidoylative Heck-reactions are rare, and the only 
examples reported to date are intramolecular processes, relying on specialized, 
hard to access starting materials.[4] However, an intermolecular Heck imidoylation 
would allow us to significantly increase the chemical complexity of targeted 
heterocyclic cores, affording e.g. the biselectrophilic iminoacrylates 16. Utilizing 
aryl halide reagents bearing an internal nucleophile on the ortho position (11) 
should allow for the one-pot cascade synthesis of bicyclic structures 14 via a 
conjugate addition and subsequent cyclolactamization of the intermediate 
iminoacrylate 16. This scaffold bears structural similarities to the promising anti-
cancer compound 17,[5] and several other indolenine- and indoline-based natural 
products.[6]  
 
Scheme 3. Intermolecular imidoylative Heck-coupling/Michael/lactamization cascade 
We suspect that similar synthetic pathways can be exploited when the side reaction 
mentioned in Chapter 3 is utilized[7], combining ligands other than XantPhos with 
o-bromoanilines and isocyanides in the presence of a palladium catalyst to 
generate the (imino)indolamines 20. The propensity of these o-bromoanilines 18 to 
undergo the double insertion/amination allows for facile post-insertion 
modification of the formed (imino)indolamines 20. For example, addition of 
(monosubstituted) phenylenediamines affords the tetracyclic indoloquinoxalines 
21, in which the intermediate 20 is used as a biselectrophile. Further examples of 
diversification via post-imidoylation cascade include the addition of amidines, and 
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a base to afford the electron-deficient indoloimidazoles 22. A similar condensation 
cascade can be initiated by the post-imidoylation addition of primary imines, which 
would afford the corresponding aromatic dihydroimidazoindoles 23. Initial 
transimination with α-amino acids can also be followed by aromatizing δ-
lactamization, affording  fused indolopyrazinones 24.  
 
Scheme 4. Divergent synthesis of nitrogeneous heterocycles by utilization of common intermediate 
20. 
Finally, reacting the intermediate bisnucleophilic (imino)indolamines 20 with boron 
trifluoride affords the fluorophoric diazaborole 25, which is expected to exhibit 
BODIPY-like fluorescence. Furthermore, we envision a novel imidoylative pathway 
towards benzodiazepines, positive allosteric modulators (PAMs) for GABAA 
receptors.[8] This highly modular synthetic route would allow for the rapid synthesis 
of various diversely substituted analogs of medicinally relevant benzodiazepines 31. 
The reaction relies on an intermolecular imidoylative Suzuki coupling of (protected) 
o-bromoanilines 26. The protecting group is not required if the transmetalation of 
intermediate imidoyl palladium species with aryl boronic acids outcompetes the 





mentioned intermediate 20. We imagine the isocyanide-derived tert-butylimine 
undergoes smooth de-tert-butylation in the presence of chloroacetyl chloride 30. 
Subsequent biscondensation of the liberated amine and imine moiety should afford 
the benzodiazepine structures 31 in a one-pot manner (Scheme 5), although 
stepwise (double) de-tert-butylation and biscondensation should afford the same 
product.  
 
Scheme 5. Imidoylative Suzuki-Miyaura in a one-pot synthesis of benzodiazepines. 
This method is based on the reliable insertion of tert-butyl isocyanide. Although this 
transformation can be realized in a single reaction step if α-isocyanoacetates are 
used, we consider this cross-coupling unlikely to afford products similar to 29, due 
to competing processes (i.e. double insertion[7], or metal-catalyzed oxazole 
formation).[9] 
Alternatively, a stepwise approach to these benzodiazepines 35 is shown in Scheme 
6. Earlier research from our group implied the α-isocyanoacetamides 34 are readily 
synthesized from the corresponding isocyanoacetates 33 and amines,[10] although 
conversion to isocyanoacetanilides was not attempted. If simple condensation of 
o-haloanilines 32 and isocyanoacetates 33 towards 34 is not successful, an 
alternative, linear route towards isocyanoacetanilides 34 has been reported by 
Torroba et al.[11] This route relies on amide synthesis from 32 and 36, followed by 
Gabriel reaction with potassium phthalimide and hydrazine. Subsequent 
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formamidation and dehydration would also afford the isocyanoacetanilide, without 
risk of oxazole side product formation, albeit in a less efficient and direct manner. 
 
Scheme 6. Alternative approach to benzodiazepines through imidoylative Suzuki-Miyaura coupling. 
Tetrazolobenzodiazepines 44 can serve as structural analogs of benzodiazepine 
drugs. These compounds can be synthesized via a similar imidoylative Suzuki 
approach starting from the aryl halides 43, which bear a tethered isocyanide 
substituent. The synthesis of this reagent can be achieved through an Ugi/azide 4-
CR with aldehyde 39, electron-rich benzylamine 41, and o-haloaryl isocyanide 38. 
The resulting intermediate 42 will undergo acid-mediated debenzylation, and 
subsequent formylation under the same conditions. Dehydration of the generated 
formamide affords the complex isocyanide 43, which serves as a specialized input 
in the imidoylative Suzuki cross-coupling, directly affording the fused 
tetrazolobenzodiazepines 44. These transformations are not based solely on the 
depicted imidoylative Suzuki, but might also be accomplished by palladium-
catalyzed imidoylative cross-couplings with other coupling partners (e.g. Grignard 







Scheme 7. Modular approach to tetrazolobenzodiazepines 
7.2.2.  Sequential insertion of different isocyanides. 
The constantly expanding scope of palladium-catalyzed imidoylative cross-
couplings also motivated us to explore new synthetic avenues using tethered 
bifunctional isocyanides. An illustrative example of this catalytic reactivity is shown 
in Scheme 8, where o-isocyano halobenzene 46 undergoes isocyanide insertion. 
The higher electron density of alkyl isocyanides 19 guarantees the initial insertion 
forms 47, rather than following a dimerization process through insertion of a 
second aryl isocyanide 46. Next, the generated imidoylpalladium species 47 
undergoes a second, proximity-driven isocyanide insertion with the o-isocyano 
moiety. This affords the synthetically diverse indolenine palladium intermediate 48. 
This intermediate can be trapped with ambient nucleophiles, like water or amines, 
leading to the formation of indolines derivatives 49, and 50, respectively. If we 
would carefully add a superstoichiometric amount of isocyanide 19, this 
methodology can also afford the triple isocyanide insertion products 52. 
 




Scheme 8. Divergent syntheses of various heterocycles, based on heterobisimidoylation with tethered 
o-halophenyl isocyanides. 
Furthermore, the use of tryptamine-derived isocyanide 53 allows for trapping of 
the corresponding organopalladium intermediate 48 with the indole as a 
nucleophile. This directly generates the (azepino)diindole 54, the core of the 
iheyamine class of natural products.[14] The structures 54 are known to 
spontaneously oxidize to iheyamines when exposed to air.[15] 
7.3. Future Directions in Base Metal-Catalyzed Imidoylations 
 





As acknowledged in Chapter 2, significant advancements have been made in the 
development of base metal-catalyzed isocyanide insertions over the past decades. 
Maturation of these processes will continue in the future, improving yields, 
reaction conditions, and further increasing the synthetic potential of isocyanide 
insertion reactions.  
During our investigation of the nickel-catalyzed synthesis of pyrimidouracils 
(Chapter 5), we serendipitously discovered the synthesis of diiminoimidazole 56a. 
This bright yellow compound is formed by the nickel-catalyzed double insertion of 
tert-butyl isocyanide into N,N’-unsubstituted benzamidines 55 (Scheme 9). The 
ease with which this compound was formed (50 °C, 1 h) prompted further 
investigation, considering the fact that the diiminoimidazoles 56a are readily 
converted to the corresponding (imidoazo)diazoboroles 57. These fluorophoric 
bicycles[16] may show similar reactivities and applicabilities as the structurally 
related BOIMPYs[17], BODIPYs[18] and aza-BODIPYs.[19] However, most attempted 
syntheses of 56a led to a mixture of products, most notably triazene 56b, its 
hydrolyzed analog triazenone 56c, and the curious double insertion/hydrolysis 
product 56d.  
 
Scheme 10. Attempted NiII-catalyzed synthesis of 4-aminoquinazolines, and product amidine amide 
When we changed the amidine from benzamidines 55 to N-aryl benzamidine 58,  
the reactivity shifted significantly (Scheme 10). We attempted a nickel-catalyzed 
isocyanide insertion, followed by an electrophilic aromatic substitution of the 
formed imidoyl nickel species to obtain 4-aminoquinazolines 59, similar to the 
oxidative palladium-catalyzed reaction reported by Zhu et al.[20] However, we 
instead obtained the double insertion/hydrolysis product 60 in 80 % yield . With 
results obtained in control experiments mentioned in Chapter 5[21], we postulate 
the formation of 65 proceeds via the β-hydride elimination of imidoylnickel 
intermediate 62, affording the transient carbodiimide 64, although the substitution 
pathway towards 63 cannot be fully excluded. The nature of the carbodiimide 
implies an addition of a second isocyanide molecule, followed by hydrolysis of the 
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formed nitrilium species. However, the addition of either a Brønsted or a Lewis acid 
might activate either the imidoyl nickel species 62 or the carbodiimide 64 towards 
electrophilic aromatic substitution, although such additives were not yet 
investigated. 
 
Scheme 11. Diversification of in situ formed imidoylnickel intermediate towards various aromatic 
heterocycles. 
Additionally, several highly decorated heterocycles are accessible when the 
addition of an external nucleophile outcompetes this second isocyanide attack. For 
example, the addition of sodium cyanate forms a highly electron-deficient 
carbamimidoyl isocyanate, which after cycloaromatization affords 
aminotriazenones 66. On the other hand, the use of malonates as a nucleophile will 
afford the corresponding oxo-pyrimidin-5-carboxylates 67 after an 
addition/condensation cascade. Similarly, α-substituted Meldrum’s acid serves as 
an activated analog of ester nucleophiles, which generates polysubstituted 
pyrimidines 68 after decarboxylation of the formed β-ketoester intermediate. 
Furthermore, the addition of substituted hydrazines will form the 1,2,4-triazoles 69 
after aromatizing expulsion of the aniline part of amidine 65. While this 
condensation is not very atom-economic, it does allow for the tethering of amidine 





toward triazoles 69, in which the solid supported aniline fragment of amidine 71 
can be recycled. 
 
Scheme 12. Conversion of solid supported amidine to 3-amino-1,2,4-triazoles, and recycling. 
As indicated in Chapter 6, CuII is a highly efficient catalyst for the coupling between 
aromatic isocyanides and nucleophiles. Coupling hydrazines with o-
isocyanobenzoates affords the corresponding the arylformimidohydrazide 78 as an 
intermediate. This intermediate can also be used in a aza-Fischer cyclization. While 
utilization of these uncommon intermediates is rare, several examples of this aza-
Fischer cyclization have been reported to date.[22] A combination of our copper-
catalyzed isocyanide insertion methodology (Chapter 6) with this (Lewis) acid 
mediated Fischer-type cyclization could provide a one-pot route towards complex 
substituted 1-arylbenzimidazoles 80 (Scheme 13).  
 
Scheme 13. CuII-catalyzed amination of aryl isocyanides and subsequent aza-Fisher cyclization to N-
arylated benzimidazoles. 
If it is possible to outcompete the protodemetalation following the nucleophilic 
attack on the isocyanide, (e.g. by introducing a proximal insertion partner) more 
interesting heterocycles can be synthesized in this manner. The use of o-
alkynylated aryl isocyanides 81 in this CuII-catalyzed amination would afford the 
intermediate imidoylcopper species 83.  




Scheme 14. Copper-catalyzed amination of o-alkynylaryl isocyanides. 
When alkyne insertion is favored over protodemetalation this would afford the 
arylcopper intermediate 84, possibly through anti-addition to an external copper 
complex. Subsequent protodemetalation would afford the corresponding 2-
aminoquinolines 85 (Scheme 14). Furthermore, there is additional precedent in the 
literature that suggests the possibility of an outside attack of a nucleophile (e.g. 
water or carbonate) to facilitate the formation of 2-aminoquinazolin-4-ones 88, 
either directly (R’=H), or via 87, after aqueous workup (R’=CO2-, Ac).[23] 
 
Scheme 15. Cobalt-catalyzed three-component reaction towards substituted arylguanidines. 
The known formation of carbodiimides 92 via denitrogenation starting from 
sulfonyl azides 89 and isocyanides 90 (Chapter 2, Scheme 39-41), catalyzed by a low 





established[24] that, following nitrene transfer to the isocyanide, the generated N-
sulfonyl carbodiimide 92 is highly electrophilic. The formation of this electrophile 
92 will prompt a nucleophilic attack of an ambient amine 91, leading to 
nosylamidine 93. Subsequent base-promoted desulfonylative Smiles 
rearrangement will likely afford the trisubstituted guanidines 94 or 95. It is 
expected that the regioisomeric ratio (94:95) is under kinetic control. 
Initial experiments, based on the Co(C2O4)-catalyzed denitrogenative nitrene 
transfer to isocyanides, as reported by Ji and Jiang,[24a, 25] led to surprisingly good 
results. Utilization of tert-butyl isocyanide afforded the desulfonylated product 95a 
as a single regioisomer, presumably due to the diminished nucleophilicity of the 
tert-butylated guanidine 93, implying the formed guanidine itself is basic enough to 
facilitate the Smiles rearrangement without assistance of an external base. The use 
of p-toluidine as a nucleophile afforded 95a in 69 % yield without optimization. We 
suspect the regioselectivity is derived from the steric congestion arising from the 
isocyanide input. The asymmetric guanidine 95a rapidly hydrolyzed upon treatment 
with Cs2CO3 under ambient atmosphere to afford arylaniline 96, further 
corroborating the regioselectivity in this nitrene transfer/Smiles rearrangement 
cascade. 
 
Scheme 16. Further diversification of nitrene transfer/Smiles cascade with different aryl sulfonyl 
azides. 
In addition, the initial success of this cobalt oxalate-mediated imidoylation/Smiles 
rearrangement cascade opens up interesting possibilities. If it is possible to perform 
the one-pot Smiles cascade with arylsulfonyl azides other than nosyl azide, the 
Outlook and Future Directions 
 
217 
incorporation of mesomerically electron-withdrawing aromatic substituents might 
lead to further cascade reactivities (Scheme 16a). By using 2-
(azidosulfonyl)benzoates 97, the imidoylation/Smiles cascade generates 2-
aminoquinazolin-4-ones 99 or 100, again depending on the kinetics of the 
subsequent cyclization. Furthermore, if 2-cyanobenzenesulfonyl azides 101 are 
used, this sequence affords the difficult to synthesize heterosubstituted 2,4-
diaminoquinazolines 103 or 104 (Scheme 16b).  
 
Scheme 17. Palladium-catalyzed nitrene-transfer to isocyanides. 
In 2018, Pardasani et al. reported the palladium-catalyzed nitrene transfer of 
anthranilic nitrene to isocyanides. While this transformation tends to afford the 2-
aminobenzoxazinones 106 in high yields, the isocyanide scope remains 
underinvestigated, as mostly 3° and 2° isocyanides were used. Apart from the 
increasing costs and low natural abundance of palladium, this limited scope with 
regard to the isocyanide input is a common drawback of palladium catalysts in 
isocyanide insertion chemistry.  
 





Although novel, more tolerant palladium-based catalytic systems are still being 
developed, the utilization of base metal catalysts typically tolerates a broader 
variety of isocyanides. As mentioned in Scheme 15, we have successfully performed 
such a nitrene transfer using highly electron-deficient aryl azides as starting 
materials.  
Similarly, it should be possible to omit the Smiles rearrangement, and subject o-
azidobenzoates 107 to similar denitrogenative conditions, effectively transferring 
the azide-derived nitrene to the isocyanide. This reaction may also be catalyzed by 
CoII, or possibly by tricarbonyl nitrosyl ferrate (Scheme 18), which has shown 
significant promise as a catalyst for carbonylations,[26] and also catalyzes the 
homologous carbene transfer to isocyanides.[27] The generated carbodiimide 108 
acts as a highly versatile intermediate in a number of syntheses and can undergo 
several nucleophilic attack/cyclization cascades to quinazolinediones 109, 
alkoxyquinazolin-4-ones 110, aminoquinazolin-4-ones 111 (or 112) or 
(thio)quinazoline-4-ones 113. It should be noted that in the synthesis of 112, 
compared to the nitrene transfer/Smiles rearrangement/condensation cascade 
towards 99, the kinetics favor different products. Assuming kinetics dictate the 
initial cyclization towards 115, the secondary cyclization to the corresponding 
quinazolinone affords the products 99 with the original amine substituent (R2) on 
the quinazolinone 1-position. Alternatively, the formation of guanidines from 2-
azidobenzoates leads to incorporation of the smallest guanidine substituent on the 
3-position of quinazolinone 112. 
 
Scheme 19. Regioselectivity dictated by kinetic cyclizations in in situ generated guanidines (assuming 
R1 is sterically more demanding than R2). 




The recent progress in metal-catalyzed isocyanide insertions over the past decades, 
but in particular since 2014, is undeniable. There have been many reports 
expanding the synthetic strategies towards a broad range of mostly heterocyclic 
products. In particular, palladium-catalyzed isocyanide insertions are now quite 
established, although there is still room for further development with regards to 
isocyanide tolerance and milder reaction conditions. We believe that the coming 
decade will show further maturation of imidoylative cross-coupling processes, 
focusing on the use of more abundant and economic base metals as catalytic 






7.5. Experimental section 
General information 
Chemicals were purchased from Fischer Chemicals, TCI Chemicals or Sigma Aldrich and used without 
purification. Solvents were purchased from Fischer Chemicals (toluene, DCM, hexanes, EtOAc), or 
Acros Organics (DMSO, anisole) and used without purification, unless stated otherwise. NMR 
measurements were acquired either on a Bruker Avance 300 (1H NMR: 300.13 MHz, performed in 
CDCl3 (deuteration grade >99.8 %)) or a Bruker Avance 500.23 (1H NMR: 500.23 MHz, 13C NMR: 125.78 
MHz (in APT mode)), performed in CDCl3 (deuteration grade >99.8 %) All shifts are reported in ppm 
downfield of tetramethylsilane, and are corrected according to solvent. SiO2 column chromatography 
was performed using Silicycle Siliaflash P60 Gel C60 (particle size 40-63 μm) on a Teledyne CombiFlash 
Rf automated chromatography system, or by hand on Merck Silica Gel C60 (particle size: 40-60 μm). 
TLC chromatography was performed on Merck Silica Gel C60 F254 plates (silica coat on aluminum 
support). HRMS was performed on an Ion Cyclotron Resonance (ICR) spectrometer with a positive ion 
polarity mode. All measured compounds displayed <5.0 ppm deviated from calculated values. All 
isolated yields are corrected for trace impurities, if present.  
 
 6,7,8-trimethoxy-3-methylnaphthalen-1-ol (6) 
To a solution of Pd(OAc)2 (0.011 g, 0.1 mmol) in dry toluene (5 mL) was added 
XantPhos (0.058 g, 0.2 mmol). The mixture was stirred at RT for 20 minutes, 
before DBU (0.149 mL, 1.0 mmol) and tert-butyl isocyanide (0.115 mL, 1.0 
mmol) were added. Finally, to this mixture was added a solution of 2-methyl-
1-(3,4,5-trimethoxyphenyl)allyl acetate in dry toluene (0.2 M, 2.5 mL). The 
reaction was subsequently stirred at 110 °C for 16 h. The crude reaction mixture was allowed to cool 
to room temperature, transferred to a separation funnel with DCM, and washed with saturated 
aqueous NaHCO3 (2x) and water (1x), before being concentrated in vacuo and purified by automated 
column chromatography (gradient, cHex:EtOAc ; 1:0-1:1. The title compound was isolated as a solid 
(0.049 g, 40 %). RF = 0.62 (cHex:EtOAc = 3:1). 1H NMR (500 MHz, CDCl3) δ 9.37 (s, 1H), 6.97 (t, J = 1.2 
Hz, 1H), 6.83 (s, 1H), 6.61 (d, J = 1.5 Hz, 1H), 4.13 (s, 3H), 3.94 (s, 3H), 3.93 (s, 3H), 239 (s, 1H).  13C 
NMR (126 MHz, CDCl3) δ 153.5, 152.8, 148.3, 139.0, 137.2, 132.8, 117.3, 110.9, 110.6, 102.8, 62.3, 
61.3, 55.9, 21.8. HRMS (ESI): m/z calculated for C14H17O4 [M+H]+ = 249.1121, found = 249.1101. 
 
N-(tert-butyl)-3-methyl-9H-carbazol-1-amine (8a) 
To a solution of Pd(OAc)2 (0.011 g, 0.1 mmol) in dry toluene (5 mL) was 
added XantPhos (0.058 g, 0.2 mmol). The mixture was stirred at RT for 20 
minutes, before DBU (0.149 mL, 1.0 mmol) and tert-butyl isocyanide (0.115 
mL, 1.0 mmol) were added. Finally, to this mixture was added a solution of 
2-methyl-1-(3,4,5-trimethoxyphenyl)allyl acetate in dry toluene (0.2 M, 2.5 
mL). The reaction was subsequently stirred at 110 °C for 16 h. The crude reaction mixture was allowed 
to cool to room temperature, transferred to a separation funnel with DCM, and washed with saturated 
aqueous NaHCO3 (2x) and water (1x), before being concentrated in vacuo and purified by automated 
column chromatography (gradient, cHex:EtOAc ; 1:0-1:1. The title compound was isolated as a solid 
(0.021 g, 17 %). RF = 0.55 (cHex:EtOAc = 3:1). 1H NMR (500 MHz, CDCl3) δ 8.18 (bs, 1H), 8.01 (d, J = 7.8 
Hz, 1H), 7.55 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.38 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.20 (ddd, J = 6.8, 7.3, 
1.2 Hz, 1H), 6.88 (d, J = 1.4 Hz, 1H), 2.82 (bs, 1H), 2.50 (s, 3H), 1.36 (s, 9H).  13C NMR (126 MHz, CDCl3) 
δ 139.7, 133.9, 129.9, 129.1, 125.5, 124.2, 124.1, 121.7, 120.4, 119.2, 114.6, 110.9, 53.6, 30.3, 








To a solution of (Z)-N'-(p-tolyl)benzimidamide (0.105 g, 0.5 mmol) in 
anisole (6 mL) was added Ni(OAc)2.4H2O (0.012 g, 0.05 mmol) and tert-
butyl isocyanide (0.113 mL, 1.0 mmol). The mixture was stirred at 50 °C 
for 3 hrs, until TLC indicated full conversion. Hereafter, the crude 
reaction was transferred to a separation funnel with DCM, and washed 
with saturated aqueous NaHCO3. The organic layer was dried over 
Na2SO4, concentrated in vacuo, and purified by column chromatography 
(gradient, cHex:EtOAc ; 1:0-2:1. The title compound was isolated as an off-white solid (0.157 g, 80 
%). 1H NMR (600 MHz, CDCl3) δ 8.05 (dd, J = 7.6 Hz, 2H), 7.51 (t, J = 7.4 Hz, 1H), 7.42 (t, J = 7.6 Hz, 2H), 
6.97 (d, J = 7.8 Hz, 2H), 6.89 (d, J = 7.8 Hz, 2H), 4.71 (bs, 1H), 4.45 (bs, 1H), 2.25 (s, 3H), 1.31 (s, 9H), 
1.17 (s, 9H). 13C NMR (UDEFT mode, 151 MHz, CDCl3) δ 176.0, 154.0, 152.1, 147.4, 136.6, 132.1, 131.7, 
129.54, 129.50, 128.3, 121.7, 53.2, 52.4, 29.7, 28.4, 28.0. HRMS (ESI): m/z calculated for C24H33N4O 
[M+H]+ = 393.2649, found = 393.2648.  
 
2-(tert-butyl)-1-(2-nitrophenyl)-1-(p-tolyl)guanidine (95a) 
To a solution of 2-nitrobenzenesulfonyl azide (0.5 mmol) in 4 mL dry acetonitrile 
was added cobalt oxalate (0.007 g, 0.05 mmol), p-toluidine (0.054 g, 0.5 mmol) 
and tert-butyl isocyanide (0.057 mL, 0.5 mmol). This mixture heated to 80 °C, at 
which point the characteristic pink Co(II)-color changed to a clear orange 
solution, which was stirred for 1 h. After TLC indicated complete consumption of 
the starting azide, the crude reaction mixture was allowed to cool to room 
temperature, transferred to a separation funnel with DCM, and washed with 
brine (2x), before being concentrated in vacuo and purified by column 
chromatography (gradient, cHex:EtOAc ; 1:0-2:1. The title compound was isolated as an off-white solid 
(0.111 g, 69 %). RF = 0.35 (cHex:EtOAc = 4:1). 1H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 8.1, 1.5 Hz, 1H), 
7.56 (td, J = 7.8, 1.6 Hz, 1H), 7.38-7.29 (m, 2H), 7.19 (d, J = 8.2 Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 5.33 (bs, 




To a solution of 95a (0.25 mmol) in acetonitrile (4 mL) was added Cs2CO3 (0.325 
g, 1.0 mmol). The mixture was stirred at 80 °C for 16 h, open to air. The crude 
reaction mixture was allowed to cool to room temperature, transferred to a 
separation funnel with DCM, and washed with water (2x), before being 
concentrated in vacuo and purified by column chromatography (gradient, 
cHex:EtOAc ; 1:0-4:1. The title compound was isolated as a bright orange solid (0.039 g, 68 %). RF = 
0.6 (cHex : EtOAc = 4:1). 1H NMR (500 MHz, CDCl3) δ 9.46 (bs, 1H), 8.20 (dd, J = 8.6, 1.6 Hz, 1H), 7.34 
(ddd, J = 8.6, 6.9, 1.6 Hz, 1H), 7.23 (d, J – 8.0 Hz, 2H), 7.19-7.10 (m, 3H), 6.74 (ddd, J = 8.6, 6.9, 1.3 Hz, 
1H), 2.38 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 143.8, 136.0, 135.85, 135.81, 130.4, 126.8, 124.9, 117.2, 
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Transition Metal-Catalyzed Isocyanide Insertions 
 
From Noble to Base Metal Catalysis 
 
 
There is no doubt that isocyanide insertion processes are highly valuable methods 
of generating chemical complexity. The inherent cascade-like nature of isocyanide 
insertion has shown great promise in the rapid formation of complex 
intermediates. Furthermore, the incorporation of functionalized isocyanides 
provides inherently more convergent synthetic strategies towards valuable 
nitrogeneous products. The field of metal-catalyzed imidoylations has gone 
through significant developments over the past 20 years, moving out of its infancy, 
into a mature area of research. Chapter 1 presents an updated overview of all the 
known isocyanide insertions catalyzed by palladium. Even though there are 
significant efforts being undertaken to replace palladium with cheaper and more 
naturally abundant metals, it is still the most widely employed metal in these types 
of imidoylations. Due to its unrivaled reactivity, and highly predictable chemistry, 
palladium catalysis is still unrivaled in the field of isocyanide insertions. 
This remarkable reactivity is demonstrated in Chapter 3, in which we report an 





chemistry behind an imidoylative variant of this Sonogashira transformation was 
already known, we utilized our expertise in the field of multicomponent cascade 
chemistry by following up this 3-component reaction with a conjugate 
cycloaddition.  The result is a one-pot, two-stage transformation of o-
bromoanilines 1, various functionalized isocyanides 2 and terminal alkynes 3 to 
directly furnish the biologically and medicinally interesting 4-aminoquinoline 
scaffold 4 (Scheme 1).  
 
Scheme 1. Palladium-catalyzed three component cascade reaction of bromoanilines, isocyanides and 
alkynes towards 4-aminoquinolines. 
Here, the formation of the intermediate ynimine 5 is crucial. This direct product of 
the imidoylative Sonogashira cross-coupling is susceptible to conjugate addition of 
the nucleophilic moiety already present in the aryl halide substrate. The 
generalization of this reactivity inspired us to include different nucleophiles, but 
more importantly, different electrophiles in similar cross-coupling substrates. This 
led to the research reported in chapter 4, where we replaced the transmetalation 
of the in situ formed copper acetylide with nucleophilic attack of a cyanate  (Scheme 
2). The resulting intermediate 8 bears significant structural resemblance to 5, but 




underinvestigated 4-aminoquinazolin-2-ones and 4-aminobenzoxazin-2-ones in 
moderate to good yields, in a three-component cross-coupling. Due to the 
increased electrophilicity of the intermediate 8 no acids are required to facilitate 
the cyclization. 
 
Scheme 2. Palladium-catalyzed three component cascade reaction of bromoanilines or 
bromophenols, isocyanides and cyanate towards 4-aminoquinazolinones and 4-
aminobenzoxazinones. 
While the synthetic applications of palladium-catalyzed imidoylations have 
improved significantly over the past 20 years, recent efforts have led to a surge in 
the use of more readily available base metals in this type if isocyanide insertion 
chemistry. The benefits of using row IV metals over the well-defined noble metals 
in any type of catalysis are myriad. Isocyanide insertion reactions are no exception, 
and many novel reactivities of isocyanides under base metal catalytic conditions 
have been reported, in particular over the past 5 years. Chapter 2 gives a detailed 
summary of all known base metal-catalyzed isocyanide insertion reaction known at 
the time of writing, and puts emphasis on the catalytic reactivity of the row IV 
metals. The synthetic utility of any isocyanide insertion reaction is highly dependent 
on the incorporation of both the isocyanide carbon and nitrogen, but also on the 
nature of the isocyanide substituent. Hence, additional attention was payed to the 
tolerance of all reported isocyanide insertions with respect to different types of 
isocyanides. From the collection of research displayed in chapter 2, the growth of 
the entire isocyanide insertion field is visible, with base metals opening up new 
catalytic pathways not previously accessible through the use of noble metals. 





conditions, the base metal-catalyzed insertion of isocyanides has evolved into a 
more mature, and commercially viable branch of synthetic chemistry. 
 
Scheme 3. Pyrimidouracil synthesis through nickel(II)-catalyzed oxidative dehydrogenative isocyanide 
insertion into amidinouracils 
In addition to the mentioned palladium-catalyzed imidoylative cross-couplings, we 
were also able to utilize the much more cheaper and readily available Ni(OAc)2.4H2O 
as an effective catalyst in the oxidative imidoylative cross-coupling of 
amidinouracils 9. As described in chapter 5, we were able to devise a synthetic 
strategy that affords the highly underinvestigated pyrimidouracils 10 under 
remarkably mild conditions (i.e. base metal catalyst, recommended solvent, low 
temperatures, and open to air.) The oxidative imidoylation proceeds highly 
efficiently, affording the product 10 typically in high yield, regardless of the 
substituents on the substrate amidinouracil 9. The reaction also shows a high 
tolerance to functionalized isocyanides 2.  
 
Scheme 4. Synthesis of quinazolin-2-ones through copper(II)-catalyzed amination/ lactamization 




We intended to build on the base metal-catalyzed versions of isocyanide insertions, 
and were curious to elaborate the cascade-type nature of chapter 3-4, so we 
investigated the possibility to incorporate an electrophile into the isocyanide 
moiety. We reported the copper(II)-catalyzed amination/ cyclization cascade of o-
isocyanobenzoates 11 in chapter 6. This transformation is mechanistically 
significantly different from other chapters, as the catalyst most likely functions as a 
Lewis acid. Quinazolinones 13 were typically isolated in good yields, under relatively 
mild conditions. We underlined the synthetic utility by the total synthesis of several 
natural compounds, including rutaecarpine (Scheme 4).  
The research projects highlighted in this thesis are just several examples of the high 
synthetic impact isocyanide insertion reactions. Especially when the isocyanide 
substituent can be incorporated into the final product, the benefits to the 
convergent nature of imidoylations cannot be ignored. However, it does require 
significant amounts of curiosity-driven research to develop the robust reaction 
conditions required to move these types of metal-catalyzed isocyanide insertions 
from fundamental proof of principle towards medicinally relevant syntheses.  
We believe that the further mechanistic elucidation of most base metal-
catalyzed isocyanide processes will deepen our understanding of the catalytic 
activity of these base metal/ isocyanide systems. There is no doubt that this 
understanding will lead to the development of even more robust imidoylative 
transformations. We believe further development of isocyanide insertion reactions 
in cascade chemistry, combined with rational ligand design, will lead to novel 
powerful transformations. Our goal will continue to be to continue the expansion 
of the chemists’ toolbox with regards to the development of cheaper, less toxic 
catalytic systems in these imidoylative transformations. As such, internalization of 
these cascade processes has a high capacity of generating valuable chemical 
intermediates under more benign conditions, while reducing waste-streams and 




















Overgangsmetaalgekatalyseerde Isocyanide Inserties 
 
Van Edel- Naar Onedelmetaalkatalyse 
 
Het staat buiten kijf dat isocyanide insertieprocessen zeer waardevolle methoden 
zijn om chemische complexiteit te bewerkstelligen. De inherente cascade-aard van 
isocyanide inserties leidt tot snelle vorming van complexe intermediairen. 
Bovendien zorgt de incorporatie van gefunctionaliseerde isocyanides voor meer 
convergente synthetische routes naar waardevolle stikstofhoudende producten. 
Het werkveld van metaalgekatalyseerde imidoyleringen heeft de afgelopen 20 jaar 
significante ontwikkelingen doorgemaakt, en is uit de kinderschoenen gegroeid, 
naar een ‘volwassen’ onderzoeksveld. Hoofdstuk 1 verhaalt een geüpdatet 
overzicht van alle bekende isocyanide inserties die zijn gekatalyseerd door 
palladium. Ondanks het feit dat er significante hoeveelheden onderzoek gestoken 
is in het vervangen van palladium door goedkopere, veelvoorkomendere metalen 
is palladium nog steeds het meest gebruikte overgangsmetaal in dit type 
imidoyleringen. Vanwege de ongekende reactiviteit, en vooral zeer voorspelbare 






Een voorbeeld van deze opmerkelijke reactiviteit is weergegeven in Hoofdstuk 3, 
waarin we een imidoylatieve variant van de welbekende Sonogashira reactie 
rapporteren. Hoewel de chemie achter een imidoylatieve Sonogashira al bekend 
was, pasten we onze expertise in multicomponentchemie toe door deze 
driecomponentenreactie op te volgen met een conjugaatadditie. Dit resulteerde in 
een éénpot-, tweestapsreactie van o-bromoanilines 1, gefunctionaliseerde 
isocyanides 2 en eindstandige alkynen 3, en leidt tot de directe synthese van het 
biologisch en medische relevante 4-aminoquinolineskelet (Schema 1).  
 
Schema 1. Palladium gekatalyseerde driecomponenten cascade reactie van 2-bromoanilines, 
isocyanides en alkynen naar 4-aminoquinolines. 
Hierin is de vorming van het intermediaire ynimine 5 cruciaal. Dit directe product 
van de imidoylatieve Sonogashira kruiskoppeling is ontvankelijk voor 
conjugaatadditie van de al aanwezige nucleofiele groep van het arylhalide. De 
gegeneraliseerde reactiviteit hiervan inspireerde ons verschillende nucleofielen, en 
vooral verschillende electrofielen te gebruiken als vergelijkbare 
kruiskoppelingsubstraten. Dit leidde tot het onderzoek gerapporteerd in Hoofdstuk 
4, waarin we de transmetalatie met het in situ gevormde koperacetylide vervangen 
hebben door een nucleofiele aanval van een cyanaat. Het gevormde intermediair 8 
lijkt sterk op het eerder vernoemde ynimine 5, maar is nog electrofieler. Hierdoor 




4-aminobenzoxazin-2-onen 7 (Schema 2). De opbrengt van deze driecomponenten 
kruiskoppeling is matig tot goed. Vanwege de verhoogde electrofiliciteit van het 
intermediair 8 zijn er geen toegevoegde zuren nodig om de cyclisatie te 
bewerkstelligen.   
 
Schema 2. Palladiumgekatalyseerde driecomponenten cascadereactie van bromoanilines of 
bromofenolen, isocyanides en natriumcyanaat naar 4-aminoquinazolinonen of 4-
aminobenzoxazinonen. 
Ondanks dat palladiumkatalyse zich enorm heeft ontwikkeld over de afgelopen 20 
jaar, hebben recente ontwikkelingen geleid tot een golf van beter verkrijgbare 
metalen in dergelijke typen isocyanide inserties. De voordelen van het gebruik van 
metalen uit periode IV ten opzichte van edelmetalen in metaalkatalyse zijn 
veelvoud. Isocyanide inserties zijn hierop geen uitzondering, en veel nieuwe typen 
reacties tussen onedele metalen en isocyanides zijn gerapporteerd, met name in 
de afgelopen 5 jaar. Hoofdstuk 2 geeft een gedetailleerd overzicht van alle tot nog 
toe bekende onedelmetaal gekatalyseerde isocyanide inserties, en legt de nadruk 
op de katalytische activiteit van de metalen uit periode IV. De synthetische 
bruikbaarheid van alle isocyanide insertiereacties hangt sterk af van de invoeging 
van zowel de isocyanide koolstof- en stikstofatomen, maar ook van de aard van de 
isocyanide substituent.  Hiertoe is er extra aandacht besteed aan de tolerantie van 
alle vermelde imidoyleringen met betrekking tot verschillende typen isocyanides. 
Uit het onderzoek gerapporteerd in Hoofdstuk 2 is de groei van het isocyanide 






Schema 3. Synthese van pyrimidouracils door nikkel(II) gekatalyseerde oxidatieve dehydrogenatieve 
isocyanide insertie in amidinouracils. 
katalytische mechanismes vrijmaken, welke niet beschikbaar waren bij 
edelmetaalkatalyse. Deze nieuwe reactiviteit, gecombineerd met de vaak 
verhoogde tolerantie voor atmosferische omstandigheden hebben ervoor gezorgd 
dat onedelmetaalkatalyse zich ontpopt heeft tot een beter ontwikkeld en 
commercieel levensvatbare tak van synthetische chemie. 
Naast de voorgenoemde palladium-gekatalyseerde imidoylatieve kruiskoppelingen  
waren wij ook in staat het veel goedkopere Ni(OAc)2.4H2O als een efficiente 
katalysator in te zetten in de oxidatieve imidoylering van amidinouracils 9. Zoals 
beschreven wordt in Hoofdstuk 5, waren we in staat een synthese van de 
onderbestudeerde pyrimidouracils 10 te ontwikkelen. Deze reactie voltrekt zich 
onder opmerkelijk milde condities (i.e. onedelmetalen katalysator, aangeraden 
oplosmiddel, lage temperature, en open aan de lucht). Deze oxidatieve 
imidoylering vormt de producten 10 zeer efficiënt, meestal in een hoge opbrengst, 
ongeacht het substitutiepatroon op amidinouracils 9. Tevens vertoont deze reactie 
een hoge tolerantie voor gefunctionaliseerde isocyanides 2 (Schema 3).  
Het was onze bedoeling om voort te bouwen op deze onedelmetaalgekatalyseerde 
versies van isocyanide inserties. We waren nieuwsgierig naar het uitbreiden van de 
cascade-achtige aard van de reacties in hoofdstuk 3-4. Hiertoe onderzochten we 
het aanbrengen van een electrofiel op de isocyanide reactant. Aldus rapporteerden 
we de koper(II) gekatalyseerde aminering/cyclisatie cascade van o-
isocyanobenzoaten 11 in hoofdstuk 6. Deze transformatie is mechanistisch gezien 
significant verschillend van de andere hoofdstukken, omdat de katalysator 
waarschijnlijk optreedt als Lewiszuur. Quinazolinones 13 werden gevormd, 
doorgaans met hoge opbrengst, onder relatief milde reactieomstandigheden. De 
synthetische toepasbaarheid werd onderstreept door de totaalsynthese van een 






Schema 4. Synthese van quinaolin-4-onen door middel van een koper(II) gekatalyseerde 
aminering/lactamisering cascade. 
De in dit proefschrift vermelde onderzoeksprojecten zijn slechts enkele 
voorbeelden van de synthetische ontwikkelingen op het gebied van isocyanide 
inserties. Vooral wanneer de isocyanide substituent verwerkt wordt in het 
eindproduct kunnen de voordelen van de convergente aard van imidoyleringen niet 
ontkend worden. Echter, het ontwikkelen van de robuuste condities die nodig zijn 
om deze metaalgekatalyseerde imidoyleringen om te zetten van fundamentele 
reacties in medicinaal relevante syntheses behoeft nog wel grote hoeveelheden 
onderzoek. 
Wij zijn van mening dat het verder ontrafelen van de meeste 
onedelmetaalgekatalyseerde isocyanide insertie processen het begrip van de 
katalytische activiteit van deze onedelmetaal/isocyanide systemen zal verbreden. 
Dit begrip zal zeker leiden tot de ontwikkeling van nog robuustere imidoylatieve 
transformaties. Het is onze mening dat verdere ontwikkeling van isocyanide 
insertiereacties, al dan niet gecombineerd met verder ligandontwerp, zal leiden tot 
nieuwe, krachtigere reacties. Ons doel blijft het vergroten van de chemicus’ 
gereedschapskist met betrekking tot het ontwikkelen van goedkopere, robuustere, 
en minder giftige katalytische systemen voor deze imidoylatieve omzettingen. Het 
internaliseren van dergelijke cascadeprocessen zal leiden tot de vorming van 
chemische intermediairen onder zachtere condities, alsmede het reduceren van 







And now: after some 200-odd pages of scientific maundering, the part that 
everybody does read attentively. Because everybody reads this part, I’ve decided 
to keep it fully in a common language.  
It’s been a long time since I first wandered onto the chemistry hallways of the VU, 
and it wasn’t until writing these acknowledgements that it really sunk in just how 
long it’s been, how many people I’ve met, and just how impactful, welcoming, and 
fun it has been.  
First and foremost, my thanks goes out to Romano. I was some lost bachelor 
student when I first came to the VU in late 2011, and have repeatedly joined the 
SyBOrCh group hereafter. You have given me all those opportunities, for which I am 
grateful. Additionally, you have allowed me to grow as a researcher, creating a 
climate allowing for chemical creativity where I was able to design and carry out my 
own projects (with varying results), while also delivering the right amount of 
guidance. You’ve helped me in more ways than you know, but I can never 
remember your tiramisu. I have no doubt you’ll continue all these things at AMIBM, 
and they are all the better for it. 
Additional thanks goes to Bert, my promotor from another alma mater, for the 
chance to join your group under the joint degree. I have never met anyone so 
invested in their PhD students’ research. Your dedication to your group and your 
work is inspiring. I am happy to see that the collaboration between SyBOrCh and 
ORSY is being continued by new PhD students. 
Eelco, as the person most involved in day-to-day aspects of my research, you have 
been incredibly helpful in nearly all aspects of my PhD, and possibly the most gifted 
chemist I have ever come across. There was always some eidetic image of an Org. 
Lett. from 2006 or something in the back that could overcome the exact problem 
we were facing. I always enjoy talking to you, research-related or otherwise, and I 
wish you all the best in the continuation of the group.  
More gratitude goes out to the members of my promotion committee: Prof. dr. 
Célia Fonseca Guerra for heading the committee; Herr Prof. Matthias Beller, your 




you agreed to judge my defense; Prof. dr. Jan van Maarseveen, for being the first 
to volunteer a committee position; dr. Daniël Broere, for your views on catalysis; 
and dr. Tjøstil Vlaar, for essentially laying the foundation on which this thesis is 
built.  
As much as I’d like to take all the credit for the work in this thesis, I could not have 
done it without the many students that have come my way. In somewhat 
chronological order, thanks goes out to: 
Miguel, what can I say, it’s been loud. You were my first student for an internship. 
I did not expect a foreign PhD student to show up on my very first day on the job. 
Then again, neither did anyone else until the weekend before, that’s why we 
attempted to build you your own lab. Congratulations on obtaining your own PhD.  
Basilia ‘Badass’ Pires, my first student-student. Too bad we were unable to make 
your project work. Still badass. You finally -somewhat abruptly- discovered there 
are also positive sides to having a lab hierarchy.  
Klaas, Martijn, Sam & Stan, with you guys and Basilia, I had somehow found myself 
with an entire team within 6 months of starting my PhD. Thanks for help with the 
collaboration with the University of Arizona, and congrats on surviving a month 
under Basilia’s newfound tyranny.  
Kelly, we were in a weird dynamic, that after having gone through the master 
courses together, you ended up interning with me during my PhD. You’ve been 
instrumental in the research described in chapter 3, and I think you can be proud 
of that. I’m glad you found your spot at TNO, and I’ll fondly look back on teaching 
Polish students Dutch rap lyrics, beerpong and lots of borrels. Also, it took some 
restraint, but I’ve been on a not-beating-your-student-in-the-face-with-sticks hot 
streak of multiple years now! 
Tijs, your criticism was appreciated, good luck with things in Oxford (I think?). I’m 
happy your career switch worked out.  
Mark Houtman, your project was also scooped, but nevertheless your work during 
your internship was done very well.  
Local English-Dutch Belgian Sam, I do hope you found a PhD position of your own. 
I now we made it kind of hard on you during your time here, but thanks for good 
conversations and insight. Your work on the ICCC cascade will soon be published, 





Jeffrey, you helped with all the syntheses of alkynes for the same chapter, and was 
a welcome addition to our niche in 4W19.  
Hung-Chien “Hungky” Lin, it’s been a couple of years since John came to me with 
some random guy he found at Den Bosch station, claiming it was my new student. 
I did not take him seriously at the time, but you stuck with us anyway. When you 
worked on the nickel-catalyzed isocyanide insertions, I forgot to set the boundary 
on how many examples we actually needed. Forgetting to ‘switch you off’, I found 
you synthesized so many compounds I had to spend days just checking your 
spectra. This resulted in our nice (and full) Org. Lett paper. I hope SyBOrCh didn’t 
set the bar too high, and you can still enjoy your own PhD in Groningen.  
Ilja, I have yet to meet another chemist/philosopher, and I might never. I gladly 
took you on for an internship after you hardly attended my OChem course, and 
passed with the best grade. The impressive amount of work you’ve done deserved 
better results, but that’s research for you.  
Tom, your literature thesis led to our Angewandte review, which I’m still really 
proud of and which forms the foundation of Chapter 2 (I trimmed it down about 
80%, and now it looks bigger). You’ve really grown into your own as a PhD student, 
I think you’re a great asset to the group, and look forward to see what direction 
you’re taking the imidoylation cascades.  
Bram, you stepped up in a major way to write the literature thesis other students 
wouldn’t. You really delivered, and Chapter 1 is mostly based on your work.  
Speaking of denizens, Barry K. Oppelaar, what can be said about you that hasn’t 
been said already in the large number of theses from this group over the past 
decade? Tales of your time at the VU have passed into legend (“wait, HOW many 
explosions?”) and your isocyanide distribution system is still unrivaled. It sucks we 
were not able to write a review, but you’re not to blame. The only thing you’re 
guilty of is being Barry. That is your crime. It is also your punishment.  
Simon, in your work on the ICCCCC(C) you were dealt a rough hand, but soldiered 
through. Please never stop writing poetry. Please immediately stop happily using 
sodium amide as a base (like a maniac!). You’ll be happy to know the NMR of the 
rotavap bath still serves as a cautionary tale to new students.  
Edith, as my last student, you certainly made an impression. You singlehandedly did 




time’ to a full project. Although you might not have agreed fully, the Karlijn Keijzer 
prijs was well deserved.  
There were also lots of students who were not working under my supervision, 
although I’ve more than once meddled in their research. These students were 
important for the overall atmosphere of the lab and the department, and deserve 
thanks just for that.  
Natalia & Kinga, you guys occupied the lab together with Kelly, in what might have 
been the most fun composition of SyBOrCh. While there was never a dull moment, 
sometimes it might’ve been too fun. Actually, there were times where I left a 
puddle of fun in the bushes on Friday nights. On an unrelated note, I’m never 
playing vodkapong or Krupnikpong with any of you again. Bijan, you were also 
there. The rest of the students on the lab: Sjoerd (KA387), Anouk, Benjamin, Laura, 
Krishnili, Flavia, Pim, Coen, Turbokoen, Faizeh, Lynay, Stan (again), Silvia, Ellymay, 
Vivi, Maxime, George et al.  
A job is only as fun as your coworkers, and it’s been very fun. In no particular order, 
more thanks goes out to: 
Elwin, at long last it is my turn to rotate out of the system. I remember when we 
were just having discussions over a pint in Winterhold. It has been a long time, and 
I like to think we’ve both grown since. Thank you for all the help, from explaining 
basic column chromatography back in 2011 to the more specialized UDEFT 
analyses, or early-morning astronomy. You’ve been really helpful, and more 
importantly, really nice. I’ll gladly come back from time to time to annoy Tom G. 
with a lunchtime game of fooseball.  
Handing the technician-baton to Daniël, it’s great to see how much you’ve grown 
into the role. You always go the extra mile to be even a little bit of assistance, which 
is admirable in its own right, especially in combination with your dayjob as a slum-
lord. I still smirk when I walk by a parkbench in the sun. 
Art, you have been at the VU since I can remember. You’ve always been around 
teaching all the colleagues. Your wealth of knowledge concerning teaching, when 
to call Belgian monks, the benefits of in silico chemistry, the benefits of the 5-4-1 
system, craft beers, 1 molar solutions, what does or does not constitute an actual 
sport, gold bikes and sarcasm has been less useful than you might have anticipated, 
but incredibly entertaining. You are the only colleague whose knees I’ve seen as 





Corien, I started my PhD just in time to rejoin you at KA387, this time as colleagues. 
I treated the lab with moderate care, as requested.  
The Cioc-doc, Razvan, although we only had minimal overlap in the group, your 
insight and confidence has been great, and more helpful than you realize. I want to 
give you more compliments, but you’re likely too humble to accept them. The best 
of luck with your postdocs at UU, and with starting your own family in a place that 
doesn’t require excessive commuting.  
Gydo, I know you like to passive-aggressively thank people, so let me return the 
favor. You have been nothing but helpful ever since we started sharing an ‘office’. 
Thanks for always listening whenever I came up with some new, crazy convoluted 
synthetic route, and for all the inside jokes. Your patience with students and 
coworkers alike is something to aspire to. It’s still hard to force myself to go out 
running, but at least it’s not on all-stars anymore. 
Jordy, we started out as baffled BSc. students together in W&N, and continued 
through the master and PhD, as well as postdocs in the same groups. It has been 
great, both professionally and personally. I’ll fondly look back on all the discussions 
in our 32°C office, all the borrels, fooseball, piles of Rodizio, murdering my fridge, 
BBQs in the forest, Blauwe Engel, multiple lost or ‘lost’ jackets, brassing sticks, all 
the times you drove me home by bike and gave me a place to crash. Those days, 
they will not come again… I’m happy to see how much you’ve grown over that time, 
and I have full confidence your tenure-track will be as successful as your PhD.  
John, whether it was calling random Canadians Grass Mud-horses, or once again 
chilling some beers at 3 p.m. on a Wednesday, it was a lot of fun working with you 
as an officemate. After fixing every IT-related solution within a 100 m. radius of the 
group, I’m glad to see you’ve made your job into a profession. Also, I never told 
you, but rent in Antwerp is pretty doable without a roommate. Your words of 
encouragement concerning fatherhood, family, and everything inbetween are well-
received.  
Meester Mark, it has never been quiet at our desk-island since you joined as a 
postdoc, and I think the group’s all the better for it. Thanks to you I now always 
work with 80s synthwave in the background, much to the dismay of anyone within 
earshot. I’ll remember our discussions on exotic organometallic complexes, as well 
as all the cyriak, shitty flute and you’re tearing me apart, Lisa. Thanks for all the 
work you put into the design of ridiculously complex graphic representations, like 




translate the summary, but decided to thank you instead. I’ll look forward to your 
own graduation. 
Matteo, at a time when the SyBOrCh residency was dwindling, your arrival was 
quite welcome. Filling your own little office with as many students and Matteos as 
you could find, I think you’ve done a great job of starting what looks like your own 
group. While service at Café Matteo has been somewhat lacking, the price/quality 
ratio has been consistently decent (3,5 stars).  
Brendan, you have been dealt a tricky hand project-wise, and I do not envy 
elucidating your spectra (which I think I’ve made abundantly clear over the years). 
You’ve inspired several ideas for Smiles cascades on my end, and I have full 
confidence you’ll bring your own PhD to a successful end. 
Coralie, even though we’ve only spent a month together on the lab, I still think it’s 
nice you’re including me three years down the line. I like the overlap between our 
research topics, and am excited to see your continuation of hot isocyanides, even 
though you nooit de juiste taal gebruikt om ons uit te nodigen voor een meeting. I 
wish you all the best in the final stretch of your own PhD. 
Other coworkers for contributing to the general atmosphere of the group, I hold 
you in part responsible for creating the intellectual and socially stimulating 
environment that is the SyBOrCh group, including, but not limited to: Matthijs, 
Guido, Sanne, Ester, Vero, and Giulia. We weren’t that close, but you were 
important either way. 
Also, thanks to everyone in the Antwerp office, in particular Pieter, Gilles, and 
Jeroen, as office roomies. Sorry for so often stinking up the place, but I’ve quit 
smoking since. Also Philippe and Evelien for everything you do for that department, 
and everything you had to patiently show me. Additionally, Julien, Michal, Sovan 
and Brett for general conversation and introduction into the group.  
I know none of you helped with labwork, but a major thank goes out to the guys, 
for their constant presence. Ferdi “vieze Fur” Hartzema, Nicky “G” Geerse, Giel, 
Guus, Stefan and Hans. Although none of you likely have an idea of what exactly 
I’ve been doing over the past couple of years, the Thursday evening beers have 
helped massively in keeping my sanity over the years. It was pretty well known 
among coworkers I wouldn’t show up before 10 AM on Fridays. 
Additional thanks to Jurriaan “Johnny Rocketfingers” van Bezu en Alex “Sander” 





Marianne & Job (P&M of O&O), for all the support, be it financially, 
gastronomically, or parental advisory. I could not have done it without you.  
Lieve Shuri, jij hebt mijn prioriteiten in één klap verlegd, zonder het te weten. Je 
kijkt me aan terwijl ik dit schrijf, als verreweg het mooiste dat ik gemaakt heb. 
Ris, achter elke man staat een succesvolle vrouw. Wij kregen een relatie toen ik net 
een maand begonnen was met mijn PhD, in wat -tot recentelijk- de meest 
veranderlijke maand van mijn leven was. Excuses voor elke keer dat ik laat 
thuiskwam, dat ik ‘nog even’ op het lab zat, voor alle keren dat ik weer reacties zat 
te schetsen op de bank, voor steeds vertrekken naar Antwerpen. Jij bent degene 
geweest die me altijd heeft geaard in de afgelopen jaren, en de reden dat ons huis 
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